1
00:00:05,600 --> 00:00:09,960
WELCOME STAFF AND GUESTS.

2
00:00:09,960 --> 00:00:11,720
BEFORE WE BEGIN TODAY, THERE'S

3
00:00:11,720 --> 00:00:13,640
SOME REQUIRED HOUSEKEEPING AND I

4
00:00:13,640 --> 00:00:14,840
MUST ATTEND TO.

5
00:00:14,840 --> 00:00:16,600
MEMBERS OF THE PUBLIC WHO MAY

6
00:00:16,600 --> 00:00:19,880
WISH TO EXPRESS VIEWS REGARDING

7
00:00:19,880 --> 00:00:22,360
ANY DISCUSS MAY DO BY WRITING

8
00:00:22,360 --> 00:00:23,760
SECRETARY OF THE BOARD AND

9
00:00:23,760 --> 00:00:24,600
WITHIN 10 DAYS FOLLOWING THE

10
00:00:24,600 --> 00:00:30,200
VIRTUAL MEETING.

11
00:00:30,200 --> 00:00:31,280
THEY WILL RECEIVE CAREFUL

12
00:00:31,280 --> 00:00:31,600
CONSIDERATION.

13
00:00:31,600 --> 00:00:34,240
I WANT TO REMIND YOU, YOU MUST

14
00:00:34,240 --> 00:00:35,920
ABSENT YOURSELF DURING

15
00:00:35,920 --> 00:00:37,840
DISCUSSIONS WHEN YOU ARE

16
00:00:37,840 --> 00:00:38,720
PARTICIPATION AND DELIBERATIONS

17
00:00:38,720 --> 00:00:41,080
ON A PROJECT, PROGRAM OR OTHER

18
00:00:41,080 --> 00:00:43,520
SPECIFIC MALTERS WHO CONSTITUTE

19
00:00:43,520 --> 00:00:45,160
A CONFLICT OF INTEREST OR CREATE

20
00:00:45,160 --> 00:00:47,280
THE APPEARANCE OF ONE.

21
00:00:47,280 --> 00:00:48,840
ADVISE THE SECRETARY AND ABSTAIN

22
00:00:48,840 --> 00:00:50,240
FROM PARTICIPATION AND

23
00:00:50,240 --> 00:00:51,600
DISCUSSION OR ACTION REGARDING

24
00:00:51,600 --> 00:00:53,240
THAT MATTER.

25
00:00:53,240 --> 00:00:55,480
IN LIGHT OF THE CURRENT POLICIES

26
00:00:55,480 --> 00:00:57,280
AND CONFLICT OF INTEREST ON

27
00:00:57,280 --> 00:00:58,480
FINANCIAL HOLDINGS AND SPECIAL

28
00:00:58,480 --> 00:00:59,720
GOVERNMENT EMPLOYEES WHICH

29
00:00:59,720 --> 00:01:01,440
INCLUDE ALL MEMBERS OF THIS

30
00:01:01,440 --> 00:01:03,760
BOARD, WE MUST DEPEND ON YOU TO

31
00:01:03,760 --> 00:01:05,920
ABSENT YOURSELF DURING ALL AND

32
00:01:05,920 --> 00:01:07,480
DISCUSSION MATTERS THAT COULD

33
00:01:07,480 --> 00:01:09,280
IMPACT THE STATUS OF THOSE

34
00:01:09,280 --> 00:01:09,720
HOLDINGS.

35
00:01:09,720 --> 00:01:12,200
WE TRUST YOUR JUDGMENT IN THESE

36
00:01:12,200 --> 00:01:12,520
INSTANCES.

37
00:01:12,520 --> 00:01:14,640
TO ENSURE NO INTERRUPTS TODAY,

38
00:01:14,640 --> 00:01:19,040
PLEASE MUTE YOURSELVES AND

39
00:01:19,040 --> 00:01:21,040
REMAIN SO UNTIL RECOGNIZED

40
00:01:21,040 --> 00:01:23,400
MYSELF, PAULETTE, AT THE NCI

41
00:01:23,400 --> 00:01:33,880
DIRECTOR AND THESE SPEAKERS.

42
00:01:34,800 --> 00:01:42,560
BY WE CAN'T PREDICT THE TIME OR

43
00:01:42,560 --> 00:01:43,840
CURRENT OF MOTION YOUR PRESENCE

44
00:01:43,840 --> 00:01:45,520
IN THE VIRTUAL MEETING ROOM FOR

45
00:01:45,520 --> 00:01:48,920
ALL SEGMENTS OF THE MEETINGS IS

46
00:01:48,920 --> 00:01:50,320
A MUST.

47
00:01:50,320 --> 00:01:53,440
OUR NEXT MEETING SPANS

48
00:01:53,440 --> 00:01:55,800
JUNE 14th AND 15th OF THIS

49
00:01:55,800 --> 00:01:56,000
YEAR.

50
00:01:56,000 --> 00:01:57,440
THIS IS GOING TO BE A JOINT

51
00:01:57,440 --> 00:01:59,440
MEETING WITH THE NATIONAL CANCER

52
00:01:59,440 --> 00:02:01,360
ADVISORY BOARD AND IT WILL BE AN

53
00:02:01,360 --> 00:02:02,160
IN-PERSON MEETING.

54
00:02:02,160 --> 00:02:04,720
OUR FIRST ONE IN THREE YEARS.

55
00:02:04,720 --> 00:02:06,920
WITH HYBRID PARTICIPATION

56
00:02:06,920 --> 00:02:08,120
POTENTIAL FOR THOSE WHO ARE

57
00:02:08,120 --> 00:02:10,040
UNABLE TO MAKE IT IN-PERSON.

58
00:02:10,040 --> 00:02:12,400
PLEASE MARK YOUR CALENDARS.

59
00:02:12,400 --> 00:02:14,040
A LIST OF FUTURE MEETING DATES

60
00:02:14,040 --> 00:02:16,080
IS ON THE AGENDA.

61
00:02:16,080 --> 00:02:19,840
AS SUCH, WE NEED TO CONFIRM THE

62
00:02:19,840 --> 00:02:21,240
2025 MEETING DATES WHICH ARE

63
00:02:21,240 --> 00:02:26,560
ALSO LISTED ON THE AGENDA.

64
00:02:26,560 --> 00:02:31,240
I'D LIKE TO CALL FOR A MOTION

65
00:02:31,240 --> 00:02:32,480
SECOND AND DISCUSSION REGARDING

66
00:02:32,480 --> 00:02:34,080
THE PROPOSED MEETING DATES.

67
00:02:34,080 --> 00:02:36,640
I THINK PAULETTE, THAT'S THE

68
00:02:36,640 --> 00:02:38,720
ONLY ITEM SPECIFICALLY AT THIS

69
00:02:38,720 --> 00:02:39,480
POINT?

70
00:02:39,480 --> 00:02:42,920
>> CORRECT.

71
00:02:42,920 --> 00:02:44,080
>> Dr. Flaherty: GREAT.

72
00:02:44,080 --> 00:02:45,080
I'M ASSUMING YOU ALL REVIEWED

73
00:02:45,080 --> 00:02:47,960
THE AGENDA WITH THOSE DATES

74
00:02:47,960 --> 00:02:51,920
BASICALLY I NEED A MOTION AND A

75
00:02:51,920 --> 00:02:53,440
SECOND TO GET US MOVING IN THAT

76
00:02:53,440 --> 00:02:54,000
DIRECTION.

77
00:02:54,000 --> 00:02:54,320
THANK YOU.

78
00:02:54,320 --> 00:02:55,640
>> MOVE TO APPROVE.

79
00:02:55,640 --> 00:02:57,160
>> Dr. Flaherty: THANK
YOU.

80
00:02:57,160 --> 00:02:58,000
AND AS WELL.

81
00:02:58,000 --> 00:03:00,480
SO THAT WAS A MOTION AND A

82
00:03:00,480 --> 00:03:00,960
SECOND.

83
00:03:00,960 --> 00:03:02,520
ANY DISCUSSION REGARDING THE

84
00:03:02,520 --> 00:03:05,880
PROPOSED MEETING DATES?

85
00:03:05,880 --> 00:03:10,240
OBVIOUS CONFLICTS THAT MIGHT

86
00:03:10,240 --> 00:03:12,920
INTERFERE WITH MEETING ON THOSE

87
00:03:12,920 --> 00:03:13,120
DATES.

88
00:03:13,120 --> 00:03:14,520
>> JUST QUICK
CLARIFICATION,

89
00:03:14,520 --> 00:03:16,320
VERY MUCH APPRECIATED THAT WOULD

90
00:03:16,320 --> 00:03:19,720
BE GREAT AND SO, AM I TO ASSUME

91
00:03:19,720 --> 00:03:21,360
TENTATIVE SCHEDULE AS YOU COME

92
00:03:21,360 --> 00:03:23,760
IN ON THE 14th OR COME IN ON

93
00:03:23,760 --> 00:03:27,200
THE 15th BECAUSE IT'S TWO FULL

94
00:03:27,200 --> 00:03:27,400
DAYS?

95
00:03:27,400 --> 00:03:30,440
>> YOU SHOULD COME IN ON
THE

96
00:03:30,440 --> 00:03:31,400
13th BECAUSE THE MEETING WILL

97
00:03:31,400 --> 00:03:32,400
START IN THE 14th.

98
00:03:32,400 --> 00:03:33,120
>> IN THE MORNING?

99
00:03:33,120 --> 00:03:33,640
OKAY.

100
00:03:33,640 --> 00:03:33,840
RIGHT.

101
00:03:33,840 --> 00:03:36,040
ALL RIGHT.

102
00:03:36,040 --> 00:03:37,160
AND WE'LL ABOUT THROUGH THE

103
00:03:37,160 --> 00:03:37,520
15th.

104
00:03:37,520 --> 00:03:39,480
I'M JUST TRYING TO PLAN

105
00:03:39,480 --> 00:03:39,880
SCHEDULES?

106
00:03:39,880 --> 00:03:41,840
>> WE HAVEN'T FOCUSED ON
THE

107
00:03:41,840 --> 00:03:52,120
JUNE AGENDA YET.

108
00:03:55,200 --> 00:03:56,640
IN THE PAST WE'VE INCLUDED

109
00:03:56,640 --> 00:03:59,560
AROUND MID-DAY ON THE SECOND

110
00:03:59,560 --> 00:03:59,720
DAY.

111
00:03:59,720 --> 00:04:10,200
>> SOMETIMES 6789 WHICH
HOPE

112
00:04:12,360 --> 00:04:14,760
THERE'S A GOOD MANY MORE

113
00:04:14,760 --> 00:04:16,680
CONCEPTS TO DISCUSS AT THE JUNE

114
00:04:16,680 --> 00:04:18,240
MEETING AND SO PAULETTE WILL

115
00:04:18,240 --> 00:04:19,760
KEEP US ADVISED IN TERMS OF THE

116
00:04:19,760 --> 00:04:21,520
NUMBER AND ITS IMPACT ON THE

117
00:04:21,520 --> 00:04:25,560
AGENDA BUT A DAY AND A HALF IS

118
00:04:25,560 --> 00:04:26,080
TYPICAL.

119
00:04:26,080 --> 00:04:31,400
ANY OTHER DISCUSSION?

120
00:04:31,400 --> 00:04:33,280
OKAY.

121
00:04:33,280 --> 00:04:35,640
SO, WITH A MOTION AND A SECOND

122
00:04:35,640 --> 00:04:38,480
TO APPROVE THESE MEETING DATES

123
00:04:38,480 --> 00:04:40,760
AND AS WITH OUR REGULAR VOTING

124
00:04:40,760 --> 00:04:42,560
PROCESS, WHEN WE'RE MEETING

125
00:04:42,560 --> 00:04:49,200
VIRTUALLY, ONLY LOOKING FOR YOUR

126
00:04:49,200 --> 00:04:50,560
PRESENCE ON CAMERAS AND EMPHASIS

127
00:04:50,560 --> 00:04:56,160
AT PRESENCE ON CAMERA IS TAKEN

128
00:04:56,160 --> 00:04:59,720
AS AN AN ACCENT.

129
00:04:59,720 --> 00:05:01,760
PEOPLE CAN ABSTAIN ALTHOUGH I DO

130
00:05:01,760 --> 00:05:04,600
NOT EXPECT ABSTENTIONS FROM THIS

131
00:05:04,600 --> 00:05:06,840
VOTE.

132
00:05:06,840 --> 00:05:09,960
ANY NAY VOTES IN TERMS OF THE

133
00:05:09,960 --> 00:05:13,840
PROPOSED MEETING DATES?

134
00:05:13,840 --> 00:05:16,080
OKAY.

135
00:05:16,080 --> 00:05:17,400
CHECKING ON THE SECOND SCREEN

136
00:05:17,400 --> 00:05:29,320
>> Dr. Flaherty: THE FIRST
IS 

137
00:05:30,400 --> 00:05:32,560
THE NCI DIRECTOR'S REPORT.

138
00:05:32,560 --> 00:05:34,760
MONICA BERTAGNOLLI.

139
00:05:34,760 --> 00:05:35,360
>> Dr. Bertagnolli: OKAY.

140
00:05:35,360 --> 00:05:39,080
THANK YOU, Dr. FLAHERTY, AND

141
00:05:39,080 --> 00:05:40,400
THANK YOU Dr. GRAY.

142
00:05:40,400 --> 00:05:41,120
IT'S WONDERFUL TO SEE YOU ALL

143
00:05:41,120 --> 00:05:43,720
AND I'M LOOKING FORWARD TO AN

144
00:05:43,720 --> 00:05:45,000
IN-PERSON MEETING IN JUNE.

145
00:05:45,000 --> 00:05:51,720
THAT WILL BE FANTASTIC.

146
00:05:51,720 --> 00:05:53,840
SO TODAY, I'LL GOING TO TALK

147
00:05:53,840 --> 00:05:57,400
ABOUT RESENT PROGRESS.

148
00:05:57,400 --> 00:05:58,920
A LITTLE BIT ABOUT OUR BUDGET

149
00:05:58,920 --> 00:06:00,720
OUTLOOK, ABOUT THE NATIONAL

150
00:06:00,720 --> 00:06:02,720
CANCER PLAN AND THEN ALSO SOME

151
00:06:02,720 --> 00:06:04,000
BRIEF, VERY BRIEF PROGRAM AND

152
00:06:04,000 --> 00:06:06,800
RESEARCH UPDATES.

153
00:06:06,800 --> 00:06:08,760
I'M SURE MANY OF YOU SAW THE

154
00:06:08,760 --> 00:06:11,560
STATE OF THE UNION ADDRESS

155
00:06:11,560 --> 00:06:12,240
PRESIDENT JOE BIDEN CONTINUES TO

156
00:06:12,240 --> 00:06:17,400
SHOW VERY STRONG SUPPORT FOR

157
00:06:17,400 --> 00:06:19,640
WHAT WE ALL SEEK TO DO.

158
00:06:19,640 --> 00:06:21,720
LAST MONTH, HE REITERATED HIS

159
00:06:21,720 --> 00:06:22,800
MESSAGE HE WILL GO BIG IN ORDER

160
00:06:22,800 --> 00:06:25,280
TO ACHIEVE BOLD GOALS FOR

161
00:06:25,280 --> 00:06:27,080
PROGRESS AGAINST CANCER AND HIS

162
00:06:27,080 --> 00:06:28,080
SPEECH WAS TOUCHING.

163
00:06:28,080 --> 00:06:31,880
YOU KNOW, IN HIS UNIQUE WAY, HE

164
00:06:31,880 --> 00:06:35,200
ALWAYS MAKES SURE WE KNOW WHO

165
00:06:35,200 --> 00:06:36,040
WE'RE HERE TO SERVE.

166
00:06:36,040 --> 00:06:37,840
HE CALLED ATTENTION TO EVA, WHO

167
00:06:37,840 --> 00:06:40,760
IS A 3-YEAR-OLD GIRL WITH A RARE

168
00:06:40,760 --> 00:06:42,160
KIDNEY CANCER AND HER PARENTS

169
00:06:42,160 --> 00:06:43,560
WERE UNTIL THE AUDIENCE THERE

170
00:06:43,560 --> 00:06:44,880
AND YOU COULD REALLY SEE ON

171
00:06:44,880 --> 00:06:46,360
THEIR FACES THE STRUGGLE THEY'VE

172
00:06:46,360 --> 00:06:48,600
BEEN THROUGH, THEIR COURAGE AND

173
00:06:48,600 --> 00:06:49,320
THEIR HOPE.

174
00:06:49,320 --> 00:06:52,640
THE GREAT NEWS IS THAT EVA'S

175
00:06:52,640 --> 00:06:56,360
OUTLOOK APPEARS VERY PROMISING.

176
00:06:56,360 --> 00:06:57,640
WE CAN NEVER FORGET IT'S PEOPLE

177
00:06:57,640 --> 00:06:59,680
LIKE HER AND HER PAMLY THAT

178
00:06:59,680 --> 00:07:00,360
WE'RE HERE TO SERVE.

179
00:07:00,360 --> 00:07:03,480
NEXT SLIDE, PLEASE.

180
00:07:03,480 --> 00:07:07,960
>> SO THE SER MOONSHOT,

181
00:07:07,960 --> 00:07:10,000
PRESIDENT BIDEN HAS REITERATED

182
00:07:10,000 --> 00:07:11,560
HIS CALL TO END CANCER AS WE

183
00:07:11,560 --> 00:07:12,080
KNOW IT.

184
00:07:12,080 --> 00:07:16,520
WE HAVE A FIRM GOAL TO CUT THE

185
00:07:16,520 --> 00:07:18,360
MORTALITY RATE BY 50% IN 25

186
00:07:18,360 --> 00:07:21,280
YEARS TO TURN MORE CANCERS FROM

187
00:07:21,280 --> 00:07:23,040
DEATH SENTENCES INTO TREATABLE

188
00:07:23,040 --> 00:07:24,360
DISEASES AND PROVIDE MORE

189
00:07:24,360 --> 00:07:26,680
SUPPORT FOR PATIENTS AND

190
00:07:26,680 --> 00:07:28,640
FAMILIES.

191
00:07:28,640 --> 00:07:32,560
ACHIEVING THIS WILL CERTAINLY BE

192
00:07:32,560 --> 00:07:33,760
TRANSFORM THE EXPERIENCE WITH

193
00:07:33,760 --> 00:07:36,280
CANCER AND SOMETHING WE THINK

194
00:07:36,280 --> 00:07:40,200
NOT ONLY IMPORTANT AND IT'S VERY

195
00:07:40,200 --> 00:07:41,320
ACHIEVABLE.

196
00:07:41,320 --> 00:07:43,800
WE'LL EXCELLENT DONE BY NCI

197
00:07:43,800 --> 00:07:51,200
DIVISION OF CANCER AND GENETICS

198
00:07:51,200 --> 00:08:01,840
ANAND IT AND THERE ANNA COMPANY

199
00:08:04,880 --> 00:08:05,680
COMMENTARY AS WELL SOME EFFORTS

200
00:08:05,680 --> 00:08:08,720
UPCOMING AT AACR IN APRIL.

201
00:08:08,720 --> 00:08:11,280
SO, KEEP ON THE LOOK OUT FOR

202
00:08:11,280 --> 00:08:13,720
THIS.

203
00:08:13,720 --> 00:08:15,040
NEXT SLIDE.

204
00:08:15,040 --> 00:08:19,200
THE 2024 BUDGET BREAKDOWN.

205
00:08:19,200 --> 00:08:20,240
WELL, PRESIDENT JOE BIDEN SHOWED

206
00:08:20,240 --> 00:08:24,200
HOW MUCH OF A PRIORITY CANCER

207
00:08:24,200 --> 00:08:25,040
PROGRESS IS TO HIM.

208
00:08:25,040 --> 00:08:27,200
IN HIS FISCAL YEAR 2024 BUDGET

209
00:08:27,200 --> 00:08:28,800
REQUEST JUST RELEASED LAST WEEK.

210
00:08:28,800 --> 00:08:33,440
HE PROPOSED A TOTAL BUDGET OF

211
00:08:33,440 --> 00:08:36,840
7.8 BILLION FOR NCI FOR FISCAL

212
00:08:36,840 --> 00:08:37,640
YEAR 2024.

213
00:08:37,640 --> 00:08:41,200
WHICH WOULD BE A 6.9% INCREASE.

214
00:08:41,200 --> 00:08:43,560
THAT WOULD BE A GREAT BOOST.

215
00:08:43,560 --> 00:08:45,440
AS YOU KNOW, WE'RE IN THE LAST

216
00:08:45,440 --> 00:08:47,480
YEAR OF 21st CENTURY CURES

217
00:08:47,480 --> 00:08:51,760
AGENT FUNDING PROVIDED THE

218
00:08:51,760 --> 00:08:53,560
MOONSHOT PENDING HELPED US TO

219
00:08:53,560 --> 00:08:55,200
LAUNCH AN INCREDIBLE ARRAY OF

220
00:08:55,200 --> 00:08:56,520
TRANSFORMATIVE RESEARCH

221
00:08:56,520 --> 00:08:56,880
PROJECTS.

222
00:08:56,880 --> 00:08:57,960
THE PRESIDENT'S BUDGET WOULD

223
00:08:57,960 --> 00:09:03,480
HELP US AVOID A FUNDING CLIFF

224
00:09:03,480 --> 00:09:04,280
WITH 216 MILLION YOU SEE THERE

225
00:09:04,280 --> 00:09:05,840
IN THE MIDDLE, WHICH MATCHES

226
00:09:05,840 --> 00:09:07,080
THIS YEAR'S AMOUNT.

227
00:09:07,080 --> 00:09:11,400
HE ALSO CALLED FOR A

228
00:09:11,400 --> 00:09:13,360
$500 MILLION INCREASE FOR NEXT

229
00:09:13,360 --> 00:09:15,440
YEAR GIVING US $716 MILLION

230
00:09:15,440 --> 00:09:20,480
TOTAL INCREASE FOR NCI FOR 2024.

231
00:09:20,480 --> 00:09:24,320
ONE SOMEWHAT UNUSUAL AND

232
00:09:24,320 --> 00:09:26,080
EXCITING ASPECT OF THE BUDGET IS

233
00:09:26,080 --> 00:09:30,960
IT ALSO PROPOSES REAUTHORIZATION

234
00:09:30,960 --> 00:09:32,600
OF THE 21st CENTURY CURES ACT

235
00:09:32,600 --> 00:09:39,720
AND MANDATORY FUNDING OF

236
00:09:39,720 --> 00:09:40,880
$1.45 BILLION BUDGET AUTHORITY

237
00:09:40,880 --> 00:09:45,200
FOR NCI IN FISCAL YEAR 2025 AND

238
00:09:45,200 --> 00:09:46,000
2026.

239
00:09:46,000 --> 00:09:49,680
SO, WE ARE VERY EXCITED TO

240
00:09:49,680 --> 00:09:50,240
SUPPORT THOSE AUTHORIZING

241
00:09:50,240 --> 00:09:57,240
EFFORTS HAD THE FUTURE.

242
00:09:57,240 --> 00:10:00,160
YOU SEE HERE THAT IN RESENT

243
00:10:00,160 --> 00:10:01,560
YEARS, CONGRESS APPROPRIATION

244
00:10:01,560 --> 00:10:03,760
HAS COME IN HIGHER THAN THE

245
00:10:03,760 --> 00:10:05,040
PRESIDENT'S NUMBERS SIGNALING

246
00:10:05,040 --> 00:10:06,840
THEIR STEADY COMMITMENT TO

247
00:10:06,840 --> 00:10:07,640
CANCER PROGRESS.

248
00:10:07,640 --> 00:10:10,160
WITH THIS BUDGET REQUEST,

249
00:10:10,160 --> 00:10:11,200
HOWEVER, PRESIDENT JOE BIDEN HAS

250
00:10:11,200 --> 00:10:13,280
TRULY COMMUNICATED TO CONGRESS

251
00:10:13,280 --> 00:10:15,320
THAT HE WANTS TO GO BIG.

252
00:10:15,320 --> 00:10:17,600
IT WILL BE UP TO CONGRESS TO

253
00:10:17,600 --> 00:10:19,120
DECIDE HOW MUCH FUNDING IS

254
00:10:19,120 --> 00:10:20,400
ACTUALLY APPROPRIATED TO HAVE

255
00:10:20,400 --> 00:10:24,960
NCI AND ACROSS ALL FEDERAL

256
00:10:24,960 --> 00:10:28,400
AGENCIES.

257
00:10:28,400 --> 00:10:29,920
M.K. HOLOHAN WILL SPEAK ABOUT

258
00:10:29,920 --> 00:10:32,560
WHAT IT MEANS IN HER SECTION TO

259
00:10:32,560 --> 00:10:33,280
FOLLOW.

260
00:10:33,280 --> 00:10:35,120
WE GOT GOOD NEWS FROM CONGRESS

261
00:10:35,120 --> 00:10:36,440
IN DECEMBER.

262
00:10:36,440 --> 00:10:37,360
PRESIDENT JOE BIDEN SIGNED

263
00:10:37,360 --> 00:10:40,360
LEGISLATION THAT PROVIDED BIDE

264
00:10:40,360 --> 00:10:46,760
THROUGH SEPTEMBER 30th OF THIS

265
00:10:46,760 --> 00:10:48,160
YEAR TO OUR BASE BUDGET

266
00:10:48,160 --> 00:10:49,840
AS WELL AS A $22 MILLION

267
00:10:49,840 --> 00:10:52,320
INCREASE TO THE FINAL YEAR OF

268
00:10:52,320 --> 00:10:57,040
INITIAL MOONSHOT FUNDING.

269
00:10:57,040 --> 00:10:59,400
THAT MEANS, WHEN YOU ADD IT ALL

270
00:10:59,400 --> 00:11:02,160
UP, WE RECEIVED $216 MILLION IN

271
00:11:02,160 --> 00:11:03,960
MOONSHOT FUNDING FOR 2023 AS

272
00:11:03,960 --> 00:11:06,200
ANTICIPATED FROM THE 21s

273
00:11:06,200 --> 00:11:06,800
21st CENTURY CURES ACT.

274
00:11:06,800 --> 00:11:08,520
THE ADDITIONAL INCREASE TO OUR

275
00:11:08,520 --> 00:11:12,680
BASE MADE IT POSSIBLE TO FUND

276
00:11:12,680 --> 00:11:19,640
MORE COMPELLING BELONG WORKER

277
00:11:19,640 --> 00:11:21,040
EFFORTS OUTSIDE OF THE POOL LIKE

278
00:11:21,040 --> 00:11:22,720
OUR CLINICAL TRIALS NETWORKS,

279
00:11:22,720 --> 00:11:28,080
CORE SUPPORT FOR NCI DESIGNATED

280
00:11:28,080 --> 00:11:38,480
CANCER CENTERS AND THIS

281
00:11:41,560 --> 00:11:44,640
CONTINUES OUR UPWARD TREND FROM

282
00:11:44,640 --> 00:11:46,840
THE EIGHTH PERCENTILE IN 2019

283
00:11:46,840 --> 00:11:51,120
AND IT'S STILL NOT AS HIGH AS WE

284
00:11:51,120 --> 00:11:56,320
WOULD LIKE AND WE'RE STILL LEAVG

285
00:11:56,320 --> 00:11:57,440
INNOVATIVE IDEAS ON THE TABLE.

286
00:11:57,440 --> 00:11:59,080
IT SHOWS THAT WE'VE MADE STEADY

287
00:11:59,080 --> 00:12:01,680
PROGRESS IN OUR ABILITY TO FUND

288
00:12:01,680 --> 00:12:02,880
IMPORTANT RESEARCH.

289
00:12:02,880 --> 00:12:04,200
WE WERE ALSO ABLE TO INCREASE

290
00:12:04,200 --> 00:12:05,880
THE EARLY STAGE INVESTIGATOR

291
00:12:05,880 --> 00:12:10,640
RO1s TO THE 17th PERCENT UP

292
00:12:10,640 --> 00:12:11,120
FROM 16 PERCENT.

293
00:12:11,120 --> 00:12:14,160
BECAUSE OF THESE PAYLINE

294
00:12:14,160 --> 00:12:16,200
INCREASES, WE ARE ABLE TO FUND

295
00:12:16,200 --> 00:12:18,240
MORE THAN 100 ADDITIONAL RO1s

296
00:12:18,240 --> 00:12:21,080
AND THE ESI AWARDS COMPARED TO

297
00:12:21,080 --> 00:12:22,400
LAST YEAR.

298
00:12:22,400 --> 00:12:24,160
RPG FUNDING IS CRITICAL.

299
00:12:24,160 --> 00:12:25,840
IT ALLOWS INVESTIGATORS ACROSS

300
00:12:25,840 --> 00:12:28,120
THE NATION TO SUBMIT THEIR VERY

301
00:12:28,120 --> 00:12:30,360
BEST IDEAS AND TURN THEM INTO

302
00:12:30,360 --> 00:12:33,600
ANSWERS THAT DRIVE PROGRESS.

303
00:12:33,600 --> 00:12:36,080
IF IN ADDITION, FUNDING CRITICAL

304
00:12:36,080 --> 00:12:38,120
INFRASTRUCTURE INCLUDING

305
00:12:38,120 --> 00:12:42,200
INFORMATION TECHNOLOGY IS OF A

306
00:12:42,200 --> 00:12:42,920
BIG PRIORITY FOR NCI.

307
00:12:42,920 --> 00:12:44,680
THESE ARE THE THINGS THAT

308
00:12:44,680 --> 00:12:46,720
AMPLIFY RESEARCH RESULTS, DRIVE

309
00:12:46,720 --> 00:12:49,560
NEW COLLABORATION AND ENSURE

310
00:12:49,560 --> 00:12:50,160
MAXIMAL USE OF OUR PRIOR

311
00:12:50,160 --> 00:12:51,800
INVESTMENTS IN RESEARCH.

312
00:12:51,800 --> 00:12:54,200
SO WE'VE ALSO ALLOCATED NEW

313
00:12:54,200 --> 00:12:57,600
FUNDING TO MEET THESE GOALS.

314
00:12:57,600 --> 00:12:59,480
UNFORTUNATELY, WE, LIKE ALL OF

315
00:12:59,480 --> 00:13:03,960
YOU, HAVE NOT BEEN MANY UN IMMUO

316
00:13:03,960 --> 00:13:04,760
SIGNIFICANT INFLATION.

317
00:13:04,760 --> 00:13:07,760
AS A RESULT, THESE DECISIONS TO

318
00:13:07,760 --> 00:13:11,440
SUPPORT THE RPG POOL AND SUPPORT

319
00:13:11,440 --> 00:13:12,760
OUR INFRASTRUCTURE ALSO MEANS

320
00:13:12,760 --> 00:13:14,520
WE'VE NEEDED COST-CUTTING

321
00:13:14,520 --> 00:13:15,120
ELSEWHERE.

322
00:13:15,120 --> 00:13:17,520
WE DECIDE TODAY PAY MOST

323
00:13:17,520 --> 00:13:20,600
CONTINUING RAIN CON POM EATING

324
00:13:20,600 --> 00:13:21,560
GRANTS THAT IS YEARS TWO THROUGH

325
00:13:21,560 --> 00:13:26,360
FIVE OF THE FIVE-YEAR GRANT AT

326
00:13:26,360 --> 00:13:36,880
98% AND -- JUST AS WE ASKED OUR

327
00:13:40,800 --> 00:13:44,720
INTRAMURAL RESEARCHERS TO DO.

328
00:13:44,720 --> 00:13:46,280
AND THIS SLIDE JUST ILLUSTRATES

329
00:13:46,280 --> 00:13:49,760
THE CHALLENGE THAT -- AND YOU

330
00:13:49,760 --> 00:13:51,800
MIGHT HAVE SEEN THIS IN OUR

331
00:13:51,800 --> 00:13:54,640
FISCAL YEAR 2024, PROFESSIONAL

332
00:13:54,640 --> 00:13:56,360
JUDGMENT BUDGET ON THE WEBSITE

333
00:13:56,360 --> 00:13:57,880
SHOWS THE CHALLENGE WE TAKE ON

334
00:13:57,880 --> 00:14:00,840
EVERY TIME WE RAISE THE PAYLINE

335
00:14:00,840 --> 00:14:01,440
BY 1%.

336
00:14:01,440 --> 00:14:06,320
WHEN WE INCREASE THIS, WE MAKE A

337
00:14:06,320 --> 00:14:07,640
COMMITMENT TO SUSTAIN THOSE NEW

338
00:14:07,640 --> 00:14:11,120
GRANTS FOR FIVE YEARS IN THE

339
00:14:11,120 --> 00:14:11,680
FUTURE.

340
00:14:11,680 --> 00:14:13,280
WE ALWAYS REQUIRE ADDITIONAL

341
00:14:13,280 --> 00:14:15,400
RESOURCES IN THE OUT YEARS WHICH

342
00:14:15,400 --> 00:14:17,320
ARE YEARS TWO THROUGH FIVE JUST

343
00:14:17,320 --> 00:14:19,720
TO SUSTAIN FUNDING AT THAT

344
00:14:19,720 --> 00:14:22,480
PERCENT STYLE LEVEL.

345
00:14:22,480 --> 00:14:24,200
AND EVEN MORE, IF WE ARE TO GO

346
00:14:24,200 --> 00:14:25,920
ON TO FURTHER INCREASE THE

347
00:14:25,920 --> 00:14:26,280
PAYLINE.

348
00:14:26,280 --> 00:14:30,320
LET ME EMPHASIS OUR PAYLINE AT

349
00:14:30,320 --> 00:14:32,440
12% THIS YEAR IS THE HIGHEST IT

350
00:14:32,440 --> 00:14:35,320
HAS BEEN SINCE 2010.

351
00:14:35,320 --> 00:14:36,440
I'M SURE YOU WILL AUTOMATIC SEE

352
00:14:36,440 --> 00:14:41,480
ALL SEE THEIMPORTANCE MUCH THIST

353
00:14:41,480 --> 00:14:43,000
INTRODUCES FUNDING CHALLENGES

354
00:14:43,000 --> 00:14:44,440
FOR FUTURE AND HAS ALSO ASKED US

355
00:14:44,440 --> 00:14:49,680
TO DO SOME BELT-TIGHTENING

356
00:14:49,680 --> 00:14:52,120
ELSEWHERE.

357
00:14:52,120 --> 00:14:53,720
I WROTE ABOUT THESE BUDGET

358
00:14:53,720 --> 00:14:55,840
DECISIONS IN A RESENT POST ON

359
00:14:55,840 --> 00:14:57,720
THE NCI BOTTOM LINE BLOG.

360
00:14:57,720 --> 00:14:59,760
AS FOR THE NCI CANCER CURRENT

361
00:14:59,760 --> 00:15:02,640
BLOGS, I ALSO WROTE A POST THAT

362
00:15:02,640 --> 00:15:04,400
EMPHASIZES THAT THIS REALLY IS A

363
00:15:04,400 --> 00:15:05,840
GREAT OPPORTUNITY FOR CANCER

364
00:15:05,840 --> 00:15:08,000
RESEARCH.

365
00:15:08,000 --> 00:15:10,000
HIGHLIGHTING PROGRESS FROM

366
00:15:10,000 --> 00:15:11,200
DECADES OF INVESTMENTS,

367
00:15:11,200 --> 00:15:12,240
PRESIDENT JOE BIDEN'S

368
00:15:12,240 --> 00:15:14,840
COMMITMENT, AND IMPORTANT NEW

369
00:15:14,840 --> 00:15:15,760
NCI PROGRAMS.

370
00:15:15,760 --> 00:15:17,720
I ALSO UNDERSCORED IN THIS BLOG

371
00:15:17,720 --> 00:15:21,400
THE IMPORTANCE OF THE LAST MILE.

372
00:15:21,400 --> 00:15:25,080
FROM VALIDATION OF A SUCCESSFUL

373
00:15:25,080 --> 00:15:27,440
INTERVENTION AGAINST CANCER TO

374
00:15:27,440 --> 00:15:29,480
ITS WIDESPREAD ADOPTION AND

375
00:15:29,480 --> 00:15:33,000
BROAD IMPLEMENTATION.

376
00:15:33,000 --> 00:15:35,000
THIS LAST MILE REQUIRES

377
00:15:35,000 --> 00:15:36,080
PARTICIPATION FROM SO MANY

378
00:15:36,080 --> 00:15:39,920
OTHERS THROUGHOUT OUR SOCIETY.

379
00:15:39,920 --> 00:15:41,880
I WANT TO EMPHASIZE IF WE ARE

380
00:15:41,880 --> 00:15:43,200
GOING TO END CANCER AS WE KNOW

381
00:15:43,200 --> 00:15:45,520
IT AND NOT SURE ALL OF OUR

382
00:15:45,520 --> 00:15:47,640
ADVANCES BENEFIT EVERYONE WHO

383
00:15:47,640 --> 00:15:52,120
NEEDS THEM, IT TAKES ALL OF

384
00:15:52,120 --> 00:15:55,200
SOCIETY APPROACH TO BRIDGE THE

385
00:15:55,200 --> 00:15:55,680
GAP.

386
00:15:55,680 --> 00:15:58,640
NCI CANNOT DO THIS ALONE.

387
00:15:58,640 --> 00:16:00,400
IN THIS POST, I ALSO TOUCHED

388
00:16:00,400 --> 00:16:02,440
BRIEFLY ON OUR NEW NATIONAL

389
00:16:02,440 --> 00:16:05,680
CANCER PLAN, WHICH IS AIMED AT

390
00:16:05,680 --> 00:16:10,360
EXACTLY THIS LAST-MILE ISSUE.

391
00:16:10,360 --> 00:16:12,160
OVER THE LAST FEW MONTHS, WE

392
00:16:12,160 --> 00:16:14,200
WORKED WITH RESEARCHERS

393
00:16:14,200 --> 00:16:14,720
REPEATING BOTH WITHIN AND

394
00:16:14,720 --> 00:16:16,440
OUTSIDE OF THE NCI TO PRODUCE A

395
00:16:16,440 --> 00:16:18,480
NEW NATIONAL CANCER PLAN TO

396
00:16:18,480 --> 00:16:20,840
ALIGN BROAD SOCIETAL ENGAGEMENT

397
00:16:20,840 --> 00:16:22,480
AND FOCUS ON CRITICAL NEEDS TO

398
00:16:22,480 --> 00:16:32,920
END CAP SER AS WE KNOW IT.

399
00:16:33,320 --> 00:16:35,160
AND THAT MEANS EVERYBODY WITH

400
00:16:35,160 --> 00:16:36,920
CANCER AND EVERY CANCER.

401
00:16:36,920 --> 00:16:39,000
IT EMBRACES THE IDEA THAT

402
00:16:39,000 --> 00:16:40,760
EVERYONE HAS A ROLE TO PLAY

403
00:16:40,760 --> 00:16:42,360
ACROSS FEDERAL AGENCIES AND AS

404
00:16:42,360 --> 00:16:45,080
WELL AS INDUSTRY AND ANG A

405
00:16:45,080 --> 00:16:47,520
DAMIA, ADVOCACY GROUPS, NON

406
00:16:47,520 --> 00:16:50,960
PROFITS EVEN CAREGIVERS AND

407
00:16:50,960 --> 00:16:51,400
INDIVIDUAL PATIENTS.

408
00:16:51,400 --> 00:16:54,160
OUR INTENT IS WHEN ANY

409
00:16:54,160 --> 00:16:55,960
ORGANIZATION OR PERSON LOOKS AT

410
00:16:55,960 --> 00:16:57,720
THIS PLAN, THEY WILL SEE WHERE

411
00:16:57,720 --> 00:17:01,320
THEY FIT AS A CONTRIBUTE OOR TO

412
00:17:01,320 --> 00:17:01,880
PROGRESS.

413
00:17:01,880 --> 00:17:03,680
IT PROVIDES A FRAMEWORK THAT

414
00:17:03,680 --> 00:17:06,000
WILL HELP EVERYONE SEE THE FULL

415
00:17:06,000 --> 00:17:09,320
RANGE OF WHAT IS NECESSARY TO BE

416
00:17:09,320 --> 00:17:11,800
ABLE TO STRATEGIZE AND MOST

417
00:17:11,800 --> 00:17:13,120
IMPORTANT OF ALL TO WORK

418
00:17:13,120 --> 00:17:15,720
TOGETHER TO SUSTAIN AND

419
00:17:15,720 --> 00:17:16,280
ACCELERATE PROGRESS.

420
00:17:16,280 --> 00:17:18,280
WE'RE IN THE FINAL PHASES NOW

421
00:17:18,280 --> 00:17:20,760
AND WE ARE GETTING INPUT FROM

422
00:17:20,760 --> 00:17:22,920
SUCH A WIDE RANGE OF

423
00:17:22,920 --> 00:17:24,800
STAKEHOLDERS ON THIS PLAN.

424
00:17:24,800 --> 00:17:27,880
IT WILL VERY SOON BE FINALIZED

425
00:17:27,880 --> 00:17:30,600
AND COMMUNICATED WIDELY TO BE TO

426
00:17:30,600 --> 00:17:31,200
THE PUBLIC.

427
00:17:31,200 --> 00:17:33,600
JUST TO BE CLEAR, THE NATIONAL

428
00:17:33,600 --> 00:17:35,480
CANCER PLAN IS NOT THE SAME AS

429
00:17:35,480 --> 00:17:38,320
THE REIGNITED CANCER MOONSHOT.

430
00:17:38,320 --> 00:17:41,440
THE CANCER PLAN IS ALIGNED WITH

431
00:17:41,440 --> 00:17:43,600
ALL OF THE MOONSHOT GOALS.

432
00:17:43,600 --> 00:17:45,520
IT PROVIDES A VISION FOR

433
00:17:45,520 --> 00:17:47,160
EVERYONE ACROSS ALL SOCIETY TEE

434
00:17:47,160 --> 00:17:49,680
TO WORK TOWARDS THOSE GOALS AND

435
00:17:49,680 --> 00:17:52,920
REALLY FOCUSES ON HOW WE WILL

436
00:17:52,920 --> 00:17:55,600
UTILIZE OUR COLLECTIVE RESOURCES

437
00:17:55,600 --> 00:17:58,200
SO THAT WE ACHIEVE THE FASTEST

438
00:17:58,200 --> 00:17:59,640
POSSIBLE RESULTS TO END CANCER

439
00:17:59,640 --> 00:18:06,280
AS WE KNOW IT FOR ALL PEOPLE.

440
00:18:06,280 --> 00:18:07,560
THE MOONSHOT IS HOW THE

441
00:18:07,560 --> 00:18:09,920
PRESIDENT IS CALLING ON ALL OF

442
00:18:09,920 --> 00:18:11,000
US TO MOBILE SIZE SOCIETY TO

443
00:18:11,000 --> 00:18:12,920
TAKE ACTION, BRING GOVERNMENT

444
00:18:12,920 --> 00:18:16,320
AGENCIES TOGETHER TO FOCUS AND

445
00:18:16,320 --> 00:18:18,200
WORK TOGETHER AND HE IS ALSO

446
00:18:18,200 --> 00:18:20,360
ADVOCATING FOR THE RESOURCES

447
00:18:20,360 --> 00:18:22,200
NEEDED TO ACCELERATE OUR

448
00:18:22,200 --> 00:18:22,720
PROGRESS.

449
00:18:22,720 --> 00:18:24,880
SO IN THIS WAY, THE NATIONAL

450
00:18:24,880 --> 00:18:27,800
CANCER PLAN AND THE MOONSHOT

451
00:18:27,800 --> 00:18:31,880
WORK VERY MUCH HAND IN HAND.

452
00:18:31,880 --> 00:18:33,280
AND WE ARE COORDINATING WITH THE

453
00:18:33,280 --> 00:18:35,240
WHITE HOUSE TO ENSURE THE

454
00:18:35,240 --> 00:18:37,240
NATIONAL CANCER PLAN PROVIDES A

455
00:18:37,240 --> 00:18:39,240
FOCUS FOR ACHIEVING THE GOALS OF

456
00:18:39,240 --> 00:18:45,560
THE CANCER MOONSHOT.

457
00:18:45,560 --> 00:18:48,280
ANOTHER VERY IMPORTANT THING TO

458
00:18:48,280 --> 00:18:50,160
DRY YOUR ATTENTION TO IS ARPA-H.

459
00:18:50,160 --> 00:18:52,560
THE NEW ADVANCED RESEARCH

460
00:18:52,560 --> 00:18:53,520
PROJECTS AGENCY FOR HEALTH.

461
00:18:53,520 --> 00:18:55,760
A VERY IMPORTANT -- NEW PARTNER

462
00:18:55,760 --> 00:18:58,440
FOR CANCER RESEARCH.

463
00:18:58,440 --> 00:19:02,600
RENEE WEGRZYN AND I TALK

464
00:19:02,600 --> 00:19:03,800
FREQUENTLY AND WORKING TOGETHER

465
00:19:03,800 --> 00:19:06,800
TO DECIDE HOW ARPA-H AND NCI CAN

466
00:19:06,800 --> 00:19:09,240
HAVE THE MOST POWERFUL

467
00:19:09,240 --> 00:19:09,960
COLLABORATION.

468
00:19:09,960 --> 00:19:11,960
I CAN TELL YOU THAT ACROSS ALL

469
00:19:11,960 --> 00:19:13,880
OF NIH, WE'RE GIVING HER MANY

470
00:19:13,880 --> 00:19:16,600
GOOD IDEAS FOR HOW THIS NEW

471
00:19:16,600 --> 00:19:18,920
AGENCY CAN HELP ALL OF US.

472
00:19:18,920 --> 00:19:20,720
WE KNOW THAT THERE WILL BE SOME

473
00:19:20,720 --> 00:19:23,120
NOTABLE DIFFERENCES IN HOW FAR

474
00:19:23,120 --> 00:19:25,320
NCI AND ARPA-H WILL OPERATE.

475
00:19:25,320 --> 00:19:28,680
THESE WILL HELP US TO BE

476
00:19:28,680 --> 00:19:29,960
COMPLIMENTARY.

477
00:19:29,960 --> 00:19:33,440
WHAT NCI DOES, OFTEN REQUIRED

478
00:19:33,440 --> 00:19:34,000
MANY DECADES.

479
00:19:34,000 --> 00:19:38,200
WE TAKE THE LONG VIEW AND

480
00:19:38,200 --> 00:19:41,360
SUSTAIN OUR PROGRAMS OVER TIME.

481
00:19:41,360 --> 00:19:43,560
WE ARE RESPONSIBLE AT NCI FOR

482
00:19:43,560 --> 00:19:45,800
EVERYTHING FROM FUNDAMENTAL

483
00:19:45,800 --> 00:19:48,680
SCIENCE ALL THE WAY TO CARE

484
00:19:48,680 --> 00:19:50,200
DELIVERY RESEARCH TO ENSURE THAT

485
00:19:50,200 --> 00:19:52,320
A LABORATORY DISCOVERY

486
00:19:52,320 --> 00:19:54,920
TRANSLATES INTO A OF CLINICALLY

487
00:19:54,920 --> 00:19:57,400
TESTED PROCEDURES DRUG OR DEVICE

488
00:19:57,400 --> 00:19:59,520
THAT BENEFITS PEOPLE.

489
00:19:59,520 --> 00:20:02,880
ARPA-H IS FOCUS IS VERY

490
00:20:02,880 --> 00:20:03,400
DIFFERENT.

491
00:20:03,400 --> 00:20:06,960
THINK OF IT AS A SWAT TEAM OR

492
00:20:06,960 --> 00:20:09,800
RAPID DEPLOYMENT THAT IDENTIFIES

493
00:20:09,800 --> 00:20:11,920
KEY ISSUES WITH HIGH-RISK, HIGH

494
00:20:11,920 --> 00:20:15,280
REWARD, RESEARCH FOCUS.

495
00:20:15,280 --> 00:20:17,320
THEY THEN NOT ENGAGE THE MOST

496
00:20:17,320 --> 00:20:19,480
IMPORTANT PLAYERS FROM ACROSS

497
00:20:19,480 --> 00:20:24,920
THE RESEARCH AND DEVELOPMENT

498
00:20:24,920 --> 00:20:26,120
ECOSYSTEM TO SOLVE A PROBLEM IN

499
00:20:26,120 --> 00:20:27,680
A RELATIVELY SHORT TIMEFRAME.

500
00:20:27,680 --> 00:20:29,440
WE'RE VERY EXCITE TODAY WORK IN

501
00:20:29,440 --> 00:20:31,560
WAYS THAT COMPLIMENT WHAT ARPA-H

502
00:20:31,560 --> 00:20:31,920
BRINGS.

503
00:20:31,920 --> 00:20:38,560
WE VIEW OURSELVES AS THE RECEIVE

504
00:20:38,560 --> 00:20:41,080
OF THESE SOLUTIONS TO PROBLEMS

505
00:20:41,080 --> 00:20:43,360
THAT ARPA-H PRODUCES.

506
00:20:43,360 --> 00:20:45,000
AND THOSE PROVIDING SCIENTIFIC

507
00:20:45,000 --> 00:20:48,440
LEADERSHIP TO THEIR PROJECTS O

508
00:20:48,440 --> 00:20:51,120
THEY BEST ADDRESS THE NEEDS OF

509
00:20:51,120 --> 00:20:52,600
CANCER RESEARCH.

510
00:20:52,600 --> 00:20:53,280
NEXT SLIDE.

511
00:20:53,280 --> 00:20:58,880
I'M ALSO PLEASED TO SAY THAT THE

512
00:20:58,880 --> 00:21:00,440
CANCER GRAND CHALLENGES

513
00:21:00,440 --> 00:21:01,640
COLLABORATION HAS ENTERED INTO A

514
00:21:01,640 --> 00:21:02,920
NEW PHASE THROUGH OUR

515
00:21:02,920 --> 00:21:04,840
PARTNERSHIP WITH CANCER RESEARCH

516
00:21:04,840 --> 00:21:07,560
U.K., WE JUST ANNOUNCED NINE NEW

517
00:21:07,560 --> 00:21:10,840
RESEARCH CHALLENGES AIMED AT

518
00:21:10,840 --> 00:21:12,480
TACKLING PROFOUND PROBLEMS IN

519
00:21:12,480 --> 00:21:23,000
RESEARCH, YOU SEE THEM LISTED.

520
00:21:33,960 --> 00:21:36,400
TO SUPPORT THE BRIGHTEST MINDS

521
00:21:36,400 --> 00:21:37,800
ACROSS THE GLOBAL RESEARCH

522
00:21:37,800 --> 00:21:38,920
COMMUNITY AS THEY TACKLE SOME OF

523
00:21:38,920 --> 00:21:40,920
THE MOST COMPLEX CHALLENGES IN

524
00:21:40,920 --> 00:21:46,360
CANCER RESEARCH.

525
00:21:46,360 --> 00:21:48,960
NCI CLINICAL TRIALS ARE

526
00:21:48,960 --> 00:21:50,400
ABSOLUTELY ESSENTIAL.

527
00:21:50,400 --> 00:21:52,840
THEY TURN POSSIBILITIES INTO

528
00:21:52,840 --> 00:21:54,440
TREATMENT PREVENTION AND EARLY

529
00:21:54,440 --> 00:21:56,960
DETECTION OR DIAGNOSIS METHODS.

530
00:21:56,960 --> 00:21:59,520
FOR A VARIETY OF REASONS, WE

531
00:21:59,520 --> 00:22:01,480
JUST DON'T HAVE ENOUGH PEOPLE

532
00:22:01,480 --> 00:22:03,680
PARTICIPATING IN OUR TRIALS AND

533
00:22:03,680 --> 00:22:05,280
ESPECIALLY THOSE FROM MINORITY

534
00:22:05,280 --> 00:22:09,000
GROUPS OR FROM RURAL AREAS AND

535
00:22:09,000 --> 00:22:11,880
WE ALSO DON'T GET RESULTS FAST

536
00:22:11,880 --> 00:22:12,440
ENOUGH.

537
00:22:12,440 --> 00:22:14,200
WE NEED NEW STRUCTURES THAT ARE

538
00:22:14,200 --> 00:22:16,960
MORE NIMBLE AND MORE INCLUSIVE

539
00:22:16,960 --> 00:22:18,640
OF ALL OF THE PEOPLE WE'RE HERE

540
00:22:18,640 --> 00:22:19,960
TO SERVE.

541
00:22:19,960 --> 00:22:22,680
SO AT NCI WE'VE LAUNCHED WHAT

542
00:22:22,680 --> 00:22:24,600
WE'RE CALLING OUR CLINICAL

543
00:22:24,600 --> 00:22:28,120
TRIALS INNOVATION UNIT TO

544
00:22:28,120 --> 00:22:28,760
SPEARHEAD PROGRESS.

545
00:22:28,760 --> 00:22:32,040
THIS IS A VERY EXCITING

546
00:22:32,040 --> 00:22:34,680
COLLABORATION BETWEEN NCI, THE

547
00:22:34,680 --> 00:22:36,640
FDA, AND THE EXTRAMURAL CANCER

548
00:22:36,640 --> 00:22:39,200
CLINICAL RESEARCH COMMUNITY.

549
00:22:39,200 --> 00:22:43,560
THE UNIT WILL SELECT A FEW VERY

550
00:22:43,560 --> 00:22:44,320
HIVE PRIORITIES SCIENTIFIC

551
00:22:44,320 --> 00:22:50,120
QUESTIONS THAT ARE PARTICULARLY

552
00:22:50,120 --> 00:22:52,320
STUDY DESIGN AND OPERATIONAL

553
00:22:52,320 --> 00:22:55,400
PROCEDURES.

554
00:22:55,400 --> 00:23:05,840
THIS IS FOR THIS INNOVATION

555
00:23:13,120 --> 00:23:14,560
UNIT, ALL ASPECTS ARE ON THE

556
00:23:14,560 --> 00:23:15,160
STABLE.

557
00:23:15,160 --> 00:23:19,280
STUDY ELIGIBILITY, COMPARE ARMS,

558
00:23:19,280 --> 00:23:21,040
ENDPOINTS, DIAGNOSTICS, USE OF

559
00:23:21,040 --> 00:23:22,760
TELEHEALTH AND OTHER STUDY DATA

560
00:23:22,760 --> 00:23:24,960
COLLECTION AND PROCEDURES AND

561
00:23:24,960 --> 00:23:27,600
PARTICIPANT ENGAGEMENT

562
00:23:27,600 --> 00:23:29,240
STRATEGIES AND EVERYTHING THAT

563
00:23:29,240 --> 00:23:35,640
CAN HELP US ENGAGE MORE BROADLY

564
00:23:35,640 --> 00:23:37,240
AND DELIVERING RESULTS FASTER IS

565
00:23:37,240 --> 00:23:37,880
OPT TABLE.

566
00:23:37,880 --> 00:23:42,120
WE ANTICIPATE SUCCESS WILL

567
00:23:42,120 --> 00:23:52,680
APPROACH US AND -- WE HAVE A FEW

568
00:23:58,720 --> 00:23:59,360
IMPORTANT UPDATES.

569
00:23:59,360 --> 00:24:01,200
EARLY DETECTION OF CANCERS CAN

570
00:24:01,200 --> 00:24:02,720
SIGNIFICANTLY IMPROVE OUTCOMES

571
00:24:02,720 --> 00:24:04,720
BUT THAT UNFORTUNATELY, NOT

572
00:24:04,720 --> 00:24:08,280
ENOUGH PEOPLE ARE GETTING THE

573
00:24:08,280 --> 00:24:09,240
RECOMMENDEDDED SCREENING.

574
00:24:09,240 --> 00:24:11,040
A NEW NCI FUNDED STUDY FOUND

575
00:24:11,040 --> 00:24:13,000
THAT AMONG A SAMPLE OF PRIVATE

576
00:24:13,000 --> 00:24:15,000
SECTOR WORKERS, MEMBER OGRAPHY

577
00:24:15,000 --> 00:24:18,040
AND COLORECTAL SCREENING, WERE

578
00:24:18,040 --> 00:24:27,400
HIGHER IN AREAS WHERE THIS

579
00:24:27,400 --> 00:24:28,960
SUGGESTS A LACK OF PAID SICK

580
00:24:28,960 --> 00:24:30,840
LEAVE COVERAGE PREVENTS A

581
00:24:30,840 --> 00:24:33,840
BARRIER TO CANCER SCREENING AND

582
00:24:33,840 --> 00:24:34,880
INFORM POTENTIAL POLICY SOLUTION

583
00:24:34,880 --> 00:24:37,120
THAT'S COULD BOOST SCREENING AND

584
00:24:37,120 --> 00:24:38,080
SAVE LIVES.

585
00:24:38,080 --> 00:24:39,640
WE KNOW THAT ALCOHOL CAN

586
00:24:39,640 --> 00:24:41,400
INCREASE RISK OF DEVELOPING

587
00:24:41,400 --> 00:24:45,040
SEVERAL CANCER TYPES.

588
00:24:45,040 --> 00:24:46,800
AND AN NCI STUDY FOUND THAT MOST

589
00:24:46,800 --> 00:24:48,200
AMERICANS WEREN'T AWARE OF THIS

590
00:24:48,200 --> 00:24:49,720
CONNECTION.

591
00:24:49,720 --> 00:24:52,360
THE RESEARCHERS CONCLUDED THAT

592
00:24:52,360 --> 00:24:54,120
CHANGES NEED TO BE MADE TO RAISE

593
00:24:54,120 --> 00:24:56,760
PUBLIC AWARENESS OF THIS

594
00:24:56,760 --> 00:24:57,520
IMPORTANT FACT.

595
00:24:57,520 --> 00:25:02,160
WE KNOW THAT AWARENESS DOESN'T

596
00:25:02,160 --> 00:25:03,320
GUARANTEE ACTION.

597
00:25:03,320 --> 00:25:04,600
WE'LL NEED FURTHER RESEARCH TO

598
00:25:04,600 --> 00:25:07,240
SOLVE THESE CHALLENGES.

599
00:25:07,240 --> 00:25:12,120
WE MAY BE ON THE PATH TO NEW

600
00:25:12,120 --> 00:25:15,440
ANSWERS TO A CHILDHOOD CANCER

601
00:25:15,440 --> 00:25:17,960
THAT IS DIFFICULT TO TREAT.

602
00:25:17,960 --> 00:25:19,480
EVEN OCCURS IN SOME

603
00:25:19,480 --> 00:25:20,440
DIFFICULTIES.

604
00:25:20,440 --> 00:25:23,880
RESEARCH SPONSORED BY OUR CANCER

605
00:25:23,880 --> 00:25:25,840
MOONSHOT'S FUSION ONCOPROTEINS

606
00:25:25,840 --> 00:25:28,960
IN FOUND THAT THE EVT6 PROTEIN

607
00:25:28,960 --> 00:25:31,320
MODULATES THE INFUSION ON CO

608
00:25:31,320 --> 00:25:32,720
PROTEIN RESPONSIBLE FOR THE

609
00:25:32,720 --> 00:25:37,720
MAJORITY OF EWING CAR COMA.

610
00:25:37,720 --> 00:25:40,080
IT'S HOPED IT WILL PREVENT A

611
00:25:40,080 --> 00:25:41,400
TARGETED DRUG THAT INTER FIERCE

612
00:25:41,400 --> 00:25:44,760
WITH THE ACTION BETWEEN EVT6 AND

613
00:25:44,760 --> 00:25:48,080
THE FUSION ON CO PROTEIN AND

614
00:25:48,080 --> 00:25:48,760
LEAD TO TREATMENT.

615
00:25:48,760 --> 00:25:50,440
WE ANTICIPATE SEEING MORE MORE

616
00:25:50,440 --> 00:25:54,960
RESULTS OUT OF THIS VERY

617
00:25:54,960 --> 00:25:59,440
IMPORTANT MOONSHOT CONSORTIUM.

618
00:25:59,440 --> 00:26:01,120
THE CHILDHOOD CANCER DATA

619
00:26:01,120 --> 00:26:04,160
INITIATIVE IS REALLY PROCESSING

620
00:26:04,160 --> 00:26:05,600
IN LINE WITH ALL OF OUR HOPES

621
00:26:05,600 --> 00:26:07,600
FOR THIS IMPORTANT PROGRAM.

622
00:26:07,600 --> 00:26:09,160
GETTING DATA WE NEED TO IMPROVE

623
00:26:09,160 --> 00:26:11,360
OUR UNDERSTANDING OF CANCER,

624
00:26:11,360 --> 00:26:13,600
ESPECIALLY CHILDHOOD CANCER,

625
00:26:13,600 --> 00:26:14,800
WHERE DATA HAS BEEN DIFFICULT TO

626
00:26:14,800 --> 00:26:16,920
COME BY IS VERY CHALLENGE AND

627
00:26:16,920 --> 00:26:19,840
COSTLY AND THE GOOD NEWS IS HEAD

628
00:26:19,840 --> 00:26:23,720
LAY AND TO GET MUCH CHILD AND

629
00:26:23,720 --> 00:26:26,320
INTO THE HANDS OF SCIENTISTS

630
00:26:26,320 --> 00:26:28,320
THROUGH CCDI.

631
00:26:28,320 --> 00:26:31,080
THIS FOCUS PROGRAM HAS MADE

632
00:26:31,080 --> 00:26:32,880
TREMENDOUS PROGRESS TO

633
00:26:32,880 --> 00:26:35,480
ACCUMULATE DATA THAT HAS BEEN

634
00:26:35,480 --> 00:26:37,000
HISTORICALLY VERY DIFFICULT FOR

635
00:26:37,000 --> 00:26:38,760
RESEARCHERS TO ACCESS AND FOR

636
00:26:38,760 --> 00:26:40,960
RESEARCH TEAMS TO SHARE.

637
00:26:40,960 --> 00:26:43,080
THE AGREEMENT IS TAKEN CHARGE OF

638
00:26:43,080 --> 00:26:46,400
CCDI BRINGING HIS VAST

639
00:26:46,400 --> 00:26:47,960
EXPERIENCE FROM TIME LEADING AND

640
00:26:47,960 --> 00:26:51,400
ALSO WORKING AT FDI AND

641
00:26:51,400 --> 00:26:56,560
MARCH 21st, CCDI WILL HOST THE

642
00:26:56,560 --> 00:27:00,320
SYMPOSIUM TO GATHER EXPERTS FROM

643
00:27:00,320 --> 00:27:02,120
ACROSS COUNTRY AND WE'RE VERY

644
00:27:02,120 --> 00:27:04,120
EXCITED TO HIGHLIGHT NEW

645
00:27:04,120 --> 00:27:05,840
RESOURCES THAT ARE AVAILABLE TO

646
00:27:05,840 --> 00:27:08,920
THE SCIENTIST I CAN COMMUNITY.

647
00:27:08,920 --> 00:27:13,160
AS WELL AS HIGHLIGHT FUTURE AND

648
00:27:13,160 --> 00:27:15,160
OPPORTUNITIES.

649
00:27:15,160 --> 00:27:16,320
AND TO INTEND YOU CAN DO IT

650
00:27:16,320 --> 00:27:18,200
IN-PERSON EVEN IF YOU ARE NOT

651
00:27:18,200 --> 00:27:21,080
AND RESEARCHER BUT IF YOU ARE

652
00:27:21,080 --> 00:27:22,720
PARTICULARLY INTERESTED IN

653
00:27:22,720 --> 00:27:32,240
CHILDHOOD CANCER AND TO ALL OF

654
00:27:32,240 --> 00:27:32,680
OUR WORK.

655
00:27:32,680 --> 00:27:34,040
IT'S A PLAN FOR THE FUTURE.

656
00:27:34,040 --> 00:27:36,040
I THINK MORE THAN ANYTHING THAT

657
00:27:36,040 --> 00:27:38,200
WE'VE DONE, CCDI IS

658
00:27:38,200 --> 00:27:39,720
DEMONSTRATING THE GREAT POWER OF

659
00:27:39,720 --> 00:27:41,720
DATA SHARING AND COLLABORATION

660
00:27:41,720 --> 00:27:44,560
AND WE REALLY THINK THIS CAN BE

661
00:27:44,560 --> 00:27:46,560
A PARADIGM FOR WHAT WE CAN DO

662
00:27:46,560 --> 00:27:48,600
FOR EVERYONE WITH CANCER AND

663
00:27:48,600 --> 00:27:52,160
EVERY RESEARCH TEAM.

664
00:27:52,160 --> 00:27:55,000
SOME FINAL THOUGHTS, THERE'S A

665
00:27:55,000 --> 00:27:55,840
LOT HAPPENING.

666
00:27:55,840 --> 00:27:57,840
FROM STEP-BY-STEP SCIENCE THAT

667
00:27:57,840 --> 00:28:00,320
WE SIMPLY WON'T MAKE PROGRESS

668
00:28:00,320 --> 00:28:01,840
WITHOUT, WHICH WE'RE VERY HAPPY

669
00:28:01,840 --> 00:28:04,440
TO SAY WE'LL INCREASE WITH MORE

670
00:28:04,440 --> 00:28:07,280
RO1 FUNDING, TO HIGH-LEVEL

671
00:28:07,280 --> 00:28:09,880
PLANNING TO LEAD OF BEST ALIGN

672
00:28:09,880 --> 00:28:12,960
THE CANCER RESEARCH ENTERPRISE

673
00:28:12,960 --> 00:28:15,680
AND TRULY ALL OF OUR SOCIETY AS

674
00:28:15,680 --> 00:28:18,160
WE ACHIEVE THE PROGRESS EVERYONE

675
00:28:18,160 --> 00:28:20,240
IS COUNTING ON.

676
00:28:20,240 --> 00:28:22,480
WE'RE STILL VERY FAR FROM WHERE

677
00:28:22,480 --> 00:28:23,680
WE NEED TO BE FOR THE PEOPLE WHO

678
00:28:23,680 --> 00:28:25,120
ARE COUNTING ON US.

679
00:28:25,120 --> 00:28:27,360
BUT I'M REALLY EXCITED ABOUT THE

680
00:28:27,360 --> 00:28:30,120
STEPS WE'RE TAKING NOW AND

681
00:28:30,120 --> 00:28:34,280
RECENT ACCOMPLISHMENTS TO ENSURE

682
00:28:34,280 --> 00:28:35,600
WE CAN WORK TOGETHER AND WE'RE

683
00:28:35,600 --> 00:28:37,360
ON THE RIGHT PATH TO DO SO.

684
00:28:37,360 --> 00:28:39,120
SO LET ME END HERE, AND GET TO

685
00:28:39,120 --> 00:28:40,440
THE BEST PART WHICH IS TO TAKE

686
00:28:40,440 --> 00:28:45,840
ALL OF YOUR QUESTIONS.

687
00:28:45,840 --> 00:28:51,040
IF YOU.

688
00:28:51,040 --> 00:28:52,000
>> HI.

689
00:28:52,000 --> 00:28:53,600
THANK YOU, THAT'S ABSOLUTELY

690
00:28:53,600 --> 00:28:54,240
WONDERFUL.

691
00:28:54,240 --> 00:28:55,280
SO EXCITE TO GO SEE.

692
00:28:55,280 --> 00:28:56,560
I'M CURIOUS ABOUT THE

693
00:28:56,560 --> 00:28:58,120
INNOVATIONS FOR CLINICAL TRIALS.

694
00:28:58,120 --> 00:29:00,160
YOU MENTIONED THE BROAD SCOPE.

695
00:29:00,160 --> 00:29:01,280
I KNOW YOU KNOW WHAT I'M GOING

696
00:29:01,280 --> 00:29:02,040
TO ASK.

697
00:29:02,040 --> 00:29:04,160
DOES INNOVATIONS INCLUDE BETTER

698
00:29:04,160 --> 00:29:05,480
WAYS TO WRITE TRIALS AND AUTHOR

699
00:29:05,480 --> 00:29:06,560
TRIALS AND WHAT ARE YOUR

700
00:29:06,560 --> 00:29:10,720
THOUGHTS ABOUT WAYS WE CAN

701
00:29:10,720 --> 00:29:12,480
ENCOURAGE THE SPONSORS TO USE

702
00:29:12,480 --> 00:29:13,760
STRUCTURED FORMS OF AUTHORIZING

703
00:29:13,760 --> 00:29:16,720
TRIALS THAT MAKE IT EASIER TO DO

704
00:29:16,720 --> 00:29:19,760
DOWNSTREAM INA LIT TICKS AND.

705
00:29:19,760 --> 00:29:22,000
>> EVERY PASS OF TRIAL
DESIGN IS

706
00:29:22,000 --> 00:29:26,960
ON THE STABLE AND AND INCLUDING

707
00:29:26,960 --> 00:29:28,160
WHAT YOU JUST DESCRIBED AND WHAT

708
00:29:28,160 --> 00:29:32,080
IS GIVING US, GOT US REALLY

709
00:29:32,080 --> 00:29:33,840
EXCITED AND YOU MENTIONED

710
00:29:33,840 --> 00:29:37,720
INDUSTRY AND I MEAN, ANY

711
00:29:37,720 --> 00:29:39,600
COLLABORATORS AND WE'RE EXCITED

712
00:29:39,600 --> 00:29:43,240
ABOUT FDA IS AT THE TABLE

713
00:29:43,240 --> 00:29:44,560
THEY'RE WEIGHING IN AND I CAN

714
00:29:44,560 --> 00:29:50,640
TELL YOU THAT THE FIRST TRIAL TO

715
00:29:50,640 --> 00:29:52,800
COME OUT OF THE FIRST-GENERATION

716
00:29:52,800 --> 00:29:55,800
OF THE TRIALS AND IT'S A

717
00:29:55,800 --> 00:29:57,600
REGISTRATION TRIAL DESIGNED TO

718
00:29:57,600 --> 00:30:01,560
BE REALLY, REALLY NIMBLE AND

719
00:30:01,560 --> 00:30:05,440
SIMPLE AND STRAIGHT FORWARD AND

720
00:30:05,440 --> 00:30:07,600
ABLE TO EVERY COMMUNITY AND

721
00:30:07,600 --> 00:30:10,400
UNITED STATES THROUGH THE NCTN

722
00:30:10,400 --> 00:30:11,960
AND THE ENCORE SO HAVING FDA

723
00:30:11,960 --> 00:30:13,440
THERE HAS BEEN A POWERFUL FORCED

724
00:30:13,440 --> 00:30:17,360
TO MAKE SURE THAT WE CAN DO

725
00:30:17,360 --> 00:30:21,520
THIS.

726
00:30:21,520 --> 00:30:23,640
KAREN.

727
00:30:23,640 --> 00:30:33,720
>>

728
00:30:34,040 --> 00:30:35,000
>> THANK YOU FOR THAT

729
00:30:35,000 --> 00:30:36,280
PRESENTATION MONICA IT'S GREAT

730
00:30:36,280 --> 00:30:37,480
AND EXCITE TO GO SEE THE

731
00:30:37,480 --> 00:30:38,320
PROGRESS.

732
00:30:38,320 --> 00:30:48,840
ANY QUESTIONS ABOUT ARPA-H AND

733
00:30:57,240 --> 00:30:58,920
BEING DONE WITHIN NCI AND THE

734
00:30:58,920 --> 00:31:02,840
RIGHT KIND OF PROTECT OR ARPA-H.

735
00:31:02,840 --> 00:31:05,320
>> ARPA-H HAD ITS FIRST
YEAR,

736
00:31:05,320 --> 00:31:06,840
FIRST YEAR CELEBRATION AND AT

737
00:31:06,840 --> 00:31:08,760
THAT TIME, YOU CAN GO TO THEIR

738
00:31:08,760 --> 00:31:10,760
WEBSITE THERE'S NOW A BROAD

739
00:31:10,760 --> 00:31:13,800
AGENCY ANNOUNCEMENT AND OUT TO

740
00:31:13,800 --> 00:31:18,000
BE SO ANYONE CAN SUBMIT

741
00:31:18,000 --> 00:31:21,120
PROPOSALS AND ARPA-H AND THEY'RE

742
00:31:21,120 --> 00:31:24,840
AND THEIR PROJECT MAPPINGERS AND

743
00:31:24,840 --> 00:31:28,320
ANY IDEAS CAN GO THERE.

744
00:31:28,320 --> 00:31:29,680
WE'RE TELLING PEOPLE HOW TO

745
00:31:29,680 --> 00:31:32,640
COLLABORATE WITH NCI AND WE HAVE

746
00:31:32,640 --> 00:31:34,120
Dr. DINA SINGER WHO MANY OF

747
00:31:34,120 --> 00:31:39,680
YOU I'M SURE KNOW AND IS NCI

748
00:31:39,680 --> 00:31:41,000
COORDINATOR FOR INTERACTIONS

749
00:31:41,000 --> 00:31:44,520
BETWEEN NCI AND ARPA-H.

750
00:31:44,520 --> 00:31:48,400
Dr. SINGER IS HAPPY TO TAKE --

751
00:31:48,400 --> 00:31:50,600
DROP HER AN E-MAIL IF YOU SAY I

752
00:31:50,600 --> 00:31:53,840
HAVE AN IDEA THAT MIGHT

753
00:31:53,840 --> 00:31:55,720
FELLOWSHIP IN ARPA-H AND INVOLVE

754
00:31:55,720 --> 00:31:58,000
WORK THAT AND DO WITH NCI AND

755
00:31:58,000 --> 00:32:00,680
Dr. SINGER IS REALLY HELPING

756
00:32:00,680 --> 00:32:04,040
US AND MANAGE ALL OF THOSE THAT

757
00:32:04,040 --> 00:32:04,400
INTEREST.

758
00:32:04,400 --> 00:32:06,160
AND SHE'S VERY BUSY DOING THAT.

759
00:32:06,160 --> 00:32:08,520
SO IT'S EXCITING.

760
00:32:08,520 --> 00:32:11,120
WE REALLY -- WHAT WE WANT TO DO

761
00:32:11,120 --> 00:32:12,880
IS WHATEVER ARPA-H DEVELOPS, WE

762
00:32:12,880 --> 00:32:14,640
WANT TO BE THE USERS, RIGHT.

763
00:32:14,640 --> 00:32:18,320
WE WANT TO BE THE END USERS.

764
00:32:18,320 --> 00:32:20,640
THE OTHER THING I HEARD WHICH IS

765
00:32:20,640 --> 00:32:21,960
VERY POSITIVE IS WE'RE GOING TO

766
00:32:21,960 --> 00:32:25,160
BE THE TEST ENVIRONMENT.

767
00:32:25,160 --> 00:32:27,160
YOU KNOW, IF THEY DEVELOP

768
00:32:27,160 --> 00:32:28,920
SOMETHING NEW AND SEE WHETHER IT

769
00:32:28,920 --> 00:32:31,160
WORKS OR NOT, WE'LL BE WITH HER

770
00:32:31,160 --> 00:32:35,800
TO HELP ASSIST.

771
00:32:35,800 --> 00:32:36,880
TAKE A LOOK, IT'S THERE AND

772
00:32:36,880 --> 00:32:37,320
READY TO GO.

773
00:32:37,320 --> 00:32:43,160
>> GREAT, THANK YOU.

774
00:32:43,160 --> 00:32:43,720
>> Dr. Flaherty: KAREN.

775
00:32:43,720 --> 00:32:47,160
>> MONICA, I REALLY
APPRECIATE

776
00:32:47,160 --> 00:32:49,440
THE FISCAL TRANSPARENCY AND THE

777
00:32:49,440 --> 00:32:51,040
PAYLINE AND WHAT THE OPPORTUNITY

778
00:32:51,040 --> 00:32:52,920
COSTS WAS THERE AND YOU KNOW,

779
00:32:52,920 --> 00:32:55,640
KUDOS FOR GETTING THE RPG

780
00:32:55,640 --> 00:32:57,200
PAYLINE TO WHAT IT IS RIGHT NOW

781
00:32:57,200 --> 00:32:58,640
AND LOOK FORWARD TO FURTHER

782
00:32:58,640 --> 00:32:59,600
DISCUSSIONS SO THANK YOU FOR

783
00:32:59,600 --> 00:33:01,520
THAT AND MY QUESTION HAS TO DO

784
00:33:01,520 --> 00:33:03,440
WITH THE REISSUANCE OF THE

785
00:33:03,440 --> 00:33:05,280
NATIONAL CANCER ACT AND SO I'M

786
00:33:05,280 --> 00:33:06,120
WONDERING IF THERE'S ANYTHING

787
00:33:06,120 --> 00:33:08,640
YOU CAN TELL US ABOUT PROPOSED

788
00:33:08,640 --> 00:33:10,000
CHANGES, ADDITIONS, ANYTHING

789
00:33:10,000 --> 00:33:12,760
THAT WE MIGHT EXPECT AS WE THINK

790
00:33:12,760 --> 00:33:14,240
TOWARDS WHAT THAT LOOKS LIKE FOR

791
00:33:14,240 --> 00:33:17,680
THE PATH FORWARD?

792
00:33:17,680 --> 00:33:18,280
>> Dr. Bertagnolli: YEAH,
SO

793
00:33:18,280 --> 00:33:20,400
WE'RE STILL WORKING WITH THE

794
00:33:20,400 --> 00:33:22,760
OSTP WITH THE PRESIDENT ON WHAT

795
00:33:22,760 --> 00:33:24,800
A REISSUANCE WILL LOOK LIKE, YOU

796
00:33:24,800 --> 00:33:29,000
KNOW, I REALLY CAN'T SHARE A LOT

797
00:33:29,000 --> 00:33:33,880
YET OTHER THAN IT'S VERY CLEAR

798
00:33:33,880 --> 00:33:35,440
THAT THE PRESIDENT WANTS NCI TO

799
00:33:35,440 --> 00:33:36,840
HAVE ALL THE TOOLS THAT IT NEEDS

800
00:33:36,840 --> 00:33:39,240
TO MAKE THE FASTEST POSSIBLE

801
00:33:39,240 --> 00:33:40,280
PROGRESS.

802
00:33:40,280 --> 00:33:43,080
AND SO, NOW WE'RE WORKING ON

803
00:33:43,080 --> 00:33:44,680
EXACTLY WHAT THOSE TOOLS AND

804
00:33:44,680 --> 00:33:49,080
AUTHORITIES LOOK LIKE.

805
00:33:49,080 --> 00:33:54,760
AND IT'S A TOPIC THAT GOES WAY

806
00:33:54,760 --> 00:33:56,600
MOPPED HERE AND HOW WE DO OUR

807
00:33:56,600 --> 00:33:59,240
HIGHERING AND IT'S REALLY THE

808
00:33:59,240 --> 00:34:01,000
NUTS AND BOLTS AND NITTY GRITTY

809
00:34:01,000 --> 00:34:03,760
OF HOW WE GET WORK ACCOMPLISHED

810
00:34:03,760 --> 00:34:06,600
BUT I CAN JUST TELL YOU THAT THE

811
00:34:06,600 --> 00:34:10,240
PRESIDENT'S OFFICE IS BEHIND NOT

812
00:34:10,240 --> 00:34:11,720
PUTTING WHAT WE NEED IN THERE TO

813
00:34:11,720 --> 00:34:14,440
BE EFFICIENT, AND MORE NIMBLE

814
00:34:14,440 --> 00:34:15,720
THAN WE'VE BEEN AND MAKE GREAT

815
00:34:15,720 --> 00:34:17,400
PROGRESS SO WE'RE EXCITED ABOUT

816
00:34:17,400 --> 00:34:17,680
IT.

817
00:34:17,680 --> 00:34:20,520
>> ONE OF THE THINGS
THAT'S

818
00:34:20,520 --> 00:34:22,960
REFRESHING THAT WE HEARD IN YOUR

819
00:34:22,960 --> 00:34:24,240
PRESENTATION THE INCLUSION OF

820
00:34:24,240 --> 00:34:26,120
THE FDA SO YOU GET WHERE I'M

821
00:34:26,120 --> 00:34:27,640
HEADED.

822
00:34:27,640 --> 00:34:32,680
I HOPE IT IS INCLUDED IN THIS

823
00:34:32,680 --> 00:34:32,960
REISSUANCE.

824
00:34:32,960 --> 00:34:33,640
>> Dr. Bertagnolli: I CAN
TELL

825
00:34:33,640 --> 00:34:34,680
YOU ABSOLUTELY WHAT HAS ALREADY

826
00:34:34,680 --> 00:34:36,240
BEEN INCLUDED IS THE FACT THAT

827
00:34:36,240 --> 00:34:40,600
THE NATIONAL CANCER PLAN IS BEEN

828
00:34:40,600 --> 00:34:42,400
PRESENTED TO, WELL IT WILL BE

829
00:34:42,400 --> 00:34:43,400
TOMORROW, I BELIEVE, PRESENTED

830
00:34:43,400 --> 00:34:44,960
TO THE SECRETARY OF HEALTH AND

831
00:34:44,960 --> 00:34:46,320
HUMAN APP SERVICES AND IT'S

832
00:34:46,320 --> 00:34:47,800
ALREADY GONE THROUGH ALL OF

833
00:34:47,800 --> 00:34:49,080
HIS -- THIS IS WHY WE WONDER

834
00:34:49,080 --> 00:34:50,400
I'VE BEEN TALKING ABOUT THIS

835
00:34:50,400 --> 00:34:51,480
PLAN FOR A WHILE.

836
00:34:51,480 --> 00:34:53,240
WHY IS IT TAKING TIME TO

837
00:34:53,240 --> 00:34:54,200
DELIVER?

838
00:34:54,200 --> 00:34:56,320
THAT'S BECAUSE WE HAVE

839
00:34:56,320 --> 00:34:57,520
ENGAGEMENT AND INVESTMENT ACROSS

840
00:34:57,520 --> 00:34:59,680
HEALTH AND HUMAN SERVICES ACROSS

841
00:34:59,680 --> 00:35:02,760
NCI AND ACROSS OSTP AND YOU

842
00:35:02,760 --> 00:35:05,520
KNOW, SO THAT ALL OF GOVERNMENT

843
00:35:05,520 --> 00:35:07,640
APPROACH IS VERY MUCH GOING TO

844
00:35:07,640 --> 00:35:09,160
BE REFLECTED IN THE PLAN.

845
00:35:09,160 --> 00:35:10,400
WHICH IS KEY.

846
00:35:10,400 --> 00:35:13,000
WE KNOW WHAT WE NEED TO MANAGE

847
00:35:13,000 --> 00:35:15,200
TO AND WE'VE ALL AGREED -- YOU

848
00:35:15,200 --> 00:35:17,200
KNOW, WE'VE ALL SIGNED ONTO IT

849
00:35:17,200 --> 00:35:20,880
SO RIGHT THERE THAT'S A

850
00:35:20,880 --> 00:35:25,680
TREMENDOUS STEP.

851
00:35:25,680 --> 00:35:27,680
>> THANK YOU, THAT WAS
GREAT.

852
00:35:27,680 --> 00:35:29,320
I WAS HEART END TO HEART ABOUT

853
00:35:29,320 --> 00:35:31,200
THE INCREASE IN CANCER FUNDING.

854
00:35:31,200 --> 00:35:33,200
THE COST OF DOING SCIENCE IS

855
00:35:33,200 --> 00:35:34,680
REALLY GOING UP AND ESPECIALLY

856
00:35:34,680 --> 00:35:35,760
BECAUSE MANY OF US ARE FACING

857
00:35:35,760 --> 00:35:38,600
THE ISSUE OF OUR TRAININGS

858
00:35:38,600 --> 00:35:42,280
NEEDING TO BE SUPPORTED WITH THE

859
00:35:42,280 --> 00:35:44,360
LIVING RAGE AND KA OFFERING CAL

860
00:35:44,360 --> 00:35:54,800
SALARY TO INDUSTRY AND WE

861
00:35:57,000 --> 00:35:58,600
ARE NOT BUDGETED TO REALLY MEET

862
00:35:58,600 --> 00:36:01,520
THOSE SALARY INCREASES AND

863
00:36:01,520 --> 00:36:03,200
SALARY RANGE IN GRANTS ARE OUT

864
00:36:03,200 --> 00:36:06,200
DATE AND SOME OF US ARE USING

865
00:36:06,200 --> 00:36:07,600
GRANTS FUNDED YEARS AGO WHERE

866
00:36:07,600 --> 00:36:08,960
THE GRANTS YOU KNOW, WHERE THE

867
00:36:08,960 --> 00:36:12,560
SALARY RANGING ARE NOT

868
00:36:12,560 --> 00:36:15,680
UP-TO-DATE SO WHAT IS NCI THINK

869
00:36:15,680 --> 00:36:16,600
ABOUT HOW WE CAN ADDRESS THIS

870
00:36:16,600 --> 00:36:18,320
AND IS THERE ANY DISCUSSION THAT

871
00:36:18,320 --> 00:36:19,520
NCI IS HAVING WITH CANCER

872
00:36:19,520 --> 00:36:21,040
CENTERS AND INSTITUTIONS ABOUT

873
00:36:21,040 --> 00:36:23,520
HOW WE CAN SORT OF MEET THESE

874
00:36:23,520 --> 00:36:24,000
DIFFERENT PRIORITIES.

875
00:36:24,000 --> 00:36:28,480
>> OH, BOY.

876
00:36:28,480 --> 00:36:29,440
WE ARE JUST SO CONCERNED AS YOU

877
00:36:29,440 --> 00:36:31,200
ARE ABOUT THE ISSUE OF SALARY

878
00:36:31,200 --> 00:36:33,720
AND YOU KNOW, AND FOR OUR

879
00:36:33,720 --> 00:36:40,920
TRAINEES AND ABSOLUTELY AND DO

880
00:36:40,920 --> 00:36:43,560
WE WANT BIGGER GRANTS OR FEWER

881
00:36:43,560 --> 00:36:44,000
GRANTS?

882
00:36:44,000 --> 00:36:45,600
IF YOU GOT BIGGER GRANTS, YOU

883
00:36:45,600 --> 00:36:46,360
WILL HAVE FEWER.

884
00:36:46,360 --> 00:36:47,800
IF YOU HAVE THE SAME GRANTS, YOU

885
00:36:47,800 --> 00:36:51,200
CAN HAVE MORE.

886
00:36:51,200 --> 00:36:52,840
IT'S THE MATH.

887
00:36:52,840 --> 00:36:59,480
SO, WE ARE ABSOLUTELY OPEN TO --

888
00:36:59,480 --> 00:37:02,840
IF WE RAISE, WE CAN RAISE THE

889
00:37:02,840 --> 00:37:04,840
AMOUNT OF -- WE CAN RAISE

890
00:37:04,840 --> 00:37:06,360
SALARIES BUT THAT WOULD BE FEWER

891
00:37:06,360 --> 00:37:07,320
GRANTS OVER ALL.

892
00:37:07,320 --> 00:37:11,200
THE PAYLINE WILL GO DOWN.

893
00:37:11,200 --> 00:37:15,040
THAT'S WHAT WE'RE GOING TO BE

894
00:37:15,040 --> 00:37:16,920
FIGHTING.

895
00:37:16,920 --> 00:37:19,360
THAT'S PART OF AN ONGOING

896
00:37:19,360 --> 00:37:22,040
DISCUSSION WE'RE HAVING WITH THE

897
00:37:22,040 --> 00:37:23,000
CANCER CENTER DIRECTORS AND

898
00:37:23,000 --> 00:37:26,400
WE'LL HAVE A RETREAT IN MAY

899
00:37:26,400 --> 00:37:30,240
COMING UP AND THAT'S THE MATH.

900
00:37:30,240 --> 00:37:32,240
THAT'S THE ONLY TIME YOU NEED --

901
00:37:32,240 --> 00:37:33,160
>> I KNOW.

902
00:37:33,160 --> 00:37:34,480
I GUESS ONE OF THE ISSUES IS

903
00:37:34,480 --> 00:37:37,880
MAYBE TO CREATE A SITUATION

904
00:37:37,880 --> 00:37:39,680
WHERE IN OF THE INDIVIDUAL

905
00:37:39,680 --> 00:37:41,120
INVESTIGATORS ARE SORT OF

906
00:37:41,120 --> 00:37:42,360
REQUIRED TO MEET THESE MANDATES

907
00:37:42,360 --> 00:37:52,880
BASED ON THE NOT INSTITUTIONAL

908
00:37:55,000 --> 00:37:55,920
CAN THEY MAKE SURE THERE'S A

909
00:37:55,920 --> 00:37:57,640
GRACE PERIOD TO MAKE SURE THESE

910
00:37:57,640 --> 00:38:00,440
ARE PHASED IN AS OPPOSED TO KIND

911
00:38:00,440 --> 00:38:02,360
OF PUT INTO PLACE WHICH MAKES IT

912
00:38:02,360 --> 00:38:03,640
CHALLENGES FOR INVESTIGATORS

913
00:38:03,640 --> 00:38:05,280
WORKING UNDER NCI GRANTS THAT

914
00:38:05,280 --> 00:38:10,880
ARE FUNDED YEARS AGO.

915
00:38:10,880 --> 00:38:12,160
>> I DON'T KNOW OF ANY
CHANGES

916
00:38:12,160 --> 00:38:14,920
WE'RE MANDATING AT THIS POINT.

917
00:38:14,920 --> 00:38:20,560
IT SOUNDS LIKE IT'S

918
00:38:20,560 --> 00:38:21,760
DEFINITELY -- THIS IS AN ONGOING

919
00:38:21,760 --> 00:38:22,120
CONVERSATION.

920
00:38:22,120 --> 00:38:24,360
YOU WILL SEE IN THE NATIONAL

921
00:38:24,360 --> 00:38:25,400
CANCER PLAN AND UP WITH GOAL OF

922
00:38:25,400 --> 00:38:26,960
THE PLAN IS WORKFORCE.

923
00:38:26,960 --> 00:38:28,880
AND ALL ABOUT THIS ISSUE AND HOW

924
00:38:28,880 --> 00:38:30,520
WE REALLY ALL NEED TO WORK

925
00:38:30,520 --> 00:38:34,600
TOGETHER ON THIS ON SO MANY

926
00:38:34,600 --> 00:38:35,680
LEVELS.

927
00:38:35,680 --> 00:38:36,840
THAT'S A LONG DISCUSSION AND WE

928
00:38:36,840 --> 00:38:37,920
STILL HAVE SIGNIFICANT AMOUNT OF

929
00:38:37,920 --> 00:38:40,200
WORK TO DO WITH THE COMMUNITY TO

930
00:38:40,200 --> 00:38:41,600
FIGURE OUT WHAT THE RIGHT THING

931
00:38:41,600 --> 00:38:44,480
TO DO IT IS WE'RE VERY OSHA TO

932
00:38:44,480 --> 00:38:46,680
ANY KIND OF SOLUTION THAT BRINGS

933
00:38:46,680 --> 00:38:53,320
BENEFIT TO OUR TRAINEES.

934
00:38:53,320 --> 00:38:53,960
>> Dr. Flaherty: WE'RE
GOING TO

935
00:38:53,960 --> 00:38:55,080
BE CHALLENGED FOR TIME.

936
00:38:55,080 --> 00:38:56,360
I'M GOING TO HONOR THE FIRST

937
00:38:56,360 --> 00:38:57,720
TIME SO GO AHEAD.

938
00:38:57,720 --> 00:38:59,720
>> THANK YOU.

939
00:38:59,720 --> 00:39:01,360
THIS IS GOING TO BE QUICK.

940
00:39:01,360 --> 00:39:02,640
MONICA, THANK YOU SO MUCH FOR

941
00:39:02,640 --> 00:39:02,840
THIS.

942
00:39:02,840 --> 00:39:08,040
I WAS REALLY INTERESTED ABOUT A

943
00:39:08,040 --> 00:39:11,240
CLCLINICAL TRIALS AND ALL OF

944
00:39:11,240 --> 00:39:12,560
GOVERNMENT MEANS ALL OF

945
00:39:12,560 --> 00:39:13,160
GOVERNMENT WORKS AGAIN.

946
00:39:13,160 --> 00:39:14,240
THE QUESTION IF YOU ARE WILLING

947
00:39:14,240 --> 00:39:15,880
TO SHARE IS TO WHAT EXTENT IS

948
00:39:15,880 --> 00:39:17,680
THIS GOING TO BE POINTED IN THE

949
00:39:17,680 --> 00:39:19,880
DIRECTION OF ADDRESSING REALLY

950
00:39:19,880 --> 00:39:23,600
THE SYSTEMIC BARRIERS TO

951
00:39:23,600 --> 00:39:24,560
PARTICIPATION BY PLAQUE PEOPLE,

952
00:39:24,560 --> 00:39:25,960
HISPANIC PEOPLE, NATIVE AMERICAN

953
00:39:25,960 --> 00:39:27,520
PEOPLE BECAUSE IT SEEMS TO BE

954
00:39:27,520 --> 00:39:30,560
REALLY IMPORTANT TEST BED OR

955
00:39:30,560 --> 00:39:32,360
LABORATORY FOR THIS SORT OF

956
00:39:32,360 --> 00:39:34,600
EXPERIMENT AND SIMPLIFY AND MAKE

957
00:39:34,600 --> 00:39:36,520
THEM MORE ACCESSIBLE SO MANY

958
00:39:36,520 --> 00:39:38,800
MORE PEOPLE NEED IT DESPERATELY

959
00:39:38,800 --> 00:39:41,400
CAN GET ACCESS TO LIFE SAVING

960
00:39:41,400 --> 00:39:41,840
THERAPIES.

961
00:39:41,840 --> 00:39:43,360
>> Dr. Bertagnolli: OH,
YES.

962
00:39:43,360 --> 00:39:45,440
IT'S NOT JUST SIMPLIFIED.

963
00:39:45,440 --> 00:39:48,440
IT'S MEETING EVERY DIVERSE

964
00:39:48,440 --> 00:39:49,840
COMMUNITY WHERE THEY ARE, RIGHT.

965
00:39:49,840 --> 00:39:52,320
IT'S A COMPLETELY DIFFERENT

966
00:39:52,320 --> 00:39:53,520
SOLUTION FOR SOMEONE WHO LIVES

967
00:39:53,520 --> 00:39:55,920
WHERE I GREW UP, WHICH IS

968
00:39:55,920 --> 00:39:58,320
100 MILES FROM ANY HOSPITAL IN A

969
00:39:58,320 --> 00:39:59,600
VERY RURAL LOCATION TO SOMEONE

970
00:39:59,600 --> 00:40:10,000
WHO LIVES ON A INDIAN

971
00:40:10,840 --> 00:40:12,200
RESERVATION OR A CITY WHERE THEY

972
00:40:12,200 --> 00:40:13,840
DON'T HAVE GOOD ACCESS TO

973
00:40:13,840 --> 00:40:15,760
HEALTHY FOOD.

974
00:40:15,760 --> 00:40:16,720
EVERY COMMUNITY NEEDS A

975
00:40:16,720 --> 00:40:20,160
DIFFERENT SOLUTION AND WE'VE

976
00:40:20,160 --> 00:40:22,080
LEARNED THAT THEY'RE NOTING COME

977
00:40:22,080 --> 00:40:24,320
TO US, WE NEED TO GO TO THEM.

978
00:40:24,320 --> 00:40:26,560
THAT'S INTER WOVEN THROUGH THE

979
00:40:26,560 --> 00:40:27,400
NATIONAL CANCER PLAN.

980
00:40:27,400 --> 00:40:29,320
YOU WILL SEE THIS THEME AND IT'S

981
00:40:29,320 --> 00:40:31,120
SO DIVERSE AND WE HAVE TO GO TO

982
00:40:31,120 --> 00:40:35,440
THEM THEY'RE NOT COMING TO US.

983
00:40:35,440 --> 00:40:36,280
>> Dr. Flaherty: I LOOK AT
THE

984
00:40:36,280 --> 00:40:37,480
SECOND PAGE BUT YOU ARE ON MY

985
00:40:37,480 --> 00:40:39,920
FIRST PAGE SO YOU ARE UP.

986
00:40:39,920 --> 00:40:41,400
>> WONDERFUL.

987
00:40:41,400 --> 00:40:42,960
MONICA, I'M SO EXCITED NOT ONLY

988
00:40:42,960 --> 00:40:44,600
ABOUT THE PAYLINE WHICH WE NEED

989
00:40:44,600 --> 00:40:46,160
TO OF COURSE INCREASE.

990
00:40:46,160 --> 00:40:47,320
I'M ALWAYS IN FAVOR OF MORE

991
00:40:47,320 --> 00:40:48,840
GRANTS AND SMALLER GRANTS JUST

992
00:40:48,840 --> 00:40:51,880
AS A LITTLE VOTE.

993
00:40:51,880 --> 00:40:54,360
THE CLINICAL TRIALS INNOVATION

994
00:40:54,360 --> 00:40:56,880
UNIT SOUNDS FASCINATING AND

995
00:40:56,880 --> 00:40:58,440
IMPORTANT AND I HAVE JUST SOME

996
00:40:58,440 --> 00:40:59,480
QUESTIONS ABOUT IT.

997
00:40:59,480 --> 00:41:02,320
SO FIRST OF ALL, IT WILL HELP

998
00:41:02,320 --> 00:41:04,120
WITH INCLUSION, SIMPLIFICATION

999
00:41:04,120 --> 00:41:06,520
OF TRIALS AND SAVE US ALL MONEY,

1000
00:41:06,520 --> 00:41:08,000
INCREASE EFFICIENCY AND I'M

1001
00:41:08,000 --> 00:41:09,560
WONDERING WHETHER YOU CAN

1002
00:41:09,560 --> 00:41:10,760
COMMENT A LITTLE BIT ON THE

1003
00:41:10,760 --> 00:41:12,280
PROCESS OF HOW THIS IS DEVELOPED

1004
00:41:12,280 --> 00:41:14,000
AND WHETHER THERE'S A RESEARCH

1005
00:41:14,000 --> 00:41:15,200
COMPONENT TO IT.

1006
00:41:15,200 --> 00:41:17,040
>> SO THE CLINICAL TRIALS

1007
00:41:17,040 --> 00:41:20,000
INNOVATION UNIT TAKES IDEAS.

1008
00:41:20,000 --> 00:41:23,040
THE IDEAS COME INTO THROUGH THE

1009
00:41:23,040 --> 00:41:25,680
NATIONAL CLINICAL TRIALS

1010
00:41:25,680 --> 00:41:26,240
NETWORKS LEADERS RIGHT NOW.

1011
00:41:26,240 --> 00:41:29,240
THEY CAN PROPOSAL IDEAS AND YOU

1012
00:41:29,240 --> 00:41:31,920
CAN PITCH THEM TO ANY OF THE

1013
00:41:31,920 --> 00:41:33,280
NCTN LEADERS.

1014
00:41:33,280 --> 00:41:34,960
THERE ARE ALSO TWO DIRECTORS OF

1015
00:41:34,960 --> 00:41:37,080
THE CLINICAL TRIALS UNIT AND

1016
00:41:37,080 --> 00:41:40,520
THEY'RE Dr. SHELIA PRINCIPLE

1017
00:41:40,520 --> 00:41:42,480
DA ZEAL AND CLINICAL TRIALS AND

1018
00:41:42,480 --> 00:41:45,680
CCT AT NCI AND MICHAEL MOORE IS

1019
00:41:45,680 --> 00:41:56,240
WHO IS THE CO DIRECTOR AND WHEN

1020
00:41:59,240 --> 00:42:00,800
THEY AGREE TO TAKE ON A STUDY

1021
00:42:00,800 --> 00:42:02,720
THE CLINICAL TRIALS INNOVATION

1022
00:42:02,720 --> 00:42:04,360
UNIT AGREES TO MAKE IT HAPPEN TO

1023
00:42:04,360 --> 00:42:06,520
FIND THE PARTNERS AND DEAL WITH

1024
00:42:06,520 --> 00:42:07,840
INDUSTRY AND GET IT ALL TOGETHER

1025
00:42:07,840 --> 00:42:09,520
SO THEY'RE NOT GOING TO BE ABLE

1026
00:42:09,520 --> 00:42:10,600
TO TAKE THAT MANY.

1027
00:42:10,600 --> 00:42:12,320
I AM ANTICIPATING IT'S FIRST

1028
00:42:12,320 --> 00:42:14,360
YEAR, WE'LL SEE THREE MAYBE FOUR

1029
00:42:14,360 --> 00:42:16,960
NEW STUDIES LAUNCHED BY THE UNIT

1030
00:42:16,960 --> 00:42:19,560
OVER VARIOUS AREAS.

1031
00:42:19,560 --> 00:42:21,840
BUT LIKE I SAID, AS THIS

1032
00:42:21,840 --> 00:42:24,240
HAPPENS, SOME OF THE TOOLS CAN

1033
00:42:24,240 --> 00:42:28,640
BE MORE MAINSTREAM AND FIT INTO

1034
00:42:28,640 --> 00:42:33,040
OUR RESEARCH AND MECHANISM.

1035
00:42:33,040 --> 00:42:35,280
I HOPE THAT ANSWERS YOUR

1036
00:42:35,280 --> 00:42:35,960
QUESTIONS.

1037
00:42:35,960 --> 00:42:39,240
THE IDEA TO GO TO THE UNIT.

1038
00:42:39,240 --> 00:42:41,920
>> VERY QUICK FOLLOW-UP,
RATHER

1039
00:42:41,920 --> 00:42:45,720
WE DO IMPLEMENTATIONS SCIENCE ON

1040
00:42:45,720 --> 00:42:47,480
THE RESEARCH ON THE NEW METHODS

1041
00:42:47,480 --> 00:42:49,280
THAT ARE GETTING EMPLOYED

1042
00:42:49,280 --> 00:42:50,680
WHETHER IT'S REMOTE SENSOR OR

1043
00:42:50,680 --> 00:42:51,480
OTHER ACTIVITIES?

1044
00:42:51,480 --> 00:42:53,040
>> ANYTHING IS ON THE
TABLE FOR

1045
00:42:53,040 --> 00:42:54,360
THAT UNIT.

1046
00:42:54,360 --> 00:42:55,600
THEY CAN ABSOLUTELY DO

1047
00:42:55,600 --> 00:42:56,840
IMPLEMENTATION SCIENCE, THEY CAN

1048
00:42:56,840 --> 00:43:00,840
DO BIOMARKER DEVELOPMENT,

1049
00:43:00,840 --> 00:43:01,640
ANYTHING WE NEED TO REACH

1050
00:43:01,640 --> 00:43:04,600
PATIENTS AND DO A CLINICAL

1051
00:43:04,600 --> 00:43:06,400
RESEARCH FOR IS THERE.

1052
00:43:06,400 --> 00:43:08,280
IT'S NOT GOING TO DO

1053
00:43:08,280 --> 00:43:11,080
OBSERVATIONAL STUDIES RIGHT NOW.

1054
00:43:11,080 --> 00:43:12,600
>> THANK YOU.

1055
00:43:12,600 --> 00:43:16,240
>> Dr. Flaherty: LAST
QUESTION.

1056
00:43:16,240 --> 00:43:16,760
KAREN.

1057
00:43:16,760 --> 00:43:21,520
>> THANK YOU, MONICA.

1058
00:43:21,520 --> 00:43:22,680
WONDERFUL PRESENTATION.

1059
00:43:22,680 --> 00:43:25,520
I AM ALSO GOING TO ASK JUST FOR

1060
00:43:25,520 --> 00:43:28,280
SOME MORE VERIFICATION ABOUT THE

1061
00:43:28,280 --> 00:43:31,440
CLINICAL TRIALS INNOVATION UNIT.

1062
00:43:31,440 --> 00:43:33,600
SO, A LOT OF THE EXAMPLES WERE

1063
00:43:33,600 --> 00:43:36,680
SEEMING TO FOCUS ON DEVELOPMENT

1064
00:43:36,680 --> 00:43:37,440
OF INNOVATION AROUND TREATMENT

1065
00:43:37,440 --> 00:43:38,840
TRIALS AND I'M CURIOUS ABOUT

1066
00:43:38,840 --> 00:43:42,240
YOUR PERSPECTIVE ON THE

1067
00:43:42,240 --> 00:43:43,920
PRIORITIES OF ENCORE WHICH IS A

1068
00:43:43,920 --> 00:43:44,840
LITTLE DIFFERENT FROM THE

1069
00:43:44,840 --> 00:43:46,640
PRIORITIES OF THE NCTN GROUPS

1070
00:43:46,640 --> 00:43:49,480
WITH CANCER CONTROL STUDIES, SIM

1071
00:43:49,480 --> 00:43:51,000
POM MANAGEMENT, PREVENTION

1072
00:43:51,000 --> 00:43:52,840
STUDIES AND ALSO CANCER CARE AND

1073
00:43:52,840 --> 00:43:54,880
DELIVERY AND ALL OF THAT AND

1074
00:43:54,880 --> 00:43:56,400
THERE'S A LOT OF INNOVATION THAT

1075
00:43:56,400 --> 00:43:59,280
NEEDS TO BE DONE THERE AND

1076
00:43:59,280 --> 00:44:00,520
PARTNERING SO I'M CURIOUS ON

1077
00:44:00,520 --> 00:44:01,880
YOUR THOUGHTS ABOUT THAT AND IS

1078
00:44:01,880 --> 00:44:03,680
IT PART OF WHAT YOU EXPECT TO

1079
00:44:03,680 --> 00:44:04,000
SEE?

1080
00:44:04,000 --> 00:44:05,520
>> IF THIS HELPS, TWO
IDEAS THAT

1081
00:44:05,520 --> 00:44:07,600
ARE CURRENTLY BEING THROWN

1082
00:44:07,600 --> 00:44:09,840
AROUND, NOT ACCEPTED YET BUT

1083
00:44:09,840 --> 00:44:11,400
JUST GENERAL IDEAS THAT ARE OUT

1084
00:44:11,400 --> 00:44:13,800
THERE, ONE OF THEM IS A SYMPTOM

1085
00:44:13,800 --> 00:44:15,720
INTERVENTION STUDY THAT IS

1086
00:44:15,720 --> 00:44:16,480
REALLY EXCITING AND IT ACTUALLY

1087
00:44:16,480 --> 00:44:18,320
MIGHT BE A COLLABORATION WITH

1088
00:44:18,320 --> 00:44:21,680
ONE OF THE OTHER NIH INSTITUTES

1089
00:44:21,680 --> 00:44:24,960
EVEN WHICH IS REALLY EXCITING.

1090
00:44:24,960 --> 00:44:27,520
AND THEN THERE'S ALSO ONE ABOUT

1091
00:44:27,520 --> 00:44:29,880
DATA COLLECTION FOR A CLINICAL

1092
00:44:29,880 --> 00:44:31,760
TRIAL WITH THE FDA THAT WOULD

1093
00:44:31,760 --> 00:44:33,480
USE THE ELECTRONIC HEALTH RECORD

1094
00:44:33,480 --> 00:44:34,920
AS THE SOURCE OF THE DATA.

1095
00:44:34,920 --> 00:44:37,040
SO THERE'S SOME PRETTY COOL

1096
00:44:37,040 --> 00:44:39,000
STUFF HAPPENING AND IT'S NOT

1097
00:44:39,000 --> 00:44:41,120
JUST, IT'S NOT JUST TREATMENT.

1098
00:44:41,120 --> 00:44:41,680
>> PERFECT.

1099
00:44:41,680 --> 00:44:42,800
THANK YOU.

1100
00:44:42,800 --> 00:44:44,080
>> THANK YOU, ALL.

1101
00:44:44,080 --> 00:44:48,000
THANK YOU, MONICA.

1102
00:44:48,000 --> 00:44:49,520
NEXT DEB LOWY IS GOING TO GIVE A

1103
00:44:49,520 --> 00:44:52,280
PRESENTATION ENTITLED NCI

1104
00:44:52,280 --> 00:44:56,520
RESEARCH PROJECT GRANTS BUDGET

1105
00:44:56,520 --> 00:44:59,920
IS BEYOND.

1106
00:44:59,920 --> 00:45:00,600
>> Dr. Lowy: THANK YOU,
VERY

1107
00:45:00,600 --> 00:45:00,880
MUCH.

1108
00:45:00,880 --> 00:45:04,400
GOOD MORNING TO YOU.

1109
00:45:04,400 --> 00:45:06,480
THIS IS NOT DEJA VU ALL OVER

1110
00:45:06,480 --> 00:45:07,320
AGAIN.

1111
00:45:07,320 --> 00:45:11,040
BUT I GAVE A SIMILAR TALK TO THE

1112
00:45:11,040 --> 00:45:13,920
VSA A YEAR AGO BUT WE THINK THAT

1113
00:45:13,920 --> 00:45:16,840
A FAIR AMOUNT HAS HAPPENED AND

1114
00:45:16,840 --> 00:45:19,040
THAT IS REFLECTED, FOR EXAMPLE,

1115
00:45:19,040 --> 00:45:21,600
IN THE VARIOUS QUESTIONS THAT

1116
00:45:21,600 --> 00:45:24,440
YOU HAVE ALREADY ASKED MONICA

1117
00:45:24,440 --> 00:45:28,240
AND I JUST WANT TO SAY THAT FOR

1118
00:45:28,240 --> 00:45:33,080
ANDY CHAN'S QUESTION, WE ARE

1119
00:45:33,080 --> 00:45:35,360
ACTUALLY DEVELOPING DATA LOOKING

1120
00:45:35,360 --> 00:45:45,840
AT VARIOUS OPTIONS THAT THE

1121
00:46:27,760 --> 00:46:29,480
THANK YOU FOR PUTTING THE

1122
00:46:29,480 --> 00:46:30,280
PRESENTATION TOGETHER.

1123
00:46:30,280 --> 00:46:31,600
THE NEXT SLIDE TELLS YOU ABOUT

1124
00:46:31,600 --> 00:46:33,720
THE THREE AREAS THAT I PLAN TO

1125
00:46:33,720 --> 00:46:36,520
COVER IN THE NEXT 15 MINUTES.

1126
00:46:36,520 --> 00:46:41,200
ONE THE DISTRIBUTION OF THE

1127
00:46:41,200 --> 00:46:51,720
APPROPRIATED THAT DEAD TO THE

1128
00:46:55,720 --> 00:46:59,640
POLICIES THAT YOU HAVE ALREADY

1129
00:46:59,640 --> 00:47:00,680
SEEN.

1130
00:47:00,680 --> 00:47:03,280
THE NEXT TWO SLIDES FOCUS ON THE

1131
00:47:03,280 --> 00:47:08,920
NCI BUDGET OVER ALL AND WHAT IS

1132
00:47:08,920 --> 00:47:10,960
SHOWN ON THE OUTER PART ARE

1133
00:47:10,960 --> 00:47:15,000
REALLY THE DISTRIBUTION OF THE

1134
00:47:15,000 --> 00:47:20,040
EXTRAMURAL PARTS WHICH ARE IN

1135
00:47:20,040 --> 00:47:22,240
VARIOUS SHADES OF BLUE AND THEN

1136
00:47:22,240 --> 00:47:23,800
THE OTHER FUNDING THAT INCLUDES

1137
00:47:23,800 --> 00:47:25,080
RESEARCH MANAGEMENT AND SUPPORT

1138
00:47:25,080 --> 00:47:29,160
IN THE INTRAMURAL RESEARCH AND

1139
00:47:29,160 --> 00:47:30,240
BASICALLY, ABOUT THREE QUARTERS

1140
00:47:30,240 --> 00:47:33,520
OF THE FUNDING FROM NCI GOES TO

1141
00:47:33,520 --> 00:47:37,200
EXTRAMURAL FUNDING AND ABOUT A

1142
00:47:37,200 --> 00:47:40,560
QUARTER TO COVER THESE REALLY

1143
00:47:40,560 --> 00:47:42,480
TWO AREAS OF INTRAMURAL

1144
00:47:42,480 --> 00:47:43,520
RESEARCH, RESEARCH MANAGEMENT

1145
00:47:43,520 --> 00:47:46,280
AND SUPPORT AND ALSO BUILDINGS

1146
00:47:46,280 --> 00:47:50,160
AND FACILITIES.

1147
00:47:50,160 --> 00:47:52,480
THE NEXT SLIDE SHOWS THE SAME

1148
00:47:52,480 --> 00:47:55,200
AREA BUT TO HIGHLIGHT A FEW

1149
00:47:55,200 --> 00:47:57,920
THINGS, FIRST, THE RESEARCH

1150
00:47:57,920 --> 00:48:00,080
PROJECT GRANTS, THE RPGs

1151
00:48:00,080 --> 00:48:03,880
REPRESENT THE SINGLE LARGEST

1152
00:48:03,880 --> 00:48:08,680
AMOUNT OF INVESTMENT FOR THE NCI

1153
00:48:08,680 --> 00:48:10,320
BUDGET, 44%.

1154
00:48:10,320 --> 00:48:12,440
BUT AS SHOWN IN THE TWO BULLET

1155
00:48:12,440 --> 00:48:14,600
POINTS ON THE RIGHT, NCI

1156
00:48:14,600 --> 00:48:16,520
SUPPORTS A LOT OF RESEARCH AND

1157
00:48:16,520 --> 00:48:18,200
OTHER ACTIVITIES THAT ARE

1158
00:48:18,200 --> 00:48:22,160
OUTSIDE THE RPG POOL, MONICA HAS

1159
00:48:22,160 --> 00:48:24,920
ALREADY ALLU ALLUDED TO SOME BUE

1160
00:48:24,920 --> 00:48:29,840
SECOND BULLET, CANCER CENTER

1161
00:48:29,840 --> 00:48:32,560
SUPPORT GRANTS, SPORES AND

1162
00:48:32,560 --> 00:48:33,200
TRAINING.

1163
00:48:33,200 --> 00:48:34,960
THE NEXT SLIDE LOOKS AT WHAT

1164
00:48:34,960 --> 00:48:41,800
HAVE WE DONE ESSENTIALLY WITH

1165
00:48:41,800 --> 00:48:44,280
THE $1 BILLION INCREASE THAT THE

1166
00:48:44,280 --> 00:48:49,160
NCI HAS RECEIVED FROM 2018

1167
00:48:49,160 --> 00:48:49,680
THROUGH 2022.

1168
00:48:49,680 --> 00:48:51,920
WE'RE NOT INCLUDING 2023 BECAUSE

1169
00:48:51,920 --> 00:48:53,920
WE DON'T KNOW EXACTLY WHAT THE

1170
00:48:53,920 --> 00:48:59,200
NUMBERS ARE GOING TO BE.

1171
00:48:59,200 --> 00:49:02,560
ON THE LEFT, I HOPE YOU CAN

1172
00:49:02,560 --> 00:49:08,040
APPRECIATE THAT ABOUT 53% OR

1173
00:49:08,040 --> 00:49:11,920
ABOUT $550,000,000.1.072 MILLION

1174
00:49:11,920 --> 00:49:15,720
HAS GONE TO THE RPG POOL AND 47%

1175
00:49:15,720 --> 00:49:17,280
TO ANOTHER AND JUST REMIND YOU

1176
00:49:17,280 --> 00:49:21,080
ON THE OTHER SLIDE, THAT THE RPG

1177
00:49:21,080 --> 00:49:23,520
POOL IS 44%.

1178
00:49:23,520 --> 00:49:25,200
SO WE'VE ALL OWE INDICATED MORE

1179
00:49:25,200 --> 00:49:27,960
FUNDING TO THE RPG POOL THAN TO

1180
00:49:27,960 --> 00:49:30,240
THE REST OF THE AREA.

1181
00:49:30,240 --> 00:49:35,240
OVER THAT FOUR-YEAR PERIOD, THE

1182
00:49:35,240 --> 00:49:37,240
PREPORTION OF THE RPG POOL HAS

1183
00:49:37,240 --> 00:49:40,400
GONE FRIENDSHIP 41 TO 44 PERCENT

1184
00:49:40,400 --> 00:49:42,680
AND THIS REPRESENTS AN AVERAGE

1185
00:49:42,680 --> 00:49:48,240
OF ABOUT $140 MILLION OF THE 260

1186
00:49:48,240 --> 00:49:50,200
FOR THE INCREASES THAT WE'VE

1187
00:49:50,200 --> 00:49:55,440
SEEN ON AVERAGE IN THE LAST FOUR

1188
00:49:55,440 --> 00:49:58,880
YEARS.

1189
00:49:58,880 --> 00:50:02,080
THE PERCENTAGE IS PROJECTED TO

1190
00:50:02,080 --> 00:50:03,360
INCREASE FURTHER IN '23 BUT

1191
00:50:03,360 --> 00:50:04,760
WE'RE NOT INCLUDING IT BECAUSE

1192
00:50:04,760 --> 00:50:07,840
WE DON'T KNOW THE PRECISE

1193
00:50:07,840 --> 00:50:08,800
AMOUNT.

1194
00:50:08,800 --> 00:50:12,080
THE NEXT FEW SLIDES TALK ABOUT

1195
00:50:12,080 --> 00:50:14,360
THE RPG POOL TRENDS.

1196
00:50:14,360 --> 00:50:16,360
THE NEXT SLIDE, THERE ARE FOUR

1197
00:50:16,360 --> 00:50:22,600
SLIDES IN THIS PART.

1198
00:50:22,600 --> 00:50:23,880
INDICATES WHAT WE SAW ABOUT FIVE

1199
00:50:23,880 --> 00:50:27,520
OR SIX YEARS AGO WHICH WAS THE

1200
00:50:27,520 --> 00:50:30,000
RATE OF APPLICATIONS AND NUMBER

1201
00:50:30,000 --> 00:50:35,440
OF APPLICANTS TO NCI WENT UP

1202
00:50:35,440 --> 00:50:37,280
FASTER THAN THE NUMBER OF

1203
00:50:37,280 --> 00:50:41,920
APPLICATIONS AND APPLICANTS FROM

1204
00:50:41,920 --> 00:50:45,080
OTHER INSTITUTES AND CENTERS AND

1205
00:50:45,080 --> 00:50:56,000
AS OF 2022, BETWEEN 2013 AND '2Y

1206
00:51:01,000 --> 00:51:02,480
APPLICANTS IN TERMS OF THE

1207
00:51:02,480 --> 00:51:05,320
INCREASE AND NCI AND THE NEXT

1208
00:51:05,320 --> 00:51:08,320
SLIDE, SHOWS WHAT HAS HAPPENED

1209
00:51:08,320 --> 00:51:11,520
REALLY OVER THE LAST COUPLE OF

1210
00:51:11,520 --> 00:51:14,600
DECADES FOR FUNDING WITH THE RPG

1211
00:51:14,600 --> 00:51:17,880
AND THIS IS NOT A PAYLINE, THIS

1212
00:51:17,880 --> 00:51:22,920
IS SUCCESS RATES OKAY AND THE

1213
00:51:22,920 --> 00:51:25,480
BLUE IS THE NIH AND THE ORANGE

1214
00:51:25,480 --> 00:51:26,120
IS NCI.

1215
00:51:26,120 --> 00:51:29,440
WHAT I THINK YOU WANT TO SEE AND

1216
00:51:29,440 --> 00:51:31,240
APPRECIATE IS THAT DURING THIS

1217
00:51:31,240 --> 00:51:33,080
TIME, THAT THERE WAS THIS

1218
00:51:33,080 --> 00:51:35,840
SUBSTANTIAL INCREASE IN THE

1219
00:51:35,840 --> 00:51:42,160
NUMBER OF APPLICATIONS AND OUR

1220
00:51:42,160 --> 00:51:45,680
FUNDING OF ACTUALLY OUR SUCCESS

1221
00:51:45,680 --> 00:51:48,360
RATES WENT DOWN AND THEY HAD

1222
00:51:48,360 --> 00:51:51,320
GONE UP OVER THE LAST FEW YEARS

1223
00:51:51,320 --> 00:51:55,240
BUT NOT AS HIGH AS NIH PART OF

1224
00:51:55,240 --> 00:52:02,000
THAT IS ACCOUNTED FOR BECAUSE WE

1225
00:52:02,000 --> 00:52:04,560
SUPPORT RESEARCH OUTSIDE OF THE

1226
00:52:04,560 --> 00:52:07,160
RPG AREA WHERE THE RPG PORTION

1227
00:52:07,160 --> 00:52:09,560
ACCOUNTS FOR A SUBSTANTIALLY

1228
00:52:09,560 --> 00:52:13,120
HIGHER PERCENTAGE FOR MANY OTHER

1229
00:52:13,120 --> 00:52:17,800
INSTITUTES AND CENTERS.

1230
00:52:17,800 --> 00:52:21,160
SO THIS SLIDE DEPICTS WHAT

1231
00:52:21,160 --> 00:52:23,920
HAPPENED FOR EARLY STAGE

1232
00:52:23,920 --> 00:52:25,480
INVESTIGATORS AND IN THE GREEN

1233
00:52:25,480 --> 00:52:27,800
OR THE TOTAL NUMBER OF AWARDS

1234
00:52:27,800 --> 00:52:30,560
THAT WERE MADE EACH YEAR TO THE

1235
00:52:30,560 --> 00:52:33,800
EARLY STAGE INVESTIGATORS AND IN

1236
00:52:33,800 --> 00:52:35,880
BLUE, THE PAYLINE FOR THE

1237
00:52:35,880 --> 00:52:36,960
AEROMEXICO STAGE INVESTIGATORS

1238
00:52:36,960 --> 00:52:39,680
FOR EACH OF THE YEARS.

1239
00:52:39,680 --> 00:52:44,560
I HAVE OUTLINED IN THE RED

1240
00:52:44,560 --> 00:52:45,200
RECTANGLE, 2019 BECAUSE I WANT

1241
00:52:45,200 --> 00:52:47,920
YOU HAD TO USE THAT AS A

1242
00:52:47,920 --> 00:52:50,160
REFERENCE POINT FOR THE

1243
00:52:50,160 --> 00:52:51,320
EXPERIENCED INVESTIGATORS THAT

1244
00:52:51,320 --> 00:52:53,160
YOU WILL SEE ON THE NEXT SLIDE.

1245
00:52:53,160 --> 00:52:56,360
BUT BEFORE WE GO THERE, THE

1246
00:52:56,360 --> 00:52:59,080
NUMBER OF AWARDS THAT WE'VE BEEN

1247
00:52:59,080 --> 00:53:01,360
ABLE TO MAKE TO AEROMEXICO STAGE

1248
00:53:01,360 --> 00:53:06,120
INVESTIGATORS HAS REALLY GONE UP

1249
00:53:06,120 --> 00:53:10,080
SUBSTANTIALLY SINCE THE 2016 AND

1250
00:53:10,080 --> 00:53:12,280
2017 AREA GOING FROM THE 80s

1251
00:53:12,280 --> 00:53:16,040
TO THE 130s.

1252
00:53:16,040 --> 00:53:17,840
THE NEXT SLIDE SHOWS YOU WITH

1253
00:53:17,840 --> 00:53:21,160
EXPERIENCED INVESTIGATORS, THAT

1254
00:53:21,160 --> 00:53:23,640
THE NUMBER OF AWARDS THAT WE'VE

1255
00:53:23,640 --> 00:53:28,160
BEEN ABLE TO MAKE HAS GONE UP

1256
00:53:28,160 --> 00:53:34,200
AGAIN PARTICULARLY SINCE 2019

1257
00:53:34,200 --> 00:53:39,920
WHEN WE HAD THIS LOW PAYLINE OF

1258
00:53:39,920 --> 00:53:45,320
8% AND THAT YEAR WE ACTUALLY THE

1259
00:53:45,320 --> 00:53:47,360
ESIs WERE 6 PERCENTAGE POINT

1260
00:53:47,360 --> 00:53:51,520
HIGHER FOR THE SWEPT YEARS IT'S

1261
00:53:51,520 --> 00:53:53,920
BEEN 5% POINTS HIGHER AND AS

1262
00:53:53,920 --> 00:53:57,200
MONICA POINTED OUT, WE

1263
00:53:57,200 --> 00:53:59,960
ANTICIPATE A SUB T SUBSTANTIAL

1264
00:53:59,960 --> 00:54:01,720
INCREASE IN THE TOTAL NUMBER OF

1265
00:54:01,720 --> 00:54:03,680
AWARDS IN 2023 BUT WE DON'T KNOW

1266
00:54:03,680 --> 00:54:07,640
THE NUMBERS BECAUSE WE'RE STILL

1267
00:54:07,640 --> 00:54:14,440
REALLY JUST THE FIRST HALF OF

1268
00:54:14,440 --> 00:54:15,480
THE FISCAL YEAR.

1269
00:54:15,480 --> 00:54:17,280
I NOW HAVE FIVE SLIDES FOR

1270
00:54:17,280 --> 00:54:22,720
CONSIDERATION OF FY23.

1271
00:54:22,720 --> 00:54:24,240
THE FIRST SLIDE IS BASICALLY

1272
00:54:24,240 --> 00:54:28,800
WHAT YOU HAVE SEEN ALREADY FROM

1273
00:54:28,800 --> 00:54:30,560
MONICA'S PRESENTATION WHERE THE

1274
00:54:30,560 --> 00:54:33,680
ESTABLISHED INVESTIGATORS OF THE

1275
00:54:33,680 --> 00:54:36,400
12% EARLY STAGE INVESTIGATORS,

1276
00:54:36,400 --> 00:54:37,720
17th% AND SHE DIDN'T MENTION

1277
00:54:37,720 --> 00:54:42,160
BUT THE R21s NINTH PERCENTILE

1278
00:54:42,160 --> 00:54:44,680
AND THE COMPETING GRANTS AT 98%

1279
00:54:44,680 --> 00:54:47,400
SO LET'S GO THROUGH THIS TO TRY

1280
00:54:47,400 --> 00:54:49,160
TO UNDERSTAND BETTER HOW WE GOT

1281
00:54:49,160 --> 00:54:51,200
THERE.

1282
00:54:51,200 --> 00:54:54,440
NEXT SLIDE.

1283
00:54:54,440 --> 00:54:57,080
SO, EACH YEAR, THIS ARE TWO OVER

1284
00:54:57,080 --> 00:54:58,840
ALL INVESTMENT CATEGORIES WITHIN

1285
00:54:58,840 --> 00:55:00,120
THE RPG POOL.

1286
00:55:00,120 --> 00:55:02,120
THE COMPETING AWARDS ORCHARD

1287
00:55:02,120 --> 00:55:07,400
REFOR THE NEWAWARDS AND THE SECE

1288
00:55:07,400 --> 00:55:09,600
NON COMPETING AWARDS OR THE

1289
00:55:09,600 --> 00:55:11,600
OUT-YEAR AWARDS.

1290
00:55:11,600 --> 00:55:15,400
TO PRIORITIZE FUNDING MORE NEW

1291
00:55:15,400 --> 00:55:17,160
AWARDS, WE GENERALLY FUND ONLY

1292
00:55:17,160 --> 00:55:21,760
THE FIRST YEAR OF THE AWARDS

1293
00:55:21,760 --> 00:55:24,160
WHEN THEY ARE MADE, HOWEVER,

1294
00:55:24,160 --> 00:55:25,960
THEY'RE MORE THAN ONE YEAR.

1295
00:55:25,960 --> 00:55:27,920
THE R56 AWARDS ARE NOTABLE

1296
00:55:27,920 --> 00:55:30,080
EXCEPTION JUST ONE YEAR BUT

1297
00:55:30,080 --> 00:55:31,480
MOSTLY THE VAST MAJORITY ARE

1298
00:55:31,480 --> 00:55:34,760
MORE THAN ONE YEAR AND THE

1299
00:55:34,760 --> 00:55:36,760
AVERAGE LENGTH IS FIVE YEARS AND

1300
00:55:36,760 --> 00:55:38,320
GO THROUGH SOME OF THE

1301
00:55:38,320 --> 00:55:42,160
IMPLICATIONS OF THAT.

1302
00:55:42,160 --> 00:55:45,120
NEXT SLIDE.

1303
00:55:45,120 --> 00:55:47,000
WE HAVE TWO MAIN FUNDING SOURCES

1304
00:55:47,000 --> 00:55:49,240
FOR THE RPG POOL.

1305
00:55:49,240 --> 00:55:52,080
ONE IS THE TURNOVER FUNDS FROM

1306
00:55:52,080 --> 00:55:54,680
THE NON COMPETING RPG AWARDS

1307
00:55:54,680 --> 00:56:02,240
THAT WERE COMPLETED IN THE.

1308
00:56:02,240 --> 00:56:02,960
PRIOR YEAR.

1309
00:56:02,960 --> 00:56:04,640
IF EVERYTHING WERE AT STUDY

1310
00:56:04,640 --> 00:56:07,800
STATE THAT WOULD BE SUFFICIENT.

1311
00:56:07,800 --> 00:56:10,440
THAT'S NOT SUFFICIENT AND SO WE

1312
00:56:10,440 --> 00:56:13,560
NEED TO AT FUNDS FROM THE NCI

1313
00:56:13,560 --> 00:56:15,200
APPROPRIATION BECAUSE TURNOVER

1314
00:56:15,200 --> 00:56:25,640
DOLLARS ARE INSUFFICIENT.

1315
00:56:41,640 --> 00:56:43,000
THE THE AVERAGE COST OF EACH

1316
00:56:43,000 --> 00:56:44,120
COMPETING AWARD WILL BE HIGHER

1317
00:56:44,120 --> 00:56:47,000
THAN THE COST OF EACH COMPLETED

1318
00:56:47,000 --> 00:56:48,080
AWARD.

1319
00:56:48,080 --> 00:56:52,320
AND THIRD, THE OUT YEAR COST OF

1320
00:56:52,320 --> 00:56:53,800
MULTI-YEAR AWARDS.

1321
00:56:53,800 --> 00:56:56,080
MONICA SHOWED YOU THE STAIR STEP

1322
00:56:56,080 --> 00:56:58,480
NOTION THAT WE NEED TO ADD MORE

1323
00:56:58,480 --> 00:57:00,600
FUNDING EACH YEAR IN ORDER TO

1324
00:57:00,600 --> 00:57:11,000
COVER THE OUT YEAR COST.

1325
00:57:21,720 --> 00:57:24,280
I NOW WANT TO GO TO THE NON

1326
00:57:24,280 --> 00:57:25,440
COMPETING AWARDS.

1327
00:57:25,440 --> 00:57:29,040
WHY MIGHT WE FUND THEM AT LESS

1328
00:57:29,040 --> 00:57:29,960
THAN 100% OF THE COMMITMENT

1329
00:57:29,960 --> 00:57:30,760
LEVEL?

1330
00:57:30,760 --> 00:57:33,400
THE FIRST BULLET TELLS YOU NCI

1331
00:57:33,400 --> 00:57:34,360
CONSIDERS THIS OPTION WHEN THE

1332
00:57:34,360 --> 00:57:37,520
FUNDS FROM TURNOVER COMPLETED

1333
00:57:37,520 --> 00:57:39,320
AWARDS PLUS FROM NCI

1334
00:57:39,320 --> 00:57:42,040
APPROPRIATIONS ARE I AM

1335
00:57:42,040 --> 00:57:48,800
SUFFICINSUFFICIENT.IT'S WHETHERS

1336
00:57:48,800 --> 00:57:50,360
THAT IS HAVING A HIGHER PAYLINE

1337
00:57:50,360 --> 00:57:53,040
OR TO PRIORITIZE FUNDING NON

1338
00:57:53,040 --> 00:57:55,480
COMPETING GRANTS AND ARE 100%

1339
00:57:55,480 --> 00:57:59,240
AND WE'VE CONSULTED WITH YOU AND

1340
00:57:59,240 --> 00:58:01,400
NCAB IN THE PAST AND WE ARE

1341
00:58:01,400 --> 00:58:03,800
USUALLY PRIORITIZING FUNDING

1342
00:58:03,800 --> 00:58:05,840
MORE COMPETING AWARDS BECAUSE

1343
00:58:05,840 --> 00:58:08,680
THAT SEEMS TO BE THE SENSE OF

1344
00:58:08,680 --> 00:58:12,360
THE COMMUNITY.

1345
00:58:12,360 --> 00:58:15,120
NEXT SLIDE.

1346
00:58:15,120 --> 00:58:20,440
THESE ARE SOME COLLAR DOLLAR

1347
00:58:20,440 --> 00:58:21,160
CONSIDERATIONS.

1348
00:58:21,160 --> 00:58:29,920
THE RPG PEOPLE AT THE END OF

1349
00:58:29,920 --> 00:58:34,160
2022, WAS $2.89 BILLION.

1350
00:58:34,160 --> 00:58:37,200
THE RO1s MAKE UP 60% OF THE

1351
00:58:37,200 --> 00:58:41,200
TOTAL RPG POOL.

1352
00:58:41,200 --> 00:58:42,720
EACH TIME WE INCREASE OR

1353
00:58:42,720 --> 00:58:45,680
DECREASE THE PAYLINE BY A

1354
00:58:45,680 --> 00:58:47,800
PERCENTILE POINT, WE ARE ADDING

1355
00:58:47,800 --> 00:58:52,360
OR SUBTRACTING ABOUT

1356
00:58:52,360 --> 00:58:53,080
$33 MILLION.

1357
00:58:53,080 --> 00:58:54,600
AND WHEN WE ARE LOOKING AT THE

1358
00:58:54,600 --> 00:58:59,000
NON COMPETING PERCENTILE, THAT

1359
00:58:59,000 --> 00:59:02,880
PERCENT IS $21 MILLION SO THESE

1360
00:59:02,880 --> 00:59:04,440
VARIOUS CONSIDERATIONS ARE WHAT

1361
00:59:04,440 --> 00:59:06,960
LEAD US TO MAKE THE DECISIONS.

1362
00:59:06,960 --> 00:59:12,840
THE FINAL SLIDE, REALLY IS THE

1363
00:59:12,840 --> 00:59:15,200
SUMMARY.

1364
00:59:15,200 --> 00:59:18,160
FIRST, NCI HAS PRIOR TASED RPG

1365
00:59:18,160 --> 00:59:19,640
FUNDING ABOUT $550 MILLION HAS

1366
00:59:19,640 --> 00:59:21,480
BEEN ADDED TO THE RPG POOL

1367
00:59:21,480 --> 00:59:24,240
DURING THE FOUR YEARS BETWEEN

1368
00:59:24,240 --> 00:59:34,480
2018 AND '22.

1369
00:59:39,080 --> 00:59:40,560
EXTRAMURAL FUNDING RESEARCH LIES

1370
00:59:40,560 --> 00:59:44,160
OUTSIDE THE RPG POOL AND NCI HAS

1371
00:59:44,160 --> 00:59:46,480
NOT NEGLECTED THE OTHER PARTS OF

1372
00:59:46,480 --> 00:59:47,520
THIS RESEARCH PORTFOLIO.

1373
00:59:47,520 --> 00:59:48,840
THANK YOU VERY MUCH AND I THINK

1374
00:59:48,840 --> 00:59:50,640
WE HAVE A FEW MINUTES FOR

1375
00:59:50,640 --> 00:59:58,960
QUESTIONS AND COMMENTS.

1376
00:59:58,960 --> 00:59:59,720
>> Dr. Flaherty: THANK
YOU,

1377
00:59:59,720 --> 01:00:02,760
DOUG.

1378
01:00:02,760 --> 01:00:11,400
QUESTIONS?

1379
01:00:11,400 --> 01:00:12,400
>> THANK YOU, DOUG.

1380
01:00:12,400 --> 01:00:14,200
COULD YOU COMMENT MORE ABOUT THE

1381
01:00:14,200 --> 01:00:15,720
DENOMINAT OR AND THE NUMBER OF

1382
01:00:15,720 --> 01:00:26,200
APPLICATIONS COMING TO THE NCI?

1383
01:00:26,200 --> 01:00:27,040
>> Dr. Lowy: THE NUMBER?

1384
01:00:27,040 --> 01:00:27,640
>> YEAH.

1385
01:00:27,640 --> 01:00:29,040
>> Dr. Lowy: WE GET, I
HOPE I'M

1386
01:00:29,040 --> 01:00:35,360
CORRECT, WE GET AROUND 3500

1387
01:00:35,360 --> 01:00:45,760
APPLICATIONS EACH YEAR THE

1388
01:00:45,760 --> 01:00:49,680
SUCCESS RATE IS ABOUT 14% AND SO

1389
01:00:49,680 --> 01:00:53,640
THE SUCCESS RATE FOR RPGs IS

1390
01:00:53,640 --> 01:00:59,880
WE GET ABOUT 800 SO PROBABLY

1391
01:00:59,880 --> 01:01:03,880
ABOUT 400,000 TO 5,000

1392
01:01:03,880 --> 01:01:08,280
APPLICATIONS.

1393
01:01:08,280 --> 01:01:09,960
>> I MEANT THE TRENDS AND
HOW IT

1394
01:01:09,960 --> 01:01:13,640
COMPARES TO THE OTHER

1395
01:01:13,640 --> 01:01:14,360
INSTITUTES?

1396
01:01:14,360 --> 01:01:15,800
>> Dr. Lowy: I'M SORRY,
BOB, THE

1397
01:01:15,800 --> 01:01:20,560
TRENDS ARE THAT HOURS HAVE BEEN

1398
01:01:20,560 --> 01:01:25,080
FLAT FOR THE LAST COUPLE OF

1399
01:01:25,080 --> 01:01:35,200
YEARS.

1400
01:01:38,680 --> 01:01:39,960
WE CAN SEE THE INTERPRETED WHEN

1401
01:01:39,960 --> 01:01:43,080
WE LOOK AT THE RELEVANT SLIDE.

1402
01:01:43,080 --> 01:01:44,160
>> YOU HAVE A COMMENT?

1403
01:01:44,160 --> 01:01:46,240
>> YES, THANK YOU, DOUG.

1404
01:01:46,240 --> 01:01:50,520
I WAS JUST CURE BUS THE R37

1405
01:01:50,520 --> 01:01:51,120
GRANTS.

1406
01:01:51,120 --> 01:01:53,320
IT MAY BE TOO EARLY TO SEE WHAT

1407
01:01:53,320 --> 01:01:56,520
THE IMPACT IS INTENSE ON FUNDING

1408
01:01:56,520 --> 01:01:57,840
BUT ONE -- THAT --

1409
01:01:57,840 --> 01:01:59,760
>> THAT'S A VERY IMPORTANT

1410
01:01:59,760 --> 01:02:00,240
QUESTION.

1411
01:02:00,240 --> 01:02:03,600
WE INSTITUTED THAT POLICY A

1412
01:02:03,600 --> 01:02:06,880
NUMBER OF YEARS AGO BECAUSE WE

1413
01:02:06,880 --> 01:02:08,880
WANTED EARLY STAGE INVESTIGATORS

1414
01:02:08,880 --> 01:02:11,560
TO HAVE AN EVEN GREATER

1415
01:02:11,560 --> 01:02:13,920
OPPORTUNITY TO TRY TO MAKE AN

1416
01:02:13,920 --> 01:02:18,080
IMPACT WITH THEIR FIRST AWARD.

1417
01:02:18,080 --> 01:02:20,880
AND WHAT HAPPENS IS THAT IT'S

1418
01:02:20,880 --> 01:02:22,880
NOT AUTOMATIC THAT EVER FIVE

1419
01:02:22,880 --> 01:02:25,880
YEARS THAT THEY GO TO THE EXTRA

1420
01:02:25,880 --> 01:02:26,840
TWO YEARS.

1421
01:02:26,840 --> 01:02:31,040
THEY WRITE A PROGRESS REPORT AND

1422
01:02:31,040 --> 01:02:41,560
THEN ENCLOSED SESSION AND I'M

1423
01:02:50,200 --> 01:02:51,720
PLEASED TO TELL YOU THAT THE

1424
01:02:51,720 --> 01:02:53,560
PROBLEM THAT THE VAST MAJORITY

1425
01:02:53,560 --> 01:02:56,360
OF THE PEOPLE WHO ARE ELIGIBLE

1426
01:02:56,360 --> 01:03:01,920
THUS FAR FOR THE R37, THEIR

1427
01:03:01,920 --> 01:03:12,480
PROGRESS HAS THEY'RE GERMANE TO

1428
01:03:38,400 --> 01:03:39,880
THIS STATISTIC THAT YOU

1429
01:03:39,880 --> 01:03:41,280
QUOTED -- I DID NOT APPRECIATE,

1430
01:03:41,280 --> 01:03:43,240
YOU CHANGED THE FUNDING LINE BY

1431
01:03:43,240 --> 01:03:45,080
ONE POINT OR ONE PERCENT YOU

1432
01:03:45,080 --> 01:03:48,400
SAID AND IT'S SEVERAL BILLION

1433
01:03:48,400 --> 01:03:50,320
DOLLARS OF EFFECT, IF I REMEMBER

1434
01:03:50,320 --> 01:03:51,160
THAT SLIDE.

1435
01:03:51,160 --> 01:03:53,520
THAT TO ME WAS EYE-OPENING AND I

1436
01:03:53,520 --> 01:03:54,600
WAS SITTING HERE TRYING TO THINK

1437
01:03:54,600 --> 01:03:57,080
OF HOW THAT CAN POSSIBLY BE SO

1438
01:03:57,080 --> 01:04:00,160
IF IT'S 1%, OF 3,500 GRANTS

1439
01:04:00,160 --> 01:04:02,160
WHICH IS WHAT THE ANSWER WAS TO

1440
01:04:02,160 --> 01:04:05,000
BOB'S QUESTION, THAT WOULD ONLY

1441
01:04:05,000 --> 01:04:07,160
BE 35 GRANTS.

1442
01:04:07,160 --> 01:04:08,800
SO UNDERSTANDING THAT THE LINK

1443
01:04:08,800 --> 01:04:11,480
BETWEEN THE 1% AND THE 3 BILLION

1444
01:04:11,480 --> 01:04:12,640
WOULD BE EYE-OPENING.

1445
01:04:12,640 --> 01:04:14,200
IT IS CERTAINLY A SHOCKING

1446
01:04:14,200 --> 01:04:14,800
STATISTIC.

1447
01:04:14,800 --> 01:04:19,760
>> Dr. Lowy: YEAH.

1448
01:04:19,760 --> 01:04:25,320
SO, THE THE NEW AWARDS THAT WE

1449
01:04:25,320 --> 01:04:27,560
MAKE EACH YEAR, ABOUT 60% OF

1450
01:04:27,560 --> 01:04:32,520
THEM ARE RO1 OR RO1 AWARDS.

1451
01:04:32,520 --> 01:04:36,280
AND THE 33 MILLION IS REALLY FOR

1452
01:04:36,280 --> 01:04:38,040
EACH PERCENT STYLE SO IF WE'RE

1453
01:04:38,040 --> 01:04:47,120
AT, TO USE AN EASY NUMBER AND

1454
01:04:47,120 --> 01:04:57,680
THAT WOULD BE IT'S NOT THAT EACH

1455
01:04:58,680 --> 01:05:00,000
PERCENTILE IS NOT BUT THAT'S

1456
01:05:00,000 --> 01:05:03,400
WHAT IT COMES DOWN TO SO THIS --

1457
01:05:03,400 --> 01:05:06,560
YOU KNOW, BASICALLY, FOR THE

1458
01:05:06,560 --> 01:05:09,320
12%, YOU ARE TALKING ABOUT

1459
01:05:09,320 --> 01:05:12,880
$66 MILLION PLUS THE 300 SO IN

1460
01:05:12,880 --> 01:05:15,520
ROUND FIGURES IT'S $400 MILLION

1461
01:05:15,520 --> 01:05:20,800
IN NEW RO1 AWARDS.

1462
01:05:20,800 --> 01:05:22,880
>> THANK YOU, IT'S A
STRIKING

1463
01:05:22,880 --> 01:05:23,160
STATISTIC.

1464
01:05:23,160 --> 01:05:27,520
>> BUT WHAT IS EQUALLY
IMPORTANT

1465
01:05:27,520 --> 01:05:32,360
IS THE NUMBER OF INCREDIBLY

1466
01:05:32,360 --> 01:05:36,360
OUTSTANDING APPLICATIONS THAT WE

1467
01:05:36,360 --> 01:05:37,920
CAN'T FUND.

1468
01:05:37,920 --> 01:05:43,320
AT 129% THEY WERE JUST SO MANY

1469
01:05:43,320 --> 01:05:53,840
HOW DO YOU DIS TICK WISH AND TO

1470
01:06:10,680 --> 01:06:12,760
BE POSITIVE I'VE QUOTED SUCCESS

1471
01:06:12,760 --> 01:06:23,200
RATE OF 13% AND I THINK --

1472
01:06:27,800 --> 01:06:29,280
>> THIS IS FOR ALL AWARDS.

1473
01:06:29,280 --> 01:06:33,840
THIS IS NOT JUST THE RO1s.

1474
01:06:33,840 --> 01:06:37,040
>> YEAH.

1475
01:06:37,040 --> 01:06:40,520
>> 10% OF RO1s WERE 14% I

1476
01:06:40,520 --> 01:06:42,520
BELIEVE LAST YEAR.

1477
01:06:42,520 --> 01:06:43,440
SHERRI, THIS NEEDS TO BE THE

1478
01:06:43,440 --> 01:06:49,280
LAST QUESTION, I'M SORRY.

1479
01:06:49,280 --> 01:06:50,000
>> Dr. Flaherty: THANK
YOU.

1480
01:06:50,000 --> 01:06:53,520
ASK YOUR QUESTION.

1481
01:06:53,520 --> 01:06:54,240
>> I DID.

1482
01:06:54,240 --> 01:06:59,040
I SAID THAT YOU CLOSED THE GAP.

1483
01:06:59,040 --> 01:06:59,640
>> Dr. Lowy: OH, I'M
SORRY.

1484
01:06:59,640 --> 01:07:02,720
>> AND NOW IT'S JUST 15
AND 21

1485
01:07:02,720 --> 01:07:04,040
SO WE ARE MOVING IN THE RIGHT

1486
01:07:04,040 --> 01:07:04,880
DIRECTION.

1487
01:07:04,880 --> 01:07:05,480
>> Dr. Lowy: YEAH.

1488
01:07:05,480 --> 01:07:06,680
KEITH, BACK TO YOU.

1489
01:07:06,680 --> 01:07:08,280
>> Dr. Flaherty: THANK
YOU,

1490
01:07:08,280 --> 01:07:08,960
DOUG.

1491
01:07:08,960 --> 01:07:12,320
NOW, ON TO THE LEGISLATIVE

1492
01:07:12,320 --> 01:07:14,360
REPORT.

1493
01:07:14,360 --> 01:07:20,960
M.K. HOLOHAN.

1494
01:07:20,960 --> 01:07:21,840
>> Ms. Holohan: YOU HAVE
IF

1495
01:07:21,840 --> 01:07:22,680
QUESTIONS THAT I DON'T COVER

1496
01:07:22,680 --> 01:07:24,120
HERE OR WE DON'T HAVE TIME TO

1497
01:07:24,120 --> 01:07:25,640
GET TO QUESTIONS, PLEASE REACH

1498
01:07:25,640 --> 01:07:27,520
OUT TO ME AND WE'RE HAPPY TO

1499
01:07:27,520 --> 01:07:30,840
TALK WITH YOU OR YOUR STAFF.

1500
01:07:30,840 --> 01:07:31,640
NEXT SLIDE, PLEASE.

1501
01:07:31,640 --> 01:07:33,440
I'M GOING TO TOUCH ON THESE FOUR

1502
01:07:33,440 --> 01:07:34,040
TOPICS TODAY.

1503
01:07:34,040 --> 01:07:36,680
THE DEBT LIMIT AND BUDGET

1504
01:07:36,680 --> 01:07:37,960
NEGOTIATIONS THAT JUST RELEASED

1505
01:07:37,960 --> 01:07:39,920
PRESIDENT'S BUDGET REQUEST FOR

1506
01:07:39,920 --> 01:07:42,640
FISCAL YEAR 2024 AND IT TEES OFF

1507
01:07:42,640 --> 01:07:43,880
THE CONGRESSIONAL APPROPRIATIONS

1508
01:07:43,880 --> 01:07:46,480
PROCESS AND THEN A WORD ABOUT

1509
01:07:46,480 --> 01:07:49,080
OVERSIGHT IN THIS 118

1510
01:07:49,080 --> 01:07:49,440
118th CONGRESS.

1511
01:07:49,440 --> 01:07:51,400
NEXT SLIDE, PLEASE.

1512
01:07:51,400 --> 01:07:53,760
SO THE DEBT CEILING GAME OF

1513
01:07:53,760 --> 01:07:56,400
CHICKEN BEGINS.

1514
01:07:56,400 --> 01:08:00,200
SO, DEBT LIMIT INCREASES ARE

1515
01:08:00,200 --> 01:08:00,440
ROUTINE.

1516
01:08:00,440 --> 01:08:02,280
THEY PASS IN ALL SORTS OF

1517
01:08:02,280 --> 01:08:03,840
ADMINISTRATIONS RND

1518
01:08:03,840 --> 01:08:05,840
ADMINISTRATIONS AND THEY DO

1519
01:08:05,840 --> 01:08:07,600
BECOME LEVERAGE FOR DEAL-MAKING.

1520
01:08:07,600 --> 01:08:10,000
THE URGENCY OF A DEBT LIMIT.

1521
01:08:10,000 --> 01:08:14,240
AND THE IMPENDING X DATE OF THE

1522
01:08:14,240 --> 01:08:15,920
TREASURY REFERS TO IT IT SERVING

1523
01:08:15,920 --> 01:08:20,360
AS LEVERAGE AND CREATES URGENCY

1524
01:08:20,360 --> 01:08:22,120
AND THERE'S BEEN -- A DEBT LIMIT

1525
01:08:22,120 --> 01:08:23,760
INCREASE HAS BEEN PART OF THE

1526
01:08:23,760 --> 01:08:24,960
CALCULATIONS FOR MOST OF THE THE

1527
01:08:24,960 --> 01:08:26,560
BIG BUDGET DEALS WE'VE SEEN IN

1528
01:08:26,560 --> 01:08:30,560
THE MODERN HISTORY OF THE

1529
01:08:30,560 --> 01:08:32,120
CONGRESS AND THE BUDGET CONTROL

1530
01:08:32,120 --> 01:08:34,680
ACT OF 2011 THAT SETS SPENDING

1531
01:08:34,680 --> 01:08:45,000
CAPS FOR 10 YEARS.

1532
01:09:08,400 --> 01:09:10,360
THIS WERE LOTS OF OTHER

1533
01:09:10,360 --> 01:09:12,600
CONDITIONS, SOME INVOLVED

1534
01:09:12,600 --> 01:09:13,840
PROCESS AND UNDERSTANDABLY MANY

1535
01:09:13,840 --> 01:09:15,200
MEMBERS HAVE BEEN FRUSTRATED

1536
01:09:15,200 --> 01:09:20,920
ABOUT ONLY GETTING TO SEE THESE

1537
01:09:20,920 --> 01:09:22,040
HUGE OMNIBUS BILLS.

1538
01:09:22,040 --> 01:09:23,120
UP WITH OF THE PROBLEMS THAT WAS

1539
01:09:23,120 --> 01:09:26,000
GOING TO BE THAT THEY DON'T MOVE

1540
01:09:26,000 --> 01:09:27,800
12 BILLS THROUGH FOR EACH

1541
01:09:27,800 --> 01:09:31,560
SUBCOMMITTEE SEPARATELY AND THAT

1542
01:09:31,560 --> 01:09:32,120
JUST TAKES A LOT OF TIME.

1543
01:09:32,120 --> 01:09:34,560
WE'LL GO TO THE NEXT SLIDE,

1544
01:09:34,560 --> 01:09:37,160
PLEASE.

1545
01:09:37,160 --> 01:09:39,880
SO, THE PRESIDENT RELEASED HIS

1546
01:09:39,880 --> 01:09:41,640
FY24 BUDGET REQUEST LAST WEEK

1547
01:09:41,640 --> 01:09:44,120
AND THIS WAS A BIT LATER THAN

1548
01:09:44,120 --> 01:09:45,440
NORMAL USUALLY IT'S A MONDAY AND

1549
01:09:45,440 --> 01:09:46,960
FIRST MONDAY IN FEBRUARY AND

1550
01:09:46,960 --> 01:09:48,680
COME RIGHT AFTER THE STATE OF

1551
01:09:48,680 --> 01:09:51,480
THE UNION AND FY23 WASN'T

1552
01:09:51,480 --> 01:09:52,800
COMPLETED UNTIL THE END OF THE

1553
01:09:52,800 --> 01:09:54,320
CALENDER YEAR SO SINCE BLEE

1554
01:09:54,320 --> 01:09:56,480
THERE NEEDED TO BE MORE TIME AND

1555
01:09:56,480 --> 01:09:58,920
DEVELOPING THE BUDGET REQUEST

1556
01:09:58,920 --> 01:10:00,120
AND SO UP WITH OF THE THINGS

1557
01:10:00,120 --> 01:10:04,760
THAT WE SEE HERE ARE THE BUDGET

1558
01:10:04,760 --> 01:10:07,360
REALLY SHOWCASE AND YOU'VE HEARD

1559
01:10:07,360 --> 01:10:08,560
PRESIDENT BIDEN SAY THIS, DON'T

1560
01:10:08,560 --> 01:10:11,080
TELL ME WHAT YOU VALUE SHOW ME

1561
01:10:11,080 --> 01:10:12,400
YOUR BUDGET THAT TELLS ME WHAT

1562
01:10:12,400 --> 01:10:14,040
YOU VALUE WHAT THIS BUDGET CALLS

1563
01:10:14,040 --> 01:10:16,200
FOR NEW INVESTMENT IN CLEAN

1564
01:10:16,200 --> 01:10:17,400
ENERGY AND CLIMATE SCIENCE AND

1565
01:10:17,400 --> 01:10:18,600
NEW TECHNOLOGIES.

1566
01:10:18,600 --> 01:10:21,200
A LOT OF IT IS PAID FOR BY TAX

1567
01:10:21,200 --> 01:10:22,800
INCREASES ON THE WEALTHIEST

1568
01:10:22,800 --> 01:10:24,880
AMERICANS AND CORPORATIONS AND

1569
01:10:24,880 --> 01:10:27,080
TAX CREDIT ROLL BACKS AND SOME

1570
01:10:27,080 --> 01:10:29,720
OF THE BUDGET PROVISIONS AND

1571
01:10:29,720 --> 01:10:31,400
ANTICIPATE SAVINGS FROM

1572
01:10:31,400 --> 01:10:33,040
NEGOTIATING PRESCRIPTION DRUG

1573
01:10:33,040 --> 01:10:35,760
PRICES AND SO AS YOU WOULD

1574
01:10:35,760 --> 01:10:38,800
EXPECT, THEY'RE IMMEDIATE

1575
01:10:38,800 --> 01:10:39,240
IDEOLOGICAL CLASHES.

1576
01:10:39,240 --> 01:10:40,720
HOUSE REPUBLICANS HAVE RULED OUT

1577
01:10:40,720 --> 01:10:42,240
ANY NEW TAXES AS A SOLUTION TO

1578
01:10:42,240 --> 01:10:44,480
THE FEDERAL DEBT, MUCH LESS IN A

1579
01:10:44,480 --> 01:10:46,800
NEW BUDGET PROPOSAL.

1580
01:10:46,800 --> 01:10:49,640
THIS BUDGE WET PROPOSE A 3.2%

1581
01:10:49,640 --> 01:10:50,400
INCREASE FOR DEFENSE THAT NUMBER

1582
01:10:50,400 --> 01:10:54,840
IS NOT GOING TO BE ACCEPTABLE TO

1583
01:10:54,840 --> 01:10:56,920
REPUBLICANS.

1584
01:10:56,920 --> 01:10:57,960
ONE THING WORTH CONSIDERING,

1585
01:10:57,960 --> 01:11:08,520
WHEN LOOKING AT THE IT WOULD BE

1586
01:11:09,760 --> 01:11:13,960
AN 8% CU 8 CUT WITH FY '23 AND S

1587
01:11:13,960 --> 01:11:17,320
NOT THAT ONEROUS.

1588
01:11:17,320 --> 01:11:20,200
IF YOU TAKE OUT VETERANS

1589
01:11:20,200 --> 01:11:21,640
PROGRAMS AND DEFENSE, WHICH THEY

1590
01:11:21,640 --> 01:11:23,320
WOULD NOT CUT, YOU ARE LOOKING

1591
01:11:23,320 --> 01:11:25,960
AT A 22% CUT WITH ALL THE

1592
01:11:25,960 --> 01:11:27,360
DISCRETIONARY SPENDING AND

1593
01:11:27,360 --> 01:11:28,280
THAT'S VERY SIGNIFICANT.

1594
01:11:28,280 --> 01:11:30,080
SO, THAT SORT OF THE FRAMEWORK

1595
01:11:30,080 --> 01:11:32,840
AND THE MIND SET IN WHICH THIS

1596
01:11:32,840 --> 01:11:36,440
PRESIDENT'S BUDGET PROPOSAL IS

1597
01:11:36,440 --> 01:11:37,160
BEING RECEIVED.

1598
01:11:37,160 --> 01:11:39,640
ONE PART OF THIS BUDGET THAT THE

1599
01:11:39,640 --> 01:11:41,120
PRESIDENT HAS MADE VERY CLEAR IS

1600
01:11:41,120 --> 01:11:44,640
THAT HE WANTS TO PROPOSE A UNITY

1601
01:11:44,640 --> 01:11:46,360
AGENDA PROGRAMS SORT OF SELECT

1602
01:11:46,360 --> 01:11:47,160
PIECES OF THE BUDGET REQUEST

1603
01:11:47,160 --> 01:11:49,200
THAT COULD HAVE BIPARTISAN

1604
01:11:49,200 --> 01:11:50,520
SUPPORT AND THE CANCER MOONSHOT

1605
01:11:50,520 --> 01:11:53,960
AND THE GOAL OF REDUCING CANCER

1606
01:11:53,960 --> 01:11:58,520
DEATHS BY 50% IN 25 YEARS IS ONE

1607
01:11:58,520 --> 01:12:00,640
ASPECT AND ANOTHER IS MENTAL

1608
01:12:00,640 --> 01:12:01,960
HEALTH INVESTMENTS AND VETERAN

1609
01:12:01,960 --> 01:12:03,160
PROGRAMS AND INVESTMENTS INTO

1610
01:12:03,160 --> 01:12:07,680
OPIOID DEPOSIT EPIDEMIC.

1611
01:12:07,680 --> 01:12:10,600
SO LOOKING AT THE PAST TWO

1612
01:12:10,600 --> 01:12:13,680
YEARS, WHAT YOU CAN SEE HERE IS

1613
01:12:13,680 --> 01:12:14,480
SORT OF THE NUMBERS THAT HAVE

1614
01:12:14,480 --> 01:12:17,600
BEEN PUT FOURTH FOR NCI AND NIH

1615
01:12:17,600 --> 01:12:19,720
OVER ALL AND ARPA-H.

1616
01:12:19,720 --> 01:12:23,240
THIS IS NEW AGENCY WHICH NOW

1617
01:12:23,240 --> 01:12:28,600
SITS WITHIN NIH THAT O CH COULDF

1618
01:12:28,600 --> 01:12:29,200
THERE'S AUTHORIZATION

1619
01:12:29,200 --> 01:12:30,120
LEGISLATION THAT CHANGES WHERE

1620
01:12:30,120 --> 01:12:31,840
IT SITS BUT THAT'S WHERE ARPA-H

1621
01:12:31,840 --> 01:12:32,440
IS.

1622
01:12:32,440 --> 01:12:34,040
AND I HAVE THEIR NUMBER SEVEN

1623
01:12:34,040 --> 01:12:35,120
RAT BECAUSE IT'S INTERESTING TO

1624
01:12:35,120 --> 01:12:38,400
SEE THE PROPOSED GROWTH OF THAT

1625
01:12:38,400 --> 01:12:39,120
AGENCY.

1626
01:12:39,120 --> 01:12:42,080
AND SO WHAT WE CAN SEE FOR

1627
01:12:42,080 --> 01:12:46,280
FY2024 IS FOR NCI THE PROPOSAL

1628
01:12:46,280 --> 01:12:48,520
WOULD CONTINUE THE $216 MILLION

1629
01:12:48,520 --> 01:12:51,240
THAT WE'RE RECEIVING FY2 FOR THE

1630
01:12:51,240 --> 01:12:53,800
CANCER MOONSHOT SO TAKEAWAY THAT

1631
01:12:53,800 --> 01:12:54,400
FUNDING CLIFF FOR NEXT FISCAL

1632
01:12:54,400 --> 01:12:57,160
YEAR AND IT PROPOSES AN

1633
01:12:57,160 --> 01:12:57,840
ADDITIONAL $500 MILLION FOR

1634
01:12:57,840 --> 01:12:59,280
CANCER MOONSHOT ACTIVITIES AND

1635
01:12:59,280 --> 01:13:01,440
SO THIS IS SORT OF THE SECOND

1636
01:13:01,440 --> 01:13:04,040
VERSION OF THE CANCER MOONSHOT.

1637
01:13:04,040 --> 01:13:09,600
AND THAT THIS WOULD BE ALL OF

1638
01:13:09,600 --> 01:13:11,720
GOVERNMENT APPROACH THAT Dr.

1639
01:13:11,720 --> 01:13:15,320
BERTAGNOLLI DESCRIBED IN HER

1640
01:13:15,320 --> 01:13:19,360
PRESENTATION.

1641
01:13:19,360 --> 01:13:21,480
THE OVER ALL INCREASE IS 1%

1642
01:13:21,480 --> 01:13:24,400
INCLUDING THE MONEY THAT'S BEEN

1643
01:13:24,400 --> 01:13:25,960
PROPOSED FOR NCI CANCER MOONSHOT

1644
01:13:25,960 --> 01:13:27,520
AND ARPA-H THERE'S ANOTHER

1645
01:13:27,520 --> 01:13:30,320
BILLION DOLLARS PROPOSED ANOTHER

1646
01:13:30,320 --> 01:13:31,720
THING THE PRESIDENT'S BUDGET

1647
01:13:31,720 --> 01:13:34,640
PROPOSES AND NOW THE PRESIDENT'S

1648
01:13:34,640 --> 01:13:37,640
BUDGET IS AT ITS CORE A PROPOSAL

1649
01:13:37,640 --> 01:13:38,880
FOR DISCRETION FUNDING FOR THE

1650
01:13:38,880 --> 01:13:40,560
COMING FISCAL YEAR AND IT'S ALSO

1651
01:13:40,560 --> 01:13:45,320
A MESSAGING DOCUMENT AND IT GOES

1652
01:13:45,320 --> 01:13:46,840
IN MANY OF THE PROTECTIONS THAT

1653
01:13:46,840 --> 01:13:48,520
INCLUDES SOME OF THEIR DEBT

1654
01:13:48,520 --> 01:13:50,520
REDUCTION AND SOME OF THEM ARE

1655
01:13:50,520 --> 01:13:51,840
ABOUT INVESTMENTS IN BROAD

1656
01:13:51,840 --> 01:13:58,480
PROGRAMS AND SO THIS THIS

1657
01:13:58,480 --> 01:13:59,920
PROPOSES MAPPED TORI FUNDING FOR

1658
01:13:59,920 --> 01:14:10,440
THE CANCER MOONSHOT FOR FY25 AND

1659
01:14:22,080 --> 01:14:23,320
AND HOWEVER, REAUTHORIZATION

1660
01:14:23,320 --> 01:14:26,840
SORT OF SUGGESTS OR IMPLIES THAT

1661
01:14:26,840 --> 01:14:37,400
SOMETHING A BILL NEEDS TO BE IT

1662
01:14:38,120 --> 01:14:40,440
IS FOR EXAMPLE FDA USER FEE

1663
01:14:40,440 --> 01:14:47,640
LEGISLATION AND IT'S MUSS PASS

1664
01:14:47,640 --> 01:14:52,680
LEDGETATLEDGETATION SO WHAT WE'E

1665
01:14:52,680 --> 01:14:56,480
LOOKING AT REAUTHORIZATION OF

1666
01:14:56,480 --> 01:15:06,960
THE NATIONAL NOT APPROPRIATORS

1667
01:15:13,040 --> 01:15:14,480
AND MIGHT INCLUDE A SPECIFIC

1668
01:15:14,480 --> 01:15:16,040
SECTOR FOR THE NATIONAL CANCER

1669
01:15:16,040 --> 01:15:18,720
ACT THAT MIGHT INCLUDE OTHER

1670
01:15:18,720 --> 01:15:21,120
SECTIONS RELATED TO BIO MEDICAL

1671
01:15:21,120 --> 01:15:23,040
RESEARCH AND IT COULD BE NIH AND

1672
01:15:23,040 --> 01:15:25,480
FDA AND IT COULD BE CDC AND LOTS

1673
01:15:25,480 --> 01:15:32,040
OF DIFFERENT PIECES AND COULD BE

1674
01:15:32,040 --> 01:15:33,320
ROLE INTO THAT.

1675
01:15:33,320 --> 01:15:34,920
ONE OF THE THINGS THAT I WANT

1676
01:15:34,920 --> 01:15:36,800
TODAY MAKE A POINT OF IS WHAT WE

1677
01:15:36,800 --> 01:15:38,840
REALLY HAVE SEEN IN THIS BUDGET

1678
01:15:38,840 --> 01:15:40,840
PROPOSAL IS THAT THE CANCER

1679
01:15:40,840 --> 01:15:42,240
MOONSHOT, AS ENVISIONED BY THE

1680
01:15:42,240 --> 01:15:44,760
ADMINISTRATION IS NOT LIMITED TO

1681
01:15:44,760 --> 01:15:45,600
JUST NCI.

1682
01:15:45,600 --> 01:15:47,200
AS Dr. BERTAGNOLLI EXPLAINED,

1683
01:15:47,200 --> 01:15:49,080
THIS IS PERCEIVED AS AN ALL OF

1684
01:15:49,080 --> 01:15:50,520
GOVERNMENT APPROACH WITH LOTS OF

1685
01:15:50,520 --> 01:15:51,680
COLLABORATION AND I JUST PULLED

1686
01:15:51,680 --> 01:15:53,000
A FEW EXAMPLES HERE.

1687
01:15:53,000 --> 01:15:55,080
THESE WERE KIND OF WITHIN EACH

1688
01:15:55,080 --> 01:15:57,760
OF THESE DIFFERENT AGENCIES,

1689
01:15:57,760 --> 01:16:00,080
BUDGET SECTIONS AND SO YOU CAN

1690
01:16:00,080 --> 01:16:02,080
SEE THIS 716 MILLION BEING

1691
01:16:02,080 --> 01:16:05,520
PROPOSED FOR NCI AND THERE'S

1692
01:16:05,520 --> 01:16:08,520
20 MILLION FOR HER SA,

1693
01:16:08,520 --> 01:16:09,480
180 MILLION FOR THE INDIAN

1694
01:16:09,480 --> 01:16:11,160
HEALTH SERVICE AND 70 MILLION

1695
01:16:11,160 --> 01:16:13,480
FOR IMPLEMENTATION OF THE PACKED

1696
01:16:13,480 --> 01:16:15,680
ACT AND $15 MILLION FOR CDC AND

1697
01:16:15,680 --> 01:16:17,600
FOR SOME SCREENING AND SO ON AND

1698
01:16:17,600 --> 01:16:19,520
ANOTHER THING THAT WE SAW IN

1699
01:16:19,520 --> 01:16:22,000
THIS BUDGET REQUEST WHICH IS

1700
01:16:22,000 --> 01:16:24,840
NEW, IS A PROPOSAL TO ELIMINATE

1701
01:16:24,840 --> 01:16:26,760
HEPATITIS C AND A MAJOR RISK

1702
01:16:26,760 --> 01:16:29,680
FACT OR FOR LIVER CANCER AND

1703
01:16:29,680 --> 01:16:31,440
THAT IS FOR MANDATORY FUNDING SO

1704
01:16:31,440 --> 01:16:34,240
THERE'S GOING TO BE A TALL

1705
01:16:34,240 --> 01:16:34,760
HURDLE THERE.

1706
01:16:34,760 --> 01:16:36,160
THIS IS SOMETHING NCI HAS BEEN

1707
01:16:36,160 --> 01:16:37,320
PAYING ATTENTION TO FOR MANY

1708
01:16:37,320 --> 01:16:38,640
YEARS AND EXPLORING FOR MANY

1709
01:16:38,640 --> 01:16:40,080
YEARS SO WE'RE PLEASED TO SEE

1710
01:16:40,080 --> 01:16:42,520
THE ATTENTION TO THIS IDEA OF

1711
01:16:42,520 --> 01:16:45,560
PREVENTING LIVER CANCER WITH

1712
01:16:45,560 --> 01:16:55,920
HEPATITIS C TREATMENT.

1713
01:18:07,240 --> 01:18:11,320
>> REGARDLESS OF SORT OF
THE MID

1714
01:18:11,320 --> 01:18:15,320
RECEPTION IT'S EXCITING TO SEE

1715
01:18:15,320 --> 01:18:17,720
FRESH APPROACH AND CANCER

1716
01:18:17,720 --> 01:18:18,520
RESEARCH FOR OUR COMMUNITY.

1717
01:18:18,520 --> 01:18:19,480
NEXT SLIDE, PLEASE.

1718
01:18:19,480 --> 01:18:20,760
AND I WAS GOING TO SAY TOO, EVEN

1719
01:18:20,760 --> 01:18:22,760
WHEN THE PRESIDENT AND THE

1720
01:18:22,760 --> 01:18:24,080
CHAMBERS OF CONGRESS ARE THE

1721
01:18:24,080 --> 01:18:27,160
SAME PARTY WE NEVER SEE CONGRESS

1722
01:18:27,160 --> 01:18:28,560
APPROPRIATING EXACTLY WHAT THE

1723
01:18:28,560 --> 01:18:30,280
PRESIDENT REQUESTS.

1724
01:18:30,280 --> 01:18:31,240
APPROPRIATORS TAKE THEIR JOBS

1725
01:18:31,240 --> 01:18:33,160
VERY SERIOUSLY AND THEY TEND TO

1726
01:18:33,160 --> 01:18:36,560
BE A LESS PARTISAN GROUP THAN I

1727
01:18:36,560 --> 01:18:37,960
THINK I COMMENTED IN ONE OF THE

1728
01:18:37,960 --> 01:18:39,160
LAST BOARD MEETINGS THAT THEY'RE

1729
01:18:39,160 --> 01:18:41,080
APP OLD SAYING IN D.C. THAT

1730
01:18:41,080 --> 01:18:42,840
THERE'S DEMOCRATS, REPUBLICANS

1731
01:18:42,840 --> 01:18:45,280
AND APPROPRIATORS.

1732
01:18:45,280 --> 01:18:50,520
TO THE EXTENT IT'S TRUE IN ALL

1733
01:18:50,520 --> 01:18:52,160
GOVERNMENT AGENCIES.

1734
01:18:52,160 --> 01:18:53,720
THIS SLIDE SHOWS THE TWO LEADERS

1735
01:18:53,720 --> 01:18:57,680
OF THE HOUSE PRO PRE AIGS

1736
01:18:57,680 --> 01:19:02,200
COMMITTEE AND THEY ARE SEASON

1737
01:19:02,200 --> 01:19:03,320
VETERANS AND LONG TIME

1738
01:19:03,320 --> 01:19:04,080
COLLEAGUES AND THEY HAVE A LOT

1739
01:19:04,080 --> 01:19:08,200
OF RESPECT FOR ONE ANOTHER.

1740
01:19:08,200 --> 01:19:09,360
THEY HAVE A TOUGH JOB.

1741
01:19:09,360 --> 01:19:11,280
YOU MAY KNOW ON THE SENATE SIDE,

1742
01:19:11,280 --> 01:19:12,920
THERE ARE ANOTHER TWO SET OF

1743
01:19:12,920 --> 01:19:14,960
LONG TIME COLLEAGUES WHO ARE

1744
01:19:14,960 --> 01:19:16,040
BOTH WOMEN AS WELL WHO ARE IN

1745
01:19:16,040 --> 01:19:17,200
CHARGE OF THE SENATE

1746
01:19:17,200 --> 01:19:18,120
APPROPRIATIONS COMMITTEE.

1747
01:19:18,120 --> 01:19:19,400
SENATOR PATTY MURRAY OF

1748
01:19:19,400 --> 01:19:24,560
WASHINGTON STATE AND SUSAN

1749
01:19:24,560 --> 01:19:32,400
COLLINS OF MAIN AND TH OF MAINE.

1750
01:19:32,400 --> 01:19:33,760
THIS IS THE FIRST TIME THEY'VE

1751
01:19:33,760 --> 01:19:35,320
BEEN WOMEN AND THEY HAVE BEEN

1752
01:19:35,320 --> 01:19:37,080
HAPPENED A VERY DIFFICULT TASK

1753
01:19:37,080 --> 01:19:39,960
FOR FY24 AND I WISH THAT THIS

1754
01:19:39,960 --> 01:19:41,360
GROUP HAD A LITTLE BIT MORE

1755
01:19:41,360 --> 01:19:42,520
BREATHING ROOM WITH WHAT THEY'RE

1756
01:19:42,520 --> 01:19:46,040
TRYING TO DO AND I WANTED TO

1757
01:19:46,040 --> 01:19:48,160
SHOW YOU IN THIS SLIDE, KAY

1758
01:19:48,160 --> 01:19:52,120
GRANGER, THE CHAIR OF THE

1759
01:19:52,120 --> 01:19:54,280
APPROPRIATIONS COMMITTEE HAS

1760
01:19:54,280 --> 01:19:56,080
BEEN CLEAR-CUTTING DEFENSE WON'T

1761
01:19:56,080 --> 01:19:57,880
HAPPEN WHEN SHE'S THE CHAIR OF

1762
01:19:57,880 --> 01:19:59,200
APPROPRIATIONS AND

1763
01:19:59,200 --> 01:20:00,600
CONGRESSWOMAN, THE RANKING

1764
01:20:00,600 --> 01:20:03,040
MEMBER, HAS MADE THE COMMENT

1765
01:20:03,040 --> 01:20:06,960
ABOUT THIS DEAL TO RETURN TO

1766
01:20:06,960 --> 01:20:08,800
FY22 LEVELS AND YOU CAN PASS PRO

1767
01:20:08,800 --> 01:20:09,680
PRE ALLEGATIONS BILLS IN THAT

1768
01:20:09,680 --> 01:20:10,520
WAY.

1769
01:20:10,520 --> 01:20:11,160
THE PRESIDENT WON'T SIGN THEM

1770
01:20:11,160 --> 01:20:12,200
AND THEY'RE NOT GOING TO GET

1771
01:20:12,200 --> 01:20:13,800
THROUGH COMMITTEE AND SHE MADE

1772
01:20:13,800 --> 01:20:14,880
THESE COMMENTS FAIRLY EARLY

1773
01:20:14,880 --> 01:20:17,040
SAYING IF YOU INSIST ON THIS AND

1774
01:20:17,040 --> 01:20:18,040
PROCEED WITH THAT GOAL, YOU WILL

1775
01:20:18,040 --> 01:20:20,840
BE LOOKING AT A SHUT DOWN.

1776
01:20:20,840 --> 01:20:22,240
WE'LL GET TO PREDICTION THIS IS

1777
01:20:22,240 --> 01:20:22,880
A MOMENT.

1778
01:20:22,880 --> 01:20:25,480
I WANT TODAY POINT OUT THAT

1779
01:20:25,480 --> 01:20:26,880
CHAIRMAN GRANGER ACTUALLY HAS A

1780
01:20:26,880 --> 01:20:29,120
VERY DIFFICULT TASK BECAUSE

1781
01:20:29,120 --> 01:20:30,920
AMONG THE CONCESSIONS THAT WERE

1782
01:20:30,920 --> 01:20:32,920
MADE BY SPEAKER McCARTHY,

1783
01:20:32,920 --> 01:20:36,560
EARLIER ON AS HE WAS TRYING TO

1784
01:20:36,560 --> 01:20:37,880
GET VOTES TO BE SPEAKER, HE

1785
01:20:37,880 --> 01:20:39,440
AGREED TO AN OPEN AMENDMENT

1786
01:20:39,440 --> 01:20:41,800
PROCESS AND THAT'S A LINT OF

1787
01:20:41,800 --> 01:20:45,000
PROCEDURAL DETAILS THAT IS ONLY

1788
01:20:45,000 --> 01:20:49,000
IMPORTANT FOR OUR CONVERSATIONS

1789
01:20:49,000 --> 01:20:50,080
IN THAT USUALLY LEGISLATION IS

1790
01:20:50,080 --> 01:20:51,960
CONSIDERED IN THE HOUSE UNDER A

1791
01:20:51,960 --> 01:20:52,560
CLOSED RULE.

1792
01:20:52,560 --> 01:20:55,160
SO YOU CANNOT HAVE EVERY MEMBER

1793
01:20:55,160 --> 01:20:56,680
OF THE HOUSE OFFERING AMENDMENTS

1794
01:20:56,680 --> 01:20:59,280
TO A PIECE OF LEGISLATION IN

1795
01:20:59,280 --> 01:21:01,080
SOME WAYS, SOMETIMES PEOPLE WANT

1796
01:21:01,080 --> 01:21:02,880
TO OFFER AMENDMENTS TO MAKE

1797
01:21:02,880 --> 01:21:03,480
THEIR OWN POINT TO FORCE THEIR

1798
01:21:03,480 --> 01:21:05,840
COLLEAGUES TO TAKE A VOTE ON

1799
01:21:05,840 --> 01:21:07,880
SOMETHING AND DEMOCRATS HAD AN

1800
01:21:07,880 --> 01:21:11,040
OPEN PROCESS BACK IN THE -- I

1801
01:21:11,040 --> 01:21:13,280
KNOW IT WAS -- IT ENDED IN 2009

1802
01:21:13,280 --> 01:21:14,480
WHEN THEY GAVE UP ON IT BECAUSE

1803
01:21:14,480 --> 01:21:16,280
IT JUST TOOK WAY TOO MUCH TIME.

1804
01:21:16,280 --> 01:21:18,080
SO IF YOU ARE GOING TO BE ON THE

1805
01:21:18,080 --> 01:21:19,560
HOUSE FLOOR WITH THE BILL AND

1806
01:21:19,560 --> 01:21:21,040
YOU HAVE OPEN AMENDMENTS AND

1807
01:21:21,040 --> 01:21:25,280
OPEN RULE PROCESS YOU WILL SPENE

1808
01:21:25,280 --> 01:21:27,240
TO GET THE BILL THROUGH THE RULE

1809
01:21:27,240 --> 01:21:28,400
COMMITTEE AND THROUGH THE HOUSE.

1810
01:21:28,400 --> 01:21:31,000
THAT'S GOING TO MAKE

1811
01:21:31,000 --> 01:21:33,560
CONGRESSWOMAN, CHAIRWOMAN

1812
01:21:33,560 --> 01:21:34,520
GRANGER'S JOB MUCH MORE

1813
01:21:34,520 --> 01:21:36,080
DIFFICULT MOVING THESE BILLS,

1814
01:21:36,080 --> 01:21:44,560
ESPECIALLY SINCE HER KOUAKOU HEO

1815
01:21:44,560 --> 01:21:45,640
CUT $150 BILLION THROUGH THE

1816
01:21:45,640 --> 01:21:46,160
LEVELS.

1817
01:21:46,160 --> 01:21:48,760
SHE KNOWS THE GOP COLLEAGUES AND

1818
01:21:48,760 --> 01:21:50,840
THE PRESIDENT AS COPYING RECEIPT

1819
01:21:50,840 --> 01:21:55,000
WOMAN DELAURO POINTS OUT THE

1820
01:21:55,000 --> 01:21:55,600
GOVERNMENT WON'T SIGN A BILL

1821
01:21:55,600 --> 01:21:55,840
LIKE THAT.

1822
01:21:55,840 --> 01:21:57,160
THIS IS A TOUGH JOB FOR THESE

1823
01:21:57,160 --> 01:22:00,280
TWO LEADERS.

1824
01:22:00,280 --> 01:22:02,320
I WANTED TO POINT OUT THAT WE

1825
01:22:02,320 --> 01:22:03,520
ACTUALLY HAVE NEW LEADERSHIP IN

1826
01:22:03,520 --> 01:22:07,480
THE SENATE LEADERSHIP HHS

1827
01:22:07,480 --> 01:22:10,040
SUBCOMMITTEE AND WE HAVE WE WE

1828
01:22:10,040 --> 01:22:13,320
COVERED THE NEW CHAIR IS ROBERT

1829
01:22:13,320 --> 01:22:15,560
ADDERHOLT FROM ALABAMA HE WAS

1830
01:22:15,560 --> 01:22:17,440
CHAIR OF THE THE AG SUBCOMMITTEE

1831
01:22:17,440 --> 01:22:19,440
AND LONG TIME EXPERIENCES

1832
01:22:19,440 --> 01:22:23,000
APPROPRIATOR AND CONGRESSWOMAN

1833
01:22:23,000 --> 01:22:24,320
DELAURO WAS THE RANKING POSITION

1834
01:22:24,320 --> 01:22:25,600
AND THEY KNOW EACH OTHER VERY

1835
01:22:25,600 --> 01:22:27,560
WELL FROM SERVED ON THE AG

1836
01:22:27,560 --> 01:22:29,080
COMMITTEE AND BEEN ON CONGRESS

1837
01:22:29,080 --> 01:22:30,160
FOR YEARS AND YEARS TOGETHER.

1838
01:22:30,160 --> 01:22:37,600
ON THE SENATE SIDE, SENATOR ROY

1839
01:22:37,600 --> 01:22:45,680
BANKBLUNT RETIRED AND THE RANKIG

1840
01:22:45,680 --> 01:22:51,680
MEMBER IS SHELLY MOORE CAPITO

1841
01:22:51,680 --> 01:22:52,640
AND TAMMY BALDWIN MOVED UP TO

1842
01:22:52,640 --> 01:22:54,000
SHARE THE CHAIR AND WAS NOT

1843
01:22:54,000 --> 01:22:56,200
GOING TO BE KEEP THIS

1844
01:22:56,200 --> 01:22:57,320
SUBCOMMITTEE GAVEL AS WELL.

1845
01:22:57,320 --> 01:22:59,400
SO THESE TWO MEMBERS, THESE TWO

1846
01:22:59,400 --> 01:23:01,080
SENATORS HAVE BOTH BEEN REALLY

1847
01:23:01,080 --> 01:23:04,720
STRONG SUPPORTERS OF BIOMEDICAL

1848
01:23:04,720 --> 01:23:06,480
RESEARCH AND BOTH HAVE VISITED

1849
01:23:06,480 --> 01:23:13,440
NCI IN RESENT YEARS AND SENATOR

1850
01:23:13,440 --> 01:23:15,920
CAPITO HAS BEEN A BIG SUPPORTER

1851
01:23:15,920 --> 01:23:18,160
OF CHILDHOOD CANCER RESEARCH SO

1852
01:23:18,160 --> 01:23:19,840
WE'RE PLEASED TO BE HAVING THESE

1853
01:23:19,840 --> 01:23:21,200
LEADERS IN POSITIONS WORKING

1854
01:23:21,200 --> 01:23:22,760
WITH THEM AND THERE'S A FEW NEW

1855
01:23:22,760 --> 01:23:24,080
MEMBERS ON THE SUBCOMMITTEE ON

1856
01:23:24,080 --> 01:23:28,400
THE REPUBLICAN SIDE AS WELL.

1857
01:23:28,400 --> 01:23:31,480
SO IN TERMS OF WHAT IS GOING TO

1858
01:23:31,480 --> 01:23:33,640
HAPPEN NEXT, THERE ARE BUDGET

1859
01:23:33,640 --> 01:23:36,240
HEARINGS HAPPENING AT A REALLY

1860
01:23:36,240 --> 01:23:39,120
FAST PACE RIGHT NOW.

1861
01:23:39,120 --> 01:23:40,000
SECRETARY VA SER A HAS HEARINGS

1862
01:23:40,000 --> 01:23:42,440
THIS WEEK AND THE OMB DIRECTOR

1863
01:23:42,440 --> 01:23:44,000
YOUNG HAS BEEN ATTENDING

1864
01:23:44,000 --> 01:23:44,720
CONGRESSIONAL HEARINGS.

1865
01:23:44,720 --> 01:23:46,280
WE'LL SEE ALL THE SECRETARY

1866
01:23:46,280 --> 01:23:49,760
CABINET LEVEL HEARINGS HAPPENING

1867
01:23:49,760 --> 01:23:50,120
AT FIRST.

1868
01:23:50,120 --> 01:23:52,280
TIME IS VERY TIGHT SO THERE MAY

1869
01:23:52,280 --> 01:23:53,720
NOT BE THE SAME NUMBER OF

1870
01:23:53,720 --> 01:23:56,600
HEARINGS AS WE HAVE SEEN IN

1871
01:23:56,600 --> 01:23:57,120
RESENT YEARS.

1872
01:23:57,120 --> 01:23:59,560
YOU KNOW, WE NEVER EXPECTED

1873
01:23:59,560 --> 01:24:00,600
FUNDING BILLS TO BE ENACTED

1874
01:24:00,600 --> 01:24:01,920
BEFORE THE START OF THE FISCAL

1875
01:24:01,920 --> 01:24:03,680
YEAR AND WHEN IT HAS HAPPENED

1876
01:24:03,680 --> 01:24:05,600
ONCE IN RESENT YEARS, I THINK IT

1877
01:24:05,600 --> 01:24:09,760
WAS Dr. SHARPLESS' FIRST YEAR

1878
01:24:09,760 --> 01:24:11,160
AS DIRECTOR AND HE WAS SURPRISED

1879
01:24:11,160 --> 01:24:12,720
WHEN OUR BILL WAS COMBINED WITH

1880
01:24:12,720 --> 01:24:15,280
DEFENSE AND THEY BOTH WENT INTO

1881
01:24:15,280 --> 01:24:17,960
WERE ENACTED BEFORE THE START OF

1882
01:24:17,960 --> 01:24:20,760
THE FISCAL YEAR BUT THAT HADN'T

1883
01:24:20,760 --> 01:24:22,000
HAPPENED FOR DECADES BEFORE AND

1884
01:24:22,000 --> 01:24:23,640
IT HASN'T HAPPENED SINCE.

1885
01:24:23,640 --> 01:24:26,120
WE SORT OF EXPECT CONTINUING

1886
01:24:26,120 --> 01:24:26,400
RESOLUTIONS.

1887
01:24:26,400 --> 01:24:28,120
WE REALLY DON'T KNOW HOW LONG.

1888
01:24:28,120 --> 01:24:31,040
THERE'S BEEN SOME REPORTING THAT

1889
01:24:31,040 --> 01:24:32,960
THERE MAY BE SOME SHORT TERM

1890
01:24:32,960 --> 01:24:34,720
DEBT LIMIT INCREASES IN ORDER TO

1891
01:24:34,720 --> 01:24:36,840
BUY MORE TIME FOR THE

1892
01:24:36,840 --> 01:24:37,600
APPROPRIATIONS PROCESS TO PLAY

1893
01:24:37,600 --> 01:24:38,920
OUT SO THEY'RE NOT GOING TO BE

1894
01:24:38,920 --> 01:24:43,000
UP AGAINST A WALL FOR BOTH DEBT

1895
01:24:43,000 --> 01:24:44,160
LIMIT VOTE AND CONTINUE

1896
01:24:44,160 --> 01:24:45,640
RESOLUTION TO KEEP THE

1897
01:24:45,640 --> 01:24:46,320
GOVERNMENT OPEN.

1898
01:24:46,320 --> 01:24:48,400
WE REALLY DON'T KNOW WHAT WILL

1899
01:24:48,400 --> 01:24:48,920
HAPPEN.

1900
01:24:48,920 --> 01:24:50,480
YOU WILL HEAR A LOT OF DIRE

1901
01:24:50,480 --> 01:24:52,280
PREDICTIONS ABOUT THE SHUT DOWNS

1902
01:24:52,280 --> 01:24:55,080
AND FULL UCRs.

1903
01:24:55,080 --> 01:24:56,880
YOU KNOW, DEFENSE HAS NEVER HAD

1904
01:24:56,880 --> 01:24:58,800
A FULL YEAR RC BECAUSE THERE'S

1905
01:24:58,800 --> 01:25:00,240
ALWAYS BEEN AN JUSTMENT OF SOME

1906
01:25:00,240 --> 01:25:04,560
KIND TO ALLOW THEM TO HAVE AN

1907
01:25:04,560 --> 01:25:07,680
INCREASE AND THERE'S

1908
01:25:07,680 --> 01:25:08,160
COMBINATIONS WE CAN SEE

1909
01:25:08,160 --> 01:25:08,640
HAPPENING.

1910
01:25:08,640 --> 01:25:10,920
THERE COULD BE AN OMNIBUS

1911
01:25:10,920 --> 01:25:12,000
SPENDING BILL THAT KEEPS

1912
01:25:12,000 --> 01:25:13,040
ACCOUNTS AND AGENCIES FLAT

1913
01:25:13,040 --> 01:25:20,440
FUNDED LIKE A CR WOULD.

1914
01:25:20,440 --> 01:25:21,600
THAT DOES INCREASE FOR CERTAIN

1915
01:25:21,600 --> 01:25:22,240
PROGRAMS.

1916
01:25:22,240 --> 01:25:23,240
OBVIOUSLY WE WOULD BE HOPING

1917
01:25:23,240 --> 01:25:27,000
CANCER RESEARCH WOULD BE ONE OF

1918
01:25:27,000 --> 01:25:30,120
THOSE PROGRAMS THAT COULD BE

1919
01:25:30,120 --> 01:25:31,920
SUPPORTED BY BOTH PARTIES AND

1920
01:25:31,920 --> 01:25:33,600
DEFENSE AND WE HAVE TO GET SORT

1921
01:25:33,600 --> 01:25:36,520
OF INCREASED REQUESTED IN THE

1922
01:25:36,520 --> 01:25:38,600
BUDGET PROPOSAL IF THIS IS GOING

1923
01:25:38,600 --> 01:25:41,440
TO GET BIPARTISAN SUPPORT AND WE

1924
01:25:41,440 --> 01:25:43,360
REALLY WHAT IS GOING TO HAPPEN

1925
01:25:43,360 --> 01:25:46,440
FROM THIS IS MUCH AS THE

1926
01:25:46,440 --> 01:25:47,680
ADMINISTRATION AND NEVER WANTS

1927
01:25:47,680 --> 01:25:51,240
TO ANY ADMINISTRATION NEVER

1928
01:25:51,240 --> 01:26:01,560
WANTS TO NEGOTIATE.

1929
01:26:04,200 --> 01:26:05,920
JUST A QUICK WORD ABOUT

1930
01:26:05,920 --> 01:26:07,560
OVERSIGHT AND YOU MAY HAVE SEEN

1931
01:26:07,560 --> 01:26:10,280
REPORTING, THIS WAS A HEARING

1932
01:26:10,280 --> 01:26:11,960
EARLY FEBRUARY.

1933
01:26:11,960 --> 01:26:14,560
Dr. TABAK AND CDC AND FDA

1934
01:26:14,560 --> 01:26:15,240
LEADERSHIP TESTIFIED AT A

1935
01:26:15,240 --> 01:26:17,000
HEARING THAT ENERGY AND COMMERCE

1936
01:26:17,000 --> 01:26:19,000
HELD ABOUT THE FEDERAL RESPONSE

1937
01:26:19,000 --> 01:26:21,000
TO COVID AND WE SAW ANOTHER

1938
01:26:21,000 --> 01:26:22,400
HEARING MAYBE TWO WEEKS AGO AND

1939
01:26:22,400 --> 01:26:24,080
THE COMMITTEE ON OVERSIGHT AND

1940
01:26:24,080 --> 01:26:28,840
ACCOUNTABILITY AND THESE ARE

1941
01:26:28,840 --> 01:26:30,320
BOTH HOUSE COMMITTEES ABOUT THE

1942
01:26:30,320 --> 01:26:32,040
ORIGINS OF THE NOVEL

1943
01:26:32,040 --> 01:26:35,760
SARS-CoV-2 VIRUS AND LAB LEAKS

1944
01:26:35,760 --> 01:26:41,720
VERSUS OTHER SORT OF IDEOLOGY.

1945
01:26:41,720 --> 01:26:52,200
THIS IS NOT AND THIS IS BEEN

1946
01:26:55,040 --> 01:26:58,600
SOME AND THEY WERE PUSHED AND

1947
01:26:58,600 --> 01:27:00,400
THERE WAS A THAT COULD BE DONE

1948
01:27:00,400 --> 01:27:02,640
AND THE FEDERAL AGENCIES AND IN

1949
01:27:02,640 --> 01:27:03,720
THE EXTREME CIRCUMSTANCES THEY

1950
01:27:03,720 --> 01:27:07,920
WERE FACING AND OTHER THINGS

1951
01:27:07,920 --> 01:27:18,360
THAT HAVE LED IF THERE'S

1952
01:27:25,440 --> 01:27:26,600
AUTHORIZATION LAW DEVELOP THAT

1953
01:27:26,600 --> 01:27:28,480
WOULD TOUCH ON THE HEALTH SECTOR

1954
01:27:28,480 --> 01:27:31,240
AND IN A CURES REAUTHORIZATION

1955
01:27:31,240 --> 01:27:32,280
OF THE CURES ACT, THERE MAY BE

1956
01:27:32,280 --> 01:27:34,440
SOME SORT OF CODIFICATION OF

1957
01:27:34,440 --> 01:27:36,320
OVERSIGHT PRE VISION THIS IS

1958
01:27:36,320 --> 01:27:38,320
THAT AND NOT NECESSARILY NEW

1959
01:27:38,320 --> 01:27:40,440
AUTHORITIES BUT JUST RESTATEMENT

1960
01:27:40,440 --> 01:27:43,720
OF KIND OF THE OVERSIGHT

1961
01:27:43,720 --> 01:27:45,240
RESPONSIBILITIES AND MAYBE

1962
01:27:45,240 --> 01:27:45,960
REPORTING.

1963
01:27:45,960 --> 01:27:48,080
WE MUCH SEE THAT SORT OF THING.

1964
01:27:48,080 --> 01:27:58,440
THIS IS MY LAST SLIDE.

1965
01:28:17,040 --> 01:28:18,720
>> THANK YOU FOR THE
UPDATES.

1966
01:28:18,720 --> 01:28:20,680
I GUESS I WAS CURIOUS GOING BACK

1967
01:28:20,680 --> 01:28:23,720
TO THE EARLIER CONVERSATIONS

1968
01:28:23,720 --> 01:28:26,080
AROUND LABEL COST AND HOW BEST

1969
01:28:26,080 --> 01:28:30,280
FACTORING INTO THE BUDGET AND

1970
01:28:30,280 --> 01:28:36,600
THEY MAY SAY IN THIS SIDE BAR.

1971
01:28:36,600 --> 01:28:41,800
>> I'M NOT SURE I
UNDERSTAND THE

1972
01:28:41,800 --> 01:28:42,040
QUESTION.

1973
01:28:42,040 --> 01:28:43,840
>> THE LABOR COSTS ARE
ALL-TIME

1974
01:28:43,840 --> 01:28:45,000
HIGH AND INFLATION IS A BIG

1975
01:28:45,000 --> 01:28:46,760
ISSUE AND I GUESS GOING BACK TO

1976
01:28:46,760 --> 01:28:49,280
THE QUESTION ABOUT THE PRESSURES

1977
01:28:49,280 --> 01:28:53,480
AND RESEARCH ENVIRONMENTS AND

1978
01:28:53,480 --> 01:28:54,760
IT'S NOT GOING TO BE ME IN FRONT

1979
01:28:54,760 --> 01:28:56,960
OF THIS PROCESS.

1980
01:28:56,960 --> 01:29:02,080
SO, I JUST WAS CURIOUS ABOUT HOW

1981
01:29:02,080 --> 01:29:03,200
CONSIDERATIONS ABOUT THE COST

1982
01:29:03,200 --> 01:29:04,480
INFLATION THAT CAN FACTOR INTO

1983
01:29:04,480 --> 01:29:06,800
THIS OVER ALL THEATER AS I

1984
01:29:06,800 --> 01:29:07,400
CALLED IT.

1985
01:29:07,400 --> 01:29:09,480
ON A FEDERAL BUDGETING PROCESS.

1986
01:29:09,480 --> 01:29:14,240
>> I MEAN, YOU WILL
ABSOLUTELY

1987
01:29:14,240 --> 01:29:17,320
HEAR IN HEARINGS MEMBERS AND SO

1988
01:29:17,320 --> 01:29:17,840
THERE'S PUBLIC WITNESSES

1989
01:29:17,840 --> 01:29:19,120
OPPORTUNITIES IN THESE HEARINGS

1990
01:29:19,120 --> 01:29:21,160
AS WELL AS THE AGENCY HEARINGS

1991
01:29:21,160 --> 01:29:22,480
THAT CERTAINLY SOMETHING THAT'S

1992
01:29:22,480 --> 01:29:22,960
ADDRESSED.

1993
01:29:22,960 --> 01:29:26,400
WE SORT OF ACKNOWLEDGE AND

1994
01:29:26,400 --> 01:29:27,680
REQUEST FUNDING TO COVER THE

1995
01:29:27,680 --> 01:29:30,520
COST OF INFLATION.

1996
01:29:30,520 --> 01:29:31,560
WE RARELY GET IT.

1997
01:29:31,560 --> 01:29:35,520
BUT TO THE EXTENT THE ACADEMIC

1998
01:29:35,520 --> 01:29:36,360
RESEARCH COMMUNITY CAN COME

1999
01:29:36,360 --> 01:29:38,360
TOGETHER AND MAKE THOSE POINTS

2000
01:29:38,360 --> 01:29:41,640
IN A ORGANIZED WAY IN A SORT OF

2001
01:29:41,640 --> 01:29:44,040
UNIFIED WAY, THAT'S VERY

2002
01:29:44,040 --> 01:29:44,440
HELPFUL.

2003
01:29:44,440 --> 01:29:45,720
MEMBERS AND IS SUBCOMMITTEE

2004
01:29:45,720 --> 01:29:47,240
STAFF WANT TO HEAR FROM

2005
01:29:47,240 --> 01:29:48,280
PROFESSIONAL GROUPS WHO CAN SAY,

2006
01:29:48,280 --> 01:29:50,440
HERE IS WHAT YOU MIGHT NOT

2007
01:29:50,440 --> 01:29:50,720
UNDERSTAND.

2008
01:29:50,720 --> 01:29:57,920
THEY'RE LOOKING AT WHAT WAS THE

2009
01:29:57,920 --> 01:29:59,320
SUCCESS RATE AND THE FUNDS THAT

2010
01:29:59,320 --> 01:30:01,280
GIVE US AND IN WAYS THAT WE CAN

2011
01:30:01,280 --> 01:30:11,800
SEE DELIVERABLES AND METRICS.

2012
01:30:19,720 --> 01:30:21,280
IT'S MEANINGFUL COMING FROM

2013
01:30:21,280 --> 01:30:26,560
RESEARCHERS THEMSELVES.

2014
01:30:26,560 --> 01:30:28,000
>> SEEING NO OTHER HANDS.

2015
01:30:28,000 --> 01:30:30,720
THANK YOU SO MUCH M.K.

2016
01:30:30,720 --> 01:30:32,920
NEXT WE HAVE SCIENTIFIC

2017
01:30:32,920 --> 01:30:40,480
PRESENTATIONS FROM JIM DOROSHOW.

2018
01:30:40,480 --> 01:30:43,920
JIM AS YOU KNOW IS THE NCI

2019
01:30:43,920 --> 01:30:45,000
DEPOSIT YOU TREE DIRECTOR AND

2020
01:30:45,000 --> 01:30:46,760
DIRECTOR OF DIVISION CANCER

2021
01:30:46,760 --> 01:30:48,520
TREATMENT AND DIAGNOSIS.

2022
01:30:48,520 --> 01:30:50,160
JIM, ALL YOURS.

2023
01:30:50,160 --> 01:30:52,400
>> THANK YOU, VERY MUCH,
KEITH.

2024
01:30:52,400 --> 01:30:54,440
IT'S TIMELY GIVEN THAT IT'S JUST

2025
01:30:54,440 --> 01:30:56,640
THREE YEARS SINCE ALL OF US

2026
01:30:56,640 --> 01:30:58,600
STARTED TO CONFRONT THE ISSUE OF

2027
01:30:58,600 --> 01:31:01,800
THE PANDEMIC AND OUR CLINICAL

2028
01:31:01,800 --> 01:31:02,600
RESEARCH INFRASTRUCTURE TO

2029
01:31:02,600 --> 01:31:03,680
REVIEW SOME OF THE THINGS THAT

2030
01:31:03,680 --> 01:31:05,720
HAPPENED AND SOME OF OUR

2031
01:31:05,720 --> 01:31:07,000
RESPONSES TO THOSE THINGS.

2032
01:31:07,000 --> 01:31:09,840
AND HOW WE VIEW THE FUTURE.

2033
01:31:09,840 --> 01:31:10,560
NEXT SLIDE.

2034
01:31:10,560 --> 01:31:12,800
SO MY OVERVIEW REALLY IS TO TALK

2035
01:31:12,800 --> 01:31:15,680
ABOUT THE ON GOING EFFORTS TO

2036
01:31:15,680 --> 01:31:17,000
DEAL WITH THE EFFECTS OF THE

2037
01:31:17,000 --> 01:31:18,600
PANDEMIC ON CLINICAL CANCER

2038
01:31:18,600 --> 01:31:19,080
RESEARCH.

2039
01:31:19,080 --> 01:31:21,240
TO TALK A LITTLE BIT ABOUT OUR

2040
01:31:21,240 --> 01:31:22,880
2030 STRATEGIC VISION FOR

2041
01:31:22,880 --> 01:31:24,920
CLINICAL TRIALS AND THEN TO TALK

2042
01:31:24,920 --> 01:31:26,920
ABOUT AND HOPEFULLY TALK WITH

2043
01:31:26,920 --> 01:31:29,640
YOU ABOUT ACTIVITIES TO' MILL

2044
01:31:29,640 --> 01:31:30,840
RATE THE CURRENT CLINICAL

2045
01:31:30,840 --> 01:31:32,320
RESEARCH THAT ARE IMPACTING I

2046
01:31:32,320 --> 01:31:42,600
THINK ALL OF US.

2047
01:31:59,880 --> 01:32:01,240
WHAT ABOUT THE USE OF IMAGING

2048
01:32:01,240 --> 01:32:03,720
AND LABORATORY FACILITIES THAT

2049
01:32:03,720 --> 01:32:05,280
REQUIRED PATIENTS TO COME TO

2050
01:32:05,280 --> 01:32:07,680
ACADEMIC MEDICAL CENTERS AND TO

2051
01:32:07,680 --> 01:32:08,840
COLLECT DATA THAT MIGHT OR MIGHT

2052
01:32:08,840 --> 01:32:10,520
NOT BE OF GREAT IMPORTANCE FOR

2053
01:32:10,520 --> 01:32:12,400
THE TRIALS THAT WE CONDUCT.

2054
01:32:12,400 --> 01:32:15,960
WHAT ABOUT THE NEED TO COLLECT

2055
01:32:15,960 --> 01:32:17,240
LOW-GRADE ADVERSE EFFORTS

2056
01:32:17,240 --> 01:32:17,960
DESPITE THE LACK OF THE

2057
01:32:17,960 --> 01:32:20,360
RELEVANCE OF THOSE POTENTIAL

2058
01:32:20,360 --> 01:32:22,080
STUDY END POINTS AND IMPORTANTLY

2059
01:32:22,080 --> 01:32:24,360
ABOUT WHAT THE LIMITED ACCESS TO

2060
01:32:24,360 --> 01:32:26,920
PERSONNEL AND FACILITIES AND THE

2061
01:32:26,920 --> 01:32:27,960
REPROGRAMMING OF CLINICAL

2062
01:32:27,960 --> 01:32:29,920
RESEARCH RESOURCES FOR CARE THAT

2063
01:32:29,920 --> 01:32:31,840
ALL OCCURRED VERY RAPIDLY IN

2064
01:32:31,840 --> 01:32:34,440
FEBRUARY AND MARCH AND APRIL OF

2065
01:32:34,440 --> 01:32:34,880
2020.

2066
01:32:34,880 --> 01:32:36,280
SO WE'VE ALL DEALT WITH THAT AND

2067
01:32:36,280 --> 01:32:37,480
WE'LL TALK ABOUT HOW SOME OF THE

2068
01:32:37,480 --> 01:32:39,720
THINGS THAT WE'VE DONE TO TRY TO

2069
01:32:39,720 --> 01:32:41,120
DEAL WITH THOSE ISSUES.

2070
01:32:41,120 --> 01:32:42,440
I WANT TODAY EMPHASIZE THAT

2071
01:32:42,440 --> 01:32:45,480
THERE ARE REALLY ARE MAJOR ON

2072
01:32:45,480 --> 01:32:47,120
GOING ISSUES THAT EVEN THOUGH

2073
01:32:47,120 --> 01:32:48,920
SOME OF THE WORST ASPECTS OF THE

2074
01:32:48,920 --> 01:32:50,160
PANDEMIC HAVE BEEN CONFRONTED

2075
01:32:50,160 --> 01:32:51,960
AND DEALT WITH, THEY REMAIN

2076
01:32:51,960 --> 01:32:54,040
CRITICAL SHORTAGES OF RESEARCH

2077
01:32:54,040 --> 01:32:56,800
NURSES AND CRAs AND RESEARCH

2078
01:32:56,800 --> 01:32:59,120
STAFF IN REGULATORY OFFICE

2079
01:32:59,120 --> 01:32:59,840
THAT'S ARE ESSENTIAL.

2080
01:32:59,840 --> 01:33:02,120
ESSENTIAL HEALTHCARE WORKERS IN

2081
01:33:02,120 --> 01:33:03,920
RADIOLOGY AND PATHOLOGY AND THE

2082
01:33:03,920 --> 01:33:05,080
INFRASTRUCTURE AND IN TERMS OF

2083
01:33:05,080 --> 01:33:06,880
OUR IRBs AND CONTRACTING

2084
01:33:06,880 --> 01:33:13,280
OFFICES AND REALLY HAVE

2085
01:33:13,280 --> 01:33:23,760
AUTOMATIC -- THESE HAVE LED TO

2086
01:33:28,760 --> 01:33:30,280
DELAYS IN REPORTING SO TRIALS

2087
01:33:30,280 --> 01:33:31,520
MAKE IT OPENED BUT THE DATA ARE

2088
01:33:31,520 --> 01:33:33,360
NOT GETTING REPORTED IN A TIMELY

2089
01:33:33,360 --> 01:33:38,040
FASHION IN IS SOME CASES WHICH

2090
01:33:38,040 --> 01:33:40,960
LEADS TO A DECREASE IN THE

2091
01:33:40,960 --> 01:33:44,560
TIMELINESS THAT RESULTS GET

2092
01:33:44,560 --> 01:33:46,920
PUBLISHED.

2093
01:33:46,920 --> 01:33:50,320
ALL CREDIT GOES TO MY COLLEAGUES

2094
01:33:50,320 --> 01:33:52,360
WHO THREE YEARS AGO, WORKED VERY

2095
01:33:52,360 --> 01:33:54,120
QUICKLY FOR THE NCI CLINICAL

2096
01:33:54,120 --> 01:33:55,760
TRIALS PORTFOLIOS TO CHANGE TO

2097
01:33:55,760 --> 01:33:57,320
THE USE OF THE ELECTRONIC

2098
01:33:57,320 --> 01:33:59,960
CONSENTING AND TO PROVIDE ORAL

2099
01:33:59,960 --> 01:34:01,200
INVESTIGATIONAL AGENCY TO

2100
01:34:01,200 --> 01:34:02,400
PATIENTS AND TO INITIATE

2101
01:34:02,400 --> 01:34:03,800
ELECTRONIC RATHER THAN IN-PERSON

2102
01:34:03,800 --> 01:34:04,800
STUDY AUDITS.

2103
01:34:04,800 --> 01:34:06,440
TO FACILITATE TELEMEDICINE FOR

2104
01:34:06,440 --> 01:34:08,800
STUDY VISITS AND THEN TO TAKE

2105
01:34:08,800 --> 01:34:10,120
SPECIFIC ACTION TO LIMIT THE

2106
01:34:10,120 --> 01:34:12,760
ADVERSE IMPACT OF MINOR STUDY

2107
01:34:12,760 --> 01:34:13,680
DEVIATIONS ON TRIAL CONDUCT OR

2108
01:34:13,680 --> 01:34:17,880
THE EVALUATION OF THOSE TRIALS

2109
01:34:17,880 --> 01:34:19,760
AND DEGREE CENTRALIZED TESTING

2110
01:34:19,760 --> 01:34:21,840
AND ENERGY STUDIES AND AS I'LL

2111
01:34:21,840 --> 01:34:23,200
TALK ABOUT A LITTLE BIT, DURING

2112
01:34:23,200 --> 01:34:25,400
THAT THE MIDST OF THIS OR THE

2113
01:34:25,400 --> 01:34:28,520
WORST PART OF THE PANDE PANDEMIN

2114
01:34:28,520 --> 01:34:31,080
2020 AND 2021 WE HAD A NEW PLAN

2115
01:34:31,080 --> 01:34:34,280
FOR NCI CLINICAL TRIALS PROGRAMS

2116
01:34:34,280 --> 01:34:35,960
WHICH IS IN THE MIDST OF BEING

2117
01:34:35,960 --> 01:34:36,560
IMPLEMENTED.

2118
01:34:36,560 --> 01:34:37,720
HERE IS SOME DATA.

2119
01:34:37,720 --> 01:34:39,040
AND THIS IS UP-TO-DATE DATA

2120
01:34:39,040 --> 01:34:42,200
THROUGH THE END OF 2022 AND

2121
01:34:42,200 --> 01:34:43,520
EVERYBODY KNOWS BECAUSE I THINK

2122
01:34:43,520 --> 01:34:45,200
I'VE SHOWN THIS GROUP BEFORE,

2123
01:34:45,200 --> 01:34:49,120
WHAT I CALL THE GRAND CANYON IN

2124
01:34:49,120 --> 01:34:52,200
ACCRUAL, THESE REPE DOES NOT INE

2125
01:34:52,200 --> 01:34:54,760
THE INDUSTRIAL TRIALS AND IN

2126
01:34:54,760 --> 01:34:56,080
MARCH AND APRIL AND MAY JUNE

2127
01:34:56,080 --> 01:34:59,280
THERE WAS THIS 50% DECREASE IN

2128
01:34:59,280 --> 01:35:01,560
ACCRUAL TO NCTN.

2129
01:35:01,560 --> 01:35:04,200
CO-OPERATIVE GROUP TRIALS TO

2130
01:35:04,200 --> 01:35:05,000
INVESTIGATOR INITIALED TRIALS TO

2131
01:35:05,000 --> 01:35:07,360
PEER-REVIEWED GRANT FUNDED

2132
01:35:07,360 --> 01:35:09,640
TRIALS AND THE WHAT YOU CAN SEE

2133
01:35:09,640 --> 01:35:11,560
IN GRAY IS RAPIDLY AND HAPPILY

2134
01:35:11,560 --> 01:35:14,480
FOR US, THE NCTN ACCRUAL CAME

2135
01:35:14,480 --> 01:35:16,800
BACK TO WHERE IT WAS IN 2019.

2136
01:35:16,800 --> 01:35:20,240
AND HAS MAINTAINED A STEADY

2137
01:35:20,240 --> 01:35:21,480
STATE OVER THE LAST THREE YEARS

2138
01:35:21,480 --> 01:35:25,680
BUT WHAT I THINK IS EQUALLY

2139
01:35:25,680 --> 01:35:26,720
CLEAR IN ORANGE FOR PROSECUTE

2140
01:35:26,720 --> 01:35:27,920
REVIEW TRIALS OR IN BLUE FOR

2141
01:35:27,920 --> 01:35:37,880
INVESTIGATOR INITIATED TIMES,

2142
01:35:37,880 --> 01:35:39,320
THE CANCER CENTERS THAT REPORT

2143
01:35:39,320 --> 01:35:42,920
THIS INTO THE CTRP IT'S STILL

2144
01:35:42,920 --> 01:35:46,200
ABOUT 25% BELOW WHERE IT WAS

2145
01:35:46,200 --> 01:35:47,160
BEFORE THE PANDEMIC.

2146
01:35:47,160 --> 01:35:48,880
AND THIS IS I THINK A MAJOR

2147
01:35:48,880 --> 01:35:51,840
CONCERN BECAUSE MANY OF THE

2148
01:35:51,840 --> 01:35:54,120
INNOVATIVE STUDIES THAT

2149
01:35:54,120 --> 01:35:55,560
INVESTIGATORS PURSUE WHETHER

2150
01:35:55,560 --> 01:36:01,680
THEY'RE GRANT SUPPORTED IITs

2151
01:36:01,680 --> 01:36:05,120
HAVE NOT COME BACK AND OVER THE

2152
01:36:05,120 --> 01:36:06,720
LONG-TERM, AND THREE YEARS IS

2153
01:36:06,720 --> 01:36:08,920
LONG-TERM, TO HAVE AN ADVERSE I

2154
01:36:08,920 --> 01:36:10,680
AM IMPACT ON THE A LOT OF OUR

2155
01:36:10,680 --> 01:36:11,760
CLINICAL TRIALS SYSTEM TO DO

2156
01:36:11,760 --> 01:36:18,800
WHAT IT NEEDS TO DO.

2157
01:36:18,800 --> 01:36:20,600
IF YOU LOOK AT THE BARON THE

2158
01:36:20,600 --> 01:36:26,680
LEFT, YOU SEE WHERE WE WERE IN

2159
01:36:26,680 --> 01:36:28,720
2019 AND IN 2020 EVERY CATEGORY

2160
01:36:28,720 --> 01:36:30,800
OF TRIAL WHETHER IT'S PHARMA,

2161
01:36:30,800 --> 01:36:32,240
PEER-REVIEWED STUDY AND

2162
01:36:32,240 --> 01:36:34,840
INSTITUTIONAL TRIAL OR THE NCTN

2163
01:36:34,840 --> 01:36:36,680
TRIALS HAVE ALL DIMINISHED AND

2164
01:36:36,680 --> 01:36:37,960
THEY'VE DIMINISHED SIGNIFICANTLY

2165
01:36:37,960 --> 01:36:40,320
BUT IF YOU COMPARE 2020 TO 2022

2166
01:36:40,320 --> 01:36:41,760
AND YOU LOOK AT THE NUMBERS,

2167
01:36:41,760 --> 01:36:43,360
WHAT YOU SEE IS THE PHARMA

2168
01:36:43,360 --> 01:36:45,960
ACCRUAL IS BACK TO WHERE IT WAS

2169
01:36:45,960 --> 01:36:46,880
PRE-PANDEMIC AND NONE OF THE

2170
01:36:46,880 --> 01:36:49,680
OTHER CATEGORIES SAFE FOR NCTN

2171
01:36:49,680 --> 01:36:51,400
SO SPECIFICALLY PEER REVIEW

2172
01:36:51,400 --> 01:36:54,400
TRIALS, GRANT FUNDED TRIALS AND

2173
01:36:54,400 --> 01:36:58,000
IMPORTANTLY INSTITUTIONAL IITs

2174
01:36:58,000 --> 01:37:00,040
ARE FAR PEL OWE WHERE THEY WERE

2175
01:37:00,040 --> 01:37:01,200
PRE-PANDEMIC AND IF YOU LOOK AT

2176
01:37:01,200 --> 01:37:02,400
THE LIGHT BLUE, WE'RE TALKING

2177
01:37:02,400 --> 01:37:04,280
ABOUT A DROP FROM 19,000

2178
01:37:04,280 --> 01:37:06,680
PATIENTS IN 2019 TO 14,000

2179
01:37:06,680 --> 01:37:09,280
PATIENTS ON IITs IN 2022 AND

2180
01:37:09,280 --> 01:37:12,520
I'M SURE THE MEMBERS OF THE BSA

2181
01:37:12,520 --> 01:37:14,480
WHO WORK IN CLINICAL TRIALS AT

2182
01:37:14,480 --> 01:37:15,400
THEIR CANCER CENTERS ARE WELL

2183
01:37:15,400 --> 01:37:19,920
AWARE OF THIS ISSUE.

2184
01:37:19,920 --> 01:37:21,640
WE WANTED TO FIND OUT EXACTLY

2185
01:37:21,640 --> 01:37:23,600
WHAT WAS IND LYING THIS AND I'M

2186
01:37:23,600 --> 01:37:24,760
SURE NONE OF THE DATA THAT I'M

2187
01:37:24,760 --> 01:37:26,000
GOING TO SHOW SUE GOING TO BE

2188
01:37:26,000 --> 01:37:27,200
NEW TO MOST OF YOU.

2189
01:37:27,200 --> 01:37:29,560
BUT WE DID A SURVEY THAT

2190
01:37:29,560 --> 01:37:32,240
REMARKABLY GOT A RESPONSE FROM

2191
01:37:32,240 --> 01:37:33,800
100% OF THE CANCER CENTERS THAT

2192
01:37:33,800 --> 01:37:36,960
DO CLINICAL TRIALS.

2193
01:37:36,960 --> 01:37:38,240
I WANTED TO UNDERSTAND THE

2194
01:37:38,240 --> 01:37:40,840
IMPACT OF COVID ON THE CURRENT

2195
01:37:40,840 --> 01:37:42,000
CLINICAL TRIAL CAPACITY AND I

2196
01:37:42,000 --> 01:37:44,200
THINK THE POINTS TO BE RAISED

2197
01:37:44,200 --> 01:37:47,000
ARE SHOWN IN BLUE.

2198
01:37:47,000 --> 01:37:49,480
REALLY, THE MAJOR IMPACT THAT

2199
01:37:49,480 --> 01:37:51,480
WAS FELT WAS THAT TRIALS WERE

2200
01:37:51,480 --> 01:37:55,400
NOT OPEN AS RAPIDLY AS ONE HAD

2201
01:37:55,400 --> 01:37:56,320
HOPED AND THERE WAS BECAUSE OF

2202
01:37:56,320 --> 01:37:59,200
THE LIMITED CAPACITY OF THE

2203
01:37:59,200 --> 01:38:01,240
RESEARCH STAFF, THE ACCRUAL

2204
01:38:01,240 --> 01:38:02,880
TRIALS WERE PUT ON HOLD IN TERMS

2205
01:38:02,880 --> 01:38:04,400
OF ACCRUAL AND THE ACCRUAL

2206
01:38:04,400 --> 01:38:08,760
NUMBERS DECREASED AS I SHOWED.

2207
01:38:08,760 --> 01:38:09,720
SO WHY?

2208
01:38:09,720 --> 01:38:12,200
WELL, BECAUSE WE LOST A

2209
01:38:12,200 --> 01:38:13,400
TREMENDOUS PERCENTAGE OF OUR

2210
01:38:13,400 --> 01:38:14,560
CLINICAL RESEARCH STAFF.

2211
01:38:14,560 --> 01:38:15,880
AND WHERE DID THEY GO?

2212
01:38:15,880 --> 01:38:17,800
THEY WENT BASICALLY TO CROs

2213
01:38:17,800 --> 01:38:19,720
AND PHARMA BECAUSE THOSE

2214
01:38:19,720 --> 01:38:21,960
ENTITIES WERE ABLE TO PAY

2215
01:38:21,960 --> 01:38:25,360
SUBSTANTIALLY HIGHER AMOUNTS OF

2216
01:38:25,360 --> 01:38:27,160
SALARY MONEY AND PROVIDED

2217
01:38:27,160 --> 01:38:28,720
GREATER FLEXIBILITY AT LEAST

2218
01:38:28,720 --> 01:38:30,120
INITIALLY IN TERMS OF THE

2219
01:38:30,120 --> 01:38:32,000
ABILITY TO WORK REMOTELY.

2220
01:38:32,000 --> 01:38:35,040
AND THIS IS HAD A MAJOR IMPACT,

2221
01:38:35,040 --> 01:38:35,640
NEXT SLIDE.

2222
01:38:35,640 --> 01:38:41,320
AND YOU CAN SEE THAT THIS, WE'RE

2223
01:38:41,320 --> 01:38:44,840
TALKING ABOUT HALF OF OUR LOSS

2224
01:38:44,840 --> 01:38:47,680
WAS TO PHARMA AND CROs AND

2225
01:38:47,680 --> 01:38:51,920
THIS ADVERSE IMPACT IS SUCH THAT

2226
01:38:51,920 --> 01:38:55,000
THE VAST MAJORITY OF THE NCI DES

2227
01:38:55,000 --> 01:38:55,920
EGG NATURED CANCER CENTERS IN

2228
01:38:55,920 --> 01:38:57,680
ONE WAY OR ANOTHER HAVE HAD A

2229
01:38:57,680 --> 01:38:58,960
DIFFICULT TIME IN MAINTAINING

2230
01:38:58,960 --> 01:39:00,640
THEIR CLINICAL TRIALS ACCRUAL

2231
01:39:00,640 --> 01:39:04,960
OVER THE LAST THREE YEARS.

2232
01:39:04,960 --> 01:39:08,880
NEXT SLIDE.

2233
01:39:08,880 --> 01:39:10,280
WHEN PEOPLE PROVIDE INPUT IN

2234
01:39:10,280 --> 01:39:11,400
TERMS OF THE LOSSES THEY

2235
01:39:11,400 --> 01:39:13,040
EXPERIENCE AND THE LOSSES BOTH

2236
01:39:13,040 --> 01:39:15,640
IN THE REALM OF SENIORS STAFF AS

2237
01:39:15,640 --> 01:39:18,400
WELL AS RECENT TRAINEES, WHICH

2238
01:39:18,400 --> 01:39:20,560
MEANS THAT THE ENTIRE POOL OF

2239
01:39:20,560 --> 01:39:23,520
QUALIFIED CA CANDIDATES WERE SUD

2240
01:39:23,520 --> 01:39:25,120
UP INTO A DIFFERENT SYSTEM TO DO

2241
01:39:25,120 --> 01:39:26,280
CLINICAL TRIALS AND THIS HAS HAD

2242
01:39:26,280 --> 01:39:28,640
AN ADVERSE IMPACT IN THE ABILITY

2243
01:39:28,640 --> 01:39:31,360
OF MANY CANCER CENTERS TO

2244
01:39:31,360 --> 01:39:35,880
MAINTAIN THE PACE AND THE

2245
01:39:35,880 --> 01:39:37,720
VIABILITY OFFER A PROLONGED

2246
01:39:37,720 --> 01:39:39,600
PERIOD OF TIME.

2247
01:39:39,600 --> 01:39:42,240
SO, RIGHT IN THE MIDST OF THIS,

2248
01:39:42,240 --> 01:39:44,000
WE BEGAN WORKING ON A NEW VISION

2249
01:39:44,000 --> 01:39:45,680
FOR OUR CLINICAL TRIALS

2250
01:39:45,680 --> 01:39:46,080
PROGRAMS.

2251
01:39:46,080 --> 01:39:49,240
I'D LIKE TO SHARE SOME OF THE

2252
01:39:49,240 --> 01:39:50,840
MAJOR AREAS THAT WERE

2253
01:39:50,840 --> 01:39:51,760
RECOMMENDED FOR CHANGE AND SOME

2254
01:39:51,760 --> 01:39:53,040
OF THE THINGS THAT WE'VE I AM

2255
01:39:53,040 --> 01:39:59,040
IMPLEMENTED.THIS IS APP ON GOIN,

2256
01:39:59,040 --> 01:39:59,400
NEXT SLIDE.

2257
01:39:59,400 --> 01:40:04,000
WHAT WERE THE MAJOR THEMES.

2258
01:40:04,000 --> 01:40:04,960
WHAT INFRASTRUCTURES WERE

2259
01:40:04,960 --> 01:40:05,360
CRITICAL?

2260
01:40:05,360 --> 01:40:07,360
AND THE MAJOR THEMES WERE TRIAL

2261
01:40:07,360 --> 01:40:09,120
COMPLEXITY AND COST, NO

2262
01:40:09,120 --> 01:40:11,280
SURPRISE, HOW DO WE DEAL WITH

2263
01:40:11,280 --> 01:40:13,160
DECENTRALIZED TRIAL ACTIVITIES

2264
01:40:13,160 --> 01:40:14,880
WHILE AT THE SAME TIME PROMOTING

2265
01:40:14,880 --> 01:40:15,760
ACCRUAL AND ACCESS.

2266
01:40:15,760 --> 01:40:17,800
CAN WE DEVELOP NEW DATA

2267
01:40:17,800 --> 01:40:19,800
COLLECTION APPROACHES AND HOW DO

2268
01:40:19,800 --> 01:40:22,680
WE COLLECT PRO DATA IN THIS

2269
01:40:22,680 --> 01:40:23,040
ENVIRONMENT?

2270
01:40:23,040 --> 01:40:24,240
AND SPECIFICSLY, HOW DO WE DEAL

2271
01:40:24,240 --> 01:40:28,440
WITH THE OPERATIONAL BURDEN SO

2272
01:40:28,440 --> 01:40:30,760
THERE WERE SOME STATISTIC ISSUES

2273
01:40:30,760 --> 01:40:32,320
AND AT END OF THE THIS ISSUE OF

2274
01:40:32,320 --> 01:40:33,600
WORKFORCE THAT IS CRITICALLY

2275
01:40:33,600 --> 01:40:36,600
IMPORTANT.

2276
01:40:36,600 --> 01:40:37,800
NEXT SLIDE.

2277
01:40:37,800 --> 01:40:39,640
IF WE TAKE THE 30,000-FOOT VIEW

2278
01:40:39,640 --> 01:40:46,800
OF THIS ENTIRE PROCESS, OUR GOAL

2279
01:40:46,800 --> 01:40:50,400
AND THIS IS A MULTI AND ALREADY

2280
01:40:50,400 --> 01:40:52,240
AND TRY TO DEVELOP MORE

2281
01:40:52,240 --> 01:40:56,400
FLEXIBILITY, FASTER, SIMPLER,

2282
01:40:56,400 --> 01:40:58,040
LESS EXPENSIVE TRIALS THAT

2283
01:40:58,040 --> 01:40:58,880
INTEGRATE WITH CLINICAL

2284
01:40:58,880 --> 01:41:00,680
PRACTICES AND WE MUST STREAMLINE

2285
01:41:00,680 --> 01:41:02,080
FOR TRIAL DESIGN AND EXECUTION

2286
01:41:02,080 --> 01:41:04,080
AND FOCUS ON -- I'LL TALK ABOUT

2287
01:41:04,080 --> 01:41:08,360
THIS MORE, ON THE MOST ESSENTIAL

2288
01:41:08,360 --> 01:41:08,680
END POINTS.

2289
01:41:08,680 --> 01:41:09,920
DECREASE REGULATORY BURDENS AND

2290
01:41:09,920 --> 01:41:13,040
INCREASE THE EFFICIENCY OF OUR

2291
01:41:13,040 --> 01:41:13,640
DATA COLLECTION.

2292
01:41:13,640 --> 01:41:14,960
SO I'M GOING TO TALK A LITTLE

2293
01:41:14,960 --> 01:41:17,280
BIT ABOUT STREAMLINING CLINICAL

2294
01:41:17,280 --> 01:41:18,480
TRIALS BECAUSE WE'VE REALLY MADE

2295
01:41:18,480 --> 01:41:20,000
SOME PROGRESS IN THIS AREA AND I

2296
01:41:20,000 --> 01:41:21,240
THINK IT'S GOING TO HAVE A

2297
01:41:21,240 --> 01:41:22,880
SIGNIFICANT IMPACT IN EVERYTHING

2298
01:41:22,880 --> 01:41:25,720
THAT WE DO IN TERMS OF THE NCI

2299
01:41:25,720 --> 01:41:27,520
SUPPORT CLINICAL TRIALS AND THE

2300
01:41:27,520 --> 01:41:28,840
FIRST AREA I'M GOING TO TALK

2301
01:41:28,840 --> 01:41:30,360
ABOUT IS LIMITING THE DATA

2302
01:41:30,360 --> 01:41:32,120
ELEMENTS THAT WE COLLECT.

2303
01:41:32,120 --> 01:41:33,080
YOU ALL KNOW THAT FOR EVERY

2304
01:41:33,080 --> 01:41:35,120
PIECE OF DATA YOU COLLECT, EVERY

2305
01:41:35,120 --> 01:41:37,240
DATA ELEMENT COST MONEY.

2306
01:41:37,240 --> 01:41:38,400
AND WE HAVE TO -- THE QUESTION

2307
01:41:38,400 --> 01:41:39,600
IS, DO WE NEED TO COLLECT

2308
01:41:39,600 --> 01:41:40,920
EVERYTHING THAT WE'RE CURRENTLY

2309
01:41:40,920 --> 01:41:42,920
COLLECTING, ESPECIALLY IN OUR

2310
01:41:42,920 --> 01:41:45,880
LATE PHASE PORTFOLIO OF TRIALS.

2311
01:41:45,880 --> 01:41:47,880
AND SO TO ANALYZE WHAT WE'RE

2312
01:41:47,880 --> 01:41:49,680
DOING, WE PUT TOGETHER AN EXPERT

2313
01:41:49,680 --> 01:41:51,200
WORKING GROUP AND ANALYZED A

2314
01:41:51,200 --> 01:41:55,800
LARGE SERIES OF ON GOING PHASE 3

2315
01:41:55,800 --> 01:41:57,640
TREATMENT PROTOCOLS TO

2316
01:41:57,640 --> 01:41:59,280
UNDERSTAND WHAT WE WERE

2317
01:41:59,280 --> 01:42:01,520
COLLECTING AND JUST HOW

2318
01:42:01,520 --> 01:42:03,880
IMPORTANT WERE THE DATA THAT --

2319
01:42:03,880 --> 01:42:05,640
AND NOW DID IT IMPACT THE OUT

2320
01:42:05,640 --> 01:42:07,200
PUTS FOR THESE TRIALS.

2321
01:42:07,200 --> 01:42:11,080
AND I'M ALSO GOING TO TALK ABOUT

2322
01:42:11,080 --> 01:42:15,520
THE REALLY DIFFICULT ISSUES OF

2323
01:42:15,520 --> 01:42:17,960
GETTING THE TREATMENT REGIMENTS

2324
01:42:17,960 --> 01:42:20,160
INTO OUR EHRs A PROBLEM THAT

2325
01:42:20,160 --> 01:42:21,480
DIDN'T EXIST 10 YEARS AGO THAT

2326
01:42:21,480 --> 01:42:25,120
THAT'S MADE A MAJOR IMPACT IS

2327
01:42:25,120 --> 01:42:26,040
COSTLY AND IT'S SOMETHING THAT'S

2328
01:42:26,040 --> 01:42:31,200
NOT GOTTEN A LOT OF REVIEW AND I

2329
01:42:31,200 --> 01:42:32,800
THINK I'M GOING TO HELP TO SHOW

2330
01:42:32,800 --> 01:42:34,360
YOU THAT WE'RE TRYING TO MAKE

2331
01:42:34,360 --> 01:42:36,240
SOME IMPACT IN DEALING WITH THIS

2332
01:42:36,240 --> 01:42:38,160
REALLY IMPORTANT PROBLEM AND IT

2333
01:42:38,160 --> 01:42:39,360
SLOWS DOWN THE ENTIRE PROCESS

2334
01:42:39,360 --> 01:42:42,280
AND IT'S VERY COSTLY.

2335
01:42:42,280 --> 01:42:43,480
NEXT SLIDE.

2336
01:42:43,480 --> 01:42:48,560
SO WHAT ARE THE LOW DATA VALUE

2337
01:42:48,560 --> 01:42:51,520
ELEMENTS THAT ARE EXPERT GROUP

2338
01:42:51,520 --> 01:42:52,240
CAME UP WITH.

2339
01:42:52,240 --> 01:42:53,560
WHAT IS THE SCOPE OF THE

2340
01:42:53,560 --> 01:42:54,560
RECOMMENDATION THAT'S THEY CAME

2341
01:42:54,560 --> 01:42:56,640
UP WITH SO THE FIRST WE GET IS

2342
01:42:56,640 --> 01:42:58,600
TO TRY TO UNDERSTAND WHERE COULD

2343
01:42:58,600 --> 01:43:01,880
WE FOCUS ON CHANGING THE

2344
01:43:01,880 --> 01:43:02,640
STANDARD OF PRACTICE.

2345
01:43:02,640 --> 01:43:04,880
WHAT DID WE HAVE CONTROL OVER

2346
01:43:04,880 --> 01:43:06,280
THAT COULD BE RESULTED IN

2347
01:43:06,280 --> 01:43:07,840
CHANGES THAT WE COULD MANAGE IN

2348
01:43:07,840 --> 01:43:09,600
A RELATIVELY RAPID TIMEFRAME.

2349
01:43:09,600 --> 01:43:12,600
SO WE FOCUSED INITIALLY ON

2350
01:43:12,600 --> 01:43:15,960
EVALUATING CTEP MANAGED TRIALS,

2351
01:43:15,960 --> 01:43:16,680
LATE-PHASE TRIALS, TREATMENT

2352
01:43:16,680 --> 01:43:19,520
TRIALS AND ADULT TRIALS AND IND

2353
01:43:19,520 --> 01:43:20,120
EXEMPT TRIALS.

2354
01:43:20,120 --> 01:43:22,320
IT DOESN'T MEAN THAT WE'RE NOT

2355
01:43:22,320 --> 01:43:24,120
INTERESTED IN PEDIATRIC TRIALS

2356
01:43:24,120 --> 01:43:25,640
OR PREVENTION TRIALS OR OTHER

2357
01:43:25,640 --> 01:43:27,160
KINDS OF THINGS BUT THESE THINGS

2358
01:43:27,160 --> 01:43:29,640
BECAUSE THEY'RE IND EXEMPT, AND

2359
01:43:29,640 --> 01:43:31,720
HAVE OUR MAKE UP A MAJOR PORTION

2360
01:43:31,720 --> 01:43:33,960
OF THE PORTFOLIO OF NCTN TRIALS,

2361
01:43:33,960 --> 01:43:36,000
WE COULD CHANGE WITHOUT GETTING

2362
01:43:36,000 --> 01:43:39,000
MAKING MAJOR REGULATORY HAVING

2363
01:43:39,000 --> 01:43:41,880
REGULATORY HURDLES.

2364
01:43:41,880 --> 01:43:42,640
NEXT SLIDE.

2365
01:43:42,640 --> 01:43:44,240
SO WHAT ARE THE CATEGORIES THAT

2366
01:43:44,240 --> 01:43:45,360
WE'RE EVALUATING?

2367
01:43:45,360 --> 01:43:47,280
THESE ARE THE THINGS IF YOU

2368
01:43:47,280 --> 01:43:50,800
REALLY TALK TO FOLKS WHO ARE IN

2369
01:43:50,800 --> 01:43:51,400
THE DAY-TO-DAY BUSINESS OF

2370
01:43:51,400 --> 01:43:52,800
RUNNING CLINICAL TRIALS, EVERY

2371
01:43:52,800 --> 01:43:55,760
ONE OF THESE CATEGORIES, WE

2372
01:43:55,760 --> 01:43:57,320
COULD SPEND HOURS ON THE

2373
01:43:57,320 --> 01:43:58,520
COMPLAINTS THAT PEOPLE HAVE

2374
01:43:58,520 --> 01:44:00,080
ABOUT THE EXCESS AMOUNT OF DATA

2375
01:44:00,080 --> 01:44:01,960
THAT WE COLLECT IN EVERY ONE OF

2376
01:44:01,960 --> 01:44:02,960
THESE AREAS AND I'M GOING TO

2377
01:44:02,960 --> 01:44:04,240
SHOW YOU SOME OF THE THINGS WE

2378
01:44:04,240 --> 01:44:06,400
THINK CAN BE CHANGED THAT WILL

2379
01:44:06,400 --> 01:44:08,400
STREAMLINE THE PROCESS OF OUR

2380
01:44:08,400 --> 01:44:09,600
LATE PHASE CLINICAL TRIALS

2381
01:44:09,600 --> 01:44:12,440
PROGRAMS.

2382
01:44:12,440 --> 01:44:12,920
NEXT SLIDE.

2383
01:44:12,920 --> 01:44:16,440
I WOULD SAY ON THE TOP OF THE

2384
01:44:16,440 --> 01:44:18,880
LIST OF PET PEEVES THAT CLINICAL

2385
01:44:18,880 --> 01:44:21,160
INVESTIGATORS HAVE IS WHY WE

2386
01:44:21,160 --> 01:44:24,200
SHOULD CONTINUE TO COLLECT FOR

2387
01:44:24,200 --> 01:44:26,480
WELL ESTABLISHED DRUGS THAT HAVE

2388
01:44:26,480 --> 01:44:28,400
TOXICITY PROFILES THAT ARE

2389
01:44:28,400 --> 01:44:30,400
WELL-KNOWN, WHY SHOULD WE

2390
01:44:30,400 --> 01:44:32,120
COLLECT LOW-GRADE ADVERSE EVENTS

2391
01:44:32,120 --> 01:44:33,440
AND PROBABLY WORSE, WHY SHOULD

2392
01:44:33,440 --> 01:44:36,040
WE TRY TO UNDERSTAND THE

2393
01:44:36,040 --> 01:44:38,400
ATTRIBUTION, AND WORSE OF ALL,

2394
01:44:38,400 --> 01:44:40,200
THEIR START DATE AND STOP DATES.

2395
01:44:40,200 --> 01:44:43,080
WE HAVE CRAs SPENDING HOURS

2396
01:44:43,080 --> 01:44:44,000
AND SHOWERS TRYING TO ASSESS

2397
01:44:44,000 --> 01:44:53,040
FROM THE MEDICAL RECORD THOSE

2398
01:44:53,040 --> 01:44:54,320
DATA ARE ESSENTIALLY NEVER USED

2399
01:44:54,320 --> 01:44:58,440
WHEN THE PUBLICATION COMES OUT.

2400
01:44:58,440 --> 01:44:59,880
WE THOUGHT FOUGHT CLEARLY ABOUT

2401
01:44:59,880 --> 01:45:01,640
ALL THE EXCESS LABORATORY DATA

2402
01:45:01,640 --> 01:45:03,160
THAT'S COLLECTED AND ESPECIALLY

2403
01:45:03,160 --> 01:45:04,120
LABORATORY THAT'S COLLECTED

2404
01:45:04,120 --> 01:45:06,000
BEYOND STANDARD OF CARE AND IT'S

2405
01:45:06,000 --> 01:45:07,960
UNRELATE TO STUDY ENTER POINTS

2406
01:45:07,960 --> 01:45:08,960
OR SAFETY MONITORING.

2407
01:45:08,960 --> 01:45:10,560
I'VE HAD PERSONAL EXPERIENCE

2408
01:45:10,560 --> 01:45:13,520
WHEN I WAS ON ODAC OF PEOPLE

2409
01:45:13,520 --> 01:45:17,280
WANTING TO KNOW WHAT MIGHT THE

2410
01:45:17,280 --> 01:45:19,320
HEMOGLOBIN BE ON DATE 8 OF CYCLE

2411
01:45:19,320 --> 01:45:20,880
14 OF SOME REGIMENT THAT HAD

2412
01:45:20,880 --> 01:45:22,200
NOTHING TO DO WITH THE OUTCOME

2413
01:45:22,200 --> 01:45:23,400
OF THE TRIAL.

2414
01:45:23,400 --> 01:45:24,560
WE COLLECT ALL THAT DATA.

2415
01:45:24,560 --> 01:45:26,080
WE DON'T USE THAT DATA.

2416
01:45:26,080 --> 01:45:28,440
AND THIS MEANS THAT THERE ARE UP

2417
01:45:28,440 --> 01:45:30,440
USED COMPONENTS IN LABORATORY

2418
01:45:30,440 --> 01:45:32,560
PANELS THAT GET PUT INTO CASE

2419
01:45:32,560 --> 01:45:33,880
REPORT FORMS AND THAT ARE

2420
01:45:33,880 --> 01:45:39,360
ABSOLUTELY UNNECESSARY AND TAKE

2421
01:45:39,360 --> 01:45:40,560
TIME AND NEVER HAVE SIGNIFICANT

2422
01:45:40,560 --> 01:45:41,960
IMPACT ON THE OVER ALL OUTCOME

2423
01:45:41,960 --> 01:45:44,360
OF THE TRIAL AND THE SAME CAN BE

2424
01:45:44,360 --> 01:45:46,240
SAID CHAPTER AND VERSE FOR

2425
01:45:46,240 --> 01:45:47,680
IMAGING THAT IS DONE BEYOND THE

2426
01:45:47,680 --> 01:45:50,600
STANDARD OF CARE.

2427
01:45:50,600 --> 01:45:51,760
NEXT SLIDE.

2428
01:45:51,760 --> 01:45:53,040
REMARKABLY, THERE ARE MANY

2429
01:45:53,040 --> 01:45:54,560
THINGS ABOUT HISTORY AND

2430
01:45:54,560 --> 01:45:55,760
PHYSICAL EXAMINATION.

2431
01:45:55,760 --> 01:45:57,240
THEY'RE NEVER USED.

2432
01:45:57,240 --> 01:45:59,640
WE COLLECT ENORMOUS AMOUNTS OF

2433
01:45:59,640 --> 01:46:01,680
DATA ON MEDICATION THAT'S ARE

2434
01:46:01,680 --> 01:46:02,720
COMPLETELY IRRELEVANT TO

2435
01:46:02,720 --> 01:46:03,320
PROTOCOLS.

2436
01:46:03,320 --> 01:46:06,600
WE COLLECT EVEN MORE DATA WHEN

2437
01:46:06,600 --> 01:46:10,000
THOSE CON COM TANT ARE STARTED

2438
01:46:10,000 --> 01:46:10,600
AND DIS CONTINUED THAT HAVE

2439
01:46:10,600 --> 01:46:21,000
NORTH TO DO WITH SAFETY.

2440
01:46:33,440 --> 01:46:35,840
THEY WILL BE FOCUSED ON

2441
01:46:35,840 --> 01:46:37,600
LATE-STAGE TRIALS, IND EXEMPT

2442
01:46:37,600 --> 01:46:38,920
TRIALS TO REDUCE THE OPERATIONAL

2443
01:46:38,920 --> 01:46:40,680
BURDEN OF THOSE TRIALS AND THEN

2444
01:46:40,680 --> 01:46:42,880
TO PROVIDE INSIGHTS THAT WILL

2445
01:46:42,880 --> 01:46:44,520
INFORM US IN TERMS OF WHAT IS

2446
01:46:44,520 --> 01:46:45,960
ACTUALLY NEEDED, WHAT DATA ARE

2447
01:46:45,960 --> 01:46:48,120
NEEDED TO BE COLLECTED, FOR A

2448
01:46:48,120 --> 01:46:49,760
LATE-PHASE IND RELATED TRIALS

2449
01:46:49,760 --> 01:46:51,440
AND PEDIATRIC TRIALS AND WE ARE

2450
01:46:51,440 --> 01:46:54,600
IN THE PROCESS OF TRYING TO

2451
01:46:54,600 --> 01:46:56,800
DEVELOP A BROAD STAKEHOLDER

2452
01:46:56,800 --> 01:47:00,240
ENGAGEMENT IN INPUT AND HOW TO

2453
01:47:00,240 --> 01:47:01,920
SUCCESSFULLY IMPLEMENT CHANGES

2454
01:47:01,920 --> 01:47:04,360
THAT WILL BE EMBRACED ACROSS THE

2455
01:47:04,360 --> 01:47:06,520
COMMUNITY AND REQUIRING US TO

2456
01:47:06,520 --> 01:47:08,200
COLLECT MUCH LESS DATA AND

2457
01:47:08,200 --> 01:47:11,120
HOPEFULLY WILL ALLOW US TO USE

2458
01:47:11,120 --> 01:47:12,680
OUR PERSONAL MUCH MORE

2459
01:47:12,680 --> 01:47:13,280
EFFECTIVELY.

2460
01:47:13,280 --> 01:47:14,120
NEXT SLIDE.

2461
01:47:14,120 --> 01:47:17,280
THIS IS NOT JUST A FANTASY.

2462
01:47:17,280 --> 01:47:24,280
THIS IS THE SCHEME FOR THE

2463
01:47:24,280 --> 01:47:24,840
PRAGMATIC TRIAL.

2464
01:47:24,840 --> 01:47:26,040
I WANT TO SAY TWO THINGS ABOUT

2465
01:47:26,040 --> 01:47:26,880
THIS STUDY.

2466
01:47:26,880 --> 01:47:29,360
WE STARTED TALKING ABOUT THIS

2467
01:47:29,360 --> 01:47:31,720
TRIAL LATE IN AUGUST.

2468
01:47:31,720 --> 01:47:32,200
OF 2022.

2469
01:47:32,200 --> 01:47:35,040
THE FIRST PATIENT WAS ENTERED ON

2470
01:47:35,040 --> 01:47:38,240
PRAG PRAGMATIC LAST WEEK.

2471
01:47:38,240 --> 01:47:40,040
SIX AND A HALF MONTHS FROM START

2472
01:47:40,040 --> 01:47:41,880
TO FINISH FOR A RANDOMIZED TRIAL

2473
01:47:41,880 --> 01:47:43,760
THAT WILL LEAD TO AN INDICATION

2474
01:47:43,760 --> 01:47:46,920
PROVED BY THE FDA AND A SURVIVAL

2475
01:47:46,920 --> 01:47:49,360
OUTCOME ONLY, NO PFS, WITH

2476
01:47:49,360 --> 01:47:51,960
MINIMAL IMAGING AND MINIMAL

2477
01:47:51,960 --> 01:47:54,560
LABORATORY COLLECTION, AND NO

2478
01:47:54,560 --> 01:47:58,200
ADVERSE EVENTS COLLECTED EXCEPT

2479
01:47:58,200 --> 01:47:59,600
FOR HOSPITALIZATIONS THAT HAS A

2480
01:47:59,600 --> 01:48:01,680
SCHEME A PAGE THAT IS SMALLER

2481
01:48:01,680 --> 01:48:06,720
THAN ANYONE WHO HAS WRITTEN A

2482
01:48:06,720 --> 01:48:10,440
CLIP CAL CLINICAL TRIALS BECAUSS

2483
01:48:10,440 --> 01:48:11,800
DATA BECAUSE WE'RE LOOKING FOR

2484
01:48:11,800 --> 01:48:13,280
WHETHER OR NOT THIS TRIAL, WHICH

2485
01:48:13,280 --> 01:48:14,920
IS AN EXPANSION OF A TRIAL THAT

2486
01:48:14,920 --> 01:48:17,480
WAS INITIALLY A SMALL RANDOMIZED

2487
01:48:17,480 --> 01:48:19,720
PHASE 2 STUDY IN LONG MAP, NOW

2488
01:48:19,720 --> 01:48:21,320
EXPANDED TO ABOUT 700 PATIENTS

2489
01:48:21,320 --> 01:48:23,280
WILL ACTUALLY REACH THE MOST

2490
01:48:23,280 --> 01:48:24,680
IMPORTANT END POINT THAT IS

2491
01:48:24,680 --> 01:48:26,800
THERE A COMBINATION OF A

2492
01:48:26,800 --> 01:48:29,320
INHIBITOR AND A CHECKPOINT

2493
01:48:29,320 --> 01:48:31,360
INHIBITOR WILL CHANGE THE

2494
01:48:31,360 --> 01:48:34,040
SURVIVAL IN THIRD LINE NON SMALL

2495
01:48:34,040 --> 01:48:35,000
LUNG CANCER TREATMENT.

2496
01:48:35,000 --> 01:48:35,600
THAT'S IT.

2497
01:48:35,600 --> 01:48:36,800
THAT'S THE QUESTION.

2498
01:48:36,800 --> 01:48:37,720
EITHER WILL OR IT WON'T.

2499
01:48:37,720 --> 01:48:41,040
IF IT DOES, IT'S LIKELY TO GET

2500
01:48:41,040 --> 01:48:43,360
APPROVED SPECIFICALLY BY THE FDA

2501
01:48:43,360 --> 01:48:46,320
AND WITH THE FULL CONCEPT OF

2502
01:48:46,320 --> 01:48:51,560
AMERICAMERCKAND LILLY.

2503
01:48:51,560 --> 01:48:54,080
IT'S POSSIBLE TO WRITE TRIALS

2504
01:48:54,080 --> 01:48:55,720
THAT REQUIRE MINIMAL DATA THAT

2505
01:48:55,720 --> 01:48:57,120
COULD ACTUALLY LEAD TO AN

2506
01:48:57,120 --> 01:49:00,880
IMPORTANT CHANGE IN THE STANDARD

2507
01:49:00,880 --> 01:49:01,520
OF CARE.

2508
01:49:01,520 --> 01:49:05,520
SO I'D LIKE TO SAY A WORD TO EHR

2509
01:49:05,520 --> 01:49:06,480
BILLS SO THIS IS NOT SOMETHING

2510
01:49:06,480 --> 01:49:08,720
THAT GETS A LOT OF PUBLICITY AND

2511
01:49:08,720 --> 01:49:11,120
YET IT IS THE BAIN OF THE

2512
01:49:11,120 --> 01:49:12,560
EXISTENCE OF EVERY CLINICAL

2513
01:49:12,560 --> 01:49:14,320
TRIALS OFFICE IN EVERY NCI

2514
01:49:14,320 --> 01:49:16,360
DESIGNATED CANCER CENTER.

2515
01:49:16,360 --> 01:49:17,440
SO WHAT DOES THIS MEAN?

2516
01:49:17,440 --> 01:49:18,880
IT MEANS THAT FOR THOSE WHO

2517
01:49:18,880 --> 01:49:20,040
REPEAT FAMILIAR WITH THIS, EVERY

2518
01:49:20,040 --> 01:49:22,120
TIME YOU HAVE A CLINICAL TRIAL,

2519
01:49:22,120 --> 01:49:24,040
IT REQUIRES THAT THE ORDERS FOR

2520
01:49:24,040 --> 01:49:25,800
THE THE TREATMENT AND ALL THE

2521
01:49:25,800 --> 01:49:28,520
LABORATORY STUDIES THAT WILL BE

2522
01:49:28,520 --> 01:49:30,200
PERFORMED IN ALL THE STUDY

2523
01:49:30,200 --> 01:49:32,240
VISITS GET PROGRAMMED INTO THE

2524
01:49:32,240 --> 01:49:34,600
EHR RECORD SO WHY IS THAT A

2525
01:49:34,600 --> 01:49:35,080
PROBLEM?

2526
01:49:35,080 --> 01:49:36,560
WELL THE PROBLEM IS EVERY

2527
01:49:36,560 --> 01:49:39,160
HOSPITAL THAT'S A DIFFERENT DRUG

2528
01:49:39,160 --> 01:49:41,280
FORMULARY AND EVERY HOST AND

2529
01:49:41,280 --> 01:49:42,800
CANCER CENTER HAS VARIETIES THAT

2530
01:49:42,800 --> 01:49:44,840
MAY BE MODEST AND THEY'RE STILL

2531
01:49:44,840 --> 01:49:46,160
DIFFERENT IN TERMS OF THE

2532
01:49:46,160 --> 01:49:46,840
CLINICAL PRACTICE GUIDELINES

2533
01:49:46,840 --> 01:49:51,480
THAT ARE USED FOR HOW DRUGS ARE

2534
01:49:51,480 --> 01:49:53,800
PUT INTO VARIOUS KINDS OF

2535
01:49:53,800 --> 01:49:55,480
INTERVENE US SOLUTIONS SO, IT

2536
01:49:55,480 --> 01:49:57,960
MAY BE THAT AT THE DANA FARBER

2537
01:49:57,960 --> 01:50:00,680
IS ONLY GIVEN IN SALINE AND IF

2538
01:50:00,680 --> 01:50:02,760
THE CITY OF HOPE IT MAY BE GIVEN

2539
01:50:02,760 --> 01:50:04,800
IN HALF NORMAL SALINE AND SOME

2540
01:50:04,800 --> 01:50:07,040
PLACE ELSE IT MAY BE 50CCs AND

2541
01:50:07,040 --> 01:50:09,440
SOME PLACE IT'S A LITER.

2542
01:50:09,440 --> 01:50:12,560
EVERY SINGLE TIME THAT DRUG IS

2543
01:50:12,560 --> 01:50:14,920
USED IN ANY PROTOCOL IT HAS TO

2544
01:50:14,920 --> 01:50:17,280
BE DONE IN SUCH A WAY THAT IS

2545
01:50:17,280 --> 01:50:18,800
CONSISTENT WITH THE INDIVIDUAL

2546
01:50:18,800 --> 01:50:21,040
PRACTICE IN THAT HOSPITAL.

2547
01:50:21,040 --> 01:50:24,200
SO THE ENORMOUS VARIATION ACROSS

2548
01:50:24,200 --> 01:50:26,560
PROTOCOLS, AND IN TERMS OF WHAT

2549
01:50:26,560 --> 01:50:28,320
IS IN THE PROTOCOL, AND WHAT IS

2550
01:50:28,320 --> 01:50:31,280
NOT IN THE PROTOCOL AND HOW THAT

2551
01:50:31,280 --> 01:50:33,040
GETS PUT INTO THE INDIVIDUAL

2552
01:50:33,040 --> 01:50:35,320
INSTITUTIONS EHR IS ENORMOUS AND

2553
01:50:35,320 --> 01:50:37,520
IT IS BEEN ESTIMATED THAT IT

2554
01:50:37,520 --> 01:50:39,520
TAKES OVER 24 HOURS TO BUILD A

2555
01:50:39,520 --> 01:50:41,760
TREATMENT PLANT FOR A SINGLE

2556
01:50:41,760 --> 01:50:45,560
STUDY ARM IN EPIC SO LET ME JUST

2557
01:50:45,560 --> 01:50:49,600
DO THE MATH, FOR NCI MATCH, 39

2558
01:50:49,600 --> 01:50:54,440
ARMS, ACROSS OVER 1800 SITES

2559
01:50:54,440 --> 01:50:55,760
TIMES 26 HOURS AND IT'S

2560
01:50:55,760 --> 01:50:57,400
UNBELIEVABLE AND THIS AMOUNT OF

2561
01:50:57,400 --> 01:50:59,920
WORK AND LITERALLY BILLIONS OF

2562
01:50:59,920 --> 01:51:02,480
DOLLARS TO BE ABLE TO PUT THE

2563
01:51:02,480 --> 01:51:04,520
INFORMATION THAT YOU NEED TO

2564
01:51:04,520 --> 01:51:06,880
CARRY OUT IN THE ELECTRONIC

2565
01:51:06,880 --> 01:51:09,000
HEALTH RECORD AND THE LOGO

2566
01:51:09,000 --> 01:51:10,800
RESOURCES ARE NEVER FULLY

2567
01:51:10,800 --> 01:51:13,120
REIMBURSE AND SO THIS IS A HUGE

2568
01:51:13,120 --> 01:51:14,240
PROBLEM AND WE'RE HOPING TO DO

2569
01:51:14,240 --> 01:51:21,120
AT LEAST MAKE SOME DENT IN.

2570
01:51:21,120 --> 01:51:24,880
SO, OUR GOAL IS TO TRY TO

2571
01:51:24,880 --> 01:51:28,160
FACILITATE STANDARDIZED AND

2572
01:51:28,160 --> 01:51:28,840
ACROSS CLINICAL TRIALS AND ABOUT

2573
01:51:28,840 --> 01:51:31,280
A YEAR AND A HALF AND WE FUNDED

2574
01:51:31,280 --> 01:51:41,760
TWO CONSORTIA AND CENTER TO

2575
01:51:48,000 --> 01:51:48,760
CENTER TO CENTER.

2576
01:51:48,760 --> 01:51:59,160
WE ARE IN THE PROCESS.

2577
01:52:00,720 --> 01:52:01,840
PACKAGE THESE IN FORMS THAT CAN

2578
01:52:01,840 --> 01:52:04,520
BE IMPORTED DIRECTLY INTO A SITE

2579
01:52:04,520 --> 01:52:07,600
CHR OR WILL FACILITATE LOGO

2580
01:52:07,600 --> 01:52:10,160
CUSTOMIZATION AND TO BASICALLY

2581
01:52:10,160 --> 01:52:11,600
ECONOMIZE THIS EFFORT BECAUSE

2582
01:52:11,600 --> 01:52:15,320
NOTHING COULD BE BETTER AND IF

2583
01:52:15,320 --> 01:52:16,760
WE CAN HARM ON EYES THOSE THINGS

2584
01:52:16,760 --> 01:52:24,160
IT WOULD SAVE MONTHS OF TIME TO

2585
01:52:24,160 --> 01:52:25,760
ACTIVATE PROTOCOLS SITE AFTER

2586
01:52:25,760 --> 01:52:27,920
SITE IT WOULD BE A WONDERFUL IF

2587
01:52:27,920 --> 01:52:30,760
WE CAN FORMALIZE AND A LOT

2588
01:52:30,760 --> 01:52:32,760
EASIER AND OPERATIONALIZE THEIR

2589
01:52:32,760 --> 01:52:34,840
ACTIVATION OF THEIR TRIALS AND

2590
01:52:34,840 --> 01:52:38,320
SAVE ENORMOUS AMOUNT OF MONEY.

2591
01:52:38,320 --> 01:52:39,080
NEXT SLIDE.

2592
01:52:39,080 --> 01:52:40,280
THE LAST THING I WOULD LIKE TO

2593
01:52:40,280 --> 01:52:42,280
COME BACK TO, I SAID I WANTED TO

2594
01:52:42,280 --> 01:52:43,600
ADDRESS SOME OF THESE ISSUES

2595
01:52:43,600 --> 01:52:45,160
RELATED TO WORKFORCE.

2596
01:52:45,160 --> 01:52:47,160
BECAUSE THIS IS A BIG DEAL.

2597
01:52:47,160 --> 01:52:48,720
FROM CENTER TO CENTER AND SOME

2598
01:52:48,720 --> 01:52:50,480
PLACES HAVE DEALT WITH IT BETTER

2599
01:52:50,480 --> 01:52:52,520
THAN OTHERS AND THERE ARE SITES

2600
01:52:52,520 --> 01:52:53,560
THAT LITERALLY OVER THE LAST

2601
01:52:53,560 --> 01:52:55,400
THREE YEARS HAVE LOST 60% OF

2602
01:52:55,400 --> 01:52:57,400
THEIR ENTIRE CLINICAL TRIALS

2603
01:52:57,400 --> 01:53:01,280
WORKFORCE AND THEY'VE HAD TO

2604
01:53:01,280 --> 01:53:07,360
REPLACE THOSE INDIVIDUALS THE

2605
01:53:07,360 --> 01:53:08,640
NCI CAN HELP STREAMLINE THE

2606
01:53:08,640 --> 01:53:11,040
PROCESS FOR TRIAL ACTIVATION AND

2607
01:53:11,040 --> 01:53:13,280
MOST IMPORTANTLY REDUCE THE

2608
01:53:13,280 --> 01:53:14,640
VOLUME OF WORK THAT'S REQUIRED

2609
01:53:14,640 --> 01:53:16,000
TRIAL BY TRIAL AND TRY TO

2610
01:53:16,000 --> 01:53:17,480
INCREASE THE FLEXIBILITY OF

2611
01:53:17,480 --> 01:53:18,760
DOING THESE THINGS TO MAKE IT

2612
01:53:18,760 --> 01:53:21,680
EASIER FOR CENTERS TO OPEN OUR

2613
01:53:21,680 --> 01:53:22,080
TRIALS.

2614
01:53:22,080 --> 01:53:23,200
SOME OF THE THINGS THAT I'VE

2615
01:53:23,200 --> 01:53:24,760
TALKED ABOUT BEFORE THAT WIRE

2616
01:53:24,760 --> 01:53:25,720
WORKING ON.

2617
01:53:25,720 --> 01:53:27,160
IT'S WHETHER WE CAN CONSIDER

2618
01:53:27,160 --> 01:53:28,560
DEVELOPING A TRAINING PROGRAM,

2619
01:53:28,560 --> 01:53:32,000
TO TRY TO FOCUS THE DEVELOPMENT

2620
01:53:32,000 --> 01:53:33,840
AND FACILITATE THE HIRING AND

2621
01:53:33,840 --> 01:53:35,440
TRAINING OF INDIVIDUALS WHO MANY

2622
01:53:35,440 --> 01:53:40,040
ARE IN POSTBAC PROGRAMS THAT

2623
01:53:40,040 --> 01:53:42,280
WANT TO USE TRAINING AS A CRA,

2624
01:53:42,280 --> 01:53:45,120
AS A STEPPING STONE OR WANT THIS

2625
01:53:45,120 --> 01:53:47,120
AS A LONG-TERM CAREER AND WE

2626
01:53:47,120 --> 01:53:48,080
FACILITATE DEVELOPING THOSE

2627
01:53:48,080 --> 01:53:49,840
PROGRAMS AT CANCER CENTERS TO

2628
01:53:49,840 --> 01:53:51,640
FIND THE PUMP SO WE HAVE A

2629
01:53:51,640 --> 01:53:52,800
LONGER TERM SOLUTION TO FINDING

2630
01:53:52,800 --> 01:53:55,400
THE PERSONNEL IT REQUIRES.

2631
01:53:55,400 --> 01:53:57,800
LASTLY, I HOPE TO HAVE IF ABOUT

2632
01:53:57,800 --> 01:53:59,800
SIX MONTHS HAVE ENOUGH

2633
01:53:59,800 --> 01:54:02,320
EXPERIENCE IN THIS WHAT I CALL A

2634
01:54:02,320 --> 01:54:03,960
VIRTUAL CLINICAL TRIALS OFFICE

2635
01:54:03,960 --> 01:54:05,400
PILOT STUDY WE STARTED IN THE

2636
01:54:05,400 --> 01:54:08,000
LAST FEW MONTHS AND TO TRY TO

2637
01:54:08,000 --> 01:54:18,480
BRING BACK TO YOU, INTO THE

2638
01:54:36,560 --> 01:54:37,840
METADATA RAVE SYSTEM TO TAKE

2639
01:54:37,840 --> 01:54:39,440
THIS BURDEN OFF SITE SO THEY CAN

2640
01:54:39,440 --> 01:54:40,280
ACTUALLY ACCRUE THEIR STUDIES

2641
01:54:40,280 --> 01:54:42,320
AND OPEN THEIR TRIALS AND DO IT

2642
01:54:42,320 --> 01:54:46,200
IN A MORE TIME EFFICIENT MANNER

2643
01:54:46,200 --> 01:54:47,520
AND REALLY CONTINUE THE PROCESS

2644
01:54:47,520 --> 01:54:49,880
OF OUR TRANSLATIONAL STUDIES IN

2645
01:54:49,880 --> 01:54:51,440
A MORE EFFICIENT WAY.

2646
01:54:51,440 --> 01:54:53,680
I'M HAPPY TO STOP HERE AND TAKE

2647
01:54:53,680 --> 01:54:58,080
AS MANY QUESTIONS AS WE HAVE

2648
01:54:58,080 --> 01:54:59,600
TIME FOR.

2649
01:54:59,600 --> 01:55:01,400
>> THANK YOU, ANYMORE.

2650
01:55:01,400 --> 01:55:03,800
IT'S QUITE AN INSPIRED

2651
01:55:03,800 --> 01:55:04,120
INITIATIVE.

2652
01:55:04,120 --> 01:55:07,360
I WILL JUST SAY AS A COMMENT,

2653
01:55:07,360 --> 01:55:09,080
I'LL SAVE QUESTIONS FOR MABEL

2654
01:55:09,080 --> 01:55:10,160
OFF LINE COMMUNICATIONS BUT

2655
01:55:10,160 --> 01:55:11,200
REALLY FABULOUS.

2656
01:55:11,200 --> 01:55:14,520
I THINK RAY, YOU MIGHT HAVE BEEN

2657
01:55:14,520 --> 01:55:14,840
FIRST.

2658
01:55:14,840 --> 01:55:19,800
>> YEAH, THANK YOU, KEITH.

2659
01:55:19,800 --> 01:55:24,400
SO, JIM, I HAVE TO CONGRATULATE

2660
01:55:24,400 --> 01:55:31,600
YOU FOR KEEPING THE FING FINGERF

2661
01:55:31,600 --> 01:55:31,880
THE PULSE.

2662
01:55:31,880 --> 01:55:34,360
I'M BLOWN AWAY HOW COMPREHENSIVE

2663
01:55:34,360 --> 01:55:36,120
AND HO DEEP YOUR KNOWLEDGE FROM

2664
01:55:36,120 --> 01:55:36,760
THE STANDARD EVIDENCE WHAT LIFE

2665
01:55:36,760 --> 01:55:41,320
IS LIKE ON THE STREETS AND THE

2666
01:55:41,320 --> 01:55:44,360
MINORITY UNDER SURVEY IN A HUGE

2667
01:55:44,360 --> 01:55:45,400
COMMUNITY HEALTH-CARE SYSTEM

2668
01:55:45,400 --> 01:55:47,480
ACROSS THE MISSISSIPPI DELTA AND

2669
01:55:47,480 --> 01:55:54,240
THAT HAD NO PRIOR RESEARCH

2670
01:55:54,240 --> 01:55:56,000
ACTIVITY AND YOU KNOW, A LOT OF

2671
01:55:56,000 --> 01:56:00,000
WHAT YOU HAVE RAISED ARE VERY

2672
01:56:00,000 --> 01:56:01,680
GERMANE AND SO A FEW THINGS I

2673
01:56:01,680 --> 01:56:04,760
JUST WANT TO REINFORCE, ONE IS

2674
01:56:04,760 --> 01:56:08,640
THIS COMPLEXITY OF INANE REQUEST

2675
01:56:08,640 --> 01:56:11,240
THAT JUST CLEARLY ARE NOT

2676
01:56:11,240 --> 01:56:15,760
RELEVANT TO THE WORK AT HAND

2677
01:56:15,760 --> 01:56:17,680
THAT TAKE ON A LIFE OF THEIR OWN

2678
01:56:17,680 --> 01:56:19,240
AND OCCUPY A LOT OF HUMAN

2679
01:56:19,240 --> 01:56:20,880
RESOURCE AND I THINK IT'S VERY

2680
01:56:20,880 --> 01:56:31,360
MUCH WORTHY OF IT'S LOOKING

2681
01:56:32,440 --> 01:56:34,280
CRITICALLY UNLESS IT'S REALLY

2682
01:56:34,280 --> 01:56:35,800
REDUNDANT THE THINGS THAT WE DO

2683
01:56:35,800 --> 01:56:39,400
AND QUESTION I DO HAVE, JIM, IS

2684
01:56:39,400 --> 01:56:43,080
THE END CORE RELAXATION ITEMS

2685
01:56:43,080 --> 01:56:45,440
THAT CAME OUT OF THE VANCOUVER

2686
01:56:45,440 --> 01:56:47,800
PANDEMIC, WE KEEP ASKING, WILL

2687
01:56:47,800 --> 01:56:50,160
THEY BE MADE PERMANENT.

2688
01:56:50,160 --> 01:56:53,800
WE DON'T WANT TO GO BACK TO A

2689
01:56:53,800 --> 01:56:55,920
WORLD IN WHICH THINGS THAT

2690
01:56:55,920 --> 01:56:57,440
TECHNOLOGY WILL ENABLE US TO DO

2691
01:56:57,440 --> 01:57:00,560
MORE EFFICIENTLY AND WE HAVE TO

2692
01:57:00,560 --> 01:57:03,960
DO MANUALLY SO DO YOU HAVE DO

2693
01:57:03,960 --> 01:57:07,800
YOU HAVE A WORD OF THAT?

2694
01:57:07,800 --> 01:57:17,240
>> WE'RE NOT GOING TO STOP

2695
01:57:17,240 --> 01:57:19,760
SENDING ORAL DRUGS OUT TO SITES.

2696
01:57:19,760 --> 01:57:23,680
PEOPLE ARE NOT GOING TO HAVE TO

2697
01:57:23,680 --> 01:57:24,320
DRIVE 100 MILES ON PILLS AND

2698
01:57:24,320 --> 01:57:34,840
WE'RE NOT GOING TO GO BACK TO WE

2699
01:57:39,000 --> 01:57:42,880
REALLY -- I HOPE THAT THE

2700
01:57:42,880 --> 01:57:45,480
RELAXATION IN TERMS OF BEING

2701
01:57:45,480 --> 01:57:47,360
DINGED FOR GRADE 1 APPROXIMATE

2702
01:57:47,360 --> 01:57:49,680
AEs THAT ARE USE LESS IN YOUR

2703
01:57:49,680 --> 01:57:55,000
AUDITS IT MUST STOP, RIGHT.

2704
01:57:55,000 --> 01:57:56,920
IT'S GOT TO BE THE COMMUNITY HAS

2705
01:57:56,920 --> 01:57:59,880
TO AGREE THAT WE'RE GOING TO

2706
01:57:59,880 --> 01:58:02,000
STOP THAT AND THE OUTCOME OF OUR

2707
01:58:02,000 --> 01:58:02,960
TRIALS WILL BE JUST FINE WITHOUT

2708
01:58:02,960 --> 01:58:04,800
THAT.

2709
01:58:04,800 --> 01:58:08,440
I'VE BEEN ASKED ABOUT IMPORTANT

2710
01:58:08,440 --> 01:58:09,880
ISSUES THAT I THINK YOU WOULD

2711
01:58:09,880 --> 01:58:10,840
AGREE WITH.

2712
01:58:10,840 --> 01:58:12,400
THERE ARE SOME THINGS THAT ARE

2713
01:58:12,400 --> 01:58:14,040
LOW GRADE BUT CHRONIC TALKS SIS

2714
01:58:14,040 --> 01:58:14,560
TEE.

2715
01:58:14,560 --> 01:58:16,760
ESPECIALLY IF THEY'RE NOT KNOWN.

2716
01:58:16,760 --> 01:58:17,840
WE CAN'T GIVE UP.

2717
01:58:17,840 --> 01:58:19,800
SO IF SOMEONE HAS GRADE 2

2718
01:58:19,800 --> 01:58:21,160
DIARRHEA FOR FOUR MONTHS, YOU

2719
01:58:21,160 --> 01:58:23,760
PROBABLY WANT TO KNOW THAT,

2720
01:58:23,760 --> 01:58:24,320
RIGHT.

2721
01:58:24,320 --> 01:58:26,480
YOU DON'T WANT TO KNOW IF

2722
01:58:26,480 --> 01:58:31,600
SOMEONE HAS A HEMOGLOBIN OF 9.9

2723
01:58:31,600 --> 01:58:33,480
ON CYCLE FOUR OF WHATEVER.

2724
01:58:33,480 --> 01:58:34,560
THAT'S USE LESS INFORMATION

2725
01:58:34,560 --> 01:58:35,760
THAT'S NEVER GOING TO HAVE AN

2726
01:58:35,760 --> 01:58:37,640
IMPACT ON YOUR PRACTICE, RIGHT.

2727
01:58:37,640 --> 01:58:39,880
AND THE REAL WORLD.

2728
01:58:39,880 --> 01:58:43,640
SO, MY VIEW IS THAT WE HAVE TO

2729
01:58:43,640 --> 01:58:47,320
MAKE -- AND THIS SOUNDS SO

2730
01:58:47,320 --> 01:58:48,160
BUREAUCRATIC YOU WILL JUST

2731
01:58:48,160 --> 01:58:48,880
LAUGH, RIGHT.

2732
01:58:48,880 --> 01:58:50,920
IT TURNS OUT, THAT WHAT IS THE

2733
01:58:50,920 --> 01:58:52,440
ISSUE WITH TELEHEALTH.

2734
01:58:52,440 --> 01:58:54,600
WE NEED TO LEARN HOW TO DO

2735
01:58:54,600 --> 01:58:55,920
TELEHEALTH, TELEMEDICINE IN OUR

2736
01:58:55,920 --> 01:58:56,880
TRIALS BETTER, OKAY.

2737
01:58:56,880 --> 01:59:00,840
BUT IN TERMS OF IT BEING

2738
01:59:00,840 --> 01:59:08,200
SOMETHING THAT IS ACCEPTABLE, IT

2739
01:59:08,200 --> 01:59:15,880
NEEDS TO BE TELEHEALTH AND WE

2740
01:59:15,880 --> 01:59:17,280
WEREN'T WRITING THOSE INTO

2741
01:59:17,280 --> 01:59:17,560
PROTOCOLS.

2742
01:59:17,560 --> 01:59:19,800
THIS IS BASICALLY ADMINISTRATIVE

2743
01:59:19,800 --> 01:59:21,800
GOOK THAT CAN BE CHANGED VERY

2744
01:59:21,800 --> 01:59:24,480
EASILY, RIGHT, AND SO TO ME THE

2745
01:59:24,480 --> 01:59:26,520
NEXT STEP IS WE DID ALL THESE

2746
01:59:26,520 --> 01:59:28,200
THINGS, WHAT IS THE NEXT WHOLE

2747
01:59:28,200 --> 01:59:29,360
RANGE OF THINGS THAT WE DON'T

2748
01:59:29,360 --> 01:59:30,440
HAVE TO DO?

2749
01:59:30,440 --> 01:59:34,560
NOW I'M NOT -- YOU KNOW, I'M A

2750
01:59:34,560 --> 01:59:35,880
PHASE 1 INVESTIGATOR, WE DON'T

2751
01:59:35,880 --> 01:59:38,280
NEED TO VERY CAREFULLY, VERY

2752
01:59:38,280 --> 01:59:40,080
CAREFULLY COLLECT INFORMATION ON

2753
01:59:40,080 --> 01:59:42,320
TOXICITY AND EARLY PHASE TRIALS

2754
01:59:42,320 --> 01:59:44,600
AND I DON'T MEAN TO IMPLY THAT

2755
01:59:44,600 --> 01:59:46,120
AT ALL BUT HOW MANY TIMES DO WE

2756
01:59:46,120 --> 01:59:47,640
HAVE TO RECOLLECT DATA ON

2757
01:59:47,640 --> 01:59:51,400
PATIENTS GETTING A PEM BROW,

2758
01:59:51,400 --> 01:59:52,000
RIGHT.

2759
01:59:52,000 --> 01:59:52,640
WE DON'T.

2760
01:59:52,640 --> 01:59:53,520
THIS MAKES A DIFFERENCE BECAUSE

2761
01:59:53,520 --> 01:59:55,320
I REALLY, IF YOU THINK ABOUT

2762
01:59:55,320 --> 01:59:59,320
WHAT CROs DO, AND THEY WANT TO

2763
01:59:59,320 --> 02:00:03,320
COLLECT THIS AND I DON'T MEAN T.

2764
02:00:03,320 --> 02:00:05,880
THEY GET PAID FOR EVERY DATA

2765
02:00:05,880 --> 02:00:09,080
ELEMENT SO THE MORE THINGS THAT

2766
02:00:09,080 --> 02:00:11,440
WE COLLECT, THE MORE THEY GET

2767
02:00:11,440 --> 02:00:12,000
PAID.

2768
02:00:12,000 --> 02:00:14,040
SO I THINK WE WILL RUN INTO THE

2769
02:00:14,040 --> 02:00:16,320
LESS WE DO AND IF WE CAN HAVE

2770
02:00:16,320 --> 02:00:17,400
OUTCOMES THAT SHOW WE GET THE

2771
02:00:17,400 --> 02:00:19,760
ANSWERS TO THE QUESTIONS WE'RE

2772
02:00:19,760 --> 02:00:21,880
INTERESTED IN, THEN WE'LL BE

2773
02:00:21,880 --> 02:00:23,440
PUSH BACK FROM PHARMA.

2774
02:00:23,440 --> 02:00:24,240
RIGHT.

2775
02:00:24,240 --> 02:00:25,880
BUT THAT'S THE BLESSING OF

2776
02:00:25,880 --> 02:00:27,680
HAVING THE NCI CLINICAL TRIALS

2777
02:00:27,680 --> 02:00:29,680
PROGRAM, ESPECIALLY TO DO IF WE

2778
02:00:29,680 --> 02:00:32,880
FOCUS INITIALLY ON NON IND

2779
02:00:32,880 --> 02:00:36,800
STUDIES IS WE CAN MAKE THESE

2780
02:00:36,800 --> 02:00:37,560
CHANGES.

2781
02:00:37,560 --> 02:00:38,880
AND SEE WHAT THE OUTCOMES ARE

2782
02:00:38,880 --> 02:00:39,160
GOING TO BE.

2783
02:00:39,160 --> 02:00:40,760
>> WE'RE GOING TO BE
PRESSED FOR

2784
02:00:40,760 --> 02:00:43,800
TIME.

2785
02:00:43,800 --> 02:00:44,040
OTIS --

2786
02:00:44,040 --> 02:00:48,080
>> FIRST, I JUST WANT TO
SAY

2787
02:00:48,080 --> 02:00:49,560
THANK YOU JIM.

2788
02:00:49,560 --> 02:00:50,600
YOU JUST DON'T KNOW HOW THRILLED

2789
02:00:50,600 --> 02:00:52,720
I AM TO KNOW THAT SOMEONE FROM

2790
02:00:52,720 --> 02:00:54,120
THE GOVERNMENT UNDERSTANDS ME

2791
02:00:54,120 --> 02:00:57,520
AND MY PROBLEMS.

2792
02:00:57,520 --> 02:01:03,920
THE ONE THING THAT I WOULD ADD,

2793
02:01:03,920 --> 02:01:05,480
DID THE CHARACTER IN NATURE OF

2794
02:01:05,480 --> 02:01:09,080
OUR CLINICAL TRIALS CHANGE OVER

2795
02:01:09,080 --> 02:01:11,760
THE LAST 10 YEARS AS WE WEPT TO

2796
02:01:11,760 --> 02:01:14,240
PRECISION, MEDICINE AND IMMUNO

2797
02:01:14,240 --> 02:01:15,520
THERAPIES AND OTHER THINGS AND

2798
02:01:15,520 --> 02:01:17,160
DID THAT CONTRIBUTE TO THE

2799
02:01:17,160 --> 02:01:19,000
DECLINE IN ENROLLMENT AS WELL?

2800
02:01:19,000 --> 02:01:21,280
AT OUR INSTITUTION, ENROLLMENT

2801
02:01:21,280 --> 02:01:29,240
STARTED DECLINING AND COVID JUST

2802
02:01:29,240 --> 02:01:30,200
ACCELERATED THINGS EVEN FURTHER

2803
02:01:30,200 --> 02:01:31,840
AND I'M WONDERING IF THAT'S PART

2804
02:01:31,840 --> 02:01:42,320
OF THE REASON FOR THE DECLINE

2805
02:02:12,000 --> 02:02:14,520
IT'S LIKE DECK CRATING CHRISTMAS

2806
02:02:14,520 --> 02:02:15,720
TREES AND THEY'RE PRETTY BUT

2807
02:02:15,720 --> 02:02:17,200
THEY DON'T REALLY CONTRIBUTE TO

2808
02:02:17,200 --> 02:02:18,400
THE QUESTIONS THAT WE WANT TO

2809
02:02:18,400 --> 02:02:18,920
ANSWER.

2810
02:02:18,920 --> 02:02:21,760
AND THAT'S WHAT WE HAVE TO THINK

2811
02:02:21,760 --> 02:02:25,640
ABOUT SERIOUSLY.

2812
02:02:25,640 --> 02:02:26,480
>> THANK YOU SO MUCH.

2813
02:02:26,480 --> 02:02:27,760
I MEAN, THIS IS LIKE THE

2814
02:02:27,760 --> 02:02:29,400
SOLUTION FOR THE FUTURE FOR

2815
02:02:29,400 --> 02:02:31,640
WORKFORCE ACROSS THE COUNTRY AND

2816
02:02:31,640 --> 02:02:34,120
WITH NEW FORMS OF AI, WE MAY

2817
02:02:34,120 --> 02:02:35,600
HAVE EVEN MORE POTENTIAL THERE.

2818
02:02:35,600 --> 02:02:40,760
I WANTED TO ASK YOU, I HEARD

2819
02:02:40,760 --> 02:02:43,560
CHALLENGES AND BIG PLAYERS IN

2820
02:02:43,560 --> 02:02:49,000
SOFTWARE FIELD WHETHER IT'S EPIC

2821
02:02:49,000 --> 02:02:50,200
OR ENCORE BEING COMPATIBLE SHALL

2822
02:02:50,200 --> 02:02:50,760
WE SAY.

2823
02:02:50,760 --> 02:02:55,760
WHAT CAN WE DO TO MOVE FORWARD

2824
02:02:55,760 --> 02:02:56,960
OR WHAT'S YOUR APPROACH TO THIS?

2825
02:02:56,960 --> 02:02:59,080
ARE YOU PLANNING TO START WITH

2826
02:02:59,080 --> 02:03:00,360
SOME PLAYERS FIRST AND SEE WHAT

2827
02:03:00,360 --> 02:03:02,400
WE CAN DO?

2828
02:03:02,400 --> 02:03:05,960
>> SO THAT CONSORTIUM
WORKING

2829
02:03:05,960 --> 02:03:07,240
THERE'S ABOUT 10 NCI CANCER

2830
02:03:07,240 --> 02:03:09,040
CENTERS WORKING ON THESE THINGS

2831
02:03:09,040 --> 02:03:12,440
AND EPIC IS INVOLVED WHEN

2832
02:03:12,440 --> 02:03:14,240
SENATORS INVOLVED MORE SO EPIC.

2833
02:03:14,240 --> 02:03:20,120
BUT I THINK THE PROBLEM IS -- I

2834
02:03:20,120 --> 02:03:21,600
HAD NO IDEA BECAUSE YOU KNOW, WE

2835
02:03:21,600 --> 02:03:25,840
HAVE A COMPLETELY HOMEGROWN

2836
02:03:25,840 --> 02:03:28,800
CLINICAL TRIALS MAPPINGMENT MANT

2837
02:03:28,800 --> 02:03:29,920
SYSTEM AND IT'S UNLIKE ANYTHING

2838
02:03:29,920 --> 02:03:32,760
ELSE OUT THERE AND I HAD NO IDEA

2839
02:03:32,760 --> 02:03:37,200
THAT TO PUT 80 POTENTIAL DATA

2840
02:03:37,200 --> 02:03:41,320
ELEMENTS TO ENTER ONE ORDER OF

2841
02:03:41,320 --> 02:03:43,040
SIS PLATINUM, 80 DIFFERENT

2842
02:03:43,040 --> 02:03:45,440
FIELDS THAT MIGHT CONCEIVABLY --

2843
02:03:45,440 --> 02:03:48,480
SO WE JUST HAVE TO FIGURE OUT A

2844
02:03:48,480 --> 02:03:49,680
WAY AND ACTUALLY THE QUESTION

2845
02:03:49,680 --> 02:03:51,720
CAME UP EARLIER AND I LIKE TO

2846
02:03:51,720 --> 02:03:55,560
ADDRESS THAT AND YOU KNOW, IF WE

2847
02:03:55,560 --> 02:03:56,760
WROTE PROTOCOLS WE DIDN'T WRITE

2848
02:03:56,760 --> 02:03:58,440
THEM IN ENGLISH.

2849
02:03:58,440 --> 02:04:01,040
WE WROTE THEM IN A FORMAT THAT

2850
02:04:01,040 --> 02:04:03,000
BASICALLY JUST WROTE SCHEME A

2851
02:04:03,000 --> 02:04:04,640
PAGES AND THEY COULD BE

2852
02:04:04,640 --> 02:04:06,920
DIGITIZED IT WOULD MAKE THE

2853
02:04:06,920 --> 02:04:08,280
ENTIRE PROCESS MUCH, MUCH

2854
02:04:08,280 --> 02:04:08,680
SIMPLER.

2855
02:04:08,680 --> 02:04:11,680
BUT I MEAN, YOU KNOW, IT'S JUST

2856
02:04:11,680 --> 02:04:13,440
NOT WHAT PEOPLE HAVE DONE FOR 60

2857
02:04:13,440 --> 02:04:13,840
YEARS.

2858
02:04:13,840 --> 02:04:15,240
THAT'S WHAT NEEDS TO BE DONE

2859
02:04:15,240 --> 02:04:17,280
BECAUSE THEN YOU WOULD START

2860
02:04:17,280 --> 02:04:18,360
FROM A -- EVERYONE WOULD START

2861
02:04:18,360 --> 02:04:20,000
WITH A TEMPLATE THEY COULD MUCH

2862
02:04:20,000 --> 02:04:30,480
MORE RAPIDLY ADAPT TO THEIR.

2863
02:04:30,920 --> 02:04:33,360
>> PAULETTE IS STARING AT
ME IN

2864
02:04:33,360 --> 02:04:39,000
THE SCREEN AND BOB.

2865
02:04:39,000 --> 02:04:42,600
>> THE IMPLEMENTATION AND
ONE

2866
02:04:42,600 --> 02:04:44,560
THING IS COMMENT AND THE

2867
02:04:44,560 --> 02:04:48,080
CHAINING FOR THE WORKFORCE AND

2868
02:04:48,080 --> 02:04:50,880
AND I WOULD JUST ADD ONE AND

2869
02:04:50,880 --> 02:04:56,920
THINK ABOUT IN THAT AND RESEARCH

2870
02:04:56,920 --> 02:04:58,280
BASIS AND IN THE COMMUNITY

2871
02:04:58,280 --> 02:04:59,840
ALTHOUGH THERE'S A SIGNIFICANT

2872
02:04:59,840 --> 02:05:01,240
OVERLAP BETWEEN THOSE THAT MAYBE

2873
02:05:01,240 --> 02:05:06,520
WORK IN A CTO AND THERE'S ALSO A

2874
02:05:06,520 --> 02:05:10,240
LOT THAT IS REALLY DIFFERENT AND

2875
02:05:10,240 --> 02:05:12,720
MAKING SURE THAT THOSE ENTITIES

2876
02:05:12,720 --> 02:05:14,000
COULD ALSO TAKE ADVANTAGE OF ANY

2877
02:05:14,000 --> 02:05:16,480
KIND OF TRAINING GRADE OR

2878
02:05:16,480 --> 02:05:18,000
TRAINING OPPORTUNITIES TO CREATE

2879
02:05:18,000 --> 02:05:21,200
THOSE TO GENERATE THAT WORKFORCE

2880
02:05:21,200 --> 02:05:24,880
AS WELL AND THEN MY QUESTION TO

2881
02:05:24,880 --> 02:05:28,920
YOU IS WHEN WE THINK ABOUT

2882
02:05:28,920 --> 02:05:30,440
SIMPLIFYING AND I COULDN'T AGREE

2883
02:05:30,440 --> 02:05:32,160
WITH YOU MORE AND FOR US, WITH I

2884
02:05:32,160 --> 02:05:33,440
THINK ABOUT THE RESEARCH BASE

2885
02:05:33,440 --> 02:05:38,440
THAT I WORK IN AND HAVING A

2886
02:05:38,440 --> 02:05:40,320
INVESTIGATOR PUT OUT A STUDY

2887
02:05:40,320 --> 02:05:45,680
THAT IS AGREED UPON AND BY

2888
02:05:45,680 --> 02:05:46,440
PIPELINE FOR TREATMENT GRANT AND

2889
02:05:46,440 --> 02:05:48,000
THEY HAVE TO GO BEFORE A

2890
02:05:48,000 --> 02:05:53,240
STEERING COMMITTEE FOR A PEER RW

2891
02:05:53,240 --> 02:05:54,920
AND MANY ARE RO1 THAT IS

2892
02:05:54,920 --> 02:05:57,040
PEER-REVIEWED SO IF APPROXIMATE

2893
02:05:57,040 --> 02:05:59,080
YOU WANT THESE COULD BE

2894
02:05:59,080 --> 02:06:00,280
SIMPLIFIED AND WHAT IS THE PLAN

2895
02:06:00,280 --> 02:06:03,080
TO EDUCATE ALL THE DIFFERENT

2896
02:06:03,080 --> 02:06:04,400
BODIES OF PEOPLE WHO ARE

2897
02:06:04,400 --> 02:06:05,000
REVIEWING THE GRANTS BECAUSE

2898
02:06:05,000 --> 02:06:07,560
THAT'S WHERE THEY END UP BECOME

2899
02:06:07,560 --> 02:06:08,520
SEWING SOPHISTICATED THAT

2900
02:06:08,520 --> 02:06:18,960
THEY'RE IMPOSSIBLE TO DO.

2901
02:06:20,400 --> 02:06:22,240
SO WRITE IN BLACK WHITE NEW

2902
02:06:22,240 --> 02:06:24,240
SOPs FOR WHAT IS -- AT LEAST I

2903
02:06:24,240 --> 02:06:26,240
CAN'T TELL PHARMA WHAT TO DO.

2904
02:06:26,240 --> 02:06:29,640
BUT WE CAN PUBLISH WHAT THE

2905
02:06:29,640 --> 02:06:30,880
SOPs ARE FOR NCI TRIALS.

2906
02:06:30,880 --> 02:06:33,480
WE CAN GET -- IF WE CAN BUY IN

2907
02:06:33,480 --> 02:06:36,080
FROM THE NCTN GROUPS AND IT WILL

2908
02:06:36,080 --> 02:06:36,520
CHANGE.

2909
02:06:36,520 --> 02:06:38,280
IT WILL TAKE TIME.

2910
02:06:38,280 --> 02:06:42,240
NEW STUDIES CAN BE DEVELOPED

2911
02:06:42,240 --> 02:06:44,360
SAYING WELL, WE DON'T DO IT THIS

2912
02:06:44,360 --> 02:06:44,720
WAY ANYMORE.

2913
02:06:44,720 --> 02:06:46,400
THIS IS WHAT THE ENTIRE SYSTEM

2914
02:06:46,400 --> 02:06:48,960
AS AGREED TO CHANGE AND IT WILL

2915
02:06:48,960 --> 02:06:54,000
OVER TIME IT WILL CHANGE.

2916
02:06:54,000 --> 02:06:56,080
>> YOU COULD WRITE THAT IN
AN

2917
02:06:56,080 --> 02:06:57,160
SOP BUT IF I HAVE AN

2918
02:06:57,160 --> 02:07:00,000
INVESTIGATOR WHO IS GOING AFTER

2919
02:07:00,000 --> 02:07:02,440
AFTER RO1 IN A REVIEW PANEL IT'S

2920
02:07:02,440 --> 02:07:04,320
SAYING, WE KNOW YOU ARE ONLY PUT

2921
02:07:04,320 --> 02:07:05,640
YOUR MEASURE THESE TWO OUTCOMES

2922
02:07:05,640 --> 02:07:08,000
BUT WE WANT THESE FIVE

2923
02:07:08,000 --> 02:07:12,800
COMPOUNDERS ALSO ADDED INTO THAT

2924
02:07:12,800 --> 02:07:14,800
TRIAL IT'S A PEER REVIEW LONG

2925
02:07:14,800 --> 02:07:16,920
BEFORE IT GETS TO OVER ALL

2926
02:07:16,920 --> 02:07:18,320
DEVELOPMENT SO HOW CAN WE TAKE

2927
02:07:18,320 --> 02:07:28,560
CARE OF THAT?

2928
02:07:56,840 --> 02:08:00,200
>> MAYBE WE CHALLENGE THE
USE OF

2929
02:08:00,200 --> 02:08:01,520
CLINICAL PROGRESS NOTES FOR DATA

2930
02:08:01,520 --> 02:08:02,400
COLLECTION AND LET'S JUST TAKE

2931
02:08:02,400 --> 02:08:03,280
IT ALL ON.

2932
02:08:03,280 --> 02:08:04,960
I JUST WANTED SAY QUICKLY, AMONG

2933
02:08:04,960 --> 02:08:08,880
THE STAKEHOLDERS, WE RECOGNIZE

2934
02:08:08,880 --> 02:08:14,720
WE ARE OWN OUR WORSEN MO ENEMY.

2935
02:08:14,720 --> 02:08:17,560
WE HAVE NEED DEEPER

2936
02:08:17,560 --> 02:08:18,800
CONVERSATIONS WITH PHARMA AND

2937
02:08:18,800 --> 02:08:20,320
CONTRACT RESEARCH ORGANIZATIONS.

2938
02:08:20,320 --> 02:08:21,720
AND I'VE BEEN PART OF A LOT OF

2939
02:08:21,720 --> 02:08:26,240
PANELS AND I NEVER SEE A CRO

2940
02:08:26,240 --> 02:08:27,040
REPRESENTED.

2941
02:08:27,040 --> 02:08:29,080
I DON'T KNOW WHAT CAN NCI DO TO

2942
02:08:29,080 --> 02:08:32,880
ENGAGE THE CROs SO THAT WE FIX

2943
02:08:32,880 --> 02:08:35,640
THIS, NOT JUST NCI TRIALS BUT

2944
02:08:35,640 --> 02:08:35,960
EVERYTHING?

2945
02:08:35,960 --> 02:08:39,440
>> MY TWO CENTS IS THAT
YOU

2946
02:08:39,440 --> 02:08:43,320
KNOW, PHARMA RELUCTANT BECAUSE

2947
02:08:43,320 --> 02:08:44,040
THEY HAVE -- THEY HAVE

2948
02:08:44,040 --> 02:08:46,440
PERCEPTIONS OF WHAT THE FDA

2949
02:08:46,440 --> 02:08:47,640
REQUIRES.

2950
02:08:47,640 --> 02:08:50,040
AND SO AS Dr. BERTAGNOLLI

2951
02:08:50,040 --> 02:08:53,320
SAID, DOING THINGS THAT ARE DONE

2952
02:08:53,320 --> 02:08:56,120
IN CONCERT WITH THE FDA WHERE IT

2953
02:08:56,120 --> 02:08:58,320
IS VERY CLEAR THAT THE

2954
02:08:58,320 --> 02:08:59,520
REGULATORS SAY YOU DON'T NEED

2955
02:08:59,520 --> 02:09:00,560
THIS INFORMATION AND IT'S THE

2956
02:09:00,560 --> 02:09:02,440
ONLY WAY WE'LL REACH PHARMA.

2957
02:09:02,440 --> 02:09:04,800
YOU HAVE TO KNOW IF THEY DO

2958
02:09:04,800 --> 02:09:06,240
THOSE THINGS IN A DIFFERENT WAY,

2959
02:09:06,240 --> 02:09:07,760
IF THEY'RE NOT PENALIZED WHEN

2960
02:09:07,760 --> 02:09:13,440
THEY GO FOR APPROVAL.

2961
02:09:13,440 --> 02:09:14,640
>> Dr. Flaherty: THANK YOU
FOR

2962
02:09:14,640 --> 02:09:16,480
REALLY EXCITING PRESENTATION AND

2963
02:09:16,480 --> 02:09:17,960
IF YOU DON'T MIND CHECKING THE

2964
02:09:17,960 --> 02:09:19,400
CHAT WINDOW BECAUSE THERE'S A

2965
02:09:19,400 --> 02:09:20,280
FEW OVERFLOW QUESTIONS AND

2966
02:09:20,280 --> 02:09:21,160
COMMENTS THAT WE DIDN'T HAVE

2967
02:09:21,160 --> 02:09:23,760
TIME TO GET TO.

2968
02:09:23,760 --> 02:09:26,120
LET'S MOVE TO CONCEPTS.

2969
02:09:26,120 --> 02:09:28,960
WE HAVE THREE NEW AND UNREISSUED

2970
02:09:28,960 --> 02:09:32,000
CONCEPT FOR TODAY'S DISCUSSION

2971
02:09:32,000 --> 02:09:33,400
AND BSA MEMBERS HAVE BEEN

2972
02:09:33,400 --> 02:09:35,200
REVIEWEDDERS AND INTERACTED WITH

2973
02:09:35,200 --> 02:09:37,080
THE PRESENTSERS IN ADVANCE BUT

2974
02:09:37,080 --> 02:09:38,960
WE NEED THE ENTIRETY OF THE BSA

2975
02:09:38,960 --> 02:09:41,000
TO ENGAGE IN TODAY'S DISCUSSION

2976
02:09:41,000 --> 02:09:44,760
AND ULTIMATELY VOTING FOR NEW

2977
02:09:44,760 --> 02:09:46,280
CONCEPTS, WE WILL VOTE TO

2978
02:09:46,280 --> 02:09:48,320
APPROVE DISAPPROVAL OR DEFER AND

2979
02:09:48,320 --> 02:09:50,840
FOR THE ONE REISSUE CONCEPT, WE

2980
02:09:50,840 --> 02:10:01,720
VOTE TO CONQ TO CONNECTICUT ACRD

2981
02:10:02,360 --> 02:10:03,520
JUST TO REMIND YOU WHEN WE'RE IN

2982
02:10:03,520 --> 02:10:06,200
THE VIRTUAL MODE HERE, KEEP YOUR

2983
02:10:06,200 --> 02:10:08,440
CAMERAS ON WHEN WE'RE IN

2984
02:10:08,440 --> 02:10:10,720
DISCUSSIONS AND THE VOTING PHASE

2985
02:10:10,720 --> 02:10:13,880
AND I WILL COUNT YOUR PRESENCE

2986
02:10:13,880 --> 02:10:24,640
AS A VOTE YES VO TAKE YOUR PICKD

2987
02:10:35,000 --> 02:10:36,920
NOTIFYING ME AND WALL OUT AND

2988
02:10:36,920 --> 02:10:37,840
PLEASE END INDICATE YOU ARE

2989
02:10:37,840 --> 02:10:48,400
ABSTAINING AND STATE YOUR NAME.

2990
02:10:50,200 --> 02:10:54,000
THE FIRST IS A NEW RFA AND SO

2991
02:10:54,000 --> 02:10:54,720
COOPERATIVES AGREEMENT AND

2992
02:10:54,720 --> 02:10:59,400
TRANSLATIONAL RESEARCH AND AND

2993
02:10:59,400 --> 02:11:01,160
VACCINE AND IT'S GOING TO

2994
02:11:01,160 --> 02:11:03,880
PRESENT AND THE SUBCOMMITTEE IS

2995
02:11:03,880 --> 02:11:10,200
BEING CHAIRED BY DORTHY AND MARK

2996
02:11:10,200 --> 02:11:11,720
AND BOB ARE MEMBERS OF THE

2997
02:11:11,720 --> 02:11:13,040
SUBCOMMITTEE AS WELL AND REBECA,

2998
02:11:13,040 --> 02:11:23,400
PLEASE TAKE IT AWAY.

2999
02:11:29,640 --> 02:11:32,240
DIVISION OF CANCER CONTROL AND

3000
02:11:32,240 --> 02:11:33,280
POPULATION STUDIES AND THE

3001
02:11:33,280 --> 02:11:35,560
DIVISION OF CANCER BIOLOGY AND

3002
02:11:35,560 --> 02:11:39,760
THE CENTER FOR GLOBAL HEALTH.

3003
02:11:39,760 --> 02:11:41,720
THE PURPOSE OF THE RFA IS TO

3004
02:11:41,720 --> 02:11:43,600
SUPPORT BASIC AND TRANSLATIONAL

3005
02:11:43,600 --> 02:11:45,600
RESEARCH AND IT WILL GUIDE THE

3006
02:11:45,600 --> 02:11:49,480
DEVELOPMENT OF A PREVENTATIVE OR

3007
02:11:49,480 --> 02:11:50,400
NEED YOU'D I CAN WITH THE GOAL

3008
02:11:50,400 --> 02:11:56,640
TO PREVENT AND TREAT KS AND

3009
02:11:56,640 --> 02:11:59,600
OTHER KSHV AND OTHER ASSOCIATED

3010
02:11:59,600 --> 02:12:00,400
DISEASES.

3011
02:12:00,400 --> 02:12:06,280
THERE ARE FOUR KS TYPES

3012
02:12:06,280 --> 02:12:07,920
EPIDEMIOLOGICALLY AND CLASSIC

3013
02:12:07,920 --> 02:12:10,360
KS, TYPICALLY EFFECTS ELDERLY

3014
02:12:10,360 --> 02:12:13,120
MEN OF MEDITERRANEAN DISSENT AND

3015
02:12:13,120 --> 02:12:14,760
AN DEMIC KS WHICH OCCURS

3016
02:12:14,760 --> 02:12:16,680
PRIMARILY IN CENTRAL AND

3017
02:12:16,680 --> 02:12:20,800
SOUTHEAST AFRICA AND IT'S VERY

3018
02:12:20,800 --> 02:12:21,360
AGGRESSIVE AND IMMUNO

3019
02:12:21,360 --> 02:12:24,960
SUPPRESSION ASSOCIATED KS OCCURS

3020
02:12:24,960 --> 02:12:26,480
IF TRANSPLANT PATIENTS AND

3021
02:12:26,480 --> 02:12:29,120
EPIDEMIC KS OR AIDS RELATED KS

3022
02:12:29,120 --> 02:12:33,360
JUST WANT OF THE POST COMMON HIV

3023
02:12:33,360 --> 02:12:34,560
ASSOCIATED TUMORS IN THE U.S.

3024
02:12:34,560 --> 02:12:36,560
AND THE MOST COMMON IN AFRICA

3025
02:12:36,560 --> 02:12:41,480
NEXT SLIDE, PLEASE.

3026
02:12:41,480 --> 02:12:44,440
RSHV IS HUMAN HERPESES VIRUS 8

3027
02:12:44,440 --> 02:12:45,800
IT WAS DISCOVERED IN

3028
02:12:45,800 --> 02:12:49,600
FIRST-DEGREE 9 AND THE CAUSE

3029
02:12:49,600 --> 02:12:57,280
TIVE AGENT OF KAPOSI SARCOMA AND

3030
02:12:57,280 --> 02:12:59,360
MULTI CENTRIC CASTLE MEN DISEASE

3031
02:12:59,360 --> 02:13:09,080
AND SIM LOMA ASSOCIATED WITH MCD

3032
02:13:09,080 --> 02:13:15,320
AND CYTOKINE.

3033
02:13:15,320 --> 02:13:19,880
THIS IS KS MOST MUCH OCCURS IN

3034
02:13:19,880 --> 02:13:21,600
INDIVIDUALS WITH HIV WITH 90% OF

3035
02:13:21,600 --> 02:13:23,240
THE CASES OCCURRING IF LOW AND

3036
02:13:23,240 --> 02:13:25,320
MIDDLE INCOME COUNTRY.

3037
02:13:25,320 --> 02:13:28,040
WITH OVER TWO-THIRDS OF THE

3038
02:13:28,040 --> 02:13:29,440
CASES OCCURRING IN SUB SA HER

3039
02:13:29,440 --> 02:13:31,160
ENTER AFRICA WHERE IT'S

3040
02:13:31,160 --> 02:13:33,840
SIGNIFICANTLY CAUSE OF MORBIDITY

3041
02:13:33,840 --> 02:13:34,800
AND MORTALITY.

3042
02:13:34,800 --> 02:13:37,840
IT'S IMPORTANT TO NOTE THAT WITH

3043
02:13:37,840 --> 02:13:41,640
RESPECT TO THE HIV EPIDEMIC AND

3044
02:13:41,640 --> 02:13:43,640
KS INCIDENTS, COMBINATION ANTI

3045
02:13:43,640 --> 02:13:46,040
RETRO VIRAL THERAPY DID

3046
02:13:46,040 --> 02:13:48,880
INITIALLY DECREASE THE INCIDENTS

3047
02:13:48,880 --> 02:13:51,960
OF KS IN THE UNITED STATES AND

3048
02:13:51,960 --> 02:13:53,040
OTHER DEVELOPED COUNTRIES AND

3049
02:13:53,040 --> 02:13:56,160
HOWEVER, THE DECREASE IN KS THAT

3050
02:13:56,160 --> 02:13:57,760
IS PLAT AUD AND KS IS STILL ONE

3051
02:13:57,760 --> 02:14:01,280
OF THE MOST COMMON MALIGNANCY

3052
02:14:01,280 --> 02:14:03,400
ASSOCIATED WITH HIV.

3053
02:14:03,400 --> 02:14:05,440
EVEN WHEN HIV IS WELL

3054
02:14:05,440 --> 02:14:05,880
CONTROLLED.

3055
02:14:05,880 --> 02:14:10,360
NEXT SLIDE, PLEASE.

3056
02:14:10,360 --> 02:14:13,520
THIS SLIDE DEMONSTRATES A STUDY

3057
02:14:13,520 --> 02:14:17,840
AT FOUR SITES IN EAST AFRICA.

3058
02:14:17,840 --> 02:14:19,920
IT FOLLOWED 180 ADULT S WITH

3059
02:14:19,920 --> 02:14:23,720
NEWLY DIAGNOSED HIV KS IN KENYA

3060
02:14:23,720 --> 02:14:26,440
AND UGANDA AND DESPITE BEING ON

3061
02:14:26,440 --> 02:14:36,960
SEA ART, WITH 46 OF THE PATIENTS

3062
02:14:38,920 --> 02:14:42,560
AT THIS STAGE PROGNOSIS AND

3063
02:14:42,560 --> 02:14:43,240
SURVIVAL IS POOR.

3064
02:14:43,240 --> 02:14:46,400
IN THIS STUDY, 33% OF THE

3065
02:14:46,400 --> 02:14:48,880
PATIENTS HAD DIED BY SIX MONTHS.

3066
02:14:48,880 --> 02:14:53,200
NEXT SLIDE, PLEASE.

3067
02:14:53,200 --> 02:14:55,560
NOW I'D LIKE TO PROVIDE SOME

3068
02:14:55,560 --> 02:15:01,120
BASIC INFORMATION REGARDING KSA

3069
02:15:01,120 --> 02:15:04,720
PREVALENCE AND KS AND KSV.

3070
02:15:04,720 --> 02:15:06,360
CHILDREN ARE INFECTED EARLIER IN

3071
02:15:06,360 --> 02:15:08,600
LIFE AND IN SOME COUNTRIES HAVE

3072
02:15:08,600 --> 02:15:12,080
AN 83% PREVALENCE BY AGE 19.

3073
02:15:12,080 --> 02:15:15,160
IN NORTH AMERICA, AND MOST OF

3074
02:15:15,160 --> 02:15:16,400
AUTOPSY UP, OVER ALL ZERO

3075
02:15:16,400 --> 02:15:18,600
PREVALENCE IS LOW BUT HIGHER IN

3076
02:15:18,600 --> 02:15:21,720
MEN WHO HAVE SEX WITH MEN, MSM

3077
02:15:21,720 --> 02:15:24,960
AND PERSONS FROM ENDEMIC AREAS

3078
02:15:24,960 --> 02:15:31,440
IN THE U.S., KHS AND IS 365% IN

3079
02:15:31,440 --> 02:15:34,560
HIV POSITIVE MSM AND 20% TO 30%

3080
02:15:34,560 --> 02:15:36,880
IN THE HIV NEGATIVE MSM AND

3081
02:15:36,880 --> 02:15:40,120
INCIDENTS OF KS IN THE U.K.

3082
02:15:40,120 --> 02:15:41,760
PEOPLE WITH HIV IS DECREASING

3083
02:15:41,760 --> 02:15:44,000
WITH COMBINATION ANTI RETRO

3084
02:15:44,000 --> 02:15:47,480
VIRAL THERAPY HOWEVER, INCIDENTS

3085
02:15:47,480 --> 02:15:49,840
IS INCREASING IN YOUNG BLACK MEN

3086
02:15:49,840 --> 02:15:51,040
IN THE SOUTH.

3087
02:15:51,040 --> 02:15:54,840
IN PARTS OF AFRICA, INCIDENTS OF

3088
02:15:54,840 --> 02:15:58,760
KS REMAINS HIGH EVEN WIDESPREAD

3089
02:15:58,760 --> 02:16:01,280
USE OF CR AND MULTI CENTRIC

3090
02:16:01,280 --> 02:16:02,480
CASTLE MAN DISEASE HAS BEEN

3091
02:16:02,480 --> 02:16:12,960
FOUND TO REPRESENT ALSO CAL KS

3092
02:16:15,080 --> 02:16:16,960
IS A DISEASE OF THE ELDERLY AND

3093
02:16:16,960 --> 02:16:19,000
THE HIV INFECTED POPULATION IS

3094
02:16:19,000 --> 02:16:20,800
AGING IN THE U.S.

3095
02:16:20,800 --> 02:16:22,520
THERE ARE CONCERNS THAT WE MAY

3096
02:16:22,520 --> 02:16:25,920
SEE AN INCREASE IN KS AS BOTH

3097
02:16:25,920 --> 02:16:28,440
HIV POSITIVE AND HIV NEGATIVE

3098
02:16:28,440 --> 02:16:32,160
MEN WHO HAVE SEX WITH MEN WITH

3099
02:16:32,160 --> 02:16:39,240
HSHV INFECTION AGE.

3100
02:16:39,240 --> 02:16:42,040
KSHV IS OFTEN FOUND IN ORAL

3101
02:16:42,040 --> 02:16:43,480
FLUIDS AND EVIDENCE TO DATE IND

3102
02:16:43,480 --> 02:16:45,280
INDICATES THAT THIS IS THE MAIN

3103
02:16:45,280 --> 02:16:46,920
ROUTE OF SPREAD.

3104
02:16:46,920 --> 02:16:48,480
HOWEVER, MANY QUESTIONS REMAIN

3105
02:16:48,480 --> 02:16:51,680
REGARDING PRINCIPLE MODES OF

3106
02:16:51,680 --> 02:16:52,160
TRANSMISSION.

3107
02:16:52,160 --> 02:16:54,560
IN AFRICA, ACQUISITION PRIMARILY

3108
02:16:54,560 --> 02:16:56,680
OCCURS DURING CHILDHOOD.

3109
02:16:56,680 --> 02:17:03,640
IN NON-ENDEMIC AREAS, SESSI IT S

3110
02:17:03,640 --> 02:17:05,160
IN MSN.

3111
02:17:05,160 --> 02:17:07,040
THE ROLE OF HETEROSEXUAL

3112
02:17:07,040 --> 02:17:08,360
TRANSMISSION REMAINS IN

3113
02:17:08,360 --> 02:17:10,360
CONCLUSIVE AND A PARSE TO VARY

3114
02:17:10,360 --> 02:17:12,960
IN DIFFERENT PARTS OF THE WORLD.

3115
02:17:12,960 --> 02:17:17,240
NEXT SLIDE, PLEASE.

3116
02:17:17,240 --> 02:17:19,120
THE DOC PARTICIPATING IN THIS

3117
02:17:19,120 --> 02:17:21,000
CURRENT CONCEPT PROPOSAL

3118
02:17:21,000 --> 02:17:23,280
DEVELOPED AN RFA INVESTIGATION

3119
02:17:23,280 --> 02:17:27,480
OF THE TRANSMISSION OF KSHV NINE

3120
02:17:27,480 --> 02:17:28,920
RO1 GRANTS WERE AWARDED AND THE

3121
02:17:28,920 --> 02:17:31,360
GOAL OF THE RFA WAS TO ADVANCE

3122
02:17:31,360 --> 02:17:33,640
OUR KNOWLEDGE OF KSHV

3123
02:17:33,640 --> 02:17:34,240
TRANSMISSION.

3124
02:17:34,240 --> 02:17:37,040
AREAS OF RESEARCH ADDRESSED AND

3125
02:17:37,040 --> 02:17:39,040
FUNDED GRANTS INCLUDES

3126
02:17:39,040 --> 02:17:43,080
UNDERSTANDING THE STEPS IN KSHV

3127
02:17:43,080 --> 02:17:45,080
INFECTION AND THE CHARACTERISTIC

3128
02:17:45,080 --> 02:17:47,880
OF THE INITIAL IMMUNE RESPONSE

3129
02:17:47,880 --> 02:17:52,320
TO KSHV AND KSHV IN HIGH-RISK

3130
02:17:52,320 --> 02:17:54,800
GROUPS AND UNDERSTANDING THE

3131
02:17:54,800 --> 02:17:56,800
BEHAVIORAL ENVIRONMENTAL GENETIC

3132
02:17:56,800 --> 02:17:58,960
RISK FACTORS FOR KSHV.

3133
02:17:58,960 --> 02:18:02,480
NEXT SLIDE, PLEASE.

3134
02:18:02,480 --> 02:18:06,640
THE MSA, THE NCI, BSA

3135
02:18:06,640 --> 02:18:08,280
SUBCOMMITTEE HAS BEEN DEFINING

3136
02:18:08,280 --> 02:18:13,480
GAPS IN OUR UNDERSTANDING AND IN

3137
02:18:13,480 --> 02:18:16,000
INFECTION AND SINCE AT FIRST

3138
02:18:16,000 --> 02:18:16,480
CONVENED.

3139
02:18:16,480 --> 02:18:19,920
WITH NCI'S DEVELOPMENT, OF THE

3140
02:18:19,920 --> 02:18:22,600
KSHV TRANSMISSION RFA, THE BSA

3141
02:18:22,600 --> 02:18:33,120
AD HOC WORKING GROUCH ENDORSED

3142
02:18:45,840 --> 02:18:47,000
BY THE BSA.

3143
02:18:47,000 --> 02:18:50,840
NEXT SLIDE, PLEASE.

3144
02:18:50,840 --> 02:18:55,520
IN OCTOBER OF 2021, THEY HELD A

3145
02:18:55,520 --> 02:18:59,720
VIRTUAL STATE OF THE SCIENCE

3146
02:18:59,720 --> 02:19:01,960
WORKSHOP.

3147
02:19:01,960 --> 02:19:02,640
EXPERTISE ACROSS THE SPECIFICS

3148
02:19:02,640 --> 02:19:09,640
TRUONIMMUNOLOGY AND DISCUSSING E

3149
02:19:09,640 --> 02:19:11,560
BENEFITS AND FEASIBILITY OF

3150
02:19:11,560 --> 02:19:13,680
DEVELOPING A VACCINE AGAINST

3151
02:19:13,680 --> 02:19:15,240
KSHV AND THEY DISCUSSED GAPS IN

3152
02:19:15,240 --> 02:19:18,200
KNOWLEDGE AND REGARDING KSHV

3153
02:19:18,200 --> 02:19:21,360
TRANSMISSION, EPIDEMIOLOGY AND

3154
02:19:21,360 --> 02:19:22,920
IMMUNITY TO HERPES VIRUSES, THEY

3155
02:19:22,920 --> 02:19:24,000
DISCUSSED LESSONS LEARNED FROM

3156
02:19:24,000 --> 02:19:25,720
VACCINE DEVELOPMENT TO OTHER

3157
02:19:25,720 --> 02:19:27,760
VIRUSES AND INCLUDING ON GOING

3158
02:19:27,760 --> 02:19:31,720
WORK DEVELOPING APP EBV VACCINE.

3159
02:19:31,720 --> 02:19:33,360
THEY HAD DISCUSSIONS IN THE

3160
02:19:33,360 --> 02:19:34,600
CHALLENGES AND VACCINE

3161
02:19:34,600 --> 02:19:36,640
DEVELOPMENT AND FORMULATION,

3162
02:19:36,640 --> 02:19:47,120
TESTING, AND IMPLEMENTATION.

3163
02:19:55,640 --> 02:19:56,280
IT'S A WORTH WHILE ENDEAVOR AT

3164
02:19:56,280 --> 02:19:56,720
THIS TIME.

3165
02:19:56,720 --> 02:19:58,280
THE MEETING WAS OPEN TO THE

3166
02:19:58,280 --> 02:19:59,920
PUBLIC AND A STATE OF THE

3167
02:19:59,920 --> 02:20:01,240
SCIENCE PAPER WAS GENERATED.

3168
02:20:01,240 --> 02:20:05,440
NEXT SLIDE, PLEASE.

3169
02:20:05,440 --> 02:20:06,880
THE SCOPE AND EXPECTATIONS OF

3170
02:20:06,880 --> 02:20:09,680
THE RFA.

3171
02:20:09,680 --> 02:20:11,360
LIKE TO PERFORM RESEARCH TO

3172
02:20:11,360 --> 02:20:12,560
BETTER DEFINE THE INITIAL STEPS

3173
02:20:12,560 --> 02:20:16,000
OF INFECTION WITH KSHB AND THE

3174
02:20:16,000 --> 02:20:17,400
PRIMARY MEANS OF PERSON TO

3175
02:20:17,400 --> 02:20:18,400
PERSON TRANSMISSION AND

3176
02:20:18,400 --> 02:20:19,960
DIFFERENT POPULATIONS THAT CAN

3177
02:20:19,960 --> 02:20:23,880
BE TARGETED WITH A VACCINE.

3178
02:20:23,880 --> 02:20:25,680
IDENTIFICATION AND A EVALUATION

3179
02:20:25,680 --> 02:20:27,960
OF KSHV STRUCTURAL AND NON

3180
02:20:27,960 --> 02:20:29,680
STRUCTURAL TARGETS AND FOR A

3181
02:20:29,680 --> 02:20:31,960
POTENTIAL KSHB VACCINE.

3182
02:20:31,960 --> 02:20:36,560
AND DEVELOPMENT OF ANIMAL MODELS

3183
02:20:36,560 --> 02:20:38,400
AND TO STUDENTS A PROTOCOL

3184
02:20:38,400 --> 02:20:42,320
VACCINE AND TESTING OF CAP DATES

3185
02:20:42,320 --> 02:20:45,040
AND STUDIES TO ASSESS HOW THE

3186
02:20:45,040 --> 02:20:47,600
ADVOCACY OF A PROMISING VACCINE

3187
02:20:47,600 --> 02:20:52,080
CAN BE OPTIMIZED, FOR PEOPLE

3188
02:20:52,080 --> 02:20:53,480
WITH HIV.

3189
02:20:53,480 --> 02:20:55,400
OPTIMIZIZATION AND

3190
02:20:55,400 --> 02:20:56,440
STANDARDIZATION OF DETECTION

3191
02:20:56,440 --> 02:20:56,920
METHODS.

3192
02:20:56,920 --> 02:20:59,040
THE OVER ALL GOAL IS TO EXPAND

3193
02:20:59,040 --> 02:21:02,120
THE RESEARCH SCOPE AND LEVERAGE

3194
02:21:02,120 --> 02:21:04,440
THEY MADE THROUGH THE PREVIOUS

3195
02:21:04,440 --> 02:21:06,880
RF A AND TO SUPPORT BASIC AND

3196
02:21:06,880 --> 02:21:08,160
TRANSLATIONAL RESEARCH THAT WILL

3197
02:21:08,160 --> 02:21:15,160
GUIDE THE DEVELOPMENT OF A

3198
02:21:15,160 --> 02:21:15,520
VACCINE.

3199
02:21:15,520 --> 02:21:18,040
NEXT SLIDE, PLEASE.

3200
02:21:18,040 --> 02:21:20,560
WE PERFORMED A PORTFOLIO

3201
02:21:20,560 --> 02:21:23,600
ANALYSIS FORTIS CAL YEAR '21 AND

3202
02:21:23,600 --> 02:21:24,200
'22.

3203
02:21:24,200 --> 02:21:28,200
OVER TWO ACTIVE RESEARCH PROJECT

3204
02:21:28,200 --> 02:21:32,240
GRANTS AND NIDCA AND ADDRESSING

3205
02:21:32,240 --> 02:21:33,760
KSHV VACCINE DEVELOPMENT.

3206
02:21:33,760 --> 02:21:37,240
THE NCI HAS 56 FINANCED GRANTS

3207
02:21:37,240 --> 02:21:41,840
THAT IN SOME WAY ADDRESS K IS

3208
02:21:41,840 --> 02:21:43,520
SHV RELATED RESEARCH, NINE OF

3209
02:21:43,520 --> 02:21:45,000
WHICH WERE FUNDED THROUGH THE

3210
02:21:45,000 --> 02:21:48,560
PREVIOUS RFA.

3211
02:21:48,560 --> 02:21:51,760
SIX NCI FUNDED GRANTS ADDRESS

3212
02:21:51,760 --> 02:21:54,200
ISSUES SUCH AS VIROLOGY, EARLY

3213
02:21:54,200 --> 02:21:56,000
INFECTION, ET CETERA, AND THAT

3214
02:21:56,000 --> 02:21:58,240
COULD POTENTIALLY BE IMPORTANT

3215
02:21:58,240 --> 02:22:00,840
IN VACCINE DEVELOPMENT.

3216
02:22:00,840 --> 02:22:05,680
OTHER ICs IN THE PORTFOLIO

3217
02:22:05,680 --> 02:22:07,480
FUNDED 17 GRANTS THAT IN SOME

3218
02:22:07,480 --> 02:22:18,040
WAY ADDRESS KS OR KSHV AND WHEN

3219
02:22:25,960 --> 02:22:29,480
COMPARED TO FISCAL YEAR 2015 AND

3220
02:22:29,480 --> 02:22:29,800
2016.

3221
02:22:29,800 --> 02:22:32,680
NEXT SLIDE.

3222
02:22:32,680 --> 02:22:32,960
PLEASE.

3223
02:22:32,960 --> 02:22:36,840
THEY ARE PROPOSING A $3 MILLION

3224
02:22:36,840 --> 02:22:39,600
BUDGET FOR EACH OF TWO RECEIPT

3225
02:22:39,600 --> 02:22:42,560
DATES WITH A 15 MILLION OVER ALL

3226
02:22:42,560 --> 02:22:44,600
REQUESTED FOR FIVE YEARS AND FOR

3227
02:22:44,600 --> 02:22:45,800
EACH OF TWO RECEIPT DATES.

3228
02:22:45,800 --> 02:22:49,880
WHICH WOULD INCLUDES $30 MILLION

3229
02:22:49,880 --> 02:22:54,600
TOTAL THIS WOULD SUPPORT THREE

3230
02:22:54,600 --> 02:23:05,160
TO FOUR AND THE CONCEPT HAS BEEN

3231
02:23:09,320 --> 02:23:13,000
REVIEWED BY THE OAR AND DEEMED

3232
02:23:13,000 --> 02:23:14,280
AIDS APPLIANCE.

3233
02:23:14,280 --> 02:23:18,000
A UO1 MECHANISM IS BEING

3234
02:23:18,000 --> 02:23:19,280
PROPOSED PRIMARILY BECAUSE OF

3235
02:23:19,280 --> 02:23:21,560
THE BREADTH OF INTEREST IN

3236
02:23:21,560 --> 02:23:26,440
COMPLEXITY THE SCOPE OF SCIENCE

3237
02:23:26,440 --> 02:23:27,760
AND NEEDS TO BE CATALYZED

3238
02:23:27,760 --> 02:23:29,680
THROUGH THIS INITIATIVE AND

3239
02:23:29,680 --> 02:23:30,520
INTERNATIONAL PARTNERSHIPS IN

3240
02:23:30,520 --> 02:23:32,680
LOW AND MIDDLE INCOME COUNTRIES

3241
02:23:32,680 --> 02:23:36,560
WILL BE FACILITATED BY PROGRAM

3242
02:23:36,560 --> 02:23:39,400
ENGAGEMENT IN ORDER TO OPTIMIZE

3243
02:23:39,400 --> 02:23:39,600
SUCCESS.

3244
02:23:39,600 --> 02:23:49,960
NEXT SLIDE, PLEASE.

3245
02:24:01,200 --> 02:24:05,560
>> THANK YOU, REBECA.

3246
02:24:05,560 --> 02:24:06,560
LET'S GET IT STARTED IN

3247
02:24:06,560 --> 02:24:06,960
DISCUSSION.

3248
02:24:06,960 --> 02:24:07,680
>> SURE.

3249
02:24:07,680 --> 02:24:10,320
SO THANK YOU, REBECA THAT WAS A

3250
02:24:10,320 --> 02:24:14,400
NICE PRESENTATION.

3251
02:24:14,400 --> 02:24:24,400
Dr. DOROSHOW AND HE WASN'T

3252
02:24:24,400 --> 02:24:25,920
ABLE TO MAKE THE MEETING BUT HE

3253
02:24:25,920 --> 02:24:27,040
REVIEWED THE CONCEPT STATEMENT

3254
02:24:27,040 --> 02:24:30,160
AND THE POWER POINTS AND

3255
02:24:30,160 --> 02:24:32,040
PROVIDED FEEDBACK OVER E-MAIL.

3256
02:24:32,040 --> 02:24:39,720
SO IN GENERAL, THE COMMUNITY

3257
02:24:39,720 --> 02:24:43,480
MEMBERS WHICH REPRESENTS A

3258
02:24:43,480 --> 02:24:44,440
MULTI-COLLABORATIVE EVENT ACROSS

3259
02:24:44,440 --> 02:24:48,000
THE NCI DIVISIONS AND CENTERS.

3260
02:24:48,000 --> 02:24:51,440
WE THOUGHT THAT THE FOCUS OF THE

3261
02:24:51,440 --> 02:24:53,800
RFA IS CERTAINLY HIGHLY

3262
02:24:53,800 --> 02:24:55,240
IMPORTANT IN THE NEED IS REALLY

3263
02:24:55,240 --> 02:24:58,480
GREAT, ESPECIALLY IN THE SUB

3264
02:24:58,480 --> 02:25:05,080
ZAHAR AN AFRICA.

3265
02:25:05,080 --> 02:25:07,480
WE GOT THAT THERE WAS A LOGICAL

3266
02:25:07,480 --> 02:25:08,560
PROGRESSION AND A STRONG

3267
02:25:08,560 --> 02:25:09,680
FOUNDATION FOR THE DEVELOPMENT

3268
02:25:09,680 --> 02:25:11,840
OF THIS RFA AND INCLUDING HAVING

3269
02:25:11,840 --> 02:25:14,560
THIS MULTI-DISCIPLINARY MEETING

3270
02:25:14,560 --> 02:25:16,960
ON THIS TOPIC AND

3271
02:25:16,960 --> 02:25:19,200
RECOMMENDATIONS FROM THE BSA AD

3272
02:25:19,200 --> 02:25:27,160
HOC COMMITTEES TO ADDRESS THE

3273
02:25:27,160 --> 02:25:37,680
KSHB AND ALSO THE CURRENT WAVE

3274
02:25:52,080 --> 02:25:54,360
OF RESEARCH ON THE DEVELOPMENT

3275
02:25:54,360 --> 02:25:57,800
OF OTHER TYPES OF VACCINES AND

3276
02:25:57,800 --> 02:25:59,240
FURTHERMORE SOME OF THE

3277
02:25:59,240 --> 02:26:03,080
ATTRIBUTES OF THE VIRUS MAKES IT

3278
02:26:03,080 --> 02:26:05,560
FEASIBLE TO TARGETED FOR A

3279
02:26:05,560 --> 02:26:06,040
VACCINE.

3280
02:26:06,040 --> 02:26:11,000
AND FINALLY THE PORTFOLIO

3281
02:26:11,000 --> 02:26:11,720
ANALYSIS I THINK DEMONSTRATED

3282
02:26:11,720 --> 02:26:15,480
THAT THE PROPOSAL, THIS PROPOSED

3283
02:26:15,480 --> 02:26:21,120
RFA WILL FILL A GAP OR BE

3284
02:26:21,120 --> 02:26:23,680
COMPLIMENTARY TO OTHER EXISTING

3285
02:26:23,680 --> 02:26:26,160
FUNDINGS FOR RESEARCH ON THIS

3286
02:26:26,160 --> 02:26:26,720
AREA.

3287
02:26:26,720 --> 02:26:31,040
WE DID HAVE OF A FEW CONCERNS

3288
02:26:31,040 --> 02:26:34,200
WHICH I THINK WERE ADDRESSED BUT

3289
02:26:34,200 --> 02:26:36,400
REBECA AND BOB, ONE WAS THE

3290
02:26:36,400 --> 02:26:40,640
POTENTIAL OVERLAP BETWEEN TARGET

3291
02:26:40,640 --> 02:26:43,120
AREAS IN THE PRIOR RFA VERSUS

3292
02:26:43,120 --> 02:26:48,000
THE PROPOSED RFA BUT WE WERE

3293
02:26:48,000 --> 02:26:50,360
SURE THAT THIS RFA IS THAT

3294
02:26:50,360 --> 02:26:54,840
DEVELOP AND THE VACCINES AND WE

3295
02:26:54,840 --> 02:26:56,400
HAVE QUESTIONS AND WHETHER THE

3296
02:26:56,400 --> 02:27:06,880
RESULTS FROM THE PRIOR RFA OUR

3297
02:27:07,480 --> 02:27:08,480
INVESTIGATORS WHO ARE ABLE TO

3298
02:27:08,480 --> 02:27:10,200
SECURE FUNDING AND WHAT REBECA

3299
02:27:10,200 --> 02:27:15,760
HAD MENTIONED IS THAT PROBABLY

3300
02:27:15,760 --> 02:27:18,320
THE INITIATION FEE PROPOSED RFA

3301
02:27:18,320 --> 02:27:19,960
WOULD PROBABLY OCCUR WHILE THE

3302
02:27:19,960 --> 02:27:26,360
PRIOR RFA RESULTS ARE BEING

3303
02:27:26,360 --> 02:27:27,200
GENERATED.

3304
02:27:27,200 --> 02:27:32,160
WE, I THINK, Dr. DOROSHOW HAD

3305
02:27:32,160 --> 02:27:36,600
QUESTIONS ON THE WORK OF THE EVB

3306
02:27:36,600 --> 02:27:39,640
EPSTEIN BAR VIRUS VACCINES WILL

3307
02:27:39,640 --> 02:27:44,000
HELP INFORM THE KSHV VACCINE AND

3308
02:27:44,000 --> 02:27:47,520
IN DEED THE RESPONSE WAS YES.

3309
02:27:47,520 --> 02:27:50,040
AND FINALLY, OR I GUESS NOT

3310
02:27:50,040 --> 02:27:52,400
FINALLY BUT THE OTHER

3311
02:27:52,400 --> 02:27:53,800
RECOMMENDATION THAT WE HAD IS

3312
02:27:53,800 --> 02:27:57,840
THAT THERE'S A PROPOSAL TO GET

3313
02:27:57,840 --> 02:28:00,000
THE UO1 INVESTIGATORS TOGETHER

3314
02:28:00,000 --> 02:28:01,800
TO SHARE INFORMATION WITH EACH

3315
02:28:01,800 --> 02:28:03,000
OTHER BUT WE THOUGHT IT MIGHT BE

3316
02:28:03,000 --> 02:28:07,600
GOOD TO OPEN IT UP TO OTHER

3317
02:28:07,600 --> 02:28:08,640
INVESTIGATORS THAT HAVE

3318
02:28:08,640 --> 02:28:10,480
CONDUCTED RESEARCH IN THIS

3319
02:28:10,480 --> 02:28:11,040
PARTICULAR AREA.

3320
02:28:11,040 --> 02:28:17,000
AND THEN FINALLY, THERE WAS A

3321
02:28:17,000 --> 02:28:17,840
QUESTION AS TO WHETHER CLINICAL

3322
02:28:17,840 --> 02:28:23,200
TRIALS ARE GOING TO BE REQUIRED

3323
02:28:23,200 --> 02:28:25,080
FOR THIS RFA AND THE RESPONSE

3324
02:28:25,080 --> 02:28:26,720
THAT IS THE CLINICAL TRIALS WILL

3325
02:28:26,720 --> 02:28:28,560
BE OPTIONAL.

3326
02:28:28,560 --> 02:28:32,800
SO, THAT IS IN SUMMARY OUR --

3327
02:28:32,800 --> 02:28:34,880
WHAT WE RECOMMENDED AND YOU

3328
02:28:34,880 --> 02:28:43,040
KNOW, WHAT WE FELT ABOUT THE RFA

3329
02:28:43,040 --> 02:28:45,640
AND WE'RE VERY SUPPORTIVE OF IT.

3330
02:28:45,640 --> 02:28:47,480
>> I HIGHLIGHTED YOUR
COMMENTS

3331
02:28:47,480 --> 02:28:54,120
BUT IF YOU HAVE ANY ADDITIONAL

3332
02:28:54,120 --> 02:28:54,400
COMMENTS.

3333
02:28:54,400 --> 02:29:00,600
>> YEAH, NO, I THINK IT'S
REALLY

3334
02:29:00,600 --> 02:29:02,520
WELL DONE BACKGROUND AND

3335
02:29:02,520 --> 02:29:03,280
PRESENTATIONS OF THE NEED AND

3336
02:29:03,280 --> 02:29:05,560
YOU KNOW, EARLIER TODAY WE HEARD

3337
02:29:05,560 --> 02:29:07,240
ABOUT FUNDINGS FORCES AND HOW

3338
02:29:07,240 --> 02:29:09,280
THIS GETS FUNDED IS A LITTLE BIT

3339
02:29:09,280 --> 02:29:11,000
DIFFERENT AS WELL WHICH IS

3340
02:29:11,000 --> 02:29:12,720
FAVORABLE IN TERMS OF

3341
02:29:12,720 --> 02:29:13,880
DEVELOPMENT OF THE VACCINE.

3342
02:29:13,880 --> 02:29:15,440
THE THING, THE OTHER QUESTION I

3343
02:29:15,440 --> 02:29:16,960
HAVE OVER TIME IS THIS IS A

3344
02:29:16,960 --> 02:29:24,920
MAJOR ISSUE FOR SUB ZAHAR ANT

3345
02:29:24,920 --> 02:29:26,880
AFRICA AND FOLKS HIV NEGOTIATE

3346
02:29:26,880 --> 02:29:27,960
IT TIVE AND THEY AGE IN THE

3347
02:29:27,960 --> 02:29:29,000
UNITED STATES AND I DON'T THINK

3348
02:29:29,000 --> 02:29:30,760
WE KNOW THE ANSWER TO THAT YET

3349
02:29:30,760 --> 02:29:32,920
SO HOPEFULLY DEVELOPMENT OF A

3350
02:29:32,920 --> 02:29:34,280
VACCINE WOULD GENERATE A VACCINE

3351
02:29:34,280 --> 02:29:37,360
THAT'S AFFORDABLE AND I MEAN, WE

3352
02:29:37,360 --> 02:29:44,680
NEED THE VACCINES TO THE VACCINE

3353
02:29:44,680 --> 02:29:54,800
FIRST.

3354
02:29:56,400 --> 02:29:58,480
>> WE CLARIFY IT'S
CLINICAL

3355
02:29:58,480 --> 02:30:03,360
TRIALS OPTIONAL AND THAT'S ALL I

3356
02:30:03,360 --> 02:30:13,560
HAVE TO ADD.

3357
02:30:15,360 --> 02:30:18,800
>> YOU ARE MUTED.

3358
02:30:18,800 --> 02:30:20,200
>>

3359
02:30:20,200 --> 02:30:26,320
>THANK YOU.NICE PRESENTATION
ANY

3360
02:30:26,320 --> 02:30:27,240
TIMELY.

3361
02:30:27,240 --> 02:30:28,480
I WONDER IF YOU HAD THOUGHT

3362
02:30:28,480 --> 02:30:33,680
ABOUT COLLABORATIONS WITH THE

3363
02:30:33,680 --> 02:30:34,720
NIEDCR BECAUSE ONE OF THE

3364
02:30:34,720 --> 02:30:39,440
IMPORTANT ASPECTS OF ORAL KS, AS

3365
02:30:39,440 --> 02:30:41,920
YOU KNOW, IS ASSOCIATED WITH HIV

3366
02:30:41,920 --> 02:30:42,960
POSITIVE INDIVIDUALS AND THAT

3367
02:30:42,960 --> 02:30:45,080
WOULD BE A NICE COLLABORATION TO

3368
02:30:45,080 --> 02:30:46,160
BUILD ON.

3369
02:30:46,160 --> 02:30:47,600
BUT, ONE OF THE THINGS THAT I AM

3370
02:30:47,600 --> 02:30:48,840
THINKING ABOUT, AS YOU WENT

3371
02:30:48,840 --> 02:30:54,800
THROUGH THE PRESENTATION, WAS

3372
02:30:54,800 --> 02:31:05,280
THAT YOU HAVE ABOUT IT'S 80%

3373
02:31:05,760 --> 02:31:06,880
ZERO POSITIVE.

3374
02:31:06,880 --> 02:31:09,960
IN THE EVENT THIS VACCINE

3375
02:31:09,960 --> 02:31:11,120
MATERIALIZES, TRYING TO THINK

3376
02:31:11,120 --> 02:31:15,480
ABOUT HOW THIS WOULD BE SAY

3377
02:31:15,480 --> 02:31:17,560
SOLVED IN TERMS OF TRANSMITTING

3378
02:31:17,560 --> 02:31:19,240
TO INDIVIDUALS WHO REALLY NEEDS

3379
02:31:19,240 --> 02:31:21,480
THE VACCINE, HAVE YOU THOUGHT

3380
02:31:21,480 --> 02:31:22,640
ABOUT HOW THIS MIGHT BE WORKED

3381
02:31:22,640 --> 02:31:24,520
OUT IN TERMS OF COLLABORATING

3382
02:31:24,520 --> 02:31:27,000
WITH GOVERNMENTS AND THESE

3383
02:31:27,000 --> 02:31:28,240
COUNTRIES AS WELL AS CHINESE

3384
02:31:28,240 --> 02:31:30,360
GOVERNMENTS?

3385
02:31:30,360 --> 02:31:32,720
HAS THERE BEEN DISCUSSIONS THAT

3386
02:31:32,720 --> 02:31:36,760
HAS BEEN ON GOING WITH THIS?

3387
02:31:36,760 --> 02:31:40,280
>> WELL, AS FAR AS
COLLABORATION

3388
02:31:40,280 --> 02:31:42,520
WITH THE NIDCR WHEN WE STARTED

3389
02:31:42,520 --> 02:31:44,760
THIS INITIATIVE, WE DID WORK

3390
02:31:44,760 --> 02:31:49,040
WITH THE NIDCR INITIALLY BUT

3391
02:31:49,040 --> 02:31:50,560
THERE WERE PROGRAMMATIC ISSUES

3392
02:31:50,560 --> 02:31:54,160
THAT PUT IT OUT OF THEIR REALM

3393
02:31:54,160 --> 02:31:55,440
OF PARTICIPATION.

3394
02:31:55,440 --> 02:32:06,000
SO WE'VE MOVED FORWARD I BELIEVE

3395
02:32:08,240 --> 02:32:10,280
WE HAVE TO MOVE DOWN THE

3396
02:32:10,280 --> 02:32:13,000
PIPELINE BEFORE WE CAN START

3397
02:32:13,000 --> 02:32:16,640
CERTAINLY WILL WORK THROUGH NCI

3398
02:32:16,640 --> 02:32:18,760
AS COLLABORATIVELY AND AS

3399
02:32:18,760 --> 02:32:22,520
FORWARD-THINKING AS WE CAN

3400
02:32:22,520 --> 02:32:24,280
POSSIBLY BE.

3401
02:32:24,280 --> 02:32:27,200
TO GET THIS VACCINE, IF

3402
02:32:27,200 --> 02:32:29,000
DEVELOPED, TO THE POPULATIONS

3403
02:32:29,000 --> 02:32:29,760
THAT MOST NEED IT.

3404
02:32:29,760 --> 02:32:32,440
I THINK THAT'S THE VALUE OF

3405
02:32:32,440 --> 02:32:43,000
DOING THIS RESEARCH FOR VACCINE

3406
02:32:46,400 --> 02:32:47,920
THAT PROBABLY WOULDN'T BE

3407
02:32:47,920 --> 02:32:50,560
DEVELOPED COMMERCIALLY.

3408
02:32:50,560 --> 02:32:52,560
>> I HAVE ONE OTHER
COMMENT.

3409
02:32:52,560 --> 02:32:53,120
IS THAT OKAY?

3410
02:32:53,120 --> 02:32:54,720
>> YES, PLEASE.

3411
02:32:54,720 --> 02:32:58,560
>> ONE OF THE OTHER THINGS
THEY

3412
02:32:58,560 --> 02:33:01,880
ARE THINKING ABOUT IS THIS VIRUS

3413
02:33:01,880 --> 02:33:05,440
IS DIFFERENT TO EVE OR ECV THAT

3414
02:33:05,440 --> 02:33:06,400
EFFECTS MOST OF THE OF THE

3415
02:33:06,400 --> 02:33:09,120
POPULATION AND YOU HAVE A LARGE

3416
02:33:09,120 --> 02:33:12,960
NUMBER OF ONCO GENETIC OR RF AS

3417
02:33:12,960 --> 02:33:13,440
WELL AS QUEEN'S THAT ARE

3418
02:33:13,440 --> 02:33:15,160
INVOLVED IN IMMUNE EVASION.

3419
02:33:15,160 --> 02:33:17,480
DO YOU REALLY THINK WHICH AT THE

3420
02:33:17,480 --> 02:33:18,640
POINT WHERE WE ARE READY TO

3421
02:33:18,640 --> 02:33:20,400
START PUTTING EFFORT INTO THE

3422
02:33:20,400 --> 02:33:22,520
DEVELOPING THE VACCINES WITH

3423
02:33:22,520 --> 02:33:24,640
THIS HUGE KNOWLEDGE GAP THAT IS

3424
02:33:24,640 --> 02:33:26,200
EXISTING CURRENTLY FOR THE

3425
02:33:26,200 --> 02:33:28,280
DEVELOPING SUCH A VACCINE?

3426
02:33:28,280 --> 02:33:35,240
>> I'M GOING TO SHOOT THAT
ONE

3427
02:33:35,240 --> 02:33:35,920
OVER AND.

3428
02:33:35,920 --> 02:33:38,440
>> YOU KNOW ONE CAN ALWAYS
SPLIT

3429
02:33:38,440 --> 02:33:39,920
FOR THESE THINGS AND WE HAVE

3430
02:33:39,920 --> 02:33:41,840
ENOUGH KNOWLEDGE AT THIS POINT

3431
02:33:41,840 --> 02:33:42,800
WE CAN MOVE FORWARD.

3432
02:33:42,800 --> 02:33:44,400
WE HAVE A PRETTY GOOD IDEA OF

3433
02:33:44,400 --> 02:33:51,480
SOME OF THE SURFACE PROTEINS

3434
02:33:51,480 --> 02:34:01,960
THAT IT'S ONLY TRANSMITTED IN

3435
02:34:17,760 --> 02:34:20,640
CERTAIN SETS SO ONE HAS THE

3436
02:34:20,640 --> 02:34:23,360
SENSE THAT ONE MAY NOT TO TWEAK

3437
02:34:23,360 --> 02:34:24,440
THE IMMUNE RESPONSE TO THIS

3438
02:34:24,440 --> 02:34:26,360
VIRUS THAT MUCH TO HAVE AN

3439
02:34:26,360 --> 02:34:27,280
EFFECTIVE VACCINE.

3440
02:34:27,280 --> 02:34:29,560
WE WON'T KNOW UNTIL WE DO IT BUT

3441
02:34:29,560 --> 02:34:30,640
I THINK IT'S WORTH WHILE TO GIVE

3442
02:34:30,640 --> 02:34:34,320
IT A SHOT AND WE LEARN ABOUT THE

3443
02:34:34,320 --> 02:34:37,920
BIOLOGY FOR DEVELOPING A

3444
02:34:37,920 --> 02:34:48,040
VACCINE.

3445
02:34:50,240 --> 02:34:51,040
>> Dr. Flaherty: CAN YOU
MAKE A

3446
02:34:51,040 --> 02:34:51,440
MOTION?

3447
02:34:51,440 --> 02:34:52,600
>> I MOVE TO VOTE.

3448
02:34:52,600 --> 02:34:54,280
I MOVE TO APPROVAL.

3449
02:34:54,280 --> 02:34:57,160
>> CAN I GET A SECOND.

3450
02:34:57,160 --> 02:34:59,440
>> SECOND, PLEASE.

3451
02:34:59,440 --> 02:35:01,240
THANK YOU, MARK.

3452
02:35:01,240 --> 02:35:02,080
>> Dr. Flaherty: OKAY.

3453
02:35:02,080 --> 02:35:10,160
ANY FURTHER DISCUSSION?

3454
02:35:10,160 --> 02:35:11,800
MOTION IS FOR APPROVAL.

3455
02:35:11,800 --> 02:35:15,320
AND YOUR PRESENCE ON CAMERA IS

3456
02:35:15,320 --> 02:35:16,520
VOTED APPROVAL.

3457
02:35:16,520 --> 02:35:18,360
SO YOU NEED TO RAISE YOUR HAND

3458
02:35:18,360 --> 02:35:19,920
OR VOICE DISAPPROVAL IF YOU ARE

3459
02:35:19,920 --> 02:35:27,760
VOTING IN THAT DIRECTION.

3460
02:35:27,760 --> 02:35:30,080
I SEE YOU ARE HERE NONE.

3461
02:35:30,080 --> 02:35:35,840
ANY ABSTENTIONS?

3462
02:35:35,840 --> 02:35:36,000
NO.

3463
02:35:36,000 --> 02:35:37,520
>> IT'S UNANIMOUS.

3464
02:35:37,520 --> 02:35:39,120
>> THANK YOU.

3465
02:35:39,120 --> 02:35:41,280
>> WE'VE REACHED THE POINT
OF

3466
02:35:41,280 --> 02:35:41,760
BREAK.

3467
02:35:41,760 --> 02:35:43,960
THANK YOU VERY MUCH.

3468
02:35:43,960 --> 02:35:45,160
FOR THAT REPRESENTATION AND

3469
02:35:45,160 --> 02:35:47,880
DISCUSSION.

3470
02:35:47,880 --> 02:35:49,360
I THINK WE -- IT'S SAFE TO SAY

3471
02:35:49,360 --> 02:35:51,880
WE INVESTED SOME OF OUR BREAK IN

3472
02:35:51,880 --> 02:35:57,040
THE Q&A THAT FOLLOWED JIM'S

3473
02:35:57,040 --> 02:35:58,240
PRESENTATION LET'S SHRINK OUR

3474
02:35:58,240 --> 02:35:58,920
BREAKDOWN TO FIVE MINUTES.

3475
02:35:58,920 --> 02:36:23,440
WE HAVE TO SOME HAVE MAUD' CO T.

3476
02:36:23,440 --> 02:36:26,600
>> Dr. Flaherty: WITH SAM
AND

3477
02:36:26,600 --> 02:36:29,760
JENNIFER AND ALL THREE WITH THE

3478
02:36:29,760 --> 02:36:31,400
DISCUSSION OF CONCEPT AND

3479
02:36:31,400 --> 02:36:32,680
SUZANNE COULDN'T JOIN US TODAY

3480
02:36:32,680 --> 02:36:37,440
FOR THE MEETING.

3481
02:36:37,440 --> 02:36:39,000
WE HAVE THE DISCUSSION AND GET

3482
02:36:39,000 --> 02:36:40,680
US STARTED  WHEN WE GET TO THAT

3483
02:36:40,680 --> 02:36:45,880
POINT AND SAM AS YOU CAN SEE IS

3484
02:36:45,880 --> 02:36:49,000
WITH US SUL.

3485
02:36:49,000 --> 02:36:51,360
FOR TARGETING PROTEINS IN

3486
02:36:51,360 --> 02:36:54,800
CHILDHOOD CANCER.

3487
02:36:54,800 --> 02:36:55,680
THE OTHER MEMBERS OF THE TEAM

3488
02:36:55,680 --> 02:36:56,880
WILL BE ON FOR QUESTIONS AND

3489
02:36:56,880 --> 02:36:58,200
ANSWERS AFTERWARDS.

3490
02:36:58,200 --> 02:37:05,200
FIRST POINT I WANT TO EMPHASIZE,

3491
02:37:05,200 --> 02:37:09,240
IS THE IMPORTANCE OF ACTIVE

3492
02:37:09,240 --> 02:37:11,280
TARGETED AGENTS, HAD WE HAVE

3493
02:37:11,280 --> 02:37:12,680
ACTIVE AGENTS FOR A CANCER WE

3494
02:37:12,680 --> 02:37:15,440
KNOW WHAT TO DO IN ORDER TO

3495
02:37:15,440 --> 02:37:22,000
IMPROVE OUTCOMES FOR CHILDREN

3496
02:37:22,000 --> 02:37:24,920
FOR CHILDHOOD ALL LOOKING ON FOR

3497
02:37:24,920 --> 02:37:25,960
2000 ONWARD THERE'S A 50%

3498
02:37:25,960 --> 02:37:33,800
DECLINE IN MORTALITY WE HAVE

3499
02:37:33,800 --> 02:37:37,840
INHIBITORS AND CAR T CELLS ARE

3500
02:37:37,840 --> 02:37:43,120
AVAILABLE IN THE WE SEE THIS

3501
02:37:43,120 --> 02:37:50,440
DECLINE FOR NON-HODG NON HOW MUH

3502
02:37:50,440 --> 02:37:54,760
LYMPHOMA AND CD TARGETED 20 AND

3503
02:37:54,760 --> 02:38:03,000
I AM H20 ANDOTHERS AND FINALLY N

3504
02:38:03,000 --> 02:38:06,840
LYMPHOMA 80% DECLINE OF

3505
02:38:06,840 --> 02:38:11,480
MORTALITY AND ACTIVATIONS AND

3506
02:38:11,480 --> 02:38:14,320
LOOKING AVAILABLE IN THE LAST 10

3507
02:38:14,320 --> 02:38:14,880
YEARS.

3508
02:38:14,880 --> 02:38:16,680
WE CAN IMPROVE THAT OUTCOME WHEN

3509
02:38:16,680 --> 02:38:18,840
WE HAVE THESE ACTIVE NEW

3510
02:38:18,840 --> 02:38:19,400
TARGETED AGENTS.

3511
02:38:19,400 --> 02:38:21,080
IT'S A DIFFERENT STORY WHEN YOU

3512
02:38:21,080 --> 02:38:24,120
LOOK AT SOFT TISSUE CANCER,

3513
02:38:24,120 --> 02:38:26,440
CANCER LIKE SARCOMA AND WE LOOK

3514
02:38:26,440 --> 02:38:30,120
AT BONE CANCER AND THOSE INCLUDE

3515
02:38:30,120 --> 02:38:37,560
CANCERS LIKE OSTEO CAR COMA SO

3516
02:38:37,560 --> 02:38:46,520
IT EMPHASISES NEEDED FOR CAN ZAR

3517
02:38:46,520 --> 02:38:47,840
AND IN ORDER TO CURE MORE WITH

3518
02:38:47,840 --> 02:38:49,240
THESE CANCER AND MANY OF THESE

3519
02:38:49,240 --> 02:38:52,720
HARD TO TREAT CANCER WHICH HAS

3520
02:38:52,720 --> 02:38:58,840
BEEN LITTLE PROGRESS ARE DRIVEN

3521
02:38:58,840 --> 02:39:00,480
BY FUSION ONCA PROTEIN.

3522
02:39:00,480 --> 02:39:05,560
IT BUILDS UPON THE NCI MOONSHOT

3523
02:39:05,560 --> 02:39:06,160
INITIATIVE.

3524
02:39:06,160 --> 02:39:09,200
THERE WERE NINE GRANTS U54

3525
02:39:09,200 --> 02:39:12,800
GRANTS IN SIX DIFFERENT FUSION

3526
02:39:12,800 --> 02:39:16,680
ONCA PROTEINS AND STUDY FROM

3527
02:39:16,680 --> 02:39:18,840
REMODELING, PHASE SEPARATION,

3528
02:39:18,840 --> 02:39:21,680
MODEL DEVELOPMENT, PRO TAX AND

3529
02:39:21,680 --> 02:39:24,880
APPLY STRATEGIES AND STUDYING

3530
02:39:24,880 --> 02:39:27,760
CRITICAL DEPENDENCIES AND

3531
02:39:27,760 --> 02:39:29,480
PROGRESS WAS MADE.

3532
02:39:29,480 --> 02:39:31,120
Dr. BERTAGNOLLI DESCRIBED THE

3533
02:39:31,120 --> 02:39:33,120
ADVANCES, THE IDENTIFICATION OF

3534
02:39:33,120 --> 02:39:42,200
ETV6 IS A CRITICAL DEBEN SEE AND

3535
02:39:42,200 --> 02:39:43,760
OTHER OTHER ADVANCE AND I DON'T

3536
02:39:43,760 --> 02:39:45,040
HAVE TIME TO GO THROUGH ALL OF

3537
02:39:45,040 --> 02:39:47,640
THESE BUT JUST TO MENTION A FEW.

3538
02:39:47,640 --> 02:39:51,320
KIM AND HER TEAM SHOWED THAT

3539
02:39:51,320 --> 02:39:54,880
TRIM 8 REGULATES EWS51 PROTEIN

3540
02:39:54,880 --> 02:39:57,680
LEVELS AND EITHER TOO MUCH EWS51

3541
02:39:57,680 --> 02:39:59,240
OR TOO LITTLE IS DETERMINED BY

3542
02:39:59,240 --> 02:40:05,680
THE ACTIVITY CAN BE TOXIC TO

3543
02:40:05,680 --> 02:40:10,600
EWING SARCOMA CELLS AND AS WELL,

3544
02:40:10,600 --> 02:40:13,400
JOHN BUSHWELLER HAS IDENTIFIED

3545
02:40:13,400 --> 02:40:17,200
SMALL MOLECULES THAT STABILIZE

3546
02:40:17,200 --> 02:40:18,360
FLIGHT 1 AND ANOTHER

3547
02:40:18,360 --> 02:40:19,440
TRANSCRIPTION FACTORS THIS

3548
02:40:19,440 --> 02:40:21,840
SHIFTS THE EQUILIBRIUM AWAY FROM

3549
02:40:21,840 --> 02:40:24,200
DNA BINDING AND INHIBITS THE

3550
02:40:24,200 --> 02:40:25,840
ACTIVITIES OF THESE

3551
02:40:25,840 --> 02:40:26,440
TRANSCRIPTION FACTORS AND

3552
02:40:26,440 --> 02:40:29,200
ANOTHER EXAMPLE, CHARLES

3553
02:40:29,200 --> 02:40:31,960
MULLIGAN AND HIS U54 TEAM

3554
02:40:31,960 --> 02:40:34,120
IDENTIFIED A CRITICAL DEPENDENCY

3555
02:40:34,120 --> 02:40:36,120
AND REARRANGED LEUKEMIA AND THIS

3556
02:40:36,120 --> 02:40:38,520
IS SOMETHING THAT CAN HAVE

3557
02:40:38,520 --> 02:40:44,560
IMMEDIATE CLINICAL TRANSLATION

3558
02:40:44,560 --> 02:40:54,960
BECAUSE MODELING AND CAN

3559
02:40:56,480 --> 02:40:57,960
BE USED FOR DRUG SCREENING.

3560
02:40:57,960 --> 02:41:00,160
WE DID HAVE EX INTERPRETTAL

3561
02:41:00,160 --> 02:41:01,240
SCIENTIFIC CONSULT APARTMENTS TO

3562
02:41:01,240 --> 02:41:03,280
ADVISE US ON NEXT ACCEPTS TO

3563
02:41:03,280 --> 02:41:12,520
FOLLOW THROUGH THE CONSORTIUM.

3564
02:41:12,520 --> 02:41:14,640
WHERE NCI MAKES CONTRIBUTIONS

3565
02:41:14,640 --> 02:41:16,880
AND ANOTHER DIVERSIFYING THE

3566
02:41:16,880 --> 02:41:19,560
PROTEINS INCLUDED IN FUTURE

3567
02:41:19,560 --> 02:41:22,200
EFFORTS AND THEY RECOMMENDED

3568
02:41:22,200 --> 02:41:24,320
APPLYING STATE OF THE ART

3569
02:41:24,320 --> 02:41:28,840
METHODS TO DIRECTLY TARGETING

3570
02:41:28,840 --> 02:41:30,840
INFUSION ONCA PROTEINS AND THEY

3571
02:41:30,840 --> 02:41:37,680
HAVE SUCH A STATE IT'S POSSIBLE

3572
02:41:37,680 --> 02:41:46,520
TO -- AND INNOVATIVE DRUG

3573
02:41:46,520 --> 02:41:48,400
DEVELOPMENTS TO ALL OF THE

3574
02:41:48,400 --> 02:41:49,560
INVESTIGATORS THAT ARE MEMBERS

3575
02:41:49,560 --> 02:41:55,040
OF THE NETWORK AND TO DO

3576
02:41:55,040 --> 02:41:57,080
DILIGENCE IN THE REASSURE

3577
02:41:57,080 --> 02:41:58,400
OURSELVES IT'S SCIENTIFIC

3578
02:41:58,400 --> 02:42:00,520
OPPORTUNITIES ARE AVAILABLE AND

3579
02:42:00,520 --> 02:42:03,960
THERE'S INTEREST IN THE RESEARCH

3580
02:42:03,960 --> 02:42:07,480
COMMUNITY WE ORGANIZED WEBINAR

3581
02:42:07,480 --> 02:42:08,920
SERIES LAST YEAR ON NOVEL

3582
02:42:08,920 --> 02:42:11,760
CHEMICAL APPROACHES FOR

3583
02:42:11,760 --> 02:42:13,320
TARGETING FUSION ONCA PROTEINS

3584
02:42:13,320 --> 02:42:16,480
AND WE HAD 1,000 HIGH LEVEL OF

3585
02:42:16,480 --> 02:42:20,080
INTEREST IN THIS TOPIC AND

3586
02:42:20,080 --> 02:42:22,360
REALLY THE -- WE CAME AWAY WITH

3587
02:42:22,360 --> 02:42:31,240
MORE ENTHUSIASM I DON'T HAVE

3588
02:42:31,240 --> 02:42:33,360
TIME TO GO THROUGH THE

3589
02:42:33,360 --> 02:42:34,480
OPPORTUNITIES BUT THE METHODS

3590
02:42:34,480 --> 02:42:37,760
FOR PROTEIN DEGRADATION FOR

3591
02:42:37,760 --> 02:42:41,960
SCREENING, CO VARIANT INHIBITORS

3592
02:42:41,960 --> 02:42:44,560
AND ALL OF THESE THINGS CREATE

3593
02:42:44,560 --> 02:42:48,720
AN OPPORTUNITY FOR PROGRESS.

3594
02:42:48,720 --> 02:42:50,480
SO, THE NETWORK THAT WE'RE

3595
02:42:50,480 --> 02:42:53,120
PROPOSING HAS TWO COMPONENTS.

3596
02:42:53,120 --> 02:42:55,480
THE FIRST IS FOR PROJECTS TO

3597
02:42:55,480 --> 02:43:01,000
BETTER UNDERSTAND THE MECHANISMS

3598
02:43:01,000 --> 02:43:05,920
OF FUSION DRIVEN ONCAGENESIS AND

3599
02:43:05,920 --> 02:43:09,640
SO THOSE UO1 GRANTS STUDY THE

3600
02:43:09,640 --> 02:43:12,560
PATHWAY BY WHICH THE FUSIONS CAN

3601
02:43:12,560 --> 02:43:16,080
CAUSE CANCER, WHAT'S THEIR

3602
02:43:16,080 --> 02:43:17,040
COMPLEXES THAT THESE FUSION

3603
02:43:17,040 --> 02:43:18,080
ONCOPROTEINS ARE INVOLVED WITH

3604
02:43:18,080 --> 02:43:19,840
AND THE INTERACTIONS WITHIN THE

3605
02:43:19,840 --> 02:43:22,600
COMPLEX AND WHAT ARE THE ROLES

3606
02:43:22,600 --> 02:43:27,160
LIKE NON CODING RNAs OR IN THE

3607
02:43:27,160 --> 02:43:28,280
FUNCTION OF THESE FUSION

3608
02:43:28,280 --> 02:43:29,600
ONCOPROTEINS AND THE SECOND ARE

3609
02:43:29,600 --> 02:43:35,480
THE NEXT GENERATION CHEMISTRY

3610
02:43:35,480 --> 02:43:36,760
CENTERS AND THESE ARE LARGER

3611
02:43:36,760 --> 02:43:40,640
GRANTS THAT ALLOW SEVERAL SEEMS

3612
02:43:40,640 --> 02:43:42,560
TO WORK TOGETHER AND WITH

3613
02:43:42,560 --> 02:43:43,840
COMPLIMENTARY RESEARCH AND

3614
02:43:43,840 --> 02:43:45,240
EXPERTISE TOWARDS A COMMON GOAL

3615
02:43:45,240 --> 02:43:55,760
AND ANY OF THAT COMMON GOAL IS

3616
02:43:56,520 --> 02:43:57,760
ACTIVITIES FOR THESE AND

3617
02:43:57,760 --> 02:43:59,920
IDENTIFYING INHIBITORS OF FUSION

3618
02:43:59,920 --> 02:44:02,000
ON CO PROTEIN ACTIVITY AND

3619
02:44:02,000 --> 02:44:03,520
EITHER DIRECTING INHIBITORS

3620
02:44:03,520 --> 02:44:05,320
BLACKING CRITICAL INTERACTIONS

3621
02:44:05,320 --> 02:44:08,000
AND OR DEGRADING THE FUSION ON

3622
02:44:08,000 --> 02:44:11,240
CO PROTEIN OR THE CRITICAL DEPEN

3623
02:44:11,240 --> 02:44:12,040
DEN SEIZE.

3624
02:44:12,040 --> 02:44:13,560
THESE A SCHEMATIC OF THE HOW WE

3625
02:44:13,560 --> 02:44:15,320
I AM VISION OF THE NETWORK OF

3626
02:44:15,320 --> 02:44:19,160
STEERING COMMITTEE WITH THE

3627
02:44:19,160 --> 02:44:22,400
PIs OF THE UO1 AND THE UM1s.

3628
02:44:22,400 --> 02:44:25,720
THE UM1s AND THE UO01s HANK

3629
02:44:25,720 --> 02:44:27,400
OR THE NETWORK BUT OTHER

3630
02:44:27,400 --> 02:44:31,840
GRANTEES CAN BE ASSOCIATE

3631
02:44:31,840 --> 02:44:35,960
MEMBERS OF THE NETWORK AND THESE

3632
02:44:35,960 --> 02:44:38,400
ARE STATION FUSION THROUGH OTHER

3633
02:44:38,400 --> 02:44:41,200
NCI FUNDED GRANTS OR THESE

3634
02:44:41,200 --> 02:44:42,560
STUDYING FUSION ONCOPROTEINS AND

3635
02:44:42,560 --> 02:44:46,800
INCLUDING PATIENTS ADVOCATES AS

3636
02:44:46,800 --> 02:44:52,240
WELL AND BETWEEN THE UM1 COMES

3637
02:44:52,240 --> 02:44:54,000
THE RESEARCH TEAMS OUTSIDE OF

3638
02:44:54,000 --> 02:44:58,280
THE NETWORK EVEN AND THE UM1

3639
02:44:58,280 --> 02:44:59,680
BUDGE LET'S HAVE 15% OF THEIR

3640
02:44:59,680 --> 02:45:04,280
OVER ALL BUDGET TO APPLY THE

3641
02:45:04,280 --> 02:45:06,160
STRATEGIES WITH INTERACTIONS

3642
02:45:06,160 --> 02:45:11,560
BETWEEN THE UO1 AND THE UM1s.

3643
02:45:11,560 --> 02:45:14,280
THE AS A RESULT OF OUR

3644
02:45:14,280 --> 02:45:15,400
DISCUSSIONS WITH THE BSA

3645
02:45:15,400 --> 02:45:24,640
SUBCOMMITTEE WE WANT TO -- THE

3646
02:45:24,640 --> 02:45:27,800
NUMBER ONE IS FOCUS OF PROTEIN

3647
02:45:27,800 --> 02:45:29,920
THAT HAVE A HIGH-RISK OF FAILURE

3648
02:45:29,920 --> 02:45:30,880
AND LITTLE PROGRESS IN

3649
02:45:30,880 --> 02:45:32,960
IDENTIFYING TARGETED AGENTS AND

3650
02:45:32,960 --> 02:45:34,840
WHILE PARTICULARLY ENCOURAGED

3651
02:45:34,840 --> 02:45:36,320
APPLICATIONS WHERE THEY SOLID

3652
02:45:36,320 --> 02:45:39,360
TUMORS AND BRAIN TUMORS AND

3653
02:45:39,360 --> 02:45:48,040
EXCLUDE FUSION O ON CO ONCOPROTD

3654
02:45:48,040 --> 02:45:50,280
DATA SHARING AND COLLABORATE

3655
02:45:50,280 --> 02:45:52,080
WITH OTHER NCI PROGRAMS SUCH AS

3656
02:45:52,080 --> 02:45:54,440
THE CHILDHOOD DATA INITIATIVE TO

3657
02:45:54,440 --> 02:45:57,640
ENSURE USABILITY AND

3658
02:45:57,640 --> 02:45:58,600
ACCESSIBILITY AND SHAREABILITY

3659
02:45:58,600 --> 02:46:00,640
OF THE DATA.

3660
02:46:00,640 --> 02:46:04,040
IN TERMS OF THE BUDGET AND

3661
02:46:04,040 --> 02:46:06,280
LOGISTICS, THERE'S SEPARATE

3662
02:46:06,280 --> 02:46:09,160
RFAs, ONE FOR THE U01 AWARDS

3663
02:46:09,160 --> 02:46:11,920
AND THEY WERE TARGETING 325,000

3664
02:46:11,920 --> 02:46:14,080
DIRECTING CALLS FOR THESE AND

3665
02:46:14,080 --> 02:46:17,360
THE RFA FOR THE UM1 AWARDS, WE

3666
02:46:17,360 --> 02:46:21,520
ENVISIONED TWO UM1 AWARDS EACH

3667
02:46:21,520 --> 02:46:25,120
WITH $1.5 MILLION AND DIRECT

3668
02:46:25,120 --> 02:46:27,240
COST AND WE THE 15% OF THE

3669
02:46:27,240 --> 02:46:29,800
BUDGET BEING RESTRICTED FOR

3670
02:46:29,800 --> 02:46:31,200
COLLABORATIVE PROJECTS IN YEARS

3671
02:46:31,200 --> 02:46:41,520
TWO THROUGH FIVE.

3672
02:46:45,400 --> 02:46:46,320
WITH $8.3 MILLION ANNUALLY FOR

3673
02:46:46,320 --> 02:46:49,960
FIVE YEARS FROM FY24 TO FY28.

3674
02:46:49,960 --> 02:46:55,320
SO, OUR MARKERS OF SUCCESS

3675
02:46:55,320 --> 02:47:04,280
NUMBER ONE IS TUB THREE, NEW

3676
02:47:04,280 --> 02:47:05,720
TECHNOLOGIES AND STRATEGIES

3677
02:47:05,720 --> 02:47:08,800
IDENTIFYING FOR TARGETING FUSION

3678
02:47:08,800 --> 02:47:10,480
ONCOPROTEINS OR THEIR DEPEN DEN

3679
02:47:10,480 --> 02:47:13,280
SEIZE AND FINALLY, IDENTIFYING

3680
02:47:13,280 --> 02:47:15,520
AND DEVELOPING CHEMICAL PROBES

3681
02:47:15,520 --> 02:47:17,920
TOOLS OR ADVANCE LEADS THAT CAN

3682
02:47:17,920 --> 02:47:20,280
BE OPTIMIZED TO NEW DRUG

3683
02:47:20,280 --> 02:47:26,880
CANDIDATES SO THAT'S REALLY WHAT

3684
02:47:26,880 --> 02:47:37,280
SO MY COLLEAGUES WILL BE

3685
02:47:41,760 --> 02:47:43,040
AVAILABLE TO ADDRESS QUESTIONS

3686
02:47:43,040 --> 02:47:43,880
THE BSA MEMBERS MAY HAVE.

3687
02:47:43,880 --> 02:47:46,200
>> THANK YOU.

3688
02:47:46,200 --> 02:47:47,720
DO YOU WANT TO GET US STARTED.

3689
02:47:47,720 --> 02:47:49,880
>> HI, MALCOLM, THANK YOU
FOR

3690
02:47:49,880 --> 02:47:50,080
THAT.

3691
02:47:50,080 --> 02:47:52,240
IT WAS A WONDERFUL PRESENTATION

3692
02:47:52,240 --> 02:47:53,720
AND NICELY INCORPORATED SOME OF

3693
02:47:53,720 --> 02:47:58,840
THE DISCUSSION TOPICS THAT WE

3694
02:47:58,840 --> 02:47:59,760
HAD WHEN WE MET.

3695
02:47:59,760 --> 02:48:01,840
WE WERE VERY ENGAGE IN

3696
02:48:01,840 --> 02:48:03,160
ENTHUSIASTIC ABOUT THE CONCEPT

3697
02:48:03,160 --> 02:48:05,120
AS YOU HAVE HEARD AND IT REALLY

3698
02:48:05,120 --> 02:48:07,000
BUILDS UPON THIS SUCCESS AND

3699
02:48:07,000 --> 02:48:09,240
LESSONS LEARNED IN THE U54

3700
02:48:09,240 --> 02:48:10,280
CONSORTIUM, THE QUESTION IS WHAT

3701
02:48:10,280 --> 02:48:12,880
IS THE NEXT STEP.

3702
02:48:12,880 --> 02:48:13,880
THE WE ARE NAR SERIES SHOWED A

3703
02:48:13,880 --> 02:48:15,880
HIGH LEVEL OF ENGAGEMENT AND

3704
02:48:15,880 --> 02:48:17,680
THIS IS JUST FELT TO US VERY

3705
02:48:17,680 --> 02:48:20,640
LOGICAL AND WE WERE EXCITED BY

3706
02:48:20,640 --> 02:48:23,200
THE POSSIBILITY OF BRINGING THE

3707
02:48:23,200 --> 02:48:26,080
UM1 MECHANISM INTO NCI WHERE WHY

3708
02:48:26,080 --> 02:48:27,400
THINK IT'S A COMMON MECHANISM

3709
02:48:27,400 --> 02:48:28,560
FOR FUNDING.

3710
02:48:28,560 --> 02:48:30,840
IT'S THE MECHANISM TO FUND THE

3711
02:48:30,840 --> 02:48:32,000
CTSAs WHICH SEVERAL OF US ARE

3712
02:48:32,000 --> 02:48:33,200
VERY FAMILIAR WITH AND THE NICE

3713
02:48:33,200 --> 02:48:35,120
PART ABOUT THE UM1 MECHANISM IS

3714
02:48:35,120 --> 02:48:37,560
IT'S REALLY FLEXIBLE.

3715
02:48:37,560 --> 02:48:40,400
SO THIS PLUS THE INCENTIVIZED

3716
02:48:40,400 --> 02:48:41,920
15% COLLABORATIVE RESOURCES

3717
02:48:41,920 --> 02:48:44,040
REALLY SEEM TO US LIKE THE RIGHT

3718
02:48:44,040 --> 02:48:46,200
THING TO DO.

3719
02:48:46,200 --> 02:48:47,480
WE REALLY HAD A COUPLE OF

3720
02:48:47,480 --> 02:48:49,680
QUESTIONS AND CLARIFICATIONS

3721
02:48:49,680 --> 02:48:51,320
WHICH WERE DISCUSSED IN TERMS OF

3722
02:48:51,320 --> 02:48:54,760
OVER ALL STRUCTURE AND

3723
02:48:54,760 --> 02:48:56,640
INTERACTIONS WITH BOTH BETWEEN

3724
02:48:56,640 --> 02:48:59,960
UM1 AND UO1 AND RO1s,

3725
02:48:59,960 --> 02:49:00,880
INTRAMURAL COMMUNITY IT ALL

3726
02:49:00,880 --> 02:49:02,360
SOUNDS RIGHT.

3727
02:49:02,360 --> 02:49:04,760
THE DATA ISSUE IS LARGE, I'LL

3728
02:49:04,760 --> 02:49:06,280
LET SAM WEIGH IN ON THAT BECAUSE

3729
02:49:06,280 --> 02:49:08,320
IT'S REALLY HIS AREA OF

3730
02:49:08,320 --> 02:49:09,400
EXPERTISE.

3731
02:49:09,400 --> 02:49:11,040
UP WITH OF THE IDEAS WE GOT

3732
02:49:11,040 --> 02:49:12,360
EXCITED ABOUT IS LEARNING FROM

3733
02:49:12,360 --> 02:49:16,400
THIS SUCCESS OF THE N3C EFFORT

3734
02:49:16,400 --> 02:49:18,200
IN N CAT WHERE THERE WAS A

3735
02:49:18,200 --> 02:49:22,040
REQUIREMENT DURING COVID TO

3736
02:49:22,040 --> 02:49:23,960
SHARE ALL THE ELECTRONIC HEALTH

3737
02:49:23,960 --> 02:49:27,320
RECORDS WITH THE NIH IN ORDER TO

3738
02:49:27,320 --> 02:49:28,960
SUPPORT COVID RESEARCH.

3739
02:49:28,960 --> 02:49:31,360
THERE REALLY ISN'T ANY REASON

3740
02:49:31,360 --> 02:49:34,440
WHY NCI CAN'T LEVERAGE SUCH A

3741
02:49:34,440 --> 02:49:35,840
EFFORT WITH THE COMPREHENSIVE

3742
02:49:35,840 --> 02:49:37,520
CANCER CENTERS SO THE CANCER

3743
02:49:37,520 --> 02:49:39,240
CENTER CONSORTIUM, WHEN THE TIME

3744
02:49:39,240 --> 02:49:42,320
IS RIGHT, WHEN THE QUESTION IS

3745
02:49:42,320 --> 02:49:44,600
RIGHT, YOU CERTAINLY HAVE THE

3746
02:49:44,600 --> 02:49:45,840
POLITICAL CAPITOL TO DO IS SUCH

3747
02:49:45,840 --> 02:49:48,640
AND I THIS I IT COULD REALLY

3748
02:49:48,640 --> 02:49:49,520
CAPITALIZE WELL ON THE OTHER

3749
02:49:49,520 --> 02:49:53,480
EFFORTS WE HEARD THIS MORNING

3750
02:49:53,480 --> 02:50:03,920
AND NOT I THOUGHT THE HIGH

3751
02:50:09,760 --> 02:50:11,800
LEVEL, LET'S NOT FOX SOMETHING

3752
02:50:11,800 --> 02:50:12,960
THAT'S ALREADY SOLVED AND LET'S

3753
02:50:12,960 --> 02:50:14,160
ATTEND TO THINGS THAT ARE STILL

3754
02:50:14,160 --> 02:50:16,080
BROKEN IS A REALLY PRAGMATIC

3755
02:50:16,080 --> 02:50:16,680
RESPONSE.

3756
02:50:16,680 --> 02:50:19,000
YOU KNOW, SUZIE, SAM AND I WERE

3757
02:50:19,000 --> 02:50:21,520
ALL VERY SUPPORTIVE AND I'LL LET

3758
02:50:21,520 --> 02:50:22,840
SAM SPEAK NOW.

3759
02:50:22,840 --> 02:50:24,920
>> THANK YOU.

3760
02:50:24,920 --> 02:50:26,040
OBVIOUSLY VERY ENTHUSIASTIC

3761
02:50:26,040 --> 02:50:26,960
ABOUT THIS.

3762
02:50:26,960 --> 02:50:28,320
ESPECIALLY AS A SPEED FROM THE

3763
02:50:28,320 --> 02:50:33,880
PEDIATRICONCOLOGIST AND ALL THET

3764
02:50:33,880 --> 02:50:36,840
FROM THIS PROGRAM SO FAR.

3765
02:50:36,840 --> 02:50:37,720
OBVIOUSLY I'VE BEEN CONCERNED

3766
02:50:37,720 --> 02:50:39,720
ABOUT DATA SHARING AND WE NEED

3767
02:50:39,720 --> 02:50:41,600
TO SEE EVERY OPPORTUNITY TO

3768
02:50:41,600 --> 02:50:43,520
COLLECT AND AGO AGREE GATE AND

3769
02:50:43,520 --> 02:50:44,240
HARMONIZE DATA LIKE THIS.

3770
02:50:44,240 --> 02:50:45,520
WE HAD A DISCUSSION ABOUT THE

3771
02:50:45,520 --> 02:50:46,960
DIFFERENT MECHANISMS THAT ARE IN

3772
02:50:46,960 --> 02:50:54,840
PLACE FOR A FOR FOR AGGREGATINGO

3773
02:50:54,840 --> 02:50:56,760
SHOW HOW RESEARCH OUTPUT FROM

3774
02:50:56,760 --> 02:50:59,280
THIS PROGRAM CAN BE HARNESSES

3775
02:50:59,280 --> 02:51:00,440
AND REPURPOSES FOR OTHER FOLKS

3776
02:51:00,440 --> 02:51:01,720
THAT WANT TO USE THE DATA FOR

3777
02:51:01,720 --> 02:51:02,440
THEIR OWN RESEARCH.

3778
02:51:02,440 --> 02:51:03,480
THIS IS A GREAT OPPORTUNITY HERE

3779
02:51:03,480 --> 02:51:05,120
AND ACROSS ALL OF OUR PROGRAMS

3780
02:51:05,120 --> 02:51:05,480
OBVIOUSLY.

3781
02:51:05,480 --> 02:51:06,880
SO THANK YOU FOR LETTING ME BE A

3782
02:51:06,880 --> 02:51:09,560
PART OF THIS DISCUSSION.

3783
02:51:09,560 --> 02:51:10,120
>> THANK YOU.

3784
02:51:10,120 --> 02:51:19,360
OPEN FOR FURTHER DISCUSSION.

3785
02:51:19,360 --> 02:51:21,200
>> WHAT HAPPENS TO THE
CURRENT

3786
02:51:21,200 --> 02:51:21,680
PROGRAM?

3787
02:51:21,680 --> 02:51:23,680
IS THIS A REPLACEMENT FOR THE

3788
02:51:23,680 --> 02:51:25,800
CURRENT MOONSHOT PROGRAM?

3789
02:51:25,800 --> 02:51:31,560
>> YEAH, THE CONSORTIUM,
THESE

3790
02:51:31,560 --> 02:51:35,920
WERE MOONSHOT PROGRAMS FIVE YEAR

3791
02:51:35,920 --> 02:51:39,000
AWARDS AND THEY WERE DONE TWICE

3792
02:51:39,000 --> 02:51:41,480
AND SO SOME OF THE AWARDS WERE,

3793
02:51:41,480 --> 02:51:43,840
THEY'RE ENDING ONE YEAR APART

3794
02:51:43,840 --> 02:51:45,480
BUT THEY WERE FIVE YEAR AWARDS

3795
02:51:45,480 --> 02:51:48,480
AND SO, IN SOME WAYS, THIS

3796
02:51:48,480 --> 02:51:50,960
BUILDS UPON THAT AND WE'LL BE A

3797
02:51:50,960 --> 02:51:52,760
SUCCESS FOR THAT AND THOSE

3798
02:51:52,760 --> 02:51:54,000
AWARDS THEMSELVES WILL NOT BE

3799
02:51:54,000 --> 02:52:04,320
ABLE TO CONTINUE.

3800
02:52:18,320 --> 02:52:22,160
IN LOOKING AT THE KIND OF POINTS

3801
02:52:22,160 --> 02:52:24,480
THAT THIS RFA WOULD BE POINTING

3802
02:52:24,480 --> 02:52:26,240
TO, I'M SURPRISED THAT THERE WAS

3803
02:52:26,240 --> 02:52:29,560
NOT ANY MENTION OF AN IMMUNE

3804
02:52:29,560 --> 02:52:32,840
LOGICAL APPROACH BECAUSE FUSION

3805
02:52:32,840 --> 02:52:33,840
PROTEINS ARE GOOD TARGETS AND

3806
02:52:33,840 --> 02:52:35,720
THEY CAN ACTUALLY BE HIGHLY

3807
02:52:35,720 --> 02:52:39,040
SPECIFIC AND THEY DON'T NEGATE

3808
02:52:39,040 --> 02:52:42,640
THE DISTRICTED KIND OF SMALL

3809
02:52:42,640 --> 02:52:43,760
MOLECULE APPROACH THAT IT'S

3810
02:52:43,760 --> 02:52:44,800
TALKING ABOUT.

3811
02:52:44,800 --> 02:52:47,200
BECAUSE I DON'T KNOW MUCH ABOUT

3812
02:52:47,200 --> 02:52:57,720
THESE TUMORS AND WE HAVE AFTER

3813
02:52:59,360 --> 02:53:02,000
EFFORT WITHIN NCI, PEDIATRIC

3814
02:53:02,000 --> 02:53:04,680
IMMUNO NETWORK NOW THAT IS

3815
02:53:04,680 --> 02:53:06,360
SPECIFICALLY APP APPLICATION

3816
02:53:06,360 --> 02:53:11,040
THAT WOULD BE RIGHT WITHIN WHAT

3817
02:53:11,040 --> 02:53:12,360
THOSE PROGRAMS WERE AIMING FOR.

3818
02:53:12,360 --> 02:53:14,320
IS THERE SOMETHING ABOUT THESE

3819
02:53:14,320 --> 02:53:15,520
FUSION PROTEINS THAT STIMULATES

3820
02:53:15,520 --> 02:53:25,600
AN IMMUNE SPONSOR THAT THERE'S

3821
02:53:25,600 --> 02:53:27,280
AN ACTIVE AREA OF RESEARCH AND

3822
02:53:27,280 --> 02:53:29,040
IN PART WE DIDN'T MENTION IT

3823
02:53:29,040 --> 02:53:31,400
HERE SIMPLY BECAUSE OTHERS ARE

3824
02:53:31,400 --> 02:53:35,120
ADDRESSING IT AND OTHER

3825
02:53:35,120 --> 02:53:35,400
PROGRAMS.

3826
02:53:35,400 --> 02:53:38,600
>> THANK YOU.

3827
02:53:38,600 --> 02:53:42,360
>> SEEING NO OTHER HANDS,
WE CAN

3828
02:53:42,360 --> 02:53:46,080
MOVE TO VOTING.

3829
02:53:46,080 --> 02:53:47,720
JENNY, AS THE ACTING CHAIR, IT

3830
02:53:47,720 --> 02:53:49,280
SOUNDS LIKE YOU ARE MOVING THIS

3831
02:53:49,280 --> 02:53:50,080
IN SUPPORTIVE DIRECTION.

3832
02:53:50,080 --> 02:53:51,280
WOULD YOU LIKE IT MAKE A MOTION?

3833
02:53:51,280 --> 02:53:53,120
>> I MOVE TO APPROVE.

3834
02:53:53,120 --> 02:53:56,840
>> CAN I GET A SECOND.

3835
02:53:56,840 --> 02:54:07,280
>> ANY FURTHER DISCUSSION?

3836
02:54:08,400 --> 02:54:08,960
HEARING NONE.

3837
02:54:08,960 --> 02:54:11,600
THE ASSUMPTION IS VOTE OF

3838
02:54:11,600 --> 02:54:11,840
APPROVAL.

3839
02:54:11,840 --> 02:54:13,840
SO LOOKING FOR ANY DIS APPROVALS

3840
02:54:13,840 --> 02:54:24,320
BY RAISE OF HANDS OR VOICE.

3841
02:54:26,400 --> 02:54:28,120
I SEE AND HEAR NONE.

3842
02:54:28,120 --> 02:54:32,160
ANY ABSTENTIONS.

3843
02:54:32,160 --> 02:54:33,120
>> IT'S UNANIMOUS.

3844
02:54:33,120 --> 02:54:38,280
>> THANK YOU, ALL.

3845
02:54:38,280 --> 02:54:42,960
WE HAVE A REISSUANCE RFA AND

3846
02:54:42,960 --> 02:54:44,720
CO-OPERATIVE HAIMON TISSUE

3847
02:54:44,720 --> 02:54:49,440
NETWORK AND Dr. CHUAQUI WILL

3848
02:54:49,440 --> 02:54:50,960
PRESENT AND IT'S SHARED BY

3849
02:54:50,960 --> 02:54:54,280
SHELLY IRP AND CONSTITUTED BY

3850
02:54:54,280 --> 02:54:55,680
FELLOW ALLRIDGE AND SUSAN BAKER

3851
02:54:55,680 --> 02:54:58,120
AND AS NOTED, SUSAN COULDN'T

3852
02:54:58,120 --> 02:55:02,240
JOIN US FOR THE MEETING TODAY.

3853
02:55:02,240 --> 02:55:03,680
SHELLY AND NELLY ARE WITH US.

3854
02:55:03,680 --> 02:55:08,960
AND I'LL JUST MENTION NOW AT THE

3855
02:55:08,960 --> 02:55:15,760
OUTSET, THIS IS A LIMITED COMP

3856
02:55:15,760 --> 02:55:17,400
COMPETITION AGREEMENT AT THE

3857
02:55:17,400 --> 02:55:18,600
INSTITUTIONAL OR INTEREST LEVEL

3858
02:55:18,600 --> 02:55:22,480
AS A CONSTITUTION WE HAVE A

3859
02:55:22,480 --> 02:55:26,520
NUMBER OF CONFLICTS AND

3860
02:55:26,520 --> 02:55:27,680
ABSTENTIONS THAT COME UP AT THE

3861
02:55:27,680 --> 02:55:27,960
END.

3862
02:55:27,960 --> 02:55:32,680
SIX OF OUR MEMBERS WILL BE

3863
02:55:32,680 --> 02:55:34,920
ABSTAINING FROM THE VOTING

3864
02:55:34,920 --> 02:55:35,160
PROCESS.

3865
02:55:35,160 --> 02:55:36,600
AS WELL AS DISCUSSION WHEN WE

3866
02:55:36,600 --> 02:55:37,320
GET THERE.

3867
02:55:37,320 --> 02:55:40,280
SO JUST A FLAG THAT AS NON

3868
02:55:40,280 --> 02:55:42,760
UNUSUAL FOR LIMITED COMPETITION

3869
02:55:42,760 --> 02:55:44,280
INSTITUTIONAL LEVEL AWARDS LIKE

3870
02:55:44,280 --> 02:55:44,880
THIS.

3871
02:55:44,880 --> 02:55:46,960
SO WITH THAT SAID, RODRIGO, GO

3872
02:55:46,960 --> 02:55:48,440
AHEAD WITH THE PRESENTATION.

3873
02:55:48,440 --> 02:55:53,800
>> SORRY, DO YOU HAVE A
QUEST 

3874
02:55:53,800 --> 02:55:54,240
QUESTION?

3875
02:55:54,240 --> 02:55:58,240
>> SO THE COMPARATIVE
TISSUE

3876
02:55:58,240 --> 02:56:01,440
NETWORK IS AN NCI SUPPORTED

3877
02:56:01,440 --> 02:56:02,600
RESEARCH WHOSE MAIN GOAL IS

3878
02:56:02,600 --> 02:56:06,120
INFORM PROVIDE HIGH-QUALITY

3879
02:56:06,120 --> 02:56:08,840
SPECIMEN MAINLY FOR BASIC AND

3880
02:56:08,840 --> 02:56:11,040
EARLY TRANSLATIONAL RESEARCH AS

3881
02:56:11,040 --> 02:56:15,920
WELL AS ASSAY DEVELOPMENT.

3882
02:56:15,920 --> 02:56:16,640
NEXT SLIDE.

3883
02:56:16,640 --> 02:56:18,360
THE PROBLEM HAS BEEN FUNCTIONING

3884
02:56:18,360 --> 02:56:22,400
WITH HIGH PRODUCTIVITY SINCE

3885
02:56:22,400 --> 02:56:26,680
1987 AND HAS A WELL STRUCTURE IN

3886
02:56:26,680 --> 02:56:29,040
CONSISTING OF SIX DIVISIONS,

3887
02:56:29,040 --> 02:56:31,840
FIVE ADULT DIVISIONS THAT

3888
02:56:31,840 --> 02:56:33,120
DISTRIBUTE SPECIMENS ACCORDING

3889
02:56:33,120 --> 02:56:40,080
TO THE GEOGRAPHIC LOCATION OF

3890
02:56:40,080 --> 02:56:48,160
THE THE ADULT DIVISIONS WORK

3891
02:56:48,160 --> 02:56:58,680
WAYS BETWEEN ONE AND AND HAVE

3892
02:57:21,160 --> 02:57:25,280
SIGNIFICANTLY CONTRIBUTED TO BIO

3893
02:57:25,280 --> 02:57:35,640
SPECIMEN SCIENCE AND BIOBANKING.

3894
02:57:35,640 --> 02:57:38,000
IT'S A UNIQUE REPOP TORI UNLIKE

3895
02:57:38,000 --> 02:57:40,240
ANY FUNDED BY THE NCI.

3896
02:57:40,240 --> 02:57:43,320
IF YOU LOOK AT THE RIGHT COLUMN,

3897
02:57:43,320 --> 02:57:46,680
IT IS BASED AN PROSPECTIVE

3898
02:57:46,680 --> 02:57:49,120
PROCUREMENT MODEL AND IN

3899
02:57:49,120 --> 02:57:51,520
RESPONSE TO AN INVESTIGATOR

3900
02:57:51,520 --> 02:57:53,880
REQUESTING THOSE SAMPLES.

3901
02:57:53,880 --> 02:58:02,480
WITH LIMITED STORING.

3902
02:58:02,480 --> 02:58:04,760
THE PROSTHETIC PROCUREMENT

3903
02:58:04,760 --> 02:58:06,480
ALLOWS THE PROCESSING OF THE

3904
02:58:06,480 --> 02:58:09,400
SAMPLES TO BE CUSTOMIZED TO THE

3905
02:58:09,400 --> 02:58:12,040
INVESTIGATORS NEEDS AND THERE'S

3906
02:58:12,040 --> 02:58:13,080
FREQUENT COMMUNICATION BETWEEN

3907
02:58:13,080 --> 02:58:16,400
INVESTIGATOR AND THE CHTM.

3908
02:58:16,400 --> 02:58:18,160
IN THE NETWORKING ON THE OTHER

3909
02:58:18,160 --> 02:58:22,880
HAND, ALLOWS FOR A WIDE RANGE OF

3910
02:58:22,880 --> 02:58:24,320
SAMPLES TO BE COLLECTED

3911
02:58:24,320 --> 02:58:33,680
INCLUDING RARE SAMPLES.

3912
02:58:33,680 --> 02:58:37,200
THEY ARE PROVIDED WITH BASIC

3913
02:58:37,200 --> 02:58:43,520
DAMNGRAPH I CAN AND HISTO PATH S

3914
02:58:43,520 --> 02:58:45,320
REQUESTED FOR MORE DATA.

3915
02:58:45,320 --> 02:58:47,920
FRESH AND FROZEN SAMPLES, WHICH

3916
02:58:47,920 --> 02:58:51,760
ARE USUALLY THE LIMITING FACTOR

3917
02:58:51,760 --> 02:58:54,760
IN BIO REPOSITORIES CONSTITUTE

3918
02:58:54,760 --> 02:58:57,400
ABOUT 50% OF THE SAMPLES AND

3919
02:58:57,400 --> 02:58:59,600
THAT WERE SHIPPED IN THE LAST

3920
02:58:59,600 --> 02:59:01,240
FIVE YEARS.

3921
02:59:01,240 --> 02:59:04,320
THE CHTN IS AN OPEN RESOURCE IN

3922
02:59:04,320 --> 02:59:06,880
SEARCH OF THE ENTIRE SCIENTIFIC

3923
02:59:06,880 --> 02:59:10,320
COMMUNITY WITH A LOW PRIZE, LOW

3924
02:59:10,320 --> 02:59:13,400
BAR AND EASY ACCESS TO THE

3925
02:59:13,400 --> 02:59:14,120
SAMPLES.

3926
02:59:14,120 --> 02:59:17,640
NEXT SLIDE, PLEASE.

3927
02:59:17,640 --> 02:59:20,240
SO, THE CHTN CONTINUES TO WORK

3928
02:59:20,240 --> 02:59:25,080
WITH HIGH PRODUCTIVITY AND THIS

3929
02:59:25,080 --> 02:59:29,680
DATA REFERENCES TO FIVE YEARS,

3930
02:59:29,680 --> 02:59:32,360
2017-2021 AND OVER 1800

3931
02:59:32,360 --> 02:59:33,920
RESEARCHERS WERE SEARCHED, THREE

3932
02:59:33,920 --> 02:59:37,520
QUARTERS OF THEM WERE ACADEMIC

3933
02:59:37,520 --> 02:59:38,920
INVESTIGATORS, AND MOST OF THEM

3934
02:59:38,920 --> 02:59:41,040
ARE ONE GUARANTEE AND 23%

3935
02:59:41,040 --> 02:59:46,400
INVESTIGATORS IN INDUSTRY AND

3936
02:59:46,400 --> 02:59:48,440
OTHER GOVERNMENT IN INTRAMURAL

3937
02:59:48,440 --> 02:59:49,680
DOD.

3938
02:59:49,680 --> 02:59:53,440
ALSO, OVER 175,000 SAMPLES WERE

3939
02:59:53,440 --> 02:59:54,120
DISTRIBUTED.

3940
02:59:54,120 --> 02:59:56,280
YOU CAN SEE ON THE LEFT GRAPH,

3941
02:59:56,280 --> 02:59:58,160
THE DISTRIBUTION OF SAMPLES IN

3942
02:59:58,160 --> 03:00:01,960
THE LAST 10 YEARS, AND ON THE

3943
03:00:01,960 --> 03:00:06,200
RIGHT SIDE, YOU CAN SEE HALF THE

3944
03:00:06,200 --> 03:00:10,000
SAMPLES PRETTY MUCH WHY FRESH OR

3945
03:00:10,000 --> 03:00:11,400
FROZEN.

3946
03:00:11,400 --> 03:00:12,800
OVER 500 PUBLICATIONS WERE

3947
03:00:12,800 --> 03:00:14,400
GENERATED DURING THIS PERIOD

3948
03:00:14,400 --> 03:00:18,280
USING CHDN SAMPLES AND 55

3949
03:00:18,280 --> 03:00:20,080
PATENTS, MOST BY INDUSTRY BUT

3950
03:00:20,080 --> 03:00:26,720
ALSO WITH CONTRIBUTIONS BY AK

3951
03:00:26,720 --> 03:00:28,280
ACADEMIA, DESPITE THE PROBLEM

3952
03:00:28,280 --> 03:00:30,440
HAD TO FACE SOME CHALLENGES

3953
03:00:30,440 --> 03:00:34,440
DURING THIS PERIOD, DESPITE THE

3954
03:00:34,440 --> 03:00:36,120
INCREASED THAT WAS APPROVED FOR

3955
03:00:36,120 --> 03:00:39,440
FUNDING IN THE LAST

3956
03:00:39,440 --> 03:00:41,640
RECOMPETITION, THE POLICY OF

3957
03:00:41,640 --> 03:00:47,000
CUTS TO GRANTS OR RFAs LED TO

3958
03:00:47,000 --> 03:00:55,440
THE CURRENT FUNDING AND LAST ONE

3959
03:00:55,440 --> 03:00:58,960
WAS OPEN COMP FISSION AND ONE

3960
03:00:58,960 --> 03:01:01,640
DIVISION, THE SOUTHERN DIVISION

3961
03:01:01,640 --> 03:01:03,720
THE TEENS WAS WAS REPLACED AND

3962
03:01:03,720 --> 03:01:08,000
IT PROCESSES THAT MEANT

3963
03:01:08,000 --> 03:01:08,520
SIGNIFICANT EFFORTS AND

3964
03:01:08,520 --> 03:01:10,560
DIFFERENT LEVELS INCLUDING

3965
03:01:10,560 --> 03:01:13,560
TRAINING, AND RE-ASSIGNMENT OF

3966
03:01:13,560 --> 03:01:14,960
INVESTIGATORS, AND LEGAL

3967
03:01:14,960 --> 03:01:17,440
AGREEMENTS, AND HIRING.

3968
03:01:17,440 --> 03:01:19,920
AND OF COURSE, COVID IS MOST OF

3969
03:01:19,920 --> 03:01:24,160
SCIENCE AND IMPACTED THE

3970
03:01:24,160 --> 03:01:24,600
PROGRAM.

3971
03:01:24,600 --> 03:01:28,200
NEXT SLIDE, PLEASE.

3972
03:01:28,200 --> 03:01:36,520
AS I SAY, SOME DISTRIBUTED BY

3973
03:01:36,520 --> 03:01:39,920
CHDN AND UNIVERSITIES IN THE IN

3974
03:01:39,920 --> 03:01:40,960
CON HAVE THE CENTER

3975
03:01:40,960 --> 03:01:42,640
INVESTIGATORS AND OF COURSE

3976
03:01:42,640 --> 03:01:47,960
INTRAMURAL RESEARCHERS IN THE

3977
03:01:47,960 --> 03:01:51,040
RIGHT-OF-WAY WE INCLUDE AND WIDE

3978
03:01:51,040 --> 03:01:53,760
RANGE OF CURRENT HIGH-THROUGHPUT

3979
03:01:53,760 --> 03:01:56,800
TECHNOLOGIES AND IN WHICH

3980
03:01:56,800 --> 03:01:59,080
SAMPLES WERE USED FIVE YEARS AND

3981
03:01:59,080 --> 03:02:03,560
ALL THE WAY TO GENOMICS AND

3982
03:02:03,560 --> 03:02:05,840
TRANSCRIPT TOMB I CANS.

3983
03:02:05,840 --> 03:02:06,560
DEMONSTRATING THE HIGH-QUALITY

3984
03:02:06,560 --> 03:02:09,800
OF THE SAMPLES.

3985
03:02:09,800 --> 03:02:12,440
LAST YEAR, THE REVIEW WAS

3986
03:02:12,440 --> 03:02:15,360
CONDUCTED TO OUR PROGRAM FOR THE

3987
03:02:15,360 --> 03:02:19,880
CHTN WHICH REVIEWSERS FOR

3988
03:02:19,880 --> 03:02:23,080
BACKGROUNDS.

3989
03:02:23,080 --> 03:02:25,880
THERE WAS A HIGH VALUE FOR THE

3990
03:02:25,880 --> 03:02:27,320
RESEARCH COMMUNITIES AND

3991
03:02:27,320 --> 03:02:29,360
EMPHASIZING OUR ONE GUARANTEES

3992
03:02:29,360 --> 03:02:33,280
AND THE PROSPECTIVE MODEL PLACE

3993
03:02:33,280 --> 03:02:35,600
A KEY ROLE IN BASIC AND EARLY

3994
03:02:35,600 --> 03:02:37,040
TRANSLATIONAL RESEARCH AND AND

3995
03:02:37,040 --> 03:02:39,840
THERE WAS SUPPORT FOR A LIMITED

3996
03:02:39,840 --> 03:02:41,520
COMPETITION TO MAINTAIN THE DA

3997
03:02:41,520 --> 03:02:44,480
BILL TEE OF THE PROGRAM AND

3998
03:02:44,480 --> 03:02:48,680
REALLY THERE'S NO ALTERNATIVE TO

3999
03:02:48,680 --> 03:02:52,120
THE COMMERCIAL RESOURCES CANNOT

4000
03:02:52,120 --> 03:02:53,720
PLY THE FULL RANGE OF SERVICES

4001
03:02:53,720 --> 03:02:55,960
AND INCLUDING THE TYPES OF

4002
03:02:55,960 --> 03:03:05,960
SAMPLES AND THE PRICING.

4003
03:03:05,960 --> 03:03:11,040
GENRE PROPOSING UP TO SIX AWARDS

4004
03:03:11,040 --> 03:03:13,160
UNM GRANT AND AS I SAID THE

4005
03:03:13,160 --> 03:03:17,640
LIMITED COMPETITION PROVIDED WE

4006
03:03:17,640 --> 03:03:18,920
ALREADY HAVE ESTABLISHED A WELL

4007
03:03:18,920 --> 03:03:23,680
BUILT STRUCTURE AND THE CURRENT

4008
03:03:23,680 --> 03:03:25,840
FUNDING LEVEL IS 4.7 MILLION APE

4009
03:03:25,840 --> 03:03:28,160
YEAR AND YOU CAN SEE AT THE

4010
03:03:28,160 --> 03:03:32,760
BOTTOM HALF OF THE SLIDE MOST OF

4011
03:03:32,760 --> 03:03:35,120
THE 3.7 MILLION AND COVERS THE

4012
03:03:35,120 --> 03:03:37,400
COST OF THE PROCUREMENT AND

4013
03:03:37,400 --> 03:03:41,360
DISTRIBUTION OF SAME POLLS AND

4014
03:03:41,360 --> 03:03:45,240
THE REST IS USED FOR FUNCTIONS

4015
03:03:45,240 --> 03:03:49,280
THAT SUPPORT THE OPERATIONS AND

4016
03:03:49,280 --> 03:03:53,840
INCLUDING COORDINATION AND LOCAL

4017
03:03:53,840 --> 03:04:00,680
ID.

4018
03:04:00,680 --> 03:04:02,680
SO WE ARE QUESTIONING

4019
03:04:02,680 --> 03:04:04,200
6.2 MILLION A YEAR WITH

4020
03:04:04,200 --> 03:04:05,280
31 MILLION FOR FIVE YEARS FOR

4021
03:04:05,280 --> 03:04:14,320
SIX AWARDS AND IT'S JUSTIFIED BY

4022
03:04:14,320 --> 03:04:16,440
THE FACT THAT THERE'S BEEN

4023
03:04:16,440 --> 03:04:19,440
SIGNIFICANT INCREASE IN DEMAND

4024
03:04:19,440 --> 03:04:22,480
FOR MORE LABOR INTENSIVE

4025
03:04:22,480 --> 03:04:23,120
SAMPLES.

4026
03:04:23,120 --> 03:04:25,880
AND FRESH SAMPLES WHICH ARE

4027
03:04:25,880 --> 03:04:27,640
ACTUALLY THE MOST LABOR

4028
03:04:27,640 --> 03:04:29,760
INTENSIVE INCREASED DURING THE

4029
03:04:29,760 --> 03:04:33,920
FIVE YEARS 33% REQUESTS

4030
03:04:33,920 --> 03:04:35,360
INCLUDING CHART REVIEWS

4031
03:04:35,360 --> 03:04:38,800
INCREASED FROM 11% TO 16% OF ALL

4032
03:04:38,800 --> 03:04:40,560
THE REQUESTS.

4033
03:04:40,560 --> 03:04:42,200
THERE WAS A THREE-FOLD INCREASE

4034
03:04:42,200 --> 03:04:43,840
IN OTHER MORE DIFFICULT TO

4035
03:04:43,840 --> 03:04:46,680
FULFILL REQUESTS SUCH AS SHORT

4036
03:04:46,680 --> 03:04:50,200
ISCHEMIA TIME, FOR LABOR DATA,

4037
03:04:50,200 --> 03:04:54,720
AND HIGHER HUMOR CONTENT.

4038
03:04:54,720 --> 03:04:56,360
THERE WAS A TWO-FOLD IN THE

4039
03:04:56,360 --> 03:04:59,480
AMOUNT OF TMAs AND THE DEMANDS

4040
03:04:59,480 --> 03:05:01,200
FOR PROCUREMENT OF BLOOD

4041
03:05:01,200 --> 03:05:04,640
INCREASED IN COMPLEXITY AND

4042
03:05:04,640 --> 03:05:08,560
CTDNA AND CTCs TRIED TO.

4043
03:05:08,560 --> 03:05:12,160
SO OUR MAIN GOAL CONTINUES TO BE

4044
03:05:12,160 --> 03:05:14,320
TO SUPPLY THE ENTIRE RESEARCH

4045
03:05:14,320 --> 03:05:19,000
COMMUNITY WITH HIGH-QUALITY

4046
03:05:19,000 --> 03:05:26,120
SAMPLES.

4047
03:05:26,120 --> 03:05:29,320
GREAT, THANK YOU, VERY MUCH.

4048
03:05:29,320 --> 03:05:30,840
EXCELLENT PRESENTATION.

4049
03:05:30,840 --> 03:05:33,440
WE'LL GET STARTED ON THE

4050
03:05:33,440 --> 03:05:33,720
DISCUSSION.

4051
03:05:33,720 --> 03:05:35,000
>> YES.

4052
03:05:35,000 --> 03:05:40,320
SO SUZIE AND NELLY AND I MET

4053
03:05:40,320 --> 03:05:45,360
WITH EACH AND THAT WAS RODRIGO

4054
03:05:45,360 --> 03:05:46,880
AND AUDRYNA.

4055
03:05:46,880 --> 03:05:49,440
THERE WAS A VERY GOOD AND

4056
03:05:49,440 --> 03:05:52,040
THOROUGH -TZ OUTSIDE REVIEW THAT

4057
03:05:52,040 --> 03:06:02,680
WAS DONE THAT WAS LED BY Dr.

4058
03:06:02,680 --> 03:06:03,280
HOLLINGSWORTH AND WE TALKED

4059
03:06:03,280 --> 03:06:05,480
ABOUT A NUMBER OF ASPECTS.

4060
03:06:05,480 --> 03:06:06,960
WE HAD A NUMBER OF QUESTIONS

4061
03:06:06,960 --> 03:06:08,320
THAT WERE RAISED.

4062
03:06:08,320 --> 03:06:11,080
ONE OF THE MAJOR QUESTIONS WAS

4063
03:06:11,080 --> 03:06:21,600
YES, THIS IS DEIDENTIFIED DATA

4064
03:06:30,440 --> 03:06:31,240
SO WE HAD MADE ONE STRONG

4065
03:06:31,240 --> 03:06:34,320
SUGGESTION THAT THE RFA ACTUALLY

4066
03:06:34,320 --> 03:06:35,360
INCLUDED THAT THAT WOULD BE PART

4067
03:06:35,360 --> 03:06:39,680
OF WHAT WAS NEEDED.

4068
03:06:39,680 --> 03:06:43,360
THE FEELING WAS THERE'S A LOT OF

4069
03:06:43,360 --> 03:06:45,840
GOOD DATA THAT HAS BEEN HAD A

4070
03:06:45,840 --> 03:06:48,560
NUMBER OF ACADEMIC INSTITUTIONS,

4071
03:06:48,560 --> 03:06:50,400
I BELIEVE IT'S BETWEEN THREE AND

4072
03:06:50,400 --> 03:06:54,800
400 EACH YEAR.

4073
03:06:54,800 --> 03:07:00,000
YOU AWE 18 HUP INVESTIGATORS SO.

4074
03:07:00,000 --> 03:07:02,200
ONE OF THE QUESTIONS IS THE COST

4075
03:07:02,200 --> 03:07:03,960
ARE LOW AND WE'RE ALL WORRIED

4076
03:07:03,960 --> 03:07:14,320
ABOUT COST THESE DAYS.

4077
03:07:15,840 --> 03:07:21,640
THERE IT SHOULD BE LOOKED AT AND

4078
03:07:21,640 --> 03:07:22,680
THERE DOING THINGS THAT I DON'T

4079
03:07:22,680 --> 03:07:24,240
KNOW EXACTLY BUT THERE SHOULD BE

4080
03:07:24,240 --> 03:07:29,480
THE INDUSTRY THAT USES THIS HAVE

4081
03:07:29,480 --> 03:07:31,720
HAVE A LARGER PORTION OF THE

4082
03:07:31,720 --> 03:07:35,160
COST AND THEN WE WERE A

4083
03:07:35,160 --> 03:07:38,520
LITTLE -- THE GEOGRAPHIC

4084
03:07:38,520 --> 03:07:43,680
DISTRIBUTION IF APPROXIMATE THE

4085
03:07:43,680 --> 03:07:46,520
MATH IS TOTAL BUT ALL OF THE

4086
03:07:46,520 --> 03:07:48,760
INSTITUTIONS ARE EAST OF THE

4087
03:07:48,760 --> 03:07:51,800
MISSISSIPPI AND THE QUESTION IS

4088
03:07:51,800 --> 03:08:00,640
HOW EFFECTIVE ARE WE AT

4089
03:08:00,640 --> 03:08:02,280
DEVELOPING SAMPLING FROM A

4090
03:08:02,280 --> 03:08:05,800
EXPANDED GEOGRAPHICAL AREA.

4091
03:08:05,800 --> 03:08:07,560
THERE ARE PARTNERS FOR EACH ONE

4092
03:08:07,560 --> 03:08:10,880
OF THESE GROUPS AND WE DIDN'T

4093
03:08:10,880 --> 03:08:12,320
REALLY KNOW HOW WELL THAT WAS

4094
03:08:12,320 --> 03:08:16,080
BEING EFFECTED.

4095
03:08:16,080 --> 03:08:19,120
SO, WE DID FEEL THAT THE FOCUS

4096
03:08:19,120 --> 03:08:22,640
ON FRESH AND FROZEN SAMPLES WAS

4097
03:08:22,640 --> 03:08:25,120
PARTICULARLY APPROPRIATE.

4098
03:08:25,120 --> 03:08:32,280
MOST PEOPLE HAVE ACCESS TO FIXED

4099
03:08:32,280 --> 03:08:33,560
TISSUE SO WE THOUGHT IT WELCOME

4100
03:08:33,560 --> 03:08:35,600
BACK EMPHASIZED MORE IN THE RFA.

4101
03:08:35,600 --> 03:08:39,160
THOSE WERE MAJOR POINTS BUT I

4102
03:08:39,160 --> 03:08:40,360
THINK NELLY MAY HAVE HAD SOME

4103
03:08:40,360 --> 03:08:42,040
OTHER COMMUNITIES TOO THAT I

4104
03:08:42,040 --> 03:08:46,240
HAVE MISSED.

4105
03:08:46,240 --> 03:08:50,240
>> WELL, THANK YOU.

4106
03:08:50,240 --> 03:08:52,600
I THINK THERE'S A LOT THAT IS

4107
03:08:52,600 --> 03:08:54,640
VERY, VERY IMPORTANT ABOUT

4108
03:08:54,640 --> 03:08:56,080
BIOBANKING AND IT'S EXTREMELY

4109
03:08:56,080 --> 03:08:58,240
IMPORTANT FOR SUPPORTING RO1

4110
03:08:58,240 --> 03:09:00,880
TYPE OF RESEARCH AND WE HAD SOME

4111
03:09:00,880 --> 03:09:02,160
REALLY GOOD CONVERSATIONS

4112
03:09:02,160 --> 03:09:04,680
LOOKING ALSO AT HOW IS THE USE

4113
03:09:04,680 --> 03:09:07,280
DEVELOPED OVER TIME AND WHAT IS

4114
03:09:07,280 --> 03:09:13,640
REALLY PERHAPS THE GREATEST NEED

4115
03:09:13,640 --> 03:09:15,080
FOR THIS RESOURCE AND YEAH, I

4116
03:09:15,080 --> 03:09:25,640
THINK IT'S IMPORTANT TO CONSIDER

4117
03:09:31,520 --> 03:09:32,680
WHICH THOUGHT FOR AN INCREASE IN

4118
03:09:32,680 --> 03:09:34,880
THE BUDGET, THERE IS DEFINITELY

4119
03:09:34,880 --> 03:09:37,160
A POTENTIAL TO CONSIDER THE FEE

4120
03:09:37,160 --> 03:09:38,120
SCHEDULE FURTHER AND HOWEVER

4121
03:09:38,120 --> 03:09:39,880
THEY ALREADY ADAPTED THAT

4122
03:09:39,880 --> 03:09:42,880
SOMEWHAT AND I THINK THAT'S VERY

4123
03:09:42,880 --> 03:09:43,400
HELPFUL.

4124
03:09:43,400 --> 03:09:45,920
AND YOU KNOW, MAYBE SOME

4125
03:09:45,920 --> 03:09:46,760
STRATEGIC PLANNING WOULD BE

4126
03:09:46,760 --> 03:09:48,560
HELPFUL FOR THE FUTURE OF

4127
03:09:48,560 --> 03:09:51,680
THINKING HOW COULD THIS BESTFUL

4128
03:09:51,680 --> 03:09:53,840
FIST IN THE SCOPE OF OTHER BIO

4129
03:09:53,840 --> 03:09:55,000
REPOSITORIES THAT EXIST AND I

4130
03:09:55,000 --> 03:10:03,720
THINK OF THERE'S NO COMMERCIAL

4131
03:10:03,720 --> 03:10:05,120
SUPPORTED BUT FIXED TISSUE ARE

4132
03:10:05,120 --> 03:10:06,520
MORE EASILY AVAILABLE THESE DAYS

4133
03:10:06,520 --> 03:10:08,440
AND I THINK THAT THIS EMPHASIZE

4134
03:10:08,440 --> 03:10:12,720
ON FRESH FROZEN AND OTHER

4135
03:10:12,720 --> 03:10:14,000
SAMPLES THAT ARE REALLY

4136
03:10:14,000 --> 03:10:15,920
DIFFICULT TO OBTAIN SOMETHING

4137
03:10:15,920 --> 03:10:18,640
WHERE THERE'S A UNIQUE NICHE FOR

4138
03:10:18,640 --> 03:10:20,200
THIS RESOURCE.

4139
03:10:20,200 --> 03:10:21,880
SO, THERE WAS ALSO MENTIONED OF

4140
03:10:21,880 --> 03:10:23,520
INCREASING DIGITAL PATHOLOGY

4141
03:10:23,520 --> 03:10:26,400
WHICH THE PRIOR REVIEWERS LIKED

4142
03:10:26,400 --> 03:10:28,800
AND THOUGHT IT WOULD BE HELPFUL.

4143
03:10:28,800 --> 03:10:29,960
THERE WERE SOME PLANS OF

4144
03:10:29,960 --> 03:10:32,920
ADDITIONAL FOLLOW-UP IN CHART

4145
03:10:32,920 --> 03:10:34,480
OBSTRUCTION BY THE PRIOR

4146
03:10:34,480 --> 03:10:35,520
REVIEWERS THOUGHT IT WAS NOT THE

4147
03:10:35,520 --> 03:10:37,640
BEST USE OF MONEY FOR THIS NEXT

4148
03:10:37,640 --> 03:10:40,960
RFA SO OVER ALL, ALSO, I DON'T

4149
03:10:40,960 --> 03:10:44,400
WANT TO SAY I'VE BEEN IMPRESSED

4150
03:10:44,400 --> 03:10:47,240
THAT THIS RESOURCE HAS BEEN

4151
03:10:47,240 --> 03:10:50,120
REALLY ABLE TO SERVE THE BROADER

4152
03:10:50,120 --> 03:10:51,600
COMMUNITY ABOUT 40% OF THE

4153
03:10:51,600 --> 03:10:56,080
CURRENT USE IS GOING TO THE

4154
03:10:56,080 --> 03:10:58,360
INSTITUTIONS THAT HOLD ONE OF

4155
03:10:58,360 --> 03:11:01,440
THESE GRANTS BUT 60% DON'T AND

4156
03:11:01,440 --> 03:11:04,120
MAYBE FURTHER ADVERTISING AND

4157
03:11:04,120 --> 03:11:05,560
MAKING THIS KNOWN VERY WELL, NOT

4158
03:11:05,560 --> 03:11:08,520
JUST ON THE WEBSITE, WILL HELP

4159
03:11:08,520 --> 03:11:10,080
TO MAKE SURE THAT IT CONTINUES

4160
03:11:10,080 --> 03:11:12,400
AS A VERY IMPORTANT RESOURCE.

4161
03:11:12,400 --> 03:11:13,840
SO, OFFER ALL WE REALLY

4162
03:11:13,840 --> 03:11:14,800
APPRECIATE THE RESPONSIVENESS

4163
03:11:14,800 --> 03:11:17,480
AND THE PROVISION OF EXTRA DATA.

4164
03:11:17,480 --> 03:11:21,840
WE DO FEEL LIKE DIVERSITY IN

4165
03:11:21,840 --> 03:11:23,320
REPRESENTATIVENESS IS IMPORTANT

4166
03:11:23,320 --> 03:11:26,080
AND THAT WAS NOT SOMETHING YET

4167
03:11:26,080 --> 03:11:26,560
CONSIDERED.

4168
03:11:26,560 --> 03:11:28,560
>> THANK YOU.

4169
03:11:28,560 --> 03:11:31,920
ANY FURTHER DISCUSSION?

4170
03:11:31,920 --> 03:11:39,000
GO AHEAD, MARC.

4171
03:11:39,000 --> 03:11:41,160
>> I MIGHT HAVE MISSED IT
BUT IN

4172
03:11:41,160 --> 03:11:42,240
TERMS OF THE REQUEST FOR

4173
03:11:42,240 --> 03:11:47,880
INCREASING THE BUDGET, IT A

4174
03:11:47,880 --> 03:11:48,680
PREPORTION AIM CREASE OR IS

4175
03:11:48,680 --> 03:11:50,480
THERE MORE EFFICIENCY GAINED AND

4176
03:11:50,480 --> 03:11:52,840
MOST OF THAT BUDGET GOES INTO

4177
03:11:52,840 --> 03:11:53,960
TISSUE ACQUISITION OR HOW DOES

4178
03:11:53,960 --> 03:11:58,000
THAT PLAY OUT?

4179
03:11:58,000 --> 03:12:01,000
IN TERMS OF THAT INCREASE.

4180
03:12:01,000 --> 03:12:05,520
ADMIN COST VERSUS SPECIMEN?

4181
03:12:05,520 --> 03:12:13,400
>> THE PROCUREMENT AND
LABOR TO

4182
03:12:13,400 --> 03:12:16,360
DISTRIBUTE THE SPECIMENS, YEAH.

4183
03:12:16,360 --> 03:12:19,880
>> MAYBE WE COULD ADD AT
THIS

4184
03:12:19,880 --> 03:12:22,360
POINT THERE'S AN EQUAL FEE FOR

4185
03:12:22,360 --> 03:12:25,160
FIXED ISSUE VERSUS FRESH FROZEN

4186
03:12:25,160 --> 03:12:26,320
TISSUE SO THAT WOULD BE AN

4187
03:12:26,320 --> 03:12:28,480
OPPORTUNITY TO CONSIDER IF THERE

4188
03:12:28,480 --> 03:12:31,600
IS A GREATER WORKLOAD INVOLVED

4189
03:12:31,600 --> 03:12:33,200
TO, YOU KNOW, NOT TO MICRO

4190
03:12:33,200 --> 03:12:38,200
MANAGE THIS OF COURSE.

4191
03:12:38,200 --> 03:12:40,720
>> I'M UNCLEAR, IS THIS
JUST

4192
03:12:40,720 --> 03:12:42,480
STANDARD TISSUE BANKING?

4193
03:12:42,480 --> 03:12:45,960
YOU KNOW, AMONG PATIENTS WHO

4194
03:12:45,960 --> 03:12:48,440
GETS NIPPING REMOVED DURING

4195
03:12:48,440 --> 03:12:49,120
CLINICAL CARE?

4196
03:12:49,120 --> 03:12:50,920
OR IS THERE ANY OTHER CRITERIA

4197
03:12:50,920 --> 03:12:55,000
THAT ARE PUT ON WHAT TISSUE IS

4198
03:12:55,000 --> 03:12:56,440
COLLECTED, TISSUE OR BLOOD IT

4199
03:12:56,440 --> 03:12:57,360
SOUNDS LIKE?

4200
03:12:57,360 --> 03:13:00,600
>> IN THIS SIX PRIMARY

4201
03:13:00,600 --> 03:13:04,480
INSTITUTIONS, ANY OF SURGERY

4202
03:13:04,480 --> 03:13:12,840
THAT GENERATES IS CONSIDERED, A

4203
03:13:12,840 --> 03:13:23,400
CANDIDATE TO BE A SAMPLE AND ARE

4204
03:13:26,480 --> 03:13:36,960
STORED BECAUSE MOST OF THE MOST

4205
03:13:40,040 --> 03:13:40,880
IS PROTUREMENT.

4206
03:13:40,880 --> 03:13:41,320
>> THANK YOU.

4207
03:13:41,320 --> 03:13:45,240
>> NO OTHER HANDS.

4208
03:13:45,240 --> 03:13:49,080
WE CAN MOVE TO VOTING.

4209
03:13:49,080 --> 03:13:51,680
SO, SHELLY IT SOUNDS LIKE YOU

4210
03:13:51,680 --> 03:13:52,960
ARE IN A FAVORABLE DIRECTION,

4211
03:13:52,960 --> 03:13:54,200
WOULD YOU LIKE TO MAKE A MOTION?

4212
03:13:54,200 --> 03:13:56,200
>> YES, I WOULD LIKE TO
MAKE A

4213
03:13:56,200 --> 03:13:59,120
MOTION TO APPROVE.

4214
03:13:59,120 --> 03:14:05,640
PARTICULARLY WITH THE ADDITION

4215
03:14:05,640 --> 03:14:09,240
OF.

4216
03:14:09,240 --> 03:14:10,800
>> I'M TRANSLATE THAT INTO
A

4217
03:14:10,800 --> 03:14:16,000
MOTION TO CONCUR SINCE THIS IS A

4218
03:14:16,000 --> 03:14:16,280
REISSUANCE.

4219
03:14:16,280 --> 03:14:22,600
>> CAN I GET A SECOND ON
THAT?

4220
03:14:22,600 --> 03:14:26,640
>> ANY FURTHER AND HE?

4221
03:14:26,640 --> 03:14:34,360
>> OTHER OF HE DIDN'T JOIN
THE

4222
03:14:34,360 --> 03:14:42,040
IN-PERSON AND WHO HAD A CONFLICT

4223
03:14:42,040 --> 03:14:52,120
AND.

4224
03:14:56,200 --> 03:14:57,840
>> L YOU HAVE THE FIVE

4225
03:14:57,840 --> 03:14:58,280
EXTENSIONS I GATHER.

4226
03:14:58,280 --> 03:15:08,800
>> YES, I'LL ALL THEIR
NAMES.

4227
03:15:09,720 --> 03:15:20,000
>> WHO HAVE OBTAINED.

4228
03:15:25,360 --> 03:15:28,880
SO THE VOTE IS 21 CONCUR AND

4229
03:15:28,880 --> 03:15:31,720
ZERO NAYs AND FIVE

4230
03:15:31,720 --> 03:15:32,880
ABSTENTIONS.

4231
03:15:32,880 --> 03:15:35,720
>> Dr. Flaherty: GREAT.

4232
03:15:35,720 --> 03:15:38,040
THANK YOU.

4233
03:15:38,040 --> 03:15:43,120
ONE MORE CONCEPT A NEW RFP.

4234
03:15:43,120 --> 03:15:48,040
AND SBIR CONTRACT TOPICS AND

4235
03:15:48,040 --> 03:15:51,280
Dr. MONDAY E MONIQUE POND WILL T

4236
03:15:51,280 --> 03:15:55,240
AND SUPPORTED BY MYSELF AND

4237
03:15:55,240 --> 03:15:56,600
DAVID ALL OF WHOM WERE ALL

4238
03:15:56,600 --> 03:15:58,240
PRESENT FOR THE DISCUSSION WHEN

4239
03:15:58,240 --> 03:15:59,640
THE TIME COMES.

4240
03:15:59,640 --> 03:16:05,760
SO, MO MONIQUE, GO AHEAD WITH YR

4241
03:16:05,760 --> 03:16:08,480
PRESENTATION.

4242
03:16:08,480 --> 03:16:09,840
>> GOOD AFTERNOON,
EVERYONE,

4243
03:16:09,840 --> 03:16:10,800
THANK YOU FOR YOUR TIME.

4244
03:16:10,800 --> 03:16:13,200
I'LL BE PRESENTING THE SBIR

4245
03:16:13,200 --> 03:16:18,600
TOPICS FOR FY2024 ON BEHALF OF

4246
03:16:18,600 --> 03:16:28,280
OUR OFFICE.

4247
03:16:28,280 --> 03:16:30,880
AND STTR PROGRAM IS CONGRESS

4248
03:16:30,880 --> 03:16:32,760
LEHMAN DATING SET ASIDE THAT IS

4249
03:16:32,760 --> 03:16:34,560
REQUIRED BY FEDERAL AGENCY

4250
03:16:34,560 --> 03:16:36,680
THAT'S HAVE RND BUDGETS THAT

4251
03:16:36,680 --> 03:16:38,240
EXCEED A CERTAIN SIZE.

4252
03:16:38,240 --> 03:16:41,000
AND HERE AT NCI WE UTILIZE BOTH

4253
03:16:41,000 --> 03:16:42,280
OF GRANTS AND CONTRACT

4254
03:16:42,280 --> 03:16:46,400
MECHANISMS FOR FUNDING SO IN

4255
03:16:46,400 --> 03:16:52,960
FY202222022, 20% WENT TOWARDS.

4256
03:16:52,960 --> 03:16:55,080
WE DON'T PRESCRIBE A SET DOLLAR

4257
03:16:55,080 --> 03:16:56,720
AMOUNT TO SPEND ON GRANTS FIRST

4258
03:16:56,720 --> 03:16:58,400
OF CONTRACTS INSTEAD WE FOCUS ON

4259
03:16:58,400 --> 03:17:00,200
FUNDING THE BEST TRANSLATIONAL

4260
03:17:00,200 --> 03:17:01,400
SCIENCE AND THAT ARE HELP

4261
03:17:01,400 --> 03:17:04,640
PATIENTS WITH CANCER.

4262
03:17:04,640 --> 03:17:05,880
WITH THE CONTRACT MECHANISM,

4263
03:17:05,880 --> 03:17:08,680
WE'RE ABLE TO DEFINE NARROWLY

4264
03:17:08,680 --> 03:17:09,680
FOCUSED TOPICS THAT HAVE

4265
03:17:09,680 --> 03:17:10,720
SPECIFIC PRODUCT DEVELOPMENT

4266
03:17:10,720 --> 03:17:12,880
GOALS AND MILESTONES AND THIS IS

4267
03:17:12,880 --> 03:17:15,520
IN CONTRAST TO THE GRANTS

4268
03:17:15,520 --> 03:17:16,560
MECHANISM WHERE WE FIND

4269
03:17:16,560 --> 03:17:18,480
INVESTIGATOR INITIATED PRODUCT

4270
03:17:18,480 --> 03:17:19,120
DEVELOPMENT.

4271
03:17:19,120 --> 03:17:20,480
AND I JUST WANT TO NOTE HERE

4272
03:17:20,480 --> 03:17:22,160
THAT THE MONEY USED TO FUND

4273
03:17:22,160 --> 03:17:23,840
THESE SMALL BUSINESS AWARDS,

4274
03:17:23,840 --> 03:17:25,640
EITHER THROUGH GRANTS OR

4275
03:17:25,640 --> 03:17:30,040
CONTRACTS, DOES NOT EFFECT THE

4276
03:17:30,040 --> 03:17:38,240
RPG POOL.

4277
03:17:38,240 --> 03:17:41,200
>> SOMETIMES TOPICS
DEVELOP TO

4278
03:17:41,200 --> 03:17:45,280
ADDRESS A SPECIFIC NEED BY THE

4279
03:17:45,280 --> 03:17:47,640
CANCER COMMUNITY AND WE

4280
03:17:47,640 --> 03:17:48,600
STIMULATE COMMERCIALIZATION OF

4281
03:17:48,600 --> 03:17:49,440
PRODUCTS IN CERTAIN AREAS AND

4282
03:17:49,440 --> 03:17:51,200
THIS WOULD BE A RELATIVELY NEW

4283
03:17:51,200 --> 03:17:52,920
AREA OF RESEARCH WHERE WE WANT

4284
03:17:52,920 --> 03:17:55,400
TO STIMULATE TRANSLATION OF

4285
03:17:55,400 --> 03:17:56,800
SCIENCE INTO PRODUCTS FOR

4286
03:17:56,800 --> 03:17:58,120
PATIENTS AND OR IT COULD BE TO

4287
03:17:58,120 --> 03:18:00,840
SUPPORT DEVELOPMENT OF PRODUCTS

4288
03:18:00,840 --> 03:18:02,400
THAT IS A PARTICULARLY

4289
03:18:02,400 --> 03:18:06,520
CHALLENGING AREA OF HIGH IMAGE.

4290
03:18:06,520 --> 03:18:08,400
LASTLY WE USED THE CONTRACT

4291
03:18:08,400 --> 03:18:10,040
MECHANISM TO ADDRESS IMPORTANT

4292
03:18:10,040 --> 03:18:13,280
CANCER INDICATIONS OR PATIENT

4293
03:18:13,280 --> 03:18:14,760
POPULATIONS UNDER REPRESENTED IN

4294
03:18:14,760 --> 03:18:15,600
OUR PORTFOLIO.

4295
03:18:15,600 --> 03:18:18,280
SO SIMILAR TO THE GRANT

4296
03:18:18,280 --> 03:18:19,920
APPLICATION CONTRACT PROPOSALS

4297
03:18:19,920 --> 03:18:23,200
UNDER GO A RIGOROUS PEER REVIEW

4298
03:18:23,200 --> 03:18:23,680
PROCESS.

4299
03:18:23,680 --> 03:18:24,880
ONE MAIN DIFFERENCE IS CONTRACT

4300
03:18:24,880 --> 03:18:27,000
REVIEWS ARE CONDUCTED BY THE NCI

4301
03:18:27,000 --> 03:18:28,960
DIVISION OF EXTRAMURAL

4302
03:18:28,960 --> 03:18:30,160
ACTIVITIES INSTEAD OF NIH CENTER

4303
03:18:30,160 --> 03:18:32,480
FOR SCIENTIFIC REVIEW.

4304
03:18:32,480 --> 03:18:34,520
IN ADDITION, CONTRACT PROPOSALS

4305
03:18:34,520 --> 03:18:36,640
IN ORDER TO BE SUCCESSFUL, THEY

4306
03:18:36,640 --> 03:18:39,320
REALLY MUST ALIGN WITH THIS

4307
03:18:39,320 --> 03:18:41,000
SPECIFIC TOPIC AS WELL AS THE

4308
03:18:41,000 --> 03:18:42,240
DELIVERABLES THAT ARE DETAILED

4309
03:18:42,240 --> 03:18:44,960
IN THE SOLICITATION.

4310
03:18:44,960 --> 03:18:47,240
SO, WHILE WE PROVIDE AND YOU

4311
03:18:47,240 --> 03:18:48,520
PROBABLY NOTICED IN THE WRITE

4312
03:18:48,520 --> 03:18:50,280
UPS WE HAVE AN ESTIMATE OF THE

4313
03:18:50,280 --> 03:18:53,000
NUMBER OF PROPOSALS THAT WE

4314
03:18:53,000 --> 03:18:55,160
MIGHT FUND UNDER A IT PARTICULAR

4315
03:18:55,160 --> 03:18:57,040
TOPIC THEY HELP US WITH BUDGET

4316
03:18:57,040 --> 03:18:58,280
PLANNING.

4317
03:18:58,280 --> 03:18:59,520
IF WE DON'T RECEIVE ANY STRONG

4318
03:18:59,520 --> 03:19:00,520
PROPOSALS FOR A PARTICULAR

4319
03:19:00,520 --> 03:19:02,120
CONTRACT TOPIC, WE WON'T FUND

4320
03:19:02,120 --> 03:19:04,680
ANY PROPOSALS UNDER THAT TOPIC

4321
03:19:04,680 --> 03:19:06,200
AND THE BUDGETED FUNDING WILL

4322
03:19:06,200 --> 03:19:08,120
JUSTING USED TO SUPPORT

4323
03:19:08,120 --> 03:19:12,040
ADDITIONAL MAR TO BE YUS GRANT

4324
03:19:12,040 --> 03:19:12,400
APPLICATIONS.

4325
03:19:12,400 --> 03:19:16,840
NEXT SLIDE, PLEASE.

4326
03:19:16,840 --> 03:19:18,640
BEFORE I PRESENT THE TOPICS I

4327
03:19:18,640 --> 03:19:20,040
WOULD JUST LIKE TO GIVE YOU A

4328
03:19:20,040 --> 03:19:22,400
SHORT SUMMARY OF OUR PROCESS FOR

4329
03:19:22,400 --> 03:19:23,680
CONTRACT TOPIC DEVELOPMENT.

4330
03:19:23,680 --> 03:19:25,120
EVERY OCTOBER WE SO MANY IS ITS

4331
03:19:25,120 --> 03:19:26,680
NEW CONTRACT TOPIC ITEMS FROM

4332
03:19:26,680 --> 03:19:29,640
ACROSS THE NCI DIVISION OFFICES

4333
03:19:29,640 --> 03:19:30,880
ASK CENTERS AND WE RECEIVED

4334
03:19:30,880 --> 03:19:32,840
THESE NEW TOPICS ITEMS FOR

4335
03:19:32,840 --> 03:19:35,320
SUBJECT MATTER EXPERTS THIS

4336
03:19:35,320 --> 03:19:37,800
COULD INCLUDE THE NCI DIRECTOR,

4337
03:19:37,800 --> 03:19:42,000
DIVISION DIRECTORS, WORD PROGRAM

4338
03:19:42,000 --> 03:19:42,840
OFFICERS AS WELL.

4339
03:19:42,840 --> 03:19:44,080
BEGINNING THREE YEARS A. WE

4340
03:19:44,080 --> 03:19:50,440
STARTED COM AB RATISTART GETTINS

4341
03:19:50,440 --> 03:19:59,560
FOR TOPICS AS WELL.

4342
03:19:59,560 --> 03:20:03,240
FOR FY2024, WE RECEIVED 18

4343
03:20:03,240 --> 03:20:04,920
CONTRACT TOPIC IDEAS COMMISSIONS

4344
03:20:04,920 --> 03:20:07,560
AND THAT CAME FROM ACROSS NCI.

4345
03:20:07,560 --> 03:20:09,680
AND AS PART OF EACH COMMISSION,

4346
03:20:09,680 --> 03:20:12,280
TOPIC AUTHORS DO A PORTFOLIO

4347
03:20:12,280 --> 03:20:15,600
ANALYSIS THAT DETAILS BOTH NCI

4348
03:20:15,600 --> 03:20:17,360
AND NIH FUNDING IN THAT

4349
03:20:17,360 --> 03:20:18,600
PARTICULAR SCIENTIFIC AREA.

4350
03:20:18,600 --> 03:20:21,800
AND THIS ALSO INCLUDES FUNDING

4351
03:20:21,800 --> 03:20:25,400
THROUGH SBIR OR NON SBIR

4352
03:20:25,400 --> 03:20:26,800
MECHANISMS.

4353
03:20:26,800 --> 03:20:28,000
THIS MISSION GOES TO OUR

4354
03:20:28,000 --> 03:20:28,920
TECHNOLOGY ADVISORY GROUP WHERE

4355
03:20:28,920 --> 03:20:31,560
THEY'RE REVIEWED AND DISCUSSED

4356
03:20:31,560 --> 03:20:32,160
AND SCORED.

4357
03:20:32,160 --> 03:20:34,080
WE HAVE TWO GROUPS, EACH FOCUSED

4358
03:20:34,080 --> 03:20:38,520
ON REVIEWING TOPICS AND CERTAIN

4359
03:20:38,520 --> 03:20:43,160
SCIENTIFIC AREAS.

4360
03:20:43,160 --> 03:20:44,760
TECHNOLOGIES AND WHILE TAG 2

4361
03:20:44,760 --> 03:20:46,600
REVIEWS RADIATION THERAPY,

4362
03:20:46,600 --> 03:20:50,120
MEDICAL DEVICES AND HEALTH IT

4363
03:20:50,120 --> 03:20:50,640
TECHNOLOGIES.

4364
03:20:50,640 --> 03:20:51,880
THESE TAGS ARE COMPOSED OF

4365
03:20:51,880 --> 03:20:54,600
SUBJECT MATTER EXPERTS IN THE

4366
03:20:54,600 --> 03:20:57,360
SPECIFIC AREAS FROM ACROSS NCI

4367
03:20:57,360 --> 03:20:59,040
IN ADDITION TO THE PROGRAM

4368
03:20:59,040 --> 03:21:01,920
DIRECTORS IN THE SBIR OFFICE.

4369
03:21:01,920 --> 03:21:04,000
SO THIS YEAR 11 OF THE 18 TOPICS

4370
03:21:04,000 --> 03:21:05,480
WERE SELECTED TO MOVE FORWARD

4371
03:21:05,480 --> 03:21:09,920
FOR REVIEW BY OF SCIENTIFIC

4372
03:21:09,920 --> 03:21:17,560
PROGRAM LEADS.

4373
03:21:17,560 --> 03:21:22,800
BY THE COORDINATING COMMITTEE AS

4374
03:21:22,800 --> 03:21:26,840
HAVING MOONSHOT REL CONVENIENCE.

4375
03:21:26,840 --> 03:21:29,200
I JUST WANT TO NOTE ADDITIONAL

4376
03:21:29,200 --> 03:21:30,600
INFORMATION IS THERE ON EACH

4377
03:21:30,600 --> 03:21:41,120
TOPIC IN THE ONE PAGE WRITE-UP.

4378
03:21:42,960 --> 03:21:44,080
SO THE FIRST TOPIC FOR

4379
03:21:44,080 --> 03:21:45,880
CONSIDERATION IS THE DEVELOPMENT

4380
03:21:45,880 --> 03:21:48,080
OF ULTRAFAST DOSE RATE RADIATION

4381
03:21:48,080 --> 03:21:49,760
DETECTORS AND SAFETY SYSTEMS FOR

4382
03:21:49,760 --> 03:21:50,480
CANCER TREATMENT.

4383
03:21:50,480 --> 03:21:52,280
AND THE GOAL OF THIS TOP SICK TO

4384
03:21:52,280 --> 03:21:54,960
DEVELOP DEVICE THAT'S CAN

4385
03:21:54,960 --> 03:21:57,440
DELIVER TO PATIENTS SAFELY AND

4386
03:21:57,440 --> 03:21:58,880
EFFECTIVELY IN A CLINICAL

4387
03:21:58,880 --> 03:22:00,400
SETTING AND WITH THIS REQUEST,

4388
03:22:00,400 --> 03:22:02,160
WE'RE FOCUSED ON RADIATION

4389
03:22:02,160 --> 03:22:03,800
DETECTORS THAT CAN RELIABLY

4390
03:22:03,800 --> 03:22:06,800
FUNCTION AT DOSE RATES OF 40 TO

4391
03:22:06,800 --> 03:22:08,240
120 PER SECOND AND ALSO INCLUDE

4392
03:22:08,240 --> 03:22:10,640
SAFETY SYSTEMS CAPABLE OF

4393
03:22:10,640 --> 03:22:13,480
RECORDING DELIVERY AND SHUTTING

4394
03:22:13,480 --> 03:22:15,920
OFF DURING SLASH THERAPY IF

4395
03:22:15,920 --> 03:22:16,520
NEEDED.

4396
03:22:16,520 --> 03:22:18,560
THE PREVIOUSLY FUNDED PROPOSALS

4397
03:22:18,560 --> 03:22:21,280
WERE SUCCESSFUL AND LED TO THE

4398
03:22:21,280 --> 03:22:23,280
DEVELOPMENT OF TECHNICALLY

4399
03:22:23,280 --> 03:22:24,560
SUFFICIENT DETECTORS AND WE LIKE

4400
03:22:24,560 --> 03:22:27,120
COMPANIES TO EXPAND POP THESE

4401
03:22:27,120 --> 03:22:29,680
DETECTORS TO FULLY DEVELOP THE

4402
03:22:29,680 --> 03:22:32,360
SAFETY SYSTEM THAT GO WITH THEM.

4403
03:22:32,360 --> 03:22:34,040
SO THESE PRODUCTS WE SEE HAVE

4404
03:22:34,040 --> 03:22:35,680
THE POTENTIAL TO SIGNIFICANTLY

4405
03:22:35,680 --> 03:22:37,960
DECREASE NORMAL TISSUE TOXICITY

4406
03:22:37,960 --> 03:22:41,280
AND THEY MIGHT DELIVER

4407
03:22:41,280 --> 03:22:42,880
THERAPEUTIC BENEFITS TO PATIENTS

4408
03:22:42,880 --> 03:22:46,520
AVOIDING SOME OF THE SIDE

4409
03:22:46,520 --> 03:22:51,200
EFFECTS.

4410
03:22:51,200 --> 03:22:53,200
SO NOW I WILL SUMMARIZE SIX

4411
03:22:53,200 --> 03:22:54,360
POTENTIAL CONTRACT TOPICS IN THE

4412
03:22:54,360 --> 03:22:57,080
AREA OF CLINICAL DIAGNOSTICS AND

4413
03:22:57,080 --> 03:22:58,040
MOLECULAR ANALYSIS.

4414
03:22:58,040 --> 03:23:00,080
AS A GOAL OF THIS TOPIC,

4415
03:23:00,080 --> 03:23:03,560
TECHNOLOGY IS FOR DETECTING

4416
03:23:03,560 --> 03:23:05,600
TUMOR DERIVED AND SUPPORT IN

4417
03:23:05,600 --> 03:23:07,440
VITRO TECHNOLOGY THAT CAN

4418
03:23:07,440 --> 03:23:11,600
ENUMERATE AND IDENTIFY CELL

4419
03:23:11,600 --> 03:23:12,400
TYPES.

4420
03:23:12,400 --> 03:23:13,760
CURRENTLY THERE ARE VERY FEW

4421
03:23:13,760 --> 03:23:16,280
MARKERS AVAILABLE FOR PREDICTING

4422
03:23:16,280 --> 03:23:18,080
METASTATIC RISK AND ACCUMULATING

4423
03:23:18,080 --> 03:23:19,400
EVIDENCE THAT SUGGEST THAT THESE

4424
03:23:19,400 --> 03:23:21,400
CLUSTERS MAY BE AN IMPORTANT

4425
03:23:21,400 --> 03:23:25,240
FACTOR AND MAT METASTASIS AND

4426
03:23:25,240 --> 03:23:28,120
ASSOCIATED WITH CO PROGRESS FOR

4427
03:23:28,120 --> 03:23:29,440
SURVIVAL AND OVER ALL SURVIVAL

4428
03:23:29,440 --> 03:23:31,560
OF PATIENTS.

4429
03:23:31,560 --> 03:23:33,760
AND PHASE 1, COMPANIES WITH USE

4430
03:23:33,760 --> 03:23:36,400
ANIMAL CANCER MODELS TO

4431
03:23:36,400 --> 03:23:39,600
DEMONSTRATE USABILITY AND

4432
03:23:39,600 --> 03:23:46,920
ACCURACY.

4433
03:23:46,920 --> 03:23:49,480
MUCH WE BELIEVE THAT

4434
03:23:49,480 --> 03:23:50,800
TECHNOLOGIES THAT COULD STATIC

4435
03:23:50,800 --> 03:23:52,240
RISK EARLY ON THEY HAVE THE

4436
03:23:52,240 --> 03:23:55,960
POTENTIAL TO FACILITATE PROMPT

4437
03:23:55,960 --> 03:23:56,760
INTERVENTIONS AND PARTICULAR

4438
03:23:56,760 --> 03:24:03,840
IMPROVE CANCER OUTCOMES.

4439
03:24:03,840 --> 03:24:05,840
THE NEXT TOPIC, RAPID AND A

4440
03:24:05,840 --> 03:24:08,560
FORWARD ABLE POINT OF CARE

4441
03:24:08,560 --> 03:24:10,920
DIAGNOSTIC FOR CERVICAL CANCER

4442
03:24:10,920 --> 03:24:12,200
CONTROL.

4443
03:24:12,200 --> 03:24:15,000
AIMS TO DEVELOP TESTING AS AN

4444
03:24:15,000 --> 03:24:16,440
APPROPRIATE PRICE THAT WILL

4445
03:24:16,440 --> 03:24:18,480
ENABLE THE ESTABLISHMENT OF

4446
03:24:18,480 --> 03:24:20,640
SELF-TESTING PROGRAMS GLOBALLY.

4447
03:24:20,640 --> 03:24:22,240
SO THESE TECHNOLOGIES ARE

4448
03:24:22,240 --> 03:24:23,840
CRITICAL COMPONENTS OF THE WORLD

4449
03:24:23,840 --> 03:24:25,960
HEALTH ORGANIZATIONS CERVICAL

4450
03:24:25,960 --> 03:24:28,080
CANCER ELIMINATION STRATEGY

4451
03:24:28,080 --> 03:24:29,720
WHICH IS FOCUSED ON ADDRESSING

4452
03:24:29,720 --> 03:24:32,320
HEALTH DISPARITIES AND RESOURCE

4453
03:24:32,320 --> 03:24:35,320
SETTINGS AND FOR HPV SCREENING.

4454
03:24:35,320 --> 03:24:37,120
AND WHILE SOME PLATFORMS HAVE

4455
03:24:37,120 --> 03:24:40,560
BEEN DEVELOPED FOR HPV TESTING,

4456
03:24:40,560 --> 03:24:43,880
THERE'S STILL REMAI REMAINS A NR

4457
03:24:43,880 --> 03:24:46,480
RAPID POINT OF CARE TESTING

4458
03:24:46,480 --> 03:24:48,160
CAPABILITIES SO IN ORDER TO

4459
03:24:48,160 --> 03:24:50,160
FOCUS NCI RESOURCES ON

4460
03:24:50,160 --> 03:24:51,040
TECHNOLOGIES THAT ARE FURTHER

4461
03:24:51,040 --> 03:24:55,000
ALONG IN DEVELOPMENT, IT COULD

4462
03:24:55,000 --> 03:24:57,320
BE MODIFIED TO MEET THESE NEEDS

4463
03:24:57,320 --> 03:24:58,440
AND THIN COMMERCIALIZE RAPIDLY

4464
03:24:58,440 --> 03:25:00,560
AND THIS TOPIC WILL ONLY HAVE

4465
03:25:00,560 --> 03:25:04,360
(INAUDIBLE) TO THESE TWO

4466
03:25:04,360 --> 03:25:09,960
PROPOSALS.

4467
03:25:09,960 --> 03:25:11,520
THE NEXT TOPIC IS THE

4468
03:25:11,520 --> 03:25:14,040
TRANSLATION OF NOVEL CANCER

4469
03:25:14,040 --> 03:25:15,840
SPECIFIC AND TECHNIQUES TO

4470
03:25:15,840 --> 03:25:19,160
MEDIATE SUCCESSFUL IMAGE GUIDED

4471
03:25:19,160 --> 03:25:19,480
NERVE.

4472
03:25:19,480 --> 03:25:21,640
AND THE GOAL HERE IS TO DEVELOP

4473
03:25:21,640 --> 03:25:23,800
TECHNOLOGIES THAT ARE CAPABLE OF

4474
03:25:23,800 --> 03:25:25,560
DETECTING VERY SMALL TUMOR CELL

4475
03:25:25,560 --> 03:25:27,800
CLUSTERS IN HUMANS USING

4476
03:25:27,800 --> 03:25:28,240
IMAGING.

4477
03:25:28,240 --> 03:25:30,520
AND THIS IS A REISSUED TOPIC.

4478
03:25:30,520 --> 03:25:32,160
AND THE FOCUS HERE ON THE

4479
03:25:32,160 --> 03:25:34,000
REISSUE IS CLINICAL TRANSLATION

4480
03:25:34,000 --> 03:25:36,440
AND VALIDATION AND PREVIOUS

4481
03:25:36,440 --> 03:25:38,920
DEVELOPMENTAL SUCCESSES WITH

4482
03:25:38,920 --> 03:25:40,960
ACTIVATE ABLE DIAGNOSE TICK

4483
03:25:40,960 --> 03:25:41,720
APPROACH.

4484
03:25:41,720 --> 03:25:45,000
SO PART OF THE PHASE 1 DELIVER

4485
03:25:45,000 --> 03:25:46,160
ABLES, COMPANIES ARE REQUIRED TO

4486
03:25:46,160 --> 03:25:48,200
VALIDATE THE SENSITIVITY AND

4487
03:25:48,200 --> 03:25:50,120
SPECIFICITY OTHER TECHNOLOGY

4488
03:25:50,120 --> 03:25:54,760
ANIMAL CANCER MODELS AND OBTAIN

4489
03:25:54,760 --> 03:25:55,920
IRB APPROVAL DURING DAY TWO,

4490
03:25:55,920 --> 03:25:58,160
COMPANIES WILL BE REQUIRED TO

4491
03:25:58,160 --> 03:26:00,400
CONDUCT A DOSE SOH AND SAFETY

4492
03:26:00,400 --> 03:26:01,800
STUDY FOLLOWED BY VALIDATION

4493
03:26:01,800 --> 03:26:04,160
STUDY IN HUMANS IN THE CANCER

4494
03:26:04,160 --> 03:26:10,000
INDICATION OR INDICATIONS.

4495
03:26:10,000 --> 03:26:11,400
THE NEXT TOPIC IS THE

4496
03:26:11,400 --> 03:26:13,440
DEVELOPMENT OF MICROBIOME BASED

4497
03:26:13,440 --> 03:26:15,680
TESTS FOR CANCER RESEARCH

4498
03:26:15,680 --> 03:26:19,000
DIAGNOSIS PROGNOSIS OR PATIENT

4499
03:26:19,000 --> 03:26:19,320
MANAGEMENT.

4500
03:26:19,320 --> 03:26:21,000
LAST YEAR THE MICROBIOME WAS ADD

4501
03:26:21,000 --> 03:26:23,120
TO THE LIST OF CANCER HALLMARKS

4502
03:26:23,120 --> 03:26:28,120
AND IN ROW SEPTE RECENT YEARS, L

4503
03:26:28,120 --> 03:26:30,240
STUDIES HAVE REVEALED THAT

4504
03:26:30,240 --> 03:26:32,400
ASSOCIATION OF SPECIFIC HIGH

4505
03:26:32,400 --> 03:26:33,840
ROWE BIOME SIGNATURES WITH THEIR

4506
03:26:33,840 --> 03:26:36,640
CANCER AS WELL AS THERAPIES.

4507
03:26:36,640 --> 03:26:38,400
SO PRODUCTS THAT ARE DEVELOPED

4508
03:26:38,400 --> 03:26:42,680
UNDER THIS TOPIC COULD BE ASSAYS

4509
03:26:42,680 --> 03:26:44,680
IN THE FORMS OF KITS OR SERVICE

4510
03:26:44,680 --> 03:26:47,280
TO DETECT MICRO BIO SIGNATURES

4511
03:26:47,280 --> 03:26:48,920
RELATED TO CANCER AND THESE

4512
03:26:48,920 --> 03:26:50,560
TECHNOLOGIES WOULD BE CAPABLE OF

4513
03:26:50,560 --> 03:26:52,760
USING WITH BIOPSIES AND IT CAN

4514
03:26:52,760 --> 03:26:55,160
BE FASTER, SAFER AND MORE COST

4515
03:26:55,160 --> 03:26:58,080
EFFECTIVE TO OBTAIN THAN

4516
03:26:58,080 --> 03:27:00,000
BIOPSIES AND PARTICULARLY FOR

4517
03:27:00,000 --> 03:27:01,400
CANCERS AND TUMORS THAT ARE

4518
03:27:01,400 --> 03:27:10,000
DIFFICULT T TO ACCESS.

4519
03:27:10,000 --> 03:27:11,320
THE NEXT TOPIC IS THE

4520
03:27:11,320 --> 03:27:13,360
DEVELOPMENT OF ORGAN FOR

4521
03:27:13,360 --> 03:27:15,480
PRECLINICAL AND TRANSLATIONAL

4522
03:27:15,480 --> 03:27:16,360
RADIOLOGICAL STUDIES.

4523
03:27:16,360 --> 03:27:18,560
AND WITH THIS NEW TOPIC, WE

4524
03:27:18,560 --> 03:27:19,840
WOULD LIKE COMPANIES TO BUILD

4525
03:27:19,840 --> 03:27:23,480
UPON WORK DONE IN THE SPACE AND

4526
03:27:23,480 --> 03:27:25,720
VALIDATE THESE DEVICES IN ANIMAL

4527
03:27:25,720 --> 03:27:27,840
CANCEL MODELS AND THE FOCUS

4528
03:27:27,840 --> 03:27:29,040
SHOULD BE DEVELOPING A PRODUCT

4529
03:27:29,040 --> 03:27:32,840
THAT ENABLES RESEARCHERS IN

4530
03:27:32,840 --> 03:27:34,480
INDUSTRY SETTINGS TO CONDUCT

4531
03:27:34,480 --> 03:27:37,000
STUDIES WITH RADIATION ALONE AS

4532
03:27:37,000 --> 03:27:40,640
WELL AS SINGLE COMBINATION ALONG

4533
03:27:40,640 --> 03:27:42,040
WITH OTHERS.

4534
03:27:42,040 --> 03:27:43,960
SO THESE PRODUCTS THAT WE FEEL

4535
03:27:43,960 --> 03:27:45,880
COULD ACCELERATE PROGRESS IN THE

4536
03:27:45,880 --> 03:27:47,360
RADIO THERAPY MARKET BY

4537
03:27:47,360 --> 03:27:50,560
IMPROVING THE ABILITY TO PREDICT

4538
03:27:50,560 --> 03:27:53,080
EFFICACY AND TOXICITY OF DRUG

4539
03:27:53,080 --> 03:27:55,440
RADIATION COMBINATION AS WELL

4540
03:27:55,440 --> 03:27:57,720
THE POTENTIAL TO DECREASE THE

4541
03:27:57,720 --> 03:27:59,720
COSTS OF PRECLINICAL RESEARCH

4542
03:27:59,720 --> 03:28:03,600
WITH THERAPEUTICS.

4543
03:28:03,600 --> 03:28:06,040
SO LAST TOPIC UNDER CLINICAL

4544
03:28:06,040 --> 03:28:07,120
DIAGNOSTICS AND MOL IKE LAR

4545
03:28:07,120 --> 03:28:10,000
ANALYSIS IS POINT OF CARE

4546
03:28:10,000 --> 03:28:11,080
DETECTION OF PROSTATE SPECIFIC

4547
03:28:11,080 --> 03:28:11,640
ANTIGENS.

4548
03:28:11,640 --> 03:28:13,080
AND THE GOAL HERE IS TO DEVELOP

4549
03:28:13,080 --> 03:28:17,120
AND VALIDATE A RAPID LOW COST,

4550
03:28:17,120 --> 03:28:17,880
USER FRIENDLY, AND EQUIPMENT

4551
03:28:17,880 --> 03:28:21,880
FREE POINT OF CARE TEST FOR PSA

4552
03:28:21,880 --> 03:28:25,160
THAT REQUIRES ONLY THE USE OF

4553
03:28:25,160 --> 03:28:27,920
BLOOD VIA A FINGER STICK.

4554
03:28:27,920 --> 03:28:31,200
CURRENT TESTS AVAILABLE AND

4555
03:28:31,200 --> 03:28:34,160
EITHER THEY REQUIRE SAMPLES THAT

4556
03:28:34,160 --> 03:28:35,160
NEED TO BE MAILED TO A CENTRAL

4557
03:28:35,160 --> 03:28:39,600
LAB OR THEY ARE AT A PRICE POINT

4558
03:28:39,600 --> 03:28:44,120
THAT IT'S NOT AFFORDABLE FOR

4559
03:28:44,120 --> 03:28:45,880
FULL ADOPTION OR THEY PROVIDE

4560
03:28:45,880 --> 03:28:49,400
LESS THAN IDEAL READOUTS FOR

4561
03:28:49,400 --> 03:28:50,080
PATIENTS AS WELL.

4562
03:28:50,080 --> 03:28:52,680
SO THE AIM HERE IS THAT PRODUCTS

4563
03:28:52,680 --> 03:28:54,120
WILL BE DEVELOPED THAT WILL

4564
03:28:54,120 --> 03:28:58,120
REDUCE BARRIERS TO TESTING

4565
03:28:58,120 --> 03:28:59,560
ESPECIALLY FOR AFRICAN AMERICAN

4566
03:28:59,560 --> 03:29:01,720
MEN WHO MAY BENEFIT FROM PSA

4567
03:29:01,720 --> 03:29:03,200
SCREENING AND THE ADDRESS OF

4568
03:29:03,200 --> 03:29:07,200
SIGNIFICANT CANCER HEALTH

4569
03:29:07,200 --> 03:29:10,360
DISPARITY.

4570
03:29:10,360 --> 03:29:12,000
NOW I'LL HIGHLIGHT FOUR TOPICS

4571
03:29:12,000 --> 03:29:13,320
THAT WE HAVE RELATED TO

4572
03:29:13,320 --> 03:29:16,400
INFORMATION TECHNOLOGY AND BIO

4573
03:29:16,400 --> 03:29:18,840
INFORMATICS AND THE FIRST IS

4574
03:29:18,840 --> 03:29:22,240
CANCER REPRESSION AND TREATMENTS

4575
03:29:22,240 --> 03:29:33,760
 -- I BELIEVE WE'RE ALLFAMILIARF

4576
03:29:38,160 --> 03:29:38,600
RECRUITMENT FROM CERTAIN

4577
03:29:38,600 --> 03:29:39,760
COMMUNITIES AND AREAS OF THE

4578
03:29:39,760 --> 03:29:42,080
COUNTRY AND THIS IS WELL

4579
03:29:42,080 --> 03:29:44,880
DOCUMENTS AND WE HOPE IT

4580
03:29:44,880 --> 03:29:45,600
SUPPORTS PRODUCTS THAT ADDRESS

4581
03:29:45,600 --> 03:29:47,200
THESE ISSUES AND PROMOTE THE

4582
03:29:47,200 --> 03:29:51,040
ENGAGEMENT OF ALL PATIENTS WITH

4583
03:29:51,040 --> 03:29:56,400
CANCER AND CLINICAL TRIALS.

4584
03:29:56,400 --> 03:29:57,680
THE NEXT TOPIC IS CLOUD BASED

4585
03:29:57,680 --> 03:29:59,280
MULTI MODAL SOFTWARE FOR THE

4586
03:29:59,280 --> 03:30:08,160
CANCER RESEARCH DATA COMMONS.

4587
03:30:08,160 --> 03:30:10,200
AND OUR COLLEAGUES IDENTIFIED

4588
03:30:10,200 --> 03:30:12,720
UNMET CHALLENGES WITH BIG DATA

4589
03:30:12,720 --> 03:30:14,640
APPAL SIS THAT STILL EXIST AND

4590
03:30:14,640 --> 03:30:17,600
SO SPECIFICALLY AN AREA

4591
03:30:17,600 --> 03:30:22,000
ANALYTICAL TOOLS THAT CAN

4592
03:30:22,000 --> 03:30:24,360
INTEGRATE WITH MULTI MODAL DATA

4593
03:30:24,360 --> 03:30:26,400
AND WE'VE ADD DETAILS TO THE

4594
03:30:26,400 --> 03:30:27,920
SOLICITATION THAT HIGHLIGHTS THE

4595
03:30:27,920 --> 03:30:30,480
GAPS AND DATA ANALYSIS AND THIS

4596
03:30:30,480 --> 03:30:32,360
IS NOT AN AREA WHERE WE RECEIVED

4597
03:30:32,360 --> 03:30:33,760
MANY APPLICATIONS THROUGH OUR

4598
03:30:33,760 --> 03:30:36,520
INVESTIGATOR INITIATED OMNIBUS

4599
03:30:36,520 --> 03:30:38,040
GRANT MECHANISMS SO FUNDING

4600
03:30:38,040 --> 03:30:41,680
THROUGH THIS TOPIC IS IMPORTANT

4601
03:30:41,680 --> 03:30:43,760
TONE ABLE THE CRDC RESOURCE AND

4602
03:30:43,760 --> 03:30:46,360
BE LEVERAGED BY THE CANCER

4603
03:30:46,360 --> 03:30:47,040
RESEARCH COMMUNITY.

4604
03:30:47,040 --> 03:30:53,000
NEXT SLIDE, PLEASE.

4605
03:30:53,000 --> 03:30:56,040
CAN YOU ABOUT BACK ONE SLIDE,

4606
03:30:56,040 --> 03:30:56,800
PLEASE?

4607
03:30:56,800 --> 03:30:59,120
THE NEXT IS EVALUATION DATASETS

4608
03:30:59,120 --> 03:31:02,280
AS MEDICAL DEVELOPMENT TOOLS FOR

4609
03:31:02,280 --> 03:31:03,600
TESTING CANCER TECHNOLOGIES AND

4610
03:31:03,600 --> 03:31:05,280
THE GOAL HERE IS TO DEVELOP

4611
03:31:05,280 --> 03:31:06,800
DATASETS THAT CAN BE USED TO

4612
03:31:06,800 --> 03:31:09,160
ASSESS MEDICAL DEVICES AND

4613
03:31:09,160 --> 03:31:10,560
ONCOLOGY SETTINGS.

4614
03:31:10,560 --> 03:31:12,720
AND I JUST WANT TO HIGHLIGHT

4615
03:31:12,720 --> 03:31:13,920
HERE THAT THIS TOPIC WAS

4616
03:31:13,920 --> 03:31:15,560
DEVELOPED IN COLLABORATION WITH

4617
03:31:15,560 --> 03:31:17,320
COLLEAGUES AT THE FDA AND HAS

4618
03:31:17,320 --> 03:31:18,960
THE ADDITIONAL GOAL OF

4619
03:31:18,960 --> 03:31:20,280
SIMULATING PATIENTS OF SMALL

4620
03:31:20,280 --> 03:31:22,760
BUSINESSES AND THE FKA'S MEDICAL

4621
03:31:22,760 --> 03:31:25,200
DEVICE DEVELOPMENT TOOL PROGRAM.

4622
03:31:25,200 --> 03:31:27,960
THIS PROGRAM IS A MECHANISM THAT

4623
03:31:27,960 --> 03:31:29,160
FDA OTHERS TO QUALIFY TOOLS THAT

4624
03:31:29,160 --> 03:31:32,360
CAN FACILITATE THE REGULATORY

4625
03:31:32,360 --> 03:31:33,920
DECISION-MAKING WHEN EVALUATING

4626
03:31:33,920 --> 03:31:36,600
A MEDICAL DEVICE.

4627
03:31:36,600 --> 03:31:39,080
THIS PROGRAM WE BELIEVE BENEFITS

4628
03:31:39,080 --> 03:31:41,080
NCI FUNDED COMPANIES BECAUSE

4629
03:31:41,080 --> 03:31:44,920
THESE FDA QUALIFIED TOOLS WITH

4630
03:31:44,920 --> 03:31:46,480
TO OTHER ENTREPRENEURS WHO ARE

4631
03:31:46,480 --> 03:31:48,360
DEVELOPING NEW TECHNOLOGIES AND

4632
03:31:48,360 --> 03:31:50,000
OR USED TO EVALUATE THEIR

4633
03:31:50,000 --> 03:31:51,440
EXISTING TECHNOLOGIES AND THE

4634
03:31:51,440 --> 03:31:54,600
TOTAL PRODUCT LIFE CYCLE AND

4635
03:31:54,600 --> 03:31:56,400
THIS REALLY PROVIDES A REVENUE

4636
03:31:56,400 --> 03:31:57,600
STREAM FOR THIS SMALL BUSINESS

4637
03:31:57,600 --> 03:32:01,400
THAT ORIGINALLY DEVELOPED THE

4638
03:32:01,400 --> 03:32:02,200
TOOLS.

4639
03:32:02,200 --> 03:32:03,480
IN ADDITION, OTHER COMPANIES AND

4640
03:32:03,480 --> 03:32:05,640
THIS INCLUDES OTHER NCI FUNDED

4641
03:32:05,640 --> 03:32:07,440
SMALL BUSINESSES THAT USE THE

4642
03:32:07,440 --> 03:32:09,880
TOOL, TO EVALUATE THEIR NEW

4643
03:32:09,880 --> 03:32:10,960
TECHNOLOGIES ARE ABLE TO SPEED

4644
03:32:10,960 --> 03:32:14,120
UP THE FDA REGULATORY REVIEW

4645
03:32:14,120 --> 03:32:15,880
PROCESS AND POTENTIALLY SHORTEN

4646
03:32:15,880 --> 03:32:17,560
THEIR OVER ALL DEVICE

4647
03:32:17,560 --> 03:32:18,160
DEVELOPMENT TIMES.

4648
03:32:18,160 --> 03:32:20,320
AND THIS IS A REISSUE TOPIC AND

4649
03:32:20,320 --> 03:32:23,760
WE RECEIVED PROPOSALS PREVIOUSLY

4650
03:32:23,760 --> 03:32:25,240
BUT WE DID NOT FUND THEM BECAUSE

4651
03:32:25,240 --> 03:32:26,480
THEY WEREN'T WHAT WE WERE

4652
03:32:26,480 --> 03:32:27,080
LOOKING FOR.

4653
03:32:27,080 --> 03:32:29,560
SO WE'VE ADDED DETAILS AND

4654
03:32:29,560 --> 03:32:31,360
EXAMPLES OF PRODUCTS TO THE

4655
03:32:31,360 --> 03:32:33,000
REISSUE SOLICITATION THAT WILL

4656
03:32:33,000 --> 03:32:35,800
FACILITATE MORE RESPONSIVE

4657
03:32:35,800 --> 03:32:37,920
PROPOSALS AND WE THINK THIS IS

4658
03:32:37,920 --> 03:32:39,560
AN IMPORTANT AREA FOR NIH TO

4659
03:32:39,560 --> 03:32:41,360
FUND BECAUSE IT'S A SIGNIFICANT

4660
03:32:41,360 --> 03:32:44,400
NEED WE SEE IN THE ONCOLOGY

4661
03:32:44,400 --> 03:32:45,920
MEDICAL DEVICE COMMUNITY AS WELL

4662
03:32:45,920 --> 03:32:50,280
AS THE GAP CURRENTLY IN OUR

4663
03:32:50,280 --> 03:32:50,640
PORTFOLIO.

4664
03:32:50,640 --> 03:32:52,520
THE LAST TOPIC FOR YOUR

4665
03:32:52,520 --> 03:32:53,800
CONSIDERATION IS AUTOMATED

4666
03:32:53,800 --> 03:32:55,360
SOFTWARE FOR POINT OF CARE

4667
03:32:55,360 --> 03:32:58,240
TESTING TO IDENTIFY CANCER

4668
03:32:58,240 --> 03:33:00,360
ASSOCIATED NON NUTRITION.

4669
03:33:00,360 --> 03:33:02,360
AND THE GOAL HERE IS TO DEVELOP

4670
03:33:02,360 --> 03:33:05,320
A NUTRITION SCREENERS THAT CAN

4671
03:33:05,320 --> 03:33:07,160
DEPICT MALNUTRITION EARLY ON AS

4672
03:33:07,160 --> 03:33:08,800
WELL AS CANCER CARE PARTICULARLY

4673
03:33:08,800 --> 03:33:10,640
IN CANCER POPULATIONS WITH

4674
03:33:10,640 --> 03:33:14,720
HIGHER PREVALENCE OF NON

4675
03:33:14,720 --> 03:33:24,920
NUTRITION.

4676
03:33:32,120 --> 03:33:36,280
AND NUTRITION RISK.

4677
03:33:36,280 --> 03:33:38,560
THIS CONTRACT TOPIC WILL SUPPORT

4678
03:33:38,560 --> 03:33:41,400
PRODUCT DEVELOPMENT THAT

4679
03:33:41,400 --> 03:33:45,160
UTILIZES EITHER EXISTING

4680
03:33:45,160 --> 03:33:48,760
NUTRITION SCREENERS AS WELL AS

4681
03:33:48,760 --> 03:33:50,080
COUPLING THIS WITH SEGMENTATION

4682
03:33:50,080 --> 03:33:52,920
WITH DIAGNOSTIC IMAGING FROM CT

4683
03:33:52,920 --> 03:33:56,320
AND MRI.

4684
03:33:56,320 --> 03:34:06,640
NEXT SLIDE, PLEASE.

4685
03:34:08,320 --> 03:34:10,680
SO I WOULD JUST LIKE TO END

4686
03:34:10,680 --> 03:34:13,520
TODAY BY EMPHASIZING THE SIBR

4687
03:34:13,520 --> 03:34:15,400
CONTRACT MECHANISM HAS SUPPORTED

4688
03:34:15,400 --> 03:34:16,440
THE SUCCESSFUL COMMERCIALIZATION

4689
03:34:16,440 --> 03:34:21,000
OF MANY PRODUCTS THAT ARE USED

4690
03:34:21,000 --> 03:34:22,640
FOR DIAGNOSING OR TREATING

4691
03:34:22,640 --> 03:34:23,880
PATIENTS WITH CANCER AND HERE IS

4692
03:34:23,880 --> 03:34:25,960
A SAMPLE, A SIDE PRODUCT FROM

4693
03:34:25,960 --> 03:34:31,280
ACROSS DIFFERENT TECHNOLOGIES

4694
03:34:31,280 --> 03:34:38,160
AREAS AND FROM 2013 TO 2018 WE

4695
03:34:38,160 --> 03:34:40,240
FOUND THAT 20% OF FUNDED

4696
03:34:40,240 --> 03:34:41,800
PROJECTS HAVE RESULTED ALREADY

4697
03:34:41,800 --> 03:34:45,160
AND COMMERCIALIZED PRODUCTS.

4698
03:34:45,160 --> 03:34:48,600
AND WHEN WE LOOK THE THE EARLIER

4699
03:34:48,600 --> 03:34:51,360
YEARS, WHEN WE GOT TO 2013 THIS

4700
03:34:51,360 --> 03:34:54,840
INCREASES TO JUST OVER 30% OF

4701
03:34:54,840 --> 03:34:56,760
CONTRACT FUNDED PROJECTS THAT

4702
03:34:56,760 --> 03:34:59,720
HAVE RESULTED IN COMMERCIALIZED

4703
03:34:59,720 --> 03:35:00,280
PROJECTS.

4704
03:35:00,280 --> 03:35:01,880
AND THIS WAS SIMILAR TO WHAT WE

4705
03:35:01,880 --> 03:35:06,080
HAVE SEEN IN OUR GRANTS

4706
03:35:06,080 --> 03:35:06,520
PORTFOLIO.

4707
03:35:06,520 --> 03:35:08,120
SO, YOU KNOW, WE CONSIDER

4708
03:35:08,120 --> 03:35:11,440
CONTRACTS TO BE A VERY IMPORTANT

4709
03:35:11,440 --> 03:35:13,480
MECHANISM AND FOR NCI FUNDING

4710
03:35:13,480 --> 03:35:15,240
AND IT'S A WAY THAT WE CAN

4711
03:35:15,240 --> 03:35:17,120
REALLY SUPPORT INNOVATIVE

4712
03:35:17,120 --> 03:35:18,080
PRODUCTS, GETTING TO THE CLIP I

4713
03:35:18,080 --> 03:35:22,320
CANCLINICFOR PATIENTS WITH CANC.

4714
03:35:22,320 --> 03:35:23,840
THANK YOU FOR YOUR TIME AND I'M

4715
03:35:23,840 --> 03:35:27,600
HAPPY TO TAKE ANY QUESTIONS

4716
03:35:27,600 --> 03:35:28,680
TODAY.

4717
03:35:28,680 --> 03:35:29,560
>> Dr. Flaherty: THANK
YOU, VERY

4718
03:35:29,560 --> 03:35:30,080
MUCH.

4719
03:35:30,080 --> 03:35:30,280
KAREN.

4720
03:35:30,280 --> 03:35:34,000
>> THANK YOU, Dr. POND FOR

4721
03:35:34,000 --> 03:35:35,440
SUCH A THOUGHTFUL PRESENTATION.

4722
03:35:35,440 --> 03:35:36,840
YOU KNOW, I WAS CHAIRING THIS

4723
03:35:36,840 --> 03:35:40,840
REVIEW PANEL ALONG WITH Dr.

4724
03:35:40,840 --> 03:35:42,480
FLAHERTY AND WE HAD NOTHING BUT

4725
03:35:42,480 --> 03:35:44,600
ENTHUSIASM FOR THE SBIR PROCESS

4726
03:35:44,600 --> 03:35:55,360
AND WE VERY MUCH APPRECIATED THE

4727
03:35:55,360 --> 03:35:57,400
WE WANT IT CARRIED FORWARD FROM

4728
03:35:57,400 --> 03:35:58,120
THE NCI.

4729
03:35:58,120 --> 03:35:59,440
OUR QUESTIONS ARE WITH Dr.

4730
03:35:59,440 --> 03:36:01,640
POND AT OUR FIRST MEETING

4731
03:36:01,640 --> 03:36:02,560
AROUNDS TWO YEARS, ONE IS ON

4732
03:36:02,560 --> 03:36:03,040
PROCESS.

4733
03:36:03,040 --> 03:36:05,400
SO HOW DOES THE DECISIONS THAT

4734
03:36:05,400 --> 03:36:08,680
WERE MADE CIRCLE THE TOPIC

4735
03:36:08,680 --> 03:36:09,040
AREAS?

4736
03:36:09,040 --> 03:36:10,520
WHAT MADE IT THROUGH THAT FILTER

4737
03:36:10,520 --> 03:36:11,960
AND WHAT WAS LEFT ON THE CUTTING

4738
03:36:11,960 --> 03:36:13,360
ROOM FLOOR, IF YOU WILL AND

4739
03:36:13,360 --> 03:36:14,720
TRYING TO UNDERSTAND HOW THOSE

4740
03:36:14,720 --> 03:36:17,560
PRIORITIES WERE MADE SO WE HAD A

4741
03:36:17,560 --> 03:36:18,720
GOOD DISCUSSION ABOUT THE THINGS

4742
03:36:18,720 --> 03:36:20,360
THAT WERE REFLECTED NOW IN THIS

4743
03:36:20,360 --> 03:36:21,640
MODIFIED PRESENTATION, YOU KNOW,

4744
03:36:21,640 --> 03:36:22,560
WHAT OTHER AGENCIES WERE

4745
03:36:22,560 --> 03:36:26,680
INVOLVED AND HOW THE CALLS WERE

4746
03:36:26,680 --> 03:36:29,080
PREPARED AND HOW THE GROUP VIEWS

4747
03:36:29,080 --> 03:36:30,320
PREDICTING THE NUMBER OF AWARDS

4748
03:36:30,320 --> 03:36:32,240
AND A CERTAIN AREA THAT MAY COME

4749
03:36:32,240 --> 03:36:34,480
TO PASS SO YOU REALLY FELT VERY

4750
03:36:34,480 --> 03:36:36,640
COMFORTABLE WITH THOSE ANSWERS

4751
03:36:36,640 --> 03:36:38,520
AND SECOND AREA THAT WE FOCUSED

4752
03:36:38,520 --> 03:36:40,560
ON WAS HOW THIS RELATES TO

4753
03:36:40,560 --> 03:36:43,440
SIMILAR TYPES OF MECHANISMS AS

4754
03:36:43,440 --> 03:36:45,480
SBIR-LIKE MECHANISMS ACROSS THE

4755
03:36:45,480 --> 03:36:47,440
NIH AND WAS THERE COR DIN

4756
03:36:47,440 --> 03:36:48,240
SITUATION AND WHAT WE CAME TO

4757
03:36:48,240 --> 03:36:52,360
LEARN WERE SOME OF THE DIS FINK,

4758
03:36:52,360 --> 03:36:53,200
YES, THERE IS.

4759
03:36:53,200 --> 03:36:55,200
EX ALSO TO LEARN ABOUT THE NCI

4760
03:36:55,200 --> 03:36:57,920
VERSION OF THE SBIR PROGRAM

4761
03:36:57,920 --> 03:36:59,000
WHICH YOU HEARD ABOUT.

4762
03:36:59,000 --> 03:37:02,200
SO I THINK THERE WAS WIDESPREAD

4763
03:37:02,200 --> 03:37:03,840
ENTHUSIASM FOR THIS CONCEPT AND

4764
03:37:03,840 --> 03:37:07,920
I WILL TURN IT OVER TO Dr.

4765
03:37:07,920 --> 03:37:10,280
FLAHERTY TO SEE IF I'VE BEEN

4766
03:37:10,280 --> 03:37:11,480
COMPREHENSIVE IN MY REVIEW.

4767
03:37:11,480 --> 03:37:12,080
>> Dr. Flaherty: THANK
YOU,

4768
03:37:12,080 --> 03:37:13,560
KAREN.

4769
03:37:13,560 --> 03:37:13,760
DAVID.

4770
03:37:13,760 --> 03:37:15,000
>> SO I THINK OVER THE
YEARS

4771
03:37:15,000 --> 03:37:17,680
I'VE HAD THE OPPORTUNITY TO

4772
03:37:17,680 --> 03:37:18,760
REVEAL ALMOST ALL ASPECT

4773
03:37:18,760 --> 03:37:21,480
APPROXIMATES OF THE SBIR PROGRAM

4774
03:37:21,480 --> 03:37:22,720
AND I'M VERY CLEAR THAT IT

4775
03:37:22,720 --> 03:37:25,360
PRODUCES A TREMENDOUS AMOUNT OF

4776
03:37:25,360 --> 03:37:26,520
INNOVATION OVER ALL AND I THINK

4777
03:37:26,520 --> 03:37:27,680
THE QUESTIONS RELATED HERE AS

4778
03:37:27,680 --> 03:37:29,040
YOU SAID WERE MORE TO THE ISSUE

4779
03:37:29,040 --> 03:37:30,960
OF WHAT IS THE CONTRACT

4780
03:37:30,960 --> 03:37:33,560
MECHANISM OF WHAT GAP IT FILLS

4781
03:37:33,560 --> 03:37:35,440
AND I FEEL CONVINCED THAT THE

4782
03:37:35,440 --> 03:37:36,880
PROCESS WAS BOTH COMPREHENSIVE

4783
03:37:36,880 --> 03:37:38,440
AND IMPORTANT IN TERMS OF HOW

4784
03:37:38,440 --> 03:37:40,440
TOPICS WERE SELECTED.

4785
03:37:40,440 --> 03:37:42,120
AND I FOCUSED ON THE

4786
03:37:42,120 --> 03:37:42,960
DELIVERABLES BECAUSE IT'S

4787
03:37:42,960 --> 03:37:47,480
IMPORTANT TO SEE EXACTLY WHAT

4788
03:37:47,480 --> 03:37:50,200
HAPPENED WITH CONTRACTS VERSUS

4789
03:37:50,200 --> 03:37:52,200
THE COMPETITIVE PROGRAM AND THE

4790
03:37:52,200 --> 03:37:53,160
WIDESPREAD COMPETITIVE PROGRAM

4791
03:37:53,160 --> 03:37:54,920
AND THAT DELIVERABLES ON BOTH

4792
03:37:54,920 --> 03:37:58,840
SIDES ARE ACTUALLY QUITE

4793
03:37:58,840 --> 03:37:59,160
IMPRESSIVE.

4794
03:37:59,160 --> 03:38:02,440
REACHING 30% COMMERCIALIZATION

4795
03:38:02,440 --> 03:38:13,000
IS I AM PROSE I HAVE AND SO I'M

4796
03:38:13,480 --> 03:38:17,280
SUPPORTING AND CONTINUING IT.

4797
03:38:17,280 --> 03:38:19,840
>> THIS IS THE MOST
COMPLEX

4798
03:38:19,840 --> 03:38:21,280
PORTFOLIO ANALYSIS THAT IS TAKEN

4799
03:38:21,280 --> 03:38:22,440
WHICH IS WHERE WE CENTERED MUCH

4800
03:38:22,440 --> 03:38:24,560
OF OUR CONVERSATIONS.

4801
03:38:24,560 --> 03:38:33,080
IT CAME AWAY COMFORTABLE THAT

4802
03:38:33,080 --> 03:38:35,840
VERY IMPRESSIVE REPERTOIRE FOR A

4803
03:38:35,840 --> 03:38:36,840
DEEP DIVE ANNAL IS SIS OF WHAT

4804
03:38:36,840 --> 03:38:45,680
ELSE THE NCI IS SUPPORTING.

4805
03:38:45,680 --> 03:38:46,880
ANY A FURTHER DISCUSSION?

4806
03:38:46,880 --> 03:38:50,480
I CAN'T HEAR YOU.

4807
03:38:50,480 --> 03:39:00,840
>> WE LOST YOU AGAIN.

4808
03:39:06,760 --> 03:39:08,640
>> SO THIS IS EXCITE TO GO
SEE

4809
03:39:08,640 --> 03:39:11,040
AND I JUST CUT TO THE CHASE.

4810
03:39:11,040 --> 03:39:11,200
--

4811
03:39:11,200 --> 03:39:13,120
>> CAN YOU GET CLOSER TO
THE

4812
03:39:13,120 --> 03:39:13,280
MIC.

4813
03:39:13,280 --> 03:39:14,320
>> I AM CLOSE.

4814
03:39:14,320 --> 03:39:16,120
LET ME SEE.

4815
03:39:16,120 --> 03:39:17,440
IS THERE SOMEONE ELSE WHO WANTS

4816
03:39:17,440 --> 03:39:17,960
TO SAY --

4817
03:39:17,960 --> 03:39:19,000
>> NO.

4818
03:39:19,000 --> 03:39:20,240
JUST GET A LITTLE BIT CLOSER AND

4819
03:39:20,240 --> 03:39:23,760
WE CAN HEAR YOU.

4820
03:39:23,760 --> 03:39:27,920
>> IS THIS GOOD?

4821
03:39:27,920 --> 03:39:32,800
>> IT'S EXCITING.

4822
03:39:32,800 --> 03:39:33,640
COMPREHENSIVE EX COMPLEX.

4823
03:39:33,640 --> 03:39:40,720
A COUPLE OF QUESTIONS AND ONE IS

4824
03:39:40,720 --> 03:39:41,920
LOOKING AT THE PORTFOLIO AND

4825
03:39:41,920 --> 03:39:43,200
LOOKING INTO THE FUTURE A POINT

4826
03:39:43,200 --> 03:39:45,000
OF CARE TESTING IS GREAT BUT

4827
03:39:45,000 --> 03:39:49,960
WHAT ABOUT HOME TESTING

4828
03:39:49,960 --> 03:39:51,640
TECHNOLOGIES IF THERE'S IN THE

4829
03:39:51,640 --> 03:39:52,200
CARDS IN THE FUTURE AND THE

4830
03:39:52,200 --> 03:39:56,000
SECOND QUESTION I HAVE IS WHAT

4831
03:39:56,000 --> 03:39:57,200
IS THE PLAN AND THIS CAME BEFORE

4832
03:39:57,200 --> 03:40:00,720
US IN THE PAST SO INCREASE

4833
03:40:00,720 --> 03:40:05,520
DIVERSITY OF VENDORS AND THAT

4834
03:40:05,520 --> 03:40:08,920
CONTRACTORS AND IN THE PROCESS

4835
03:40:08,920 --> 03:40:11,760
THAT DO YOU GET VENDORS AND LET

4836
03:40:11,760 --> 03:40:14,440
ME SAVE THAT WORD, CONTRACTORS

4837
03:40:14,440 --> 03:40:17,200
OR AWARDS TO PROVIDE THAT

4838
03:40:17,200 --> 03:40:18,720
DIVERSITY AND I THINK WE WANT TO

4839
03:40:18,720 --> 03:40:21,600
SEE IN MANY OF THESE CONDITIONS

4840
03:40:21,600 --> 03:40:23,640
THAT EFFECT POPULATIONS

4841
03:40:23,640 --> 03:40:24,240
DISPROPORTIONATELY.

4842
03:40:24,240 --> 03:40:29,440
SO TWO QUESTIONS.

4843
03:40:29,440 --> 03:40:30,680
I'LL ADDRESS YOUR DIVERSITY

4844
03:40:30,680 --> 03:40:31,560
QUESTION FIRST.

4845
03:40:31,560 --> 03:40:33,520
THE QUESTION FIRST QUESTION, I

4846
03:40:33,520 --> 03:40:34,320
COULDN'T HEAR WHICH CONTRACT

4847
03:40:34,320 --> 03:40:35,600
TOPIC YOU ARE REFERRING TO YOU

4848
03:40:35,600 --> 03:40:37,000
SAID INSTEAD OF POINT OF CARE,

4849
03:40:37,000 --> 03:40:42,040
WHAT ABOUT HOME DEVICES?

4850
03:40:42,040 --> 03:40:42,200
AND.

4851
03:40:42,200 --> 03:40:44,720
>> THAT WAS MORE RATHER
THAN TO

4852
03:40:44,720 --> 03:40:46,440
ME QUESTION BECAUSE IF WE CAN DO

4853
03:40:46,440 --> 03:40:49,640
A SELF TESTING AT HOME,

4854
03:40:49,640 --> 03:40:50,600
SELF-SAMPLING AT HOME AND THE

4855
03:40:50,600 --> 03:40:52,720
PRACTICE OF TEST IS A GOOD

4856
03:40:52,720 --> 03:40:53,080
EXAMPLE.

4857
03:40:53,080 --> 03:40:59,640
CAN'T WE DO THE SELF-TESTING

4858
03:40:59,640 --> 03:41:00,080
PERHAPS IN THE FUTURE.

4859
03:41:00,080 --> 03:41:03,200
>> TO SUGGEST YOUR
QUESTION

4860
03:41:03,200 --> 03:41:06,480
DIVERSITY IS AN IMPORTANT PART

4861
03:41:06,480 --> 03:41:11,320
OF THE SBIR MISSION AND OUR

4862
03:41:11,320 --> 03:41:13,320
GOALS AND ONE OF THE CONTRACT

4863
03:41:13,320 --> 03:41:16,320
TOPICS I JUST PRESENTED, THE ONE

4864
03:41:16,320 --> 03:41:18,160
ABOUT TOOL DEVELOPMENT FOR

4865
03:41:18,160 --> 03:41:19,200
RECRUITMENT AND RETENTION OF

4866
03:41:19,200 --> 03:41:23,080
DIVERSE POPULATIONS AND THIS

4867
03:41:23,080 --> 03:41:24,040
HIGHLIGHTS ONE OF THE REAL

4868
03:41:24,040 --> 03:41:26,760
BENEFITS OF USING A CONTRACT

4869
03:41:26,760 --> 03:41:33,040
MECHANISM BECAUSE WE'RE ABLE TO

4870
03:41:33,040 --> 03:41:33,840
SPECIFICALLY REQUIRE THE PRODUCT

4871
03:41:33,840 --> 03:41:35,480
BE TESTED AND VALIDATED WITH

4872
03:41:35,480 --> 03:41:39,480
DIVERSE POPULATIONS.

4873
03:41:39,480 --> 03:41:41,320
AND SO THAT IS SOMETHING WE

4874
03:41:41,320 --> 03:41:42,480
APPRECIATE FOR THE CONTACT

4875
03:41:42,480 --> 03:41:44,640
MECHANISM AND WE FEEL IT BRINGS

4876
03:41:44,640 --> 03:41:45,600
REAL VALUE.

4877
03:41:45,600 --> 03:41:48,840
THE SECOND POINT IS, YOU KNOW,

4878
03:41:48,840 --> 03:41:50,360
OUTSIDE OF CONTRACTS AND WITH

4879
03:41:50,360 --> 03:41:52,960
OUR WHOLE PORTFOLIO, DIVERSITY

4880
03:41:52,960 --> 03:41:56,040
OF ENTREPRENEURSHIP IS A FOCUS

4881
03:41:56,040 --> 03:41:57,720
AND WE HAVE LAUNCHED WHAT WE

4882
03:41:57,720 --> 03:42:00,640
CALL OUR AAP, OUR APPLICANT

4883
03:42:00,640 --> 03:42:02,920
ASSISTANT PROGRAM AND IN 2019,

4884
03:42:02,920 --> 03:42:05,040
IT WAS THE FIRST OF ITS KIND AT

4885
03:42:05,040 --> 03:42:08,640
NIH AND THIS WAS A FREE 10-WEEK

4886
03:42:08,640 --> 03:42:09,280
PROGRAM TO PEOPLE WHO WERE NEW

4887
03:42:09,280 --> 03:42:11,360
TO ENTREPRENEURSHIP TO RECEIVE

4888
03:42:11,360 --> 03:42:12,920
MENTORING AND TRAINING AND

4889
03:42:12,920 --> 03:42:16,680
PUTTING TOGETHER THE

4890
03:42:16,680 --> 03:42:18,440
APPLICATIONS AND OUT OF THIS

4891
03:42:18,440 --> 03:42:22,640
PROGRAM, WE'VE HAD NINE COHORTS

4892
03:42:22,640 --> 03:42:26,480
THAT HAVE GONE THROUGH THIS

4893
03:42:26,480 --> 03:42:28,120
PROGRAM AND IT'S EXPAND TODAY 10

4894
03:42:28,120 --> 03:42:30,840
WHICH WE MANAGE ON BEHALF OF ALL

4895
03:42:30,840 --> 03:42:36,400
10 AND WE FOUND THAT OF THIS 55

4896
03:42:36,400 --> 03:42:38,600
OUT OF THE 63 AWARDS THAT COME

4897
03:42:38,600 --> 03:42:42,720
HAVE OUT OF THAT PROGRAM HAVE

4898
03:42:42,720 --> 03:42:46,280
BEEN TO UNDER REPRESEN REPRESEND

4899
03:42:46,280 --> 03:42:47,680
POPULATIONS SO THIS IS WOMEN AND

4900
03:42:47,680 --> 03:42:49,040
INDIVIDUALS FROM RACIAL AND NICK

4901
03:42:49,040 --> 03:42:50,840
GROUPS THAT ARE UNDER

4902
03:42:50,840 --> 03:42:53,640
REPRESENTED AS WELL AS COMPANIES

4903
03:42:53,640 --> 03:43:00,040
LOCATED IN NIDS SPACE.

4904
03:43:00,040 --> 03:43:07,400
ON HPV, YOU KNOW, THAT IS A GEE

4905
03:43:07,400 --> 03:43:08,680
GOOD QUESTION AND I WILL TURN IT

4906
03:43:08,680 --> 03:43:15,200
OVER TO MY COLLEAGUE WHO IS

4907
03:43:15,200 --> 03:43:16,640
INVOLVED IN A FEW MORE OF THE

4908
03:43:16,640 --> 03:43:17,600
DETAILS OF THIS TOPIC.

4909
03:43:17,600 --> 03:43:19,120
>> GREAT QUESTION, I
WORKED WITH

4910
03:43:19,120 --> 03:43:21,280
THE TEAM FROM DIVISION OF CANCER

4911
03:43:21,280 --> 03:43:23,280
PREVENTION ON THIS TOPIC AND

4912
03:43:23,280 --> 03:43:28,120
FROM WHAT I UNDERSTAND, THE

4913
03:43:28,120 --> 03:43:29,520
TOPIC WE'RE LOOKING FOR

4914
03:43:29,520 --> 03:43:30,960
TECHNOLOGIES THAT ARE THE POINT

4915
03:43:30,960 --> 03:43:38,200
OF CARE DELIVERY BECAUSE THERE'S

4916
03:43:38,200 --> 03:43:39,640
OPPORTUNITIES TO DO RAPID

4917
03:43:39,640 --> 03:43:42,080
TESTING AND PROVIDE TREATMENT TO

4918
03:43:42,080 --> 03:43:52,600
WOMEN IN NEED SO IT COULD BE A

4919
03:43:53,480 --> 03:43:54,480
APARTMENTED FOR HOME USE UNDER

4920
03:43:54,480 --> 03:43:55,440
THE RIGHT SITUATION BUT WE'RE

4921
03:43:55,440 --> 03:44:02,200
NOT LOOKING FOR THAT.

4922
03:44:02,200 --> 03:44:08,560
>> THANK YOU.

4923
03:44:08,560 --> 03:44:11,800
>> Dr. Flaherty: SEEING NO
OTHER

4924
03:44:11,800 --> 03:44:12,480
HANDS.

4925
03:44:12,480 --> 03:44:15,000
WE CAN MOVE TO VOTING.

4926
03:44:15,000 --> 03:44:16,280
KAREN, WOULD YOU LIKE TO MAKE A

4927
03:44:16,280 --> 03:44:16,520
MOTION.

4928
03:44:16,520 --> 03:44:17,440
>> I WOULD.

4929
03:44:17,440 --> 03:44:20,040
I'D LIKE TO MAKE A MOTION TO

4930
03:44:20,040 --> 03:44:20,800
APPROVE.

4931
03:44:20,800 --> 03:44:21,360
>> Dr. Flaherty: GREAT.

4932
03:44:21,360 --> 03:44:22,920
I WILL NOT BE THE SECONDER SINCE

4933
03:44:22,920 --> 03:44:24,920
I'M CHAIRING AND DAVID, WOULD

4934
03:44:24,920 --> 03:44:25,760
YOU LIKE TO SECOND THAT.

4935
03:44:25,760 --> 03:44:26,680
>> SECOND.

4936
03:44:26,680 --> 03:44:31,280
>> THANK YOU.

4937
03:44:31,280 --> 03:44:32,840
>> Dr. Flaherty: ANY
FURTHER

4938
03:44:32,840 --> 03:44:37,240
DISCUSSION?

4939
03:44:37,240 --> 03:44:39,080
SO WITH MOTION TO APPROVE,

4940
03:44:39,080 --> 03:44:43,040
LOOKING FOR ANY DISAPPROVAL

4941
03:44:43,040 --> 03:44:43,240
VOTES.

4942
03:44:43,240 --> 03:44:50,240
VOICE OR RAISE OF HAND.

4943
03:44:50,240 --> 03:44:53,200
ANY A ABSTENTIONS.

4944
03:44:53,200 --> 03:44:55,600
I DON'T HAVE ANY RECORDED IN

4945
03:44:55,600 --> 03:44:55,840
ADVANCE.

4946
03:44:55,840 --> 03:45:00,960
>> IT'S UNANIMOUS
APPROVAL.

4947
03:45:00,960 --> 03:45:01,600
>> Dr. Flaherty:
EXCELLENT.

4948
03:45:01,600 --> 03:45:03,560
WE REACHED THE END OF OUR BRIEF

4949
03:45:03,560 --> 03:45:05,920
REVIEW AND I HOPE TO SEE MORE

4950
03:45:05,920 --> 03:45:06,960
PROPOSALS IN THE JUNE MEETING AS

4951
03:45:06,960 --> 03:45:08,680
I SAID BEFORE.

4952
03:45:08,680 --> 03:45:11,000
THANK YOU ALL FOR EXCELLENT

4953
03:45:11,000 --> 03:45:12,440
DISCUSSION BOTH IN THE CONCEPTS

4954
03:45:12,440 --> 03:45:14,240
AND PRIOR TO THAT TIME.

4955
03:45:14,240 --> 03:45:16,960
WE ARE OVER TIME AND OUR AGENDA

4956
03:45:16,960 --> 03:45:19,800
AND THE ONLY OTHER AGENDA ITEM

4957
03:45:19,800 --> 03:45:24,600
IS ALWAYS WE USUALLY FINISH WITH

4958
03:45:24,600 --> 03:45:27,240
ANY NEW BUSINESS PRESSING ISSUES

4959
03:45:27,240 --> 03:45:28,120
FOR TODAY'S DISCUSSION AND AS

4960
03:45:28,120 --> 03:45:30,720
WELL AS CONSIDERATIONS FOR

4961
03:45:30,720 --> 03:45:32,280
FUTURE TOPICS TO DISCUSS AND

4962
03:45:32,280 --> 03:45:35,440
FUTURE MEETINGS.

4963
03:45:35,440 --> 03:45:38,960
I'LL SUGGEST THAT FOR THE FUTURE

4964
03:45:38,960 --> 03:45:42,720
MEETINGS PLEASE REACH OUT TO ME

4965
03:45:42,720 --> 03:45:44,280
DIRECTLY AND PAULETTE AND WE

4966
03:45:44,280 --> 03:45:45,360
WILL ACCUMULATE SUGGESTIONS IN

4967
03:45:45,360 --> 03:45:49,040
TERMS OF FUTURE TOPICS TO ASK

4968
03:45:49,040 --> 03:45:50,680
NCI LEADERSHIP TO LIBERATOR ON

4969
03:45:50,680 --> 03:45:52,200
WITH US AND ANY OTHER PRESSING

4970
03:45:52,200 --> 03:45:59,640
ISSUES FOR TODAY?

4971
03:45:59,640 --> 03:46:01,240
>> LOOK FORWARD TO JUNE.

4972
03:46:01,240 --> 03:46:04,880
>> Dr. Flaherty: YES,
IN-PERSON

4973
03:46:04,880 --> 03:46:06,280
IN JUNE.

4974
03:46:06,280 --> 03:46:07,000
ALL RIGHT.

4975
03:46:07,000 --> 03:46:07,320
EXCELLENT.

4976
03:46:07,320 --> 03:46:09,560
THANK YOU, ALL.

4977
03:46:09,560 --> 03:46:10,480
APPRECIATE THE PARTICIPATION.

4978
03:46:10,480 --> 03:46:10,800
>> THANK YOU.

4979
03:46:10,800 --> 03:46:11,680
>> THANK YOU, EVERYONE.

4980
03:46:11,680 --> 00:00:00,000
>> BYE.